<html lang="en" class="pb-page fonts-loaded fonts-loaded" data-request-id="38f91a3a-f064-4fd2-8d7a-c06c977ddf37" style="--article-sticky-top: 82.00019999999999px; --scroll-padding: 163.594px auto auto;"><head data-pb-dropzone="head"><meta name="pbContext" content=";product:product:elsevier\:product\:cell;article:article:pii\:S0092867420311417;website:website:cell-site;ctype:string:Journal Content;journal:journal:cell;issue:issue:pii\:S0092867419X00227;pageGroup:string:Article View;page:string:Show Full Text;requestedJournal:journal:cell;wgroup:string:Default Website Group;subPage:string:Full Text">




<!-- if there is any customization for Responsive Project widget  -->


























    
    







    
            
        



        
                <meta name="robots" content="noarchive,nocache">
            
    






    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=1, user-scalable=1">











        <meta property="og:title" content="A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer">
    


        <meta property="og:type" content="Article">
    


        <meta property="og:url" content="https://www.cell.com/cell/abstract/S0092-8674(20)31141-7">
    



        <meta property="og:site_name" content="Cell">
    


        <meta property="og:image" content="https://www.cell.com/cms/asset/02e87db8-65c7-4733-a607-6997fd7749aa/fx1.jpg">
    


        <meta property="og:description" content="In a phase Ib clinical trial, Ott et&nbsp;al. demonstrate feasibility, safety, and immunogenicity
of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients
with advanced solid tumors. Vaccine-induced T&nbsp;cells persist over time, exhibit cytotoxic
potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses
were detected following vaccination.">
    











        <meta name="twitter:title" content="A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer">
    




        <meta name="twitter:image" content="https://www.cell.com/cms/asset/02e87db8-65c7-4733-a607-6997fd7749aa/fx1.jpg">
    


        <meta name="twitter:description" content="In a phase Ib clinical trial, Ott et&nbsp;al. demonstrate feasibility, safety, and immunogenicity
of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients
with advanced solid tumors. Vaccine-induced T&nbsp;cells persist over time, exhibit cytotoxic
potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses
were detected following vaccination.">
    

        <meta name="twitter:card" content="summary_large_image">
    











    
    
            
            
        <link rel="canonical" href="https://www.cell.com/cell/fulltext/S0092-8674(20)31141-7">
    


<meta name="tdm-reservation" content="1">
<meta name="tdm-policy" content="https://www.elsevier.com/tdm/tdmrep-policy.json">

<title>A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer: Cell</title><meta name="citation_journal_title" content="Cell"> <meta name="citation_journal_abbrev" content="Cell"> <meta name="citation_publisher" content="Elsevier"> <meta name="citation_title" content="A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer"> <meta name="citation_date" content="2020/10/15"> <meta name="citation_volume" content="183"> <meta name="citation_issue" content="2"> <meta name="citation_firstpage" content="347"> <meta name="citation_lastpage" content="362.e24"> <meta name="citation_pmid" content="33064988"> <meta name="citation_abstract_html_url" content="https://www.cell.com/action/showAbstract?pii=S0092867420311417"> <meta name="citation_fulltext_html_url" content="https://www.cell.com/action/showFullText?pii=S0092867420311417"> <meta name="citation_pdf_url" content="https://www.cell.com/action/showPdf?pii=S0092867420311417"> <meta name="citation_issn" content="0092-8674"> <meta name="citation_issn" content="1097-4172"> <meta name="citation_language" content="English"> <meta name="citation_doi" content="10.1016/j.cell.2020.08.053"> <meta name="citation_pmid" content="33064988"> <meta name="citation_author" content="Patrick A. Ott"><meta name="citation_author_email" content="patrick_ott@dfci.harvard.edu"><meta name="citation_author_orcid" content="0000-0002-4253-943X"><meta name="citation_author_institution" content="Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA"><meta name="citation_author" content="Siwen Hu-Lieskovan"><meta name="citation_author_institution" content="Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"><meta name="citation_author" content="Bartosz Chmielowski"><meta name="citation_author_orcid" content="0000-0002-2374-3320"><meta name="citation_author_institution" content="Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA"><meta name="citation_author" content="Ramaswamy Govindan"><meta name="citation_author_institution" content="Washington University School of Medicine, St. Louis, MO, USA"><meta name="citation_author" content="Aung Naing"><meta name="citation_author_institution" content="Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"><meta name="citation_author" content="Nina Bhardwaj"><meta name="citation_author_institution" content="Tisch Cancer Institute, Icahn School of Medicine, New York, NY, USA"><meta name="citation_author" content="Kim Margolin"><meta name="citation_author_institution" content="Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA"><meta name="citation_author" content="Mark M. Awad"><meta name="citation_author_orcid" content="0000-0003-0928-5244"><meta name="citation_author_institution" content="Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA"><meta name="citation_author" content="Matthew D. Hellmann"><meta name="citation_author_orcid" content="0000-0002-2670-9777"><meta name="citation_author_institution" content="Memorial Sloan Kettering Cancer Center, New York, NY, USA"><meta name="citation_author" content="Jessica J. Lin"><meta name="citation_author_orcid" content="0000-0001-7373-3916"><meta name="citation_author_institution" content="Cancer Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA"><meta name="citation_author" content="Terence Friedlander"><meta name="citation_author_orcid" content="0000-0002-3630-4941"><meta name="citation_author_institution" content="Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA"><meta name="citation_author" content="Meghan E. Bushway"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Kristen N. Balogh"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Tracey E. Sciuto"><meta name="citation_author_orcid" content="0000-0002-2985-9930"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Victoria Kohler"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Samantha J. Turnbull"><meta name="citation_author_orcid" content="0000-0002-2880-6677"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Rana Besada"><meta name="citation_author_orcid" content="0000-0002-7255-3435"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Riley R. Curran"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Benjamin Trapp"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Julian Scherer"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Asaf Poran"><meta name="citation_author_orcid" content="0000-0001-9118-1051"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Dewi Harjanto"><meta name="citation_author_orcid" content="0000-0003-0754-4409"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Dominik Barthelme"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Ying Sonia Ting"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Jesse Z. Dong"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Yvonne Ware"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Yuting Huang"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Zhengping Huang"><meta name="citation_author_orcid" content="0000-0002-0406-5421"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Amy Wanamaker"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Lisa D. Cleary"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Melissa A. Moles"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Kelledy Manson"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Joel Greshock"><meta name="citation_author_orcid" content="0000-0001-6567-4266"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Zakaria S. Khondker"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Ed Fritsch"><meta name="citation_author_orcid" content="0000-0002-8412-5665"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Michael S. Rooney"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Mark DeMario"><meta name="citation_author_orcid" content="0000-0002-7368-9895"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Richard B. Gaynor"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_author" content="Lakshmi Srinivasan"><meta name="citation_author_email" content="lakshmi.srinivasan@biontech.us"><meta name="citation_author_orcid" content="0000-0003-1351-7407"><meta name="citation_author_institution" content="Neon Therapeutics/BioNTech US, Cambridge, MA, USA"><meta name="citation_keywords" content="immunotherapy; epitope spread; metastatic cancer; NEO-PV-01; cancer vaccine; T cell; neoantigen; personalized vaccine; checkpoint inhibitor; anti-PD-1"><meta name="citation_reference" content="citation_title=Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction; citation_author=J.G. Abelin; citation_author=D.B. Keskin; citation_author=S. Sarkizova; citation_author=C.R. Hartigan; citation_author=W. Zhang; citation_author=J. Sidney; citation_author=J. Stevens; citation_author=W. Lane; citation_author=G.L. Zhang; citation_author=T.M. Eisenhaure; citation_author=et al.; citation_journal_title=Immunity; citation_volume=46; citation_firstpage=315; citation_lastpage=326; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction; citation_author=J.G. Abelin; citation_author=D. Harjanto; citation_author=M. Malloy; citation_author=P. Suri; citation_author=T. Colson; citation_author=S.P. Goulding; citation_author=A.L. Creech; citation_author=L.R. Serrano; citation_author=G. Nasir; citation_author=Y. Nasrullah; citation_author=et al.; citation_journal_title=Immunity; citation_volume=51; citation_firstpage=766; citation_lastpage=779.e17; citation_publication_date=2019; "><meta name="citation_reference" content="citation_title=MHC-II neoantigens shape tumour immunity and response to immunotherapy; citation_author=E. Alspach; citation_author=D.M. Lussier; citation_author=A.P. Miceli; citation_author=I. Kizhvatov; citation_author=M. DuPage; citation_author=A.M. Luoma; citation_author=W. Meng; citation_author=C.F. Lichti; citation_author=E. Esaulova; citation_author=A.N. Vomund; citation_author=et al.; citation_journal_title=Nature; citation_volume=574; citation_firstpage=696; citation_lastpage=701; citation_publication_date=2019; "><meta name="citation_reference" content="citation_title=ea-utils: “Command-line tools for processing biological sequencing data; citation_author=E. Aronesty; citation_publication_date=2011; citation_publisher=GitHub; "><meta name="citation_reference" content="citation_title=IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade; citation_author=M. Ayers; citation_author=J. Lunceford; citation_author=M. Nebozhyn; citation_author=E. Murphy; citation_author=A. Loboda; citation_author=D.R. Kaufman; citation_author=A. Albright; citation_author=J.D. Cheng; citation_author=S.P. Kang; citation_author=V. Shankaran; citation_author=et al.; citation_journal_title=J.&nbsp;Clin. Invest.; citation_volume=127; citation_firstpage=2930; citation_lastpage=2940; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial; citation_author=A.V. Balar; citation_author=M.D. Galsky; citation_author=J.E. Rosenberg; citation_author=T. Powles; citation_author=D.P. Petrylak; citation_author=J. Bellmunt; citation_author=Y. Loriot; citation_author=A. Necchi; citation_author=J. Hoffman-Censits; citation_author=J.L. Perez-Gracia; citation_author=IMvigor210 Study Group; citation_author=et al.; citation_journal_title=Lancet; citation_volume=389; citation_firstpage=67; citation_lastpage=76; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Building and optimizing a virus-specific T&nbsp;cell receptor library for targeted immunotherapy in viral infections; citation_author=N. Banu; citation_author=A. Chia; citation_author=Z.Z. Ho; citation_author=A.T. Garcia; citation_author=K. Paravasivam; citation_author=G.M. Grotenbreg; citation_author=A. Bertoletti; citation_author=A.J. Gehring; citation_journal_title=Sci. Rep.; citation_volume=4; citation_firstpage=4166; citation_publication_date=2014; "><meta name="citation_reference" content="citation_title=Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma; citation_author=J. Bellmunt; citation_author=R. de Wit; citation_author=D.J. Vaughn; citation_author=Y. Fradet; citation_author=J.L. Lee; citation_author=L. Fong; citation_author=N.J. Vogelzang; citation_author=M.A. Climent; citation_author=D.P. Petrylak; citation_author=T.K. Choueiri; citation_author=KEYNOTE-045 Investigators; citation_author=et al.; citation_journal_title=N.&nbsp;Engl. J. Med.; citation_volume=376; citation_firstpage=1015; citation_lastpage=1026; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Sensitive and viable identification of antigen-specific CD8+ T&nbsp;cells by a flow cytometric assay for degranulation; citation_author=M.R. Betts; citation_author=J.M. Brenchley; citation_author=D.A. Price; citation_author=S.C. De Rosa; citation_author=D.C. Douek; citation_author=M. Roederer; citation_author=R.A. Koup; citation_journal_title=J.&nbsp;Immunol. Methods; citation_volume=281; citation_firstpage=65; citation_lastpage=78; citation_publication_date=2003; "><meta name="citation_reference" content="citation_title=APOE genotype and cognitive decline in a middle-aged cohort; citation_author=C.K. Blair; citation_author=A.R. Folsom; citation_author=D.S. Knopman; citation_author=M.S. Bray; citation_author=T.H. Mosley; citation_author=E. Boerwinkle; citation_journal_title=Neurology; citation_volume=64; citation_firstpage=268; citation_lastpage=276; citation_publication_date=2005; "><meta name="citation_reference" content="citation_title=Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma; citation_author=C.U. Blank; citation_author=E.A. Rozeman; citation_author=L.F. Fanchi; citation_author=K. Sikorska; citation_author=B. van de Wiel; citation_author=P. Kvistborg; citation_author=O. Krijgsman; citation_author=M. van den Braber; citation_author=D. Philips; citation_author=A. Broeks; citation_author=et al.; citation_journal_title=Nat. Med.; citation_volume=24; citation_firstpage=1655; citation_lastpage=1661; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=MiXCR: software for comprehensive adaptive immunity profiling; citation_author=D.A. Bolotin; citation_author=S. Poslavsky; citation_author=I. Mitrophanov; citation_author=M. Shugay; citation_author=I.Z. Mamedov; citation_author=E.V. Putintseva; citation_author=D.M. Chudakov; citation_journal_title=Nat. Methods; citation_volume=12; citation_firstpage=380; citation_lastpage=381; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer; citation_author=H. Borghaei; citation_author=L. Paz-Ares; citation_author=L. Horn; citation_author=D.R. Spigel; citation_author=M. Steins; citation_author=N.E. Ready; citation_author=L.Q. Chow; citation_author=E.E. Vokes; citation_author=E. Felip; citation_author=E. Holgado; citation_author=et al.; citation_journal_title=N.&nbsp;Engl. J. Med.; citation_volume=373; citation_firstpage=1627; citation_lastpage=1639; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq; citation_author=B.J. Haas; citation_author=A. Dobin; citation_author=N. Stransky; citation_author=B. Li; citation_author=X. Yang; citation_author=T. Tickle; citation_author=A. Bankapur; citation_author=C. Ganote; citation_author=T.G. Doak; citation_author=N. Pochet; citation_author=J. Sun; citation_author=C.J. Wu; citation_author=T.R. Gingeras; citation_author=A. Regev; citation_journal_title=bioRxiv; citation_doi=10.1101/120295; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer; citation_author=D.P. Carbone; citation_author=M. Reck; citation_author=L. Paz-Ares; citation_author=B. Creelan; citation_author=L. Horn; citation_author=M. Steins; citation_author=E. Felip; citation_author=M.M. van den Heuvel; citation_author=T.E. Ciuleanu; citation_author=F. Badin; citation_author=CheckMate 026 Investigators; citation_author=et al.; citation_journal_title=N.&nbsp;Engl. J. Med.; citation_volume=376; citation_firstpage=2415; citation_lastpage=2426; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T&nbsp;cells; citation_author=B.M. Carreno; citation_author=V. Magrini; citation_author=M. Becker-Hapak; citation_author=S. Kaabinejadian; citation_author=J. Hundal; citation_author=A.A. Petti; citation_author=A. Ly; citation_author=W.R. Lie; citation_author=W.H. Hildebrand; citation_author=E.R. Mardis; citation_author=G.P. Linette; citation_journal_title=Science; citation_volume=348; citation_firstpage=803; citation_lastpage=808; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=Absolute quantification of somatic DNA alterations in human cancer; citation_author=S.L. Carter; citation_author=K. Cibulskis; citation_author=E. Helman; citation_author=A. McKenna; citation_author=H. Shen; citation_author=T. Zack; citation_author=P.W. Laird; citation_author=R.C. Onofrio; citation_author=W. Winckler; citation_author=B.A. Weir; citation_author=et al.; citation_journal_title=Nat. Biotechnol.; citation_volume=30; citation_firstpage=413; citation_lastpage=421; citation_publication_date=2012; "><meta name="citation_reference" content="citation_title=An integrative variant analysis suite for whole exome next-generation sequencing data; citation_author=D. Challis; citation_author=J. Yu; citation_author=U.S. Evani; citation_author=A.R. Jackson; citation_author=S. Paithankar; citation_author=C. Coarfa; citation_author=A. Milosavljevic; citation_author=R.A. Gibbs; citation_author=F. Yu; citation_journal_title=BMC Bioinformatics; citation_volume=13; citation_firstpage=8; citation_publication_date=2012; "><meta name="citation_reference" content="citation_title=Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs; citation_author=A. Christoforides; citation_author=J.D. Carpten; citation_author=G.J. Weiss; citation_author=M.J. Demeure; citation_author=D.D. Von Hoff; citation_author=D.W. Craig; citation_journal_title=BMC Genomics; citation_volume=14; citation_firstpage=302; citation_publication_date=2013; "><meta name="citation_reference" content="citation_title=ContEst: estimating cross-contamination of human samples in next-generation sequencing data; citation_author=K. Cibulskis; citation_author=A. McKenna; citation_author=T. Fennell; citation_author=E. Banks; citation_author=M. DePristo; citation_author=G. Getz; citation_journal_title=Bioinformatics; citation_volume=27; citation_firstpage=2601; citation_lastpage=2602; citation_publication_date=2011; "><meta name="citation_reference" content="citation_title=Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples; citation_author=K. Cibulskis; citation_author=M.S. Lawrence; citation_author=S.L. Carter; citation_author=A. Sivachenko; citation_author=D. Jaffe; citation_author=C. Sougnez; citation_author=S. Gabriel; citation_author=M. Meyerson; citation_author=E.S. Lander; citation_author=G. Getz; citation_journal_title=Nat. Biotechnol.; citation_volume=31; citation_firstpage=213; citation_lastpage=219; citation_publication_date=2013; "><meta name="citation_reference" content="citation_title=Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability; citation_author=C.J. Cohen; citation_author=Y. Zhao; citation_author=Z. Zheng; citation_author=S.A. Rosenberg; citation_author=R.A. Morgan; citation_journal_title=Cancer Res.; citation_volume=66; citation_firstpage=8878; citation_lastpage=8886; citation_publication_date=2006; "><meta name="citation_reference" content="citation_title=Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases; citation_author=V. Corbière; citation_author=J. Chapiro; citation_author=V. Stroobant; citation_author=W. Ma; citation_author=C. Lurquin; citation_author=B. Lethé; citation_author=N. van Baren; citation_author=B.J. Van den Eynde; citation_author=T. Boon; citation_author=P.G. Coulie; citation_journal_title=Cancer Res.; citation_volume=71; citation_firstpage=1253; citation_lastpage=1262; citation_publication_date=2011; "><meta name="citation_reference" content="citation_title=Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC); citation_author=T.R. Cottrell; citation_author=E.D. Thompson; citation_author=P.M. Forde; citation_author=J.E. Stein; citation_author=A.S. Duffield; citation_author=V. Anagnostou; citation_author=N. Rekhtman; citation_author=R.A. Anders; citation_author=J.D. Cuda; citation_author=P.B. Illei; citation_author=et al.; citation_journal_title=Ann. Oncol.; citation_volume=29; citation_firstpage=1853; citation_lastpage=1860; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy; citation_author=R. Cristescu; citation_author=R. Mogg; citation_author=M. Ayers; citation_author=A. Albright; citation_author=E. Murphy; citation_author=J. Yearley; citation_author=X. Sher; citation_author=X.Q. Liu; citation_author=H. Lu; citation_author=M. Nebozhyn; citation_author=et al.; citation_journal_title=Science; citation_volume=362; citation_firstpage=eaar3593; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=Peripheral CD8+ T&nbsp;cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma; citation_author=B.P. Fairfax; citation_author=C.A. Taylor; citation_author=R.A. Watson; citation_author=I. Nassiri; citation_author=S. Danielli; citation_author=H. Fang; citation_author=E.A. Mahé; citation_author=R. Cooper; citation_author=V. Woodcock; citation_author=Z. Traill; citation_author=et al.; citation_journal_title=Nat. Med.; citation_volume=26; citation_firstpage=193; citation_lastpage=199; citation_publication_date=2020; "><meta name="citation_reference" content="citation_title=HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides; citation_author=D.N. Garboczi; citation_author=D.T. Hung; citation_author=D.C. Wiley; citation_journal_title=Proc. Natl. Acad. Sci. USA; citation_volume=89; citation_firstpage=3429; citation_lastpage=3433; citation_publication_date=1992; "><meta name="citation_reference" content="citation_title=A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers; citation_author=S.N. Gettinger; citation_author=J. Choi; citation_author=N. Mani; citation_author=M.F. Sanmamed; citation_author=I. Datar; citation_author=R. Sowell; citation_author=V.Y. Du; citation_author=E. Kaftan; citation_author=S. Goldberg; citation_author=W. Dong; citation_author=et al.; citation_journal_title=Nat. Commun.; citation_volume=9; citation_firstpage=3196; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy; citation_author=J.J. Havel; citation_author=D. Chowell; citation_author=T.A. Chan; citation_journal_title=Nat. Rev. Cancer; citation_volume=19; citation_firstpage=133; citation_lastpage=150; citation_publication_date=2019; "><meta name="citation_reference" content="citation_title=B cells and tertiary lymphoid structures promote immunotherapy response; citation_author=B.A. Helmink; citation_author=S.M. Reddy; citation_author=J. Gao; citation_author=S. Zhang; citation_author=R. Basar; citation_author=R. Thakur; citation_author=K. Yizhak; citation_author=M. Sade-Feldman; citation_author=J. Blando; citation_author=G. Han; citation_author=et al.; citation_journal_title=Nature; citation_volume=577; citation_firstpage=549; citation_lastpage=555; citation_publication_date=2020; "><meta name="citation_reference" content="citation_title=Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial; citation_author=R.S. Herbst; citation_author=P. Baas; citation_author=D.W. Kim; citation_author=E. Felip; citation_author=J.L. Pérez-Gracia; citation_author=J.Y. Han; citation_author=J. Molina; citation_author=J.H. Kim; citation_author=C.D. Arvis; citation_author=M.J. Ahn; citation_author=et al.; citation_journal_title=Lancet; citation_volume=387; citation_firstpage=1540; citation_lastpage=1550; citation_publication_date=2016; "><meta name="citation_reference" content="citation_title=Actively personalized vaccination trial for newly diagnosed glioblastoma; citation_author=N. Hilf; citation_author=S. Kuttruff-Coqui; citation_author=K. Frenzel; citation_author=V. Bukur; citation_author=S. Stevanović; citation_author=C. Gouttefangeas; citation_author=M. Platten; citation_author=G. Tabatabai; citation_author=V. Dutoit; citation_author=S.H. van der Burg; citation_author=et al.; citation_journal_title=Nature; citation_volume=565; citation_firstpage=240; citation_lastpage=245; citation_publication_date=2019; "><meta name="citation_reference" content="citation_title=Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy; citation_author=F.S. Hodi; citation_author=M. Ballinger; citation_author=B. Lyons; citation_author=J.C. Soria; citation_author=M. Nishino; citation_author=J. Tabernero; citation_author=T. Powles; citation_author=D. Smith; citation_author=A. Hoos; citation_author=C. McKenna; citation_author=et al.; citation_journal_title=J.&nbsp;Clin. Oncol.; citation_volume=36; citation_firstpage=850; citation_lastpage=858; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy; citation_author=A. Hosoi; citation_author=K. Takeda; citation_author=K. Nagaoka; citation_author=T. Iino; citation_author=H. Matsushita; citation_author=S. Ueha; citation_author=S. Aoki; citation_author=K. Matsushima; citation_author=M. Kubo; citation_author=T. Morikawa; citation_author=et al.; citation_journal_title=Sci. Rep.; citation_volume=8; citation_firstpage=1058; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=Towards personalized, tumour-specific, therapeutic vaccines for cancer; citation_author=Z. Hu; citation_author=P.A. Ott; citation_author=C.J. Wu; citation_journal_title=Nat. Rev. Immunol.; citation_volume=18; citation_firstpage=168; citation_lastpage=182; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma; citation_author=A.C. Huang; citation_author=R.J. Orlowski; citation_author=X. Xu; citation_author=R. Mick; citation_author=S.M. George; citation_author=P.K. Yan; citation_author=S. Manne; citation_author=A.A. Kraya; citation_author=B. Wubbenhorst; citation_author=L. Dorfman; citation_author=et al.; citation_journal_title=Nat. Med.; citation_volume=25; citation_firstpage=454; citation_lastpage=461; citation_publication_date=2019; "><meta name="citation_reference" content="citation_title=An intra-tumoral niche maintains and differentiates stem-like CD8 T&nbsp;cells; citation_author=C.S. Jansen; citation_author=N. Prokhnevska; citation_author=V.A. Master; citation_author=M.G. Sanda; citation_author=J.W. Carlisle; citation_author=M.A. Bilen; citation_author=M. Cardenas; citation_author=S. Wilkinson; citation_author=R. Lake; citation_author=A.G. Sowalsky; citation_author=et al.; citation_journal_title=Nature; citation_volume=576; citation_firstpage=465; citation_lastpage=470; citation_publication_date=2019; "><meta name="citation_reference" content="citation_title=Neoantigen vaccine generates intratumoral T&nbsp;cell responses in phase Ib glioblastoma trial; citation_author=D.B. Keskin; citation_author=A.J. Anandappa; citation_author=J. Sun; citation_author=I. Tirosh; citation_author=N.D. Mathewson; citation_author=S. Li; citation_author=G. Oliveira; citation_author=A. Giobbie-Hurder; citation_author=K. Felt; citation_author=E. Gjini; citation_author=et al.; citation_journal_title=Nature; citation_volume=565; citation_firstpage=234; citation_lastpage=239; citation_publication_date=2019; "><meta name="citation_reference" content="citation_title=T-cell receptor profiling in cancer; citation_author=I. Kirsch; citation_author=M. Vignali; citation_author=H. Robins; citation_journal_title=Mol. Oncol.; citation_volume=9; citation_firstpage=2063; citation_lastpage=2070; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing; citation_author=D.C. Koboldt; citation_author=Q. Zhang; citation_author=D.E. Larson; citation_author=D. Shen; citation_author=M.D. McLellan; citation_author=L. Lin; citation_author=C.A. Miller; citation_author=E.R. Mardis; citation_author=L. Ding; citation_author=R.K. Wilson; citation_journal_title=Genome Res.; citation_volume=22; citation_firstpage=568; citation_lastpage=576; citation_publication_date=2012; "><meta name="citation_reference" content="citation_title=Mutant MHC class II epitopes drive therapeutic immune responses to cancer; citation_author=S. Kreiter; citation_author=M. Vormehr; citation_author=N. van de Roemer; citation_author=M. Diken; citation_author=M. Löwer; citation_author=J. Diekmann; citation_author=S. Boegel; citation_author=B. Schrörs; citation_author=F. Vascotto; citation_author=J.C. Castle; citation_author=et al.; citation_journal_title=Nature; citation_volume=520; citation_firstpage=692; citation_lastpage=696; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=Facilitating matched pairing and expression of TCR chains introduced into human T&nbsp;cells; citation_author=J. Kuball; citation_author=M.L. Dossett; citation_author=M. Wolfl; citation_author=W.Y. Ho; citation_author=R.H. Voss; citation_author=C. Fowler; citation_author=P.D. Greenberg; citation_journal_title=Blood; citation_volume=109; citation_firstpage=2331; citation_lastpage=2338; citation_publication_date=2007; "><meta name="citation_reference" content="citation_title=VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research; citation_author=Z. Lai; citation_author=A. Markovets; citation_author=M. Ahdesmaki; citation_author=B. Chapman; citation_author=O. Hofmann; citation_author=R. McEwen; citation_author=J. Johnson; citation_author=B. Dougherty; citation_author=J.C. Barrett; citation_author=J.R. Dry; citation_journal_title=Nucleic Acids Res.; citation_volume=44; citation_firstpage=e108; citation_publication_date=2016; "><meta name="citation_reference" content="citation_title=Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial; citation_author=J. Larkin; citation_author=D. Minor; citation_author=S. D’Angelo; citation_author=B. Neyns; citation_author=M. Smylie; citation_author=W.H. Miller; citation_author=R. Gutzmer; citation_author=G. Linette; citation_author=B. Chmielowski; citation_author=C.D. Lao; citation_author=et al.; citation_journal_title=J.&nbsp;Clin. Oncol.; citation_volume=36; citation_firstpage=383; citation_lastpage=390; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome; citation_author=B. Li; citation_author=C.N. Dewey; citation_journal_title=BMC Bioinformatics; citation_volume=12; citation_firstpage=323; citation_publication_date=2011; "><meta name="citation_reference" content="citation_title=Fast and accurate short read alignment with Burrows-Wheeler transform; citation_author=H. Li; citation_author=R. Durbin; citation_journal_title=Bioinformatics; citation_volume=25; citation_firstpage=1754; citation_lastpage=1760; citation_publication_date=2009; "><meta name="citation_reference" content="citation_title=The Sequence Alignment/Map format and SAMtools; citation_author=H. Li; citation_author=B. Handsaker; citation_author=A. Wysoker; citation_author=T. Fennell; citation_author=J. Ruan; citation_author=N. Homer; citation_author=G. Marth; citation_author=A. Goncalo; citation_author=R. Durbin; citation_author=1000 Genome Project Data Processing Subgroup; citation_journal_title=Bioinformatics; citation_volume=25; citation_firstpage=2078; citation_lastpage=2079; citation_publication_date=2009; "><meta name="citation_reference" content="citation_title=A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy; citation_author=M. Łuksza; citation_author=N. Riaz; citation_author=V. Makarov; citation_author=V.P. Balachandran; citation_author=M.D. Hellmann; citation_author=A. Solovyov; citation_author=N.A. Rizvi; citation_author=T. Merghoub; citation_author=A.J. Levine; citation_author=T.A. Chan; citation_author=et al.; citation_journal_title=Nature; citation_volume=551; citation_firstpage=517; citation_lastpage=520; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Clonal neoantigens elicit T&nbsp;cell immunoreactivity and sensitivity to immune checkpoint blockade; citation_author=N. McGranahan; citation_author=A.J. Furness; citation_author=R. Rosenthal; citation_author=S. Ramskov; citation_author=R. Lyngaa; citation_author=S.K. Saini; citation_author=M. Jamal-Hanjani; citation_author=G.A. Wilson; citation_author=N.J. Birkbak; citation_author=C.T. Hiley; citation_author=et al.; citation_journal_title=Science; citation_volume=351; citation_firstpage=1463; citation_lastpage=1469; citation_publication_date=2016; "><meta name="citation_reference" content="citation_title=The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data; citation_author=A. McKenna; citation_author=M. Hanna; citation_author=E. Banks; citation_author=A. Sivachenko; citation_author=K. Cibulskis; citation_author=A. Kernytsky; citation_author=K. Garimella; citation_author=D. Altshuler; citation_author=S. Gabriel; citation_author=M. Daly; citation_author=M.A. DePristo; citation_journal_title=Genome Res.; citation_volume=20; citation_firstpage=1297; citation_lastpage=1303; citation_publication_date=2010; "><meta name="citation_reference" content="citation_title=NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets; citation_author=M. Nielsen; citation_author=M. Andreatta; citation_journal_title=Genome Med.; citation_volume=8; citation_firstpage=33; citation_publication_date=2016; "><meta name="citation_reference" content="citation_title=Immunotherapy: Immune-modified response criteria - an iterative learning process?; citation_author=P.A. Ott; citation_journal_title=Nat. Rev. Clin. Oncol.; citation_volume=15; citation_firstpage=267; citation_lastpage=268; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=An immunogenic personal neoantigen vaccine for patients with melanoma; citation_author=P.A. Ott; citation_author=Z. Hu; citation_author=D.B. Keskin; citation_author=S.A. Shukla; citation_author=J. Sun; citation_author=D.J. Bozym; citation_author=W. Zhang; citation_author=A. Luoma; citation_author=A. Giobbie-Hurder; citation_author=L. Peter; citation_author=et al.; citation_journal_title=Nature; citation_volume=547; citation_firstpage=217; citation_lastpage=221; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=B cells are associated with survival and immunotherapy response in sarcoma; citation_author=F. Petitprez; citation_author=A. de Reyniès; citation_author=E.Z. Keung; citation_author=T.W. Chen; citation_author=C.M. Sun; citation_author=J. Calderaro; citation_author=Y.M. Jeng; citation_author=L.P. Hsiao; citation_author=L. Lacroix; citation_author=A. Bougoüin; citation_author=et al.; citation_journal_title=Nature; citation_volume=577; citation_firstpage=556; citation_lastpage=560; citation_publication_date=2020; "><meta name="citation_reference" content="citation_title=Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications; citation_author=A. Rimmer; citation_author=H. Phan; citation_author=I. Mathieson; citation_author=Z. Iqbal; citation_author=S.R.F. Twigg; citation_author=A.O.M. Wilkie; citation_author=G. McVean; citation_author=G. Lunter; citation_author=WGS500 Consortium; citation_journal_title=Nat. Genet.; citation_volume=46; citation_firstpage=912; citation_lastpage=918; citation_publication_date=2014; "><meta name="citation_reference" content="citation_title=Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer; citation_author=N.A. Rizvi; citation_author=M.D. Hellmann; citation_author=A. Snyder; citation_author=P. Kvistborg; citation_author=V. Makarov; citation_author=J.J. Havel; citation_author=W. Lee; citation_author=J. Yuan; citation_author=P. Wong; citation_author=T.S. Ho; citation_author=et al.; citation_journal_title=Science; citation_volume=348; citation_firstpage=124; citation_lastpage=128; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=Generation of peptide-MHC class I complexes through UV-mediated ligand exchange; citation_author=B. Rodenko; citation_author=M. Toebes; citation_author=S.R. Hadrup; citation_author=W.J. van Esch; citation_author=A.M. Molenaar; citation_author=T.N. Schumacher; citation_author=H. Ovaa; citation_journal_title=Nat. Protoc.; citation_volume=1; citation_firstpage=1120; citation_lastpage=1132; citation_publication_date=2006; "><meta name="citation_reference" content="citation_title=Resistance to checkpoint blockade therapy through inactivation of antigen presentation; citation_author=M. Sade-Feldman; citation_author=Y.J. Jiao; citation_author=J.H. Chen; citation_author=M.S. Rooney; citation_author=M. Barzily-Rokni; citation_author=J.P. Eliane; citation_author=S.L. Bjorgaard; citation_author=M.R. Hammond; citation_author=H. Vitzthum; citation_author=S.M. Blackmon; citation_author=et al.; citation_journal_title=Nat. Commun.; citation_volume=8; citation_firstpage=1136; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma; citation_author=M. Sade-Feldman; citation_author=K. Yizhak; citation_author=S.L. Bjorgaard; citation_author=J.P. Ray; citation_author=C.G. de Boer; citation_author=R.W. Jenkins; citation_author=D.J. Lieb; citation_author=J.H. Chen; citation_author=D.T. Frederick; citation_author=M. Barzily-Rokni; citation_author=et al.; citation_journal_title=Cell; citation_volume=175; citation_firstpage=998; citation_lastpage=1013.e20; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer; citation_author=U. Sahin; citation_author=E. Derhovanessian; citation_author=M. Miller; citation_author=B.P. Kloke; citation_author=P. Simon; citation_author=M. Löwer; citation_author=V. Bukur; citation_author=A.D. Tadmor; citation_author=U. Luxemburger; citation_author=B. Schrörs; citation_author=et al.; citation_journal_title=Nature; citation_volume=547; citation_firstpage=222; citation_lastpage=226; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs; citation_author=C.T. Saunders; citation_author=W.S. Wong; citation_author=S. Swamy; citation_author=J. Becq; citation_author=L.J. Murray; citation_author=R.K. Cheetham; citation_journal_title=Bioinformatics; citation_volume=28; citation_firstpage=1811; citation_lastpage=1817; citation_publication_date=2012; "><meta name="citation_reference" content="citation_title=Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006); citation_author=J. Schachter; citation_author=A. Ribas; citation_author=G.V. Long; citation_author=A. Arance; citation_author=J.J. Grob; citation_author=L. Mortier; citation_author=A. Daud; citation_author=M.S. Carlino; citation_author=C. McNeil; citation_author=M. Lotem; citation_author=et al.; citation_journal_title=Lancet; citation_volume=390; citation_firstpage=1853; citation_lastpage=1862; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=NIH Image to ImageJ: 25 years of image analysis; citation_author=C.A. Schneider; citation_author=W.S. Rasband; citation_author=K.W. Eliceiri; citation_journal_title=Nature Methods; citation_volume=9; citation_firstpage=671; citation_lastpage=675; citation_publication_date=2012; "><meta name="citation_reference" content="citation_title=Neoantigens in cancer immunotherapy; citation_author=T.N. Schumacher; citation_author=R.D. Schreiber; citation_journal_title=Science; citation_volume=348; citation_firstpage=69; citation_lastpage=74; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=The future of immune checkpoint therapy; citation_author=P. Sharma; citation_author=J.P. Allison; citation_journal_title=Science; citation_volume=348; citation_firstpage=56; citation_lastpage=61; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial; citation_author=P. Sharma; citation_author=M.K. Callahan; citation_author=P. Bono; citation_author=J. Kim; citation_author=P. Spiliopoulou; citation_author=E. Calvo; citation_author=R.N. Pillai; citation_author=P.A. Ott; citation_author=F. de Braud; citation_author=M. Morse; citation_author=et al.; citation_journal_title=Lancet Oncol.; citation_volume=17; citation_firstpage=1590; citation_lastpage=1598; citation_publication_date=2016; "><meta name="citation_reference" content="citation_title=DescTools: tools for descriptive statistics; citation_author=A. Signorell; citation_author=K.A. Aho; citation_author=A. Alfons; citation_author=N. Anderegg; citation_author=T. Aragon; citation_author=A. Arppe; citation_author=A. Baddeley; citation_author=K. Barton; citation_author=B. Bolker; citation_author=H.W. Borchers; citation_author=et al.; citation_publication_date=2016; "><meta name="citation_reference" content="citation_title=LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer; citation_author=M.F. Tavazoie; citation_author=I. Pollack; citation_author=R. Tanqueco; citation_author=B.N. Ostendorf; citation_author=B.S. Reis; citation_author=F.C. Gonsalves; citation_author=I. Kurth; citation_author=C. Andreu-Agullo; citation_author=M.L. Derbyshire; citation_author=J. Posada; citation_author=et al.; citation_journal_title=Cell; citation_volume=172; citation_firstpage=825; citation_lastpage=840.e18; citation_publication_date=2018; "><meta name="citation_reference" content="citation_title=Ecological analysis of antigen-specific CTL repertoires defines the relationship between naive and immune T-cell populations; citation_author=P.G. Thomas; citation_author=A. Handel; citation_author=P.C. Doherty; citation_author=N.L. La Gruta; citation_journal_title=Proc. Natl. Acad. Sci. USA; citation_volume=110; citation_firstpage=1839; citation_lastpage=1844; citation_publication_date=2013; "><meta name="citation_reference" content="citation_title=Design and use of conditional MHC class I ligands; citation_author=M. Toebes; citation_author=M. Coccoris; citation_author=A. Bins; citation_author=B. Rodenko; citation_author=R. Gomez; citation_author=N.J. Nieuwkoop; citation_author=W. van de Kasteele; citation_author=G.F. Rimmelzwaan; citation_author=J.B. Haanen; citation_author=H. Ovaa; citation_author=T.N. Schumacher; citation_journal_title=Nat. Med.; citation_volume=12; citation_firstpage=246; citation_lastpage=251; citation_publication_date=2006; "><meta name="citation_reference" content="citation_title=Neoadjuvant checkpoint blockade for cancer immunotherapy; citation_author=S.L. Topalian; citation_author=J.M. Taube; citation_author=D.M. Pardoll; citation_journal_title=Science; citation_volume=367; citation_firstpage=eaax0182; citation_publication_date=2020; "><meta name="citation_reference" content="citation_title=Cancer immunotherapy based on mutation-specific CD4+ T&nbsp;cells in a patient with epithelial cancer; citation_author=E. Tran; citation_author=S. Turcotte; citation_author=A. Gros; citation_author=P.F. Robbins; citation_author=Y.C. Lu; citation_author=M.E. Dudley; citation_author=J.R. Wunderlich; citation_author=R.P. Somerville; citation_author=K. Hogan; citation_author=C.S. Hinrichs; citation_author=et al.; citation_journal_title=Science; citation_volume=344; citation_firstpage=641; citation_lastpage=645; citation_publication_date=2014; "><meta name="citation_reference" content="citation_title=PD-1 blockade induces responses by inhibiting adaptive immune resistance; citation_author=P.C. Tumeh; citation_author=C.L. Harview; citation_author=J.H. Yearley; citation_author=I.P. Shintaku; citation_author=E.J. Taylor; citation_author=L. Robert; citation_author=B. Chmielowski; citation_author=M. Spasic; citation_author=G. Henry; citation_author=V. Ciobanu; citation_author=et al.; citation_journal_title=Nature; citation_volume=515; citation_firstpage=568; citation_lastpage=571; citation_publication_date=2014; "><meta name="citation_reference" content="citation_title=Immune-awakening revealed by peripheral T&nbsp;cell dynamics after one cycle of immunotherapy; citation_author=S. Valpione; citation_author=E. Galvani; citation_author=J. Tweedy; citation_author=P.A. Mundra; citation_author=A. Banyard; citation_author=P. Middlehurst; citation_author=J. Barry; citation_author=S. Mills; citation_author=Z. Salih; citation_author=J. Weightman; citation_author=et al.; citation_journal_title=Nat. Can.; citation_volume=1; citation_firstpage=210; citation_lastpage=221; citation_publication_date=2020; "><meta name="citation_reference" content="citation_title=Genomic correlates of response to CTLA-4 blockade in metastatic melanoma; citation_author=E.M. Van Allen; citation_author=D. Miao; citation_author=B. Schilling; citation_author=S.A. Shukla; citation_author=C. Blank; citation_author=L. Zimmer; citation_author=A. Sucker; citation_author=U. Hillen; citation_author=M.H.G. Foppen; citation_author=S.M. Goldinger; citation_author=et al.; citation_journal_title=Science; citation_volume=350; citation_firstpage=207; citation_lastpage=211; citation_publication_date=2015; "><meta name="citation_reference" content="citation_title=High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T&nbsp;cell subsets; citation_author=C. Wang; citation_author=C.M. Sanders; citation_author=Q. Yang; citation_author=H.W. Schroeder; citation_author=E. Wang; citation_author=F. Babrzadeh; citation_author=B. Gharizadeh; citation_author=R.M. Myers; citation_author=J.R. Hudson; citation_author=R.W. Davis; citation_author=J. Han; citation_journal_title=Proc. Natl. Acad. Sci. USA; citation_volume=107; citation_firstpage=1518; citation_lastpage=1523; citation_publication_date=2010; "><meta name="citation_reference" content="citation_title=ggplot2: Elegant Graphics for Data Analysis; citation_author=H. Wickham; citation_publication_date=2016; citation_publisher=Springer; "><meta name="citation_reference" content="citation_title=Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; citation_author=J.D. Wolchok; citation_author=V. Chiarion-Sileni; citation_author=R. Gonzalez; citation_author=P. Rutkowski; citation_author=J.J. Grob; citation_author=C.L. Cowey; citation_author=C.D. Lao; citation_author=J. Wagstaff; citation_author=D. Schadendorf; citation_author=P.F. Ferrucci; citation_author=et al.; citation_journal_title=N.&nbsp;Engl. J. Med.; citation_volume=377; citation_firstpage=1345; citation_lastpage=1356; citation_publication_date=2017; "><meta name="citation_reference" content="citation_title=Tumor Mutational Burden and Response Rate to PD-1 Inhibition; citation_author=M. Yarchoan; citation_author=A. Hopkins; citation_author=E.M. Jaffee; citation_journal_title=N.&nbsp;Engl. J. Med.; citation_volume=377; citation_firstpage=2500; citation_lastpage=2501; citation_publication_date=2017; "><meta name="citation_abstract" content="<h2>Summary</h2><p>Neoantigens arise from mutations in cancer cells and are important targets of T&nbsp;cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed. <i>De novo</i> neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cell responses were observed post-vaccination in all of the patients. The vaccine-induced T cells had a cytotoxic phenotype and were capable of trafficking to the tumor and mediating cell killing. In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination. These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors (Clinicaltrials.gov: NCT02897765).</p>"><meta charset="UTF-8"><!--

    Pagebuild admin UI
-->



<script type="text/javascript" src="https://bam.nr-data.net/1/16e2192192?a=916957862&amp;sa=1&amp;v=1177.96a4d39&amp;t=Unnamed%20Transaction&amp;rst=7031&amp;ck=1&amp;ref=https://www.cell.com/cell/fulltext/S0092-8674(20)31141-7&amp;be=3435&amp;fe=6842&amp;dc=6740&amp;af=err,xhr,stn,ins,spa&amp;perf=%7B%22timing%22:%7B%22of%22:1749587855869,%22n%22:0,%22f%22:2805,%22dn%22:2805,%22dne%22:2805,%22c%22:2805,%22s%22:2805,%22ce%22:2805,%22rq%22:2806,%22rp%22:3419,%22rpe%22:4106,%22dl%22:3425,%22di%22:4333,%22ds%22:6740,%22de%22:6752,%22dc%22:6842,%22l%22:6842,%22le%22:6874%7D,%22navigation%22:%7B%7D%7D&amp;jsonp=NREUM.setToken"></script><script src="https://js-agent.newrelic.com/nr-spa-1177.min.js"></script><script type="text/javascript">
    ;window.NREUM||(NREUM={});NREUM.init={privacy:{cookies_enabled:true}};
    window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o||e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<n.length;o++)r(n[o]);return r}({1:[function(t,e,n){function r(t){try{c.console&&console.log(t)}catch(e){}}var o,i=t("ee"),a=t(26),c={};try{o=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(c.console=!0,o.indexOf("dev")!==-1&&(c.dev=!0),o.indexOf("nr_dev")!==-1&&(c.nrDev=!0))}catch(s){}c.nrDev&&i.on("internal-error",function(t){r(t.stack)}),c.dev&&i.on("fn-err",function(t,e,n){r(n.stack)}),c.dev&&(r("NR AGENT IN DEVELOPMENT MODE"),r("flags: "+a(c,function(t,e){return t}).join(", ")))},{}],2:[function(t,e,n){function r(t,e,n,r,c){try{l?l-=1:o(c||new UncaughtException(t,e,n),!0)}catch(f){try{i("ierr",[f,s.now(),!0])}catch(d){}}return"function"==typeof u&&u.apply(this,a(arguments))}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function o(t,e){var n=e?null:s.now();i("err",[t,n])}var i=t("handle"),a=t(27),c=t("ee"),s=t("loader"),f=t("gos"),u=window.onerror,d=!1,p="nr@seenError",l=0;s.features.err=!0,t(1),window.onerror=r;try{throw new Error}catch(h){"stack"in h&&(t(13),t(12),"addEventListener"in window&&t(6),s.xhrWrappable&&t(14),d=!0)}c.on("fn-start",function(t,e,n){d&&(l+=1)}),c.on("fn-err",function(t,e,n){d&&!n[p]&&(f(n,p,function(){return!0}),this.thrown=!0,o(n))}),c.on("fn-end",function(){d&&!this.thrown&&l>0&&(l-=1)}),c.on("internal-error",function(t){i("ierr",[t,s.now(),!0])})},{}],3:[function(t,e,n){t("loader").features.ins=!0},{}],4:[function(t,e,n){function r(){_++,T=g.hash,this[u]=y.now()}function o(){_--,g.hash!==T&&i(0,!0);var t=y.now();this[h]=~~this[h]+t-this[u],this[d]=t}function i(t,e){E.emit("newURL",[""+g,e])}function a(t,e){t.on(e,function(){this[e]=y.now()})}var c="-start",s="-end",f="-body",u="fn"+c,d="fn"+s,p="cb"+c,l="cb"+s,h="jsTime",m="fetch",v="addEventListener",w=window,g=w.location,y=t("loader");if(w[v]&&y.xhrWrappable){var x=t(10),b=t(11),E=t(8),R=t(6),O=t(13),N=t(7),M=t(14),P=t(9),S=t("ee"),C=S.get("tracer");t(16),y.features.spa=!0;var T,_=0;S.on(u,r),S.on(p,r),S.on(d,o),S.on(l,o),S.buffer([u,d,"xhr-done","xhr-resolved"]),R.buffer([u]),O.buffer(["setTimeout"+s,"clearTimeout"+c,u]),M.buffer([u,"new-xhr","send-xhr"+c]),N.buffer([m+c,m+"-done",m+f+c,m+f+s]),E.buffer(["newURL"]),x.buffer([u]),b.buffer(["propagate",p,l,"executor-err","resolve"+c]),C.buffer([u,"no-"+u]),P.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"]),a(M,"send-xhr"+c),a(S,"xhr-resolved"),a(S,"xhr-done"),a(N,m+c),a(N,m+"-done"),a(P,"new-jsonp"),a(P,"jsonp-end"),a(P,"cb-start"),E.on("pushState-end",i),E.on("replaceState-end",i),w[v]("hashchange",i,!0),w[v]("load",i,!0),w[v]("popstate",function(){i(0,_>1)},!0)}},{}],5:[function(t,e,n){function r(t){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var o=t("ee"),i=t("handle"),a=t(13),c=t(12),s="learResourceTimings",f="addEventListener",u="resourcetimingbufferfull",d="bstResource",p="resource",l="-start",h="-end",m="fn"+l,v="fn"+h,w="bstTimer",g="pushState",y=t("loader");y.features.stn=!0,t(8),"addEventListener"in window&&t(6);var x=NREUM.o.EV;o.on(m,function(t,e){var n=t[0];n instanceof x&&(this.bstStart=y.now())}),o.on(v,function(t,e){var n=t[0];n instanceof x&&i("bst",[n,e,this.bstStart,y.now()])}),a.on(m,function(t,e,n){this.bstStart=y.now(),this.bstType=n}),a.on(v,function(t,e){i(w,[e,this.bstStart,y.now(),this.bstType])}),c.on(m,function(){this.bstStart=y.now()}),c.on(v,function(t,e){i(w,[e,this.bstStart,y.now(),"requestAnimationFrame"])}),o.on(g+l,function(t){this.time=y.now(),this.startPath=location.pathname+location.hash}),o.on(g+h,function(t){i("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),f in window.performance&&(window.performance["c"+s]?window.performance[f](u,function(t){i(d,[window.performance.getEntriesByType(p)]),window.performance["c"+s]()},!1):window.performance[f]("webkit"+u,function(t){i(d,[window.performance.getEntriesByType(p)]),window.performance["webkitC"+s]()},!1)),document[f]("scroll",r,{passive:!0}),document[f]("keypress",r,!1),document[f]("click",r,!1)}},{}],6:[function(t,e,n){function r(t){for(var e=t;e&&!e.hasOwnProperty(u);)e=Object.getPrototypeOf(e);e&&o(e)}function o(t){c.inPlace(t,[u,d],"-",i)}function i(t,e){return t[1]}var a=t("ee").get("events"),c=t("wrap-function")(a,!0),s=t("gos"),f=XMLHttpRequest,u="addEventListener",d="removeEventListener";e.exports=a,"getPrototypeOf"in Object?(r(document),r(window),r(f.prototype)):f.prototype.hasOwnProperty(u)&&(o(window),o(f.prototype)),a.on(u+"-start",function(t,e){var n=t[1],r=s(n,"nr@wrapped",function(){function t(){if("function"==typeof n.handleEvent)return n.handleEvent.apply(n,arguments)}var e={object:t,"function":n}[typeof n];return e?c(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=t[1]=r}),a.on(d+"-start",function(t){t[1]=this.wrapped||t[1]})},{}],7:[function(t,e,n){function r(t,e,n){var r=t[e];"function"==typeof r&&(t[e]=function(){var t=i(arguments),e={};o.emit(n+"before-start",[t],e);var a;e[m]&&e[m].dt&&(a=e[m].dt);var c=r.apply(this,t);return o.emit(n+"start",[t,a],c),c.then(function(t){return o.emit(n+"end",[null,t],c),t},function(t){throw o.emit(n+"end",[t],c),t})})}var o=t("ee").get("fetch"),i=t(27),a=t(26);e.exports=o;var c=window,s="fetch-",f=s+"body-",u=["arrayBuffer","blob","json","text","formData"],d=c.Request,p=c.Response,l=c.fetch,h="prototype",m="nr@context";d&&p&&l&&(a(u,function(t,e){r(d[h],e,f),r(p[h],e,f)}),r(c,"fetch",s),o.on(s+"end",function(t,e){var n=this;if(e){var r=e.headers.get("content-length");null!==r&&(n.rxSize=r),o.emit(s+"done",[null,e],n)}else o.emit(s+"done",[t],n)}))},{}],8:[function(t,e,n){var r=t("ee").get("history"),o=t("wrap-function")(r);e.exports=r;var i=window.history&&window.history.constructor&&window.history.constructor.prototype,a=window.history;i&&i.pushState&&i.replaceState&&(a=i),o.inPlace(a,["pushState","replaceState"],"-")},{}],9:[function(t,e,n){function r(t){function e(){s.emit("jsonp-end",[],p),t.removeEventListener("load",e,!1),t.removeEventListener("error",n,!1)}function n(){s.emit("jsonp-error",[],p),s.emit("jsonp-end",[],p),t.removeEventListener("load",e,!1),t.removeEventListener("error",n,!1)}var r=t&&"string"==typeof t.nodeName&&"script"===t.nodeName.toLowerCase();if(r){var o="function"==typeof t.addEventListener;if(o){var a=i(t.src);if(a){var u=c(a),d="function"==typeof u.parent[u.key];if(d){var p={};f.inPlace(u.parent,[u.key],"cb-",p),t.addEventListener("load",e,!1),t.addEventListener("error",n,!1),s.emit("new-jsonp",[t.src],p)}}}}}function o(){return"addEventListener"in window}function i(t){var e=t.match(u);return e?e[1]:null}function a(t,e){var n=t.match(p),r=n[1],o=n[3];return o?a(o,e[r]):e[r]}function c(t){var e=t.match(d);return e&&e.length>=3?{key:e[2],parent:a(e[1],window)}:{key:t,parent:window}}var s=t("ee").get("jsonp"),f=t("wrap-function")(s);if(e.exports=s,o()){var u=/[?&](?:callback|cb)=([^&#]+)/,d=/(.*)\.([^.]+)/,p=/^(\w+)(\.|$)(.*)$/,l=["appendChild","insertBefore","replaceChild"];Node&&Node.prototype&&Node.prototype.appendChild?f.inPlace(Node.prototype,l,"dom-"):(f.inPlace(HTMLElement.prototype,l,"dom-"),f.inPlace(HTMLHeadElement.prototype,l,"dom-"),f.inPlace(HTMLBodyElement.prototype,l,"dom-")),s.on("dom-start",function(t){r(t[0])})}},{}],10:[function(t,e,n){var r=t("ee").get("mutation"),o=t("wrap-function")(r),i=NREUM.o.MO;e.exports=r,i&&(window.MutationObserver=function(t){return this instanceof i?new i(o(t,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype)},{}],11:[function(t,e,n){function r(t){var e=a.context(),n=c(t,"executor-",e),r=new f(n);return a.context(r).getCtx=function(){return e},a.emit("new-promise",[r,e],e),r}function o(t,e){return e}var i=t("wrap-function"),a=t("ee").get("promise"),c=i(a),s=t(26),f=NREUM.o.PR;e.exports=a,f&&(window.Promise=r,["all","race"].forEach(function(t){var e=f[t];f[t]=function(n){function r(t){return function(){a.emit("propagate",[null,!o],i),o=o||!t}}var o=!1;s(n,function(e,n){Promise.resolve(n).then(r("all"===t),r(!1))});var i=e.apply(f,arguments),c=f.resolve(i);return c}}),["resolve","reject"].forEach(function(t){var e=f[t];f[t]=function(t){var n=e.apply(f,arguments);return t!==n&&a.emit("propagate",[t,!0],n),n}}),f.prototype["catch"]=function(t){return this.then(null,t)},f.prototype=Object.create(f.prototype,{constructor:{value:r}}),s(Object.getOwnPropertyNames(f),function(t,e){try{r[e]=f[e]}catch(n){}}),a.on("executor-start",function(t){t[0]=c(t[0],"resolve-",this),t[1]=c(t[1],"resolve-",this)}),a.on("executor-err",function(t,e,n){t[1](n)}),c.inPlace(f.prototype,["then"],"then-",o),a.on("then-start",function(t,e){this.promise=e,t[0]=c(t[0],"cb-",this),t[1]=c(t[1],"cb-",this)}),a.on("then-end",function(t,e,n){this.nextPromise=n;var r=this.promise;a.emit("propagate",[r,!0],n)}),a.on("cb-end",function(t,e,n){a.emit("propagate",[n,!0],this.nextPromise)}),a.on("propagate",function(t,e,n){this.getCtx&&!e||(this.getCtx=function(){if(t instanceof Promise)var e=a.context(t);return e&&e.getCtx?e.getCtx():this})}),r.toString=function(){return""+f})},{}],12:[function(t,e,n){var r=t("ee").get("raf"),o=t("wrap-function")(r),i="equestAnimationFrame";e.exports=r,o.inPlace(window,["r"+i,"mozR"+i,"webkitR"+i,"msR"+i],"raf-"),r.on("raf-start",function(t){t[0]=o(t[0],"fn-")})},{}],13:[function(t,e,n){function r(t,e,n){t[0]=a(t[0],"fn-",null,n)}function o(t,e,n){this.method=n,this.timerDuration=isNaN(t[1])?0:+t[1],t[0]=a(t[0],"fn-",this,n)}var i=t("ee").get("timer"),a=t("wrap-function")(i),c="setTimeout",s="setInterval",f="clearTimeout",u="-start",d="-";e.exports=i,a.inPlace(window,[c,"setImmediate"],c+d),a.inPlace(window,[s],s+d),a.inPlace(window,[f,"clearImmediate"],f+d),i.on(s+u,r),i.on(c+u,o)},{}],14:[function(t,e,n){function r(t,e){d.inPlace(e,["onreadystatechange"],"fn-",c)}function o(){var t=this,e=u.context(t);t.readyState>3&&!e.resolved&&(e.resolved=!0,u.emit("xhr-resolved",[],t)),d.inPlace(t,g,"fn-",c)}function i(t){y.push(t),h&&(b?b.then(a):v?v(a):(E=-E,R.data=E))}function a(){for(var t=0;t<y.length;t++)r([],y[t]);y.length&&(y=[])}function c(t,e){return e}function s(t,e){for(var n in t)e[n]=t[n];return e}t(6);var f=t("ee"),u=f.get("xhr"),d=t("wrap-function")(u),p=NREUM.o,l=p.XHR,h=p.MO,m=p.PR,v=p.SI,w="readystatechange",g=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],y=[];e.exports=u;var x=window.XMLHttpRequest=function(t){var e=new l(t);try{u.emit("new-xhr",[e],e),e.addEventListener(w,o,!1)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}return e};if(s(l,x),x.prototype=l.prototype,d.inPlace(x.prototype,["open","send"],"-xhr-",c),u.on("send-xhr-start",function(t,e){r(t,e),i(e)}),u.on("open-xhr-start",r),h){var b=m&&m.resolve();if(!v&&!m){var E=1,R=document.createTextNode(E);new h(a).observe(R,{characterData:!0})}}else f.on("fn-end",function(t){t[0]&&t[0].type===w||a()})},{}],15:[function(t,e,n){function r(t){if(!c(t))return null;var e=window.NREUM;if(!e.loader_config)return null;var n=(e.loader_config.accountID||"").toString()||null,r=(e.loader_config.agentID||"").toString()||null,f=(e.loader_config.trustKey||"").toString()||null;if(!n||!r)return null;var h=l.generateSpanId(),m=l.generateTraceId(),v=Date.now(),w={spanId:h,traceId:m,timestamp:v};return(t.sameOrigin||s(t)&&p())&&(w.traceContextParentHeader=o(h,m),w.traceContextStateHeader=i(h,v,n,r,f)),(t.sameOrigin&&!u()||!t.sameOrigin&&s(t)&&d())&&(w.newrelicHeader=a(h,m,v,n,r,f)),w}function o(t,e){return"00-"+e+"-"+t+"-01"}function i(t,e,n,r,o){var i=0,a="",c=1,s="",f="";return o+"@nr="+i+"-"+c+"-"+n+"-"+r+"-"+t+"-"+a+"-"+s+"-"+f+"-"+e}function a(t,e,n,r,o,i){var a="btoa"in window&&"function"==typeof window.btoa;if(!a)return null;var c={v:[0,1],d:{ty:"Browser",ac:r,ap:o,id:t,tr:e,ti:n}};return i&&r!==i&&(c.d.tk=i),btoa(JSON.stringify(c))}function c(t){return f()&&s(t)}function s(t){var e=!1,n={};if("init"in NREUM&&"distributed_tracing"in NREUM.init&&(n=NREUM.init.distributed_tracing),t.sameOrigin)e=!0;else if(n.allowed_origins instanceof Array)for(var r=0;r<n.allowed_origins.length;r++){var o=h(n.allowed_origins[r]);if(t.hostname===o.hostname&&t.protocol===o.protocol&&t.port===o.port){e=!0;break}}return e}function f(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.enabled}function u(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.exclude_newrelic_header}function d(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&NREUM.init.distributed_tracing.cors_use_newrelic_header!==!1}function p(){return"init"in NREUM&&"distributed_tracing"in NREUM.init&&!!NREUM.init.distributed_tracing.cors_use_tracecontext_headers}var l=t(23),h=t(17);e.exports={generateTracePayload:r,shouldGenerateTrace:c}},{}],16:[function(t,e,n){function r(t){var e=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var r=0;r<p;r++)t.removeEventListener(d[r],this.listener,!1);e.aborted||(n.duration=a.now()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==e.status&&(e.status=0):i(this,t),n.cbTime=this.cbTime,u.emit("xhr-done",[t],t),c("xhr",[e,n,this.startTime]))}}function o(t,e){var n=s(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.parsedOrigin=s(e),t.sameOrigin=t.parsedOrigin.sameOrigin}function i(t,e){t.params.status=e.status;var n=v(e,t.lastSize);if(n&&(t.metrics.rxSize=n),t.sameOrigin){var r=e.getResponseHeader("X-NewRelic-App-Data");r&&(t.params.cat=r.split(", ").pop())}t.loadCaptureCalled=!0}var a=t("loader");if(a.xhrWrappable){var c=t("handle"),s=t(17),f=t(15).generateTracePayload,u=t("ee"),d=["load","error","abort","timeout"],p=d.length,l=t("id"),h=t(21),m=t(20),v=t(18),w=window.XMLHttpRequest;a.features.xhr=!0,t(14),t(7),u.on("new-xhr",function(t){var e=this;e.totalCbs=0,e.called=0,e.cbTime=0,e.end=r,e.ended=!1,e.xhrGuids={},e.lastSize=null,e.loadCaptureCalled=!1,t.addEventListener("load",function(n){i(e,t)},!1),h&&(h>34||h<10)||window.opera||t.addEventListener("progress",function(t){e.lastSize=t.loaded},!1)}),u.on("open-xhr-start",function(t){this.params={method:t[0]},o(this,t[1]),this.metrics={}}),u.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid);var n=f(this.parsedOrigin);if(n){var r=!1;n.newrelicHeader&&(e.setRequestHeader("newrelic",n.newrelicHeader),r=!0),n.traceContextParentHeader&&(e.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&e.setRequestHeader("tracestate",n.traceContextStateHeader),r=!0),r&&(this.dt=n)}}),u.on("send-xhr-start",function(t,e){var n=this.metrics,r=t[0],o=this;if(n&&r){var i=m(r);i&&(n.txSize=i)}this.startTime=a.now(),this.listener=function(t){try{"abort"!==t.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==t.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof e.onload))&&o.end(e)}catch(n){try{u.emit("internal-error",[n])}catch(r){}}};for(var c=0;c<p;c++)e.addEventListener(d[c],this.listener,!1)}),u.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),u.on("xhr-load-added",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),u.on("xhr-load-removed",function(t,e){var n=""+l(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),u.on("addEventListener-end",function(t,e){e instanceof w&&"load"===t[0]&&u.emit("xhr-load-added",[t[1],t[2]],e)}),u.on("removeEventListener-end",function(t,e){e instanceof w&&"load"===t[0]&&u.emit("xhr-load-removed",[t[1],t[2]],e)}),u.on("fn-start",function(t,e,n){e instanceof w&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=a.now()))}),u.on("fn-end",function(t,e){this.xhrCbStart&&u.emit("xhr-cb-time",[a.now()-this.xhrCbStart,this.onload,e],e)}),u.on("fetch-before-start",function(t){function e(t,e){var n=!1;return e.newrelicHeader&&(t.set("newrelic",e.newrelicHeader),n=!0),e.traceContextParentHeader&&(t.set("traceparent",e.traceContextParentHeader),e.traceContextStateHeader&&t.set("tracestate",e.traceContextStateHeader),n=!0),n}var n,r=t[1]||{};"string"==typeof t[0]?n=t[0]:t[0]&&t[0].url&&(n=t[0].url),n&&(this.parsedOrigin=s(n),this.sameOrigin=this.parsedOrigin.sameOrigin);var o=f(this.parsedOrigin);if(o&&(o.newrelicHeader||o.traceContextParentHeader))if("string"==typeof t[0]){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),e(i.headers,o)&&(this.dt=o),t.length>1?t[1]=i:t.push(i)}else t[0]&&t[0].headers&&e(t[0].headers,o)&&(this.dt=o)})}},{}],17:[function(t,e,n){var r={};e.exports=function(t){if(t in r)return r[t];var e=document.createElement("a"),n=window.location,o={};e.href=t,o.port=e.port;var i=e.href.split("://");!o.port&&i[1]&&(o.port=i[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===i[0]?"443":"80"),o.hostname=e.hostname||n.hostname,o.pathname=e.pathname,o.protocol=i[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var a=!e.protocol||":"===e.protocol||e.protocol===n.protocol,c=e.hostname===document.domain&&e.port===n.port;return o.sameOrigin=a&&(!e.hostname||c),"/"===o.pathname&&(r[t]=o),o}},{}],18:[function(t,e,n){function r(t,e){var n=t.responseType;return"json"===n&&null!==e?e:"arraybuffer"===n||"blob"===n||"json"===n?o(t.response):"text"===n||""===n||void 0===n?o(t.responseText):void 0}var o=t(20);e.exports=r},{}],19:[function(t,e,n){function r(){}function o(t,e,n){return function(){return i(t,[f.now()].concat(c(arguments)),e?null:this,n),e?void 0:this}}var i=t("handle"),a=t(26),c=t(27),s=t("ee").get("tracer"),f=t("loader"),u=NREUM;"undefined"==typeof window.newrelic&&(newrelic=u);var d=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],p="api-",l=p+"ixn-";a(d,function(t,e){u[e]=o(p+e,!0,"api")}),u.addPageAction=o(p+"addPageAction",!0),u.setCurrentRouteName=o(p+"routeName",!0),e.exports=newrelic,u.interaction=function(){return(new r).get()};var h=r.prototype={createTracer:function(t,e){var n={},r=this,o="function"==typeof e;return i(l+"tracer",[f.now(),t,n],r),function(){if(s.emit((o?"":"no-")+"fn-start",[f.now(),r,o],n),o)try{return e.apply(this,arguments)}catch(t){throw s.emit("fn-err",[arguments,this,t],n),t}finally{s.emit("fn-end",[f.now()],n)}}}};a("actionText,setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(t,e){h[e]=o(l+e)}),newrelic.noticeError=function(t,e){"string"==typeof t&&(t=new Error(t)),i("err",[t,f.now(),!1,e])}},{}],20:[function(t,e,n){e.exports=function(t){if("string"==typeof t&&t.length)return t.length;if("object"==typeof t){if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if(!("undefined"!=typeof FormData&&t instanceof FormData))try{return JSON.stringify(t).length}catch(e){return}}}},{}],21:[function(t,e,n){var r=0,o=navigator.userAgent.match(/Firefox[\/\s](\d+\.\d+)/);o&&(r=+o[1]),e.exports=r},{}],22:[function(t,e,n){function r(t,e){var n=t.getEntries();n.forEach(function(t){"first-paint"===t.name?d("timing",["fp",Math.floor(t.startTime)]):"first-contentful-paint"===t.name&&d("timing",["fcp",Math.floor(t.startTime)])})}function o(t,e){var n=t.getEntries();n.length>0&&d("lcp",[n[n.length-1]])}function i(t){t.getEntries().forEach(function(t){t.hadRecentInput||d("cls",[t])})}function a(t){if(t instanceof h&&!v){var e=Math.round(t.timeStamp),n={type:t.type};e<=p.now()?n.fid=p.now()-e:e>p.offset&&e<=Date.now()?(e-=p.offset,n.fid=p.now()-e):e=p.now(),v=!0,d("timing",["fi",e,n])}}function c(t){d("pageHide",[p.now(),t])}if(!("init"in NREUM&&"page_view_timing"in NREUM.init&&"enabled"in NREUM.init.page_view_timing&&NREUM.init.page_view_timing.enabled===!1)){var s,f,u,d=t("handle"),p=t("loader"),l=t(25),h=NREUM.o.EV;if("PerformanceObserver"in window&&"function"==typeof window.PerformanceObserver){s=new PerformanceObserver(r);try{s.observe({entryTypes:["paint"]})}catch(m){}f=new PerformanceObserver(o);try{f.observe({entryTypes:["largest-contentful-paint"]})}catch(m){}u=new PerformanceObserver(i);try{u.observe({type:"layout-shift",buffered:!0})}catch(m){}}if("addEventListener"in document){var v=!1,w=["click","keydown","mousedown","pointerdown","touchstart"];w.forEach(function(t){document.addEventListener(t,a,!1)})}l(c)}},{}],23:[function(t,e,n){function r(){function t(){return e?15&e[n++]:16*Math.random()|0}var e=null,n=0,r=window.crypto||window.msCrypto;r&&r.getRandomValues&&(e=r.getRandomValues(new Uint8Array(31)));for(var o,i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx",a="",c=0;c<i.length;c++)o=i[c],"x"===o?a+=t().toString(16):"y"===o?(o=3&t()|8,a+=o.toString(16)):a+=o;return a}function o(){return a(16)}function i(){return a(32)}function a(t){function e(){return n?15&n[r++]:16*Math.random()|0}var n=null,r=0,o=window.crypto||window.msCrypto;o&&o.getRandomValues&&Uint8Array&&(n=o.getRandomValues(new Uint8Array(31)));for(var i=[],a=0;a<t;a++)i.push(e().toString(16));return i.join("")}e.exports={generateUuid:r,generateSpanId:o,generateTraceId:i}},{}],24:[function(t,e,n){function r(t,e){if(!o)return!1;if(t!==o)return!1;if(!e)return!0;if(!i)return!1;for(var n=i.split("."),r=e.split("."),a=0;a<r.length;a++)if(r[a]!==n[a])return!1;return!0}var o=null,i=null,a=/Version\/(\S+)\s+Safari/;if(navigator.userAgent){var c=navigator.userAgent,s=c.match(a);s&&c.indexOf("Chrome")===-1&&c.indexOf("Chromium")===-1&&(o="Safari",i=s[1])}e.exports={agent:o,version:i,match:r}},{}],25:[function(t,e,n){function r(t){function e(){t(a&&document[a]?document[a]:document[o]?"hidden":"visible")}"addEventListener"in document&&i&&document.addEventListener(i,e,!1)}e.exports=r;var o,i,a;"undefined"!=typeof document.hidden?(o="hidden",i="visibilitychange",a="visibilityState"):"undefined"!=typeof document.msHidden?(o="msHidden",i="msvisibilitychange"):"undefined"!=typeof document.webkitHidden&&(o="webkitHidden",i="webkitvisibilitychange",a="webkitVisibilityState")},{}],26:[function(t,e,n){function r(t,e){var n=[],r="",i=0;for(r in t)o.call(t,r)&&(n[i]=e(r,t[r]),i+=1);return n}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],27:[function(t,e,n){function r(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(o<0?0:o);++r<o;)i[r]=t[e+r];return i}e.exports=r},{}],28:[function(t,e,n){e.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(t,e,n){function r(){}function o(t){function e(t){return t&&t instanceof r?t:t?s(t,c,i):i()}function n(n,r,o,i){if(!p.aborted||i){t&&t(n,r,o);for(var a=e(o),c=m(n),s=c.length,f=0;f<s;f++)c[f].apply(a,r);var d=u[y[n]];return d&&d.push([x,n,r,a]),a}}function l(t,e){g[t]=m(t).concat(e)}function h(t,e){var n=g[t];if(n)for(var r=0;r<n.length;r++)n[r]===e&&n.splice(r,1)}function m(t){return g[t]||[]}function v(t){return d[t]=d[t]||o(n)}function w(t,e){f(t,function(t,n){e=e||"feature",y[n]=e,e in u||(u[e]=[])})}var g={},y={},x={on:l,addEventListener:l,removeEventListener:h,emit:n,get:v,listeners:m,context:e,buffer:w,abort:a,aborted:!1};return x}function i(){return new r}function a(){(u.api||u.feature)&&(p.aborted=!0,u=p.backlog={})}var c="nr@context",s=t("gos"),f=t(26),u={},d={},p=e.exports=o();p.backlog=u},{}],gos:[function(t,e,n){function r(t,e,n){if(o.call(t,e))return t[e];var r=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return t[e]=r,r}var o=Object.prototype.hasOwnProperty;e.exports=r},{}],handle:[function(t,e,n){function r(t,e,n,r){o.buffer([t],r),o.emit(t,e,n)}var o=t("ee").get("handle");e.exports=r,r.ee=o},{}],id:[function(t,e,n){function r(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:a(t,i,function(){return o++})}var o=1,i="nr@id",a=t("gos");e.exports=r},{}],loader:[function(t,e,n){function r(){if(!E++){var t=b.info=NREUM.info,e=l.getElementsByTagName("script")[0];if(setTimeout(u.abort,3e4),!(t&&t.licenseKey&&t.applicationID&&e))return u.abort();f(y,function(e,n){t[e]||(t[e]=n)});var n=a();s("mark",["onload",n+b.offset],null,"api"),s("timing",["load",n]);var r=l.createElement("script");r.src="https://"+t.agent,e.parentNode.insertBefore(r,e)}}function o(){"complete"===l.readyState&&i()}function i(){s("mark",["domContent",a()+b.offset],null,"api")}function a(){return R.exists&&performance.now?Math.round(performance.now()):(c=Math.max((new Date).getTime(),c))-b.offset}var c=(new Date).getTime(),s=t("handle"),f=t(26),u=t("ee"),d=t(24),p=window,l=p.document,h="addEventListener",m="attachEvent",v=p.XMLHttpRequest,w=v&&v.prototype;NREUM.o={ST:setTimeout,SI:p.setImmediate,CT:clearTimeout,XHR:v,REQ:p.Request,EV:p.Event,PR:p.Promise,MO:p.MutationObserver};var g=""+location,y={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-spa-1177.min.js"},x=v&&w&&w[h]&&!/CriOS/.test(navigator.userAgent),b=e.exports={offset:c,now:a,origin:g,features:{},xhrWrappable:x,userAgent:d};t(19),t(22),l[h]?(l[h]("DOMContentLoaded",i,!1),p[h]("load",r,!1)):(l[m]("onreadystatechange",o),p[m]("onload",r)),s("mark",["firstbyte",c],null,"api");var E=0,R=t(28)},{}],"wrap-function":[function(t,e,n){function r(t){return!(t&&t instanceof Function&&t.apply&&!t[a])}var o=t("ee"),i=t(27),a="nr@original",c=Object.prototype.hasOwnProperty,s=!1;e.exports=function(t,e){function n(t,e,n,o){function nrWrapper(){var r,a,c,s;try{a=this,r=i(arguments),c="function"==typeof n?n(r,a):n||{}}catch(f){p([f,"",[r,a,o],c])}u(e+"start",[r,a,o],c);try{return s=t.apply(a,r)}catch(d){throw u(e+"err",[r,a,d],c),d}finally{u(e+"end",[r,a,s],c)}}return r(t)?t:(e||(e=""),nrWrapper[a]=t,d(t,nrWrapper),nrWrapper)}function f(t,e,o,i){o||(o="");var a,c,s,f="-"===o.charAt(0);for(s=0;s<e.length;s++)c=e[s],a=t[c],r(a)||(t[c]=n(a,f?c+o:o,i,c))}function u(n,r,o){if(!s||e){var i=s;s=!0;try{t.emit(n,r,o,e)}catch(a){p([a,n,r,o])}s=i}}function d(t,e){if(Object.defineProperty&&Object.keys)try{var n=Object.keys(t);return n.forEach(function(n){Object.defineProperty(e,n,{get:function(){return t[n]},set:function(e){return t[n]=e,e}})}),e}catch(r){p([r])}for(var o in t)c.call(t,o)&&(e[o]=t[o]);return e}function p(e){try{t.emit("internal-error",e)}catch(n){}}return t||(t=o),n.inPlace=f,n.flag=a,n}},{}]},{},["loader",2,16,5,3,4]);
    ;NREUM.loader_config={accountID:"2095297",trustKey:"2038175",agentID:"916957862",licenseKey:"16e2192192",applicationID:"916957862"}
    ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"16e2192192",applicationID:"916957862",sa:1}
</script>
    <script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="dada9834-04e2-4bcd-b5ba-cae44d498dfa"></script>
    <script type="text/javascript">
        function getCookie(name) {
            var value = "; " + document.cookie;
            var parts = value.split("; " + name + "=");
            if (parts.length == 2) {
                return true;
            }
        }
            function OptanonWrapper() {
                var optCookie = getCookie("OptanonAlertBoxClosed");
                var isActiveCategory = "false";
                var isFoundCookieBox = "false";
                if(isActiveCategory == 'false' && isFoundCookieBox == 'false' && optCookie) {
                    OneTrust.InsertScript('/pb-assets/adobe/prod/adobedtm-1616606406233.js', 'head', null, null, '2');
                }
            }
    </script>


<noscript>
    <style>.requiresJS {
        display: none
    }

    .dartAd {
        display: block !important
    }</style>
</noscript>
        <script type="text/javascript" src="/wro/o4ny~selected-legacy.js"></script>
        <link rel="stylesheet" type="text/css" href="/wro/o4ny~selected-legacy.css">
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans">
        <script>window.MSInputMethodContext && document.documentMode && document.write('<script src="https://cdn.jsdelivr.net/gh/nuxodin/ie11CustomProperties@4.1.0/ie11CustomProperties.min.js"><\x2fscript>');</script><link rel="stylesheet" href="/products/marlin/cell/releasedAssets/css/build-b26f3342b722959c7931.css"><link rel="stylesheet" href="/products/marlin/cell/releasedAssets/css/print-b26f3342b722959c7931.css" media="print"><link rel="stylesheet" href="/products/marlin/cell/releasedAssets/css/themes/theme-cell.css">







        
        
        <script class="optanon-category-4" type="text/plain" async="" src="https://www.youtube.com/iframe_api"></script>
        
    





<!---->
<meta http-equiv="X-UA-Compatible" content="IE=edge">












<script src="https://cdn.cookielaw.org/scripttemplates/202411.2.0/otBannerSdk.js" async="" type="text/javascript"></script><style id="onetrust-style">#onetrust-banner-sdk .onetrust-vendors-list-handler{cursor:pointer;color:#1f96db;font-size:inherit;font-weight:bold;text-decoration:none;margin-left:5px}#onetrust-banner-sdk .onetrust-vendors-list-handler:hover{color:#1f96db}#onetrust-banner-sdk:focus{outline:2px solid #000;outline-offset:-2px}#onetrust-banner-sdk a:focus{outline:2px solid #000}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{outline-offset:1px}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{height:64px;width:64px}#onetrust-banner-sdk .ot-tcf2-vendor-count.ot-text-bold{font-weight:bold}#onetrust-banner-sdk .ot-close-icon,#onetrust-pc-sdk .ot-close-icon,#ot-sync-ntfy .ot-close-icon{background-size:contain;background-repeat:no-repeat;background-position:center;height:12px;width:12px}#onetrust-banner-sdk .powered-by-logo,#onetrust-banner-sdk .ot-pc-footer-logo a,#onetrust-pc-sdk .powered-by-logo,#onetrust-pc-sdk .ot-pc-footer-logo a,#ot-sync-ntfy .powered-by-logo,#ot-sync-ntfy .ot-pc-footer-logo a{background-size:contain;background-repeat:no-repeat;background-position:center;height:25px;width:152px;display:block;text-decoration:none;font-size:.75em}#onetrust-banner-sdk .powered-by-logo:hover,#onetrust-banner-sdk .ot-pc-footer-logo a:hover,#onetrust-pc-sdk .powered-by-logo:hover,#onetrust-pc-sdk .ot-pc-footer-logo a:hover,#ot-sync-ntfy .powered-by-logo:hover,#ot-sync-ntfy .ot-pc-footer-logo a:hover{color:#565656}#onetrust-banner-sdk h3 *,#onetrust-banner-sdk h4 *,#onetrust-banner-sdk h6 *,#onetrust-banner-sdk button *,#onetrust-banner-sdk a[data-parent-id] *,#onetrust-pc-sdk h3 *,#onetrust-pc-sdk h4 *,#onetrust-pc-sdk h6 *,#onetrust-pc-sdk button *,#onetrust-pc-sdk a[data-parent-id] *,#ot-sync-ntfy h3 *,#ot-sync-ntfy h4 *,#ot-sync-ntfy h6 *,#ot-sync-ntfy button *,#ot-sync-ntfy a[data-parent-id] *{font-size:inherit;font-weight:inherit;color:inherit}#onetrust-banner-sdk .ot-hide,#onetrust-pc-sdk .ot-hide,#ot-sync-ntfy .ot-hide{display:none !important}#onetrust-banner-sdk button.ot-link-btn:hover,#onetrust-pc-sdk button.ot-link-btn:hover,#ot-sync-ntfy button.ot-link-btn:hover{text-decoration:underline;opacity:1}#onetrust-pc-sdk .ot-sdk-row .ot-sdk-column{padding:0}#onetrust-pc-sdk .ot-sdk-container{padding-right:0}#onetrust-pc-sdk .ot-sdk-row{flex-direction:initial;width:100%}#onetrust-pc-sdk [type=checkbox]:checked,#onetrust-pc-sdk [type=checkbox]:not(:checked){pointer-events:initial}#onetrust-pc-sdk [type=checkbox]:disabled+label::before,#onetrust-pc-sdk [type=checkbox]:disabled+label:after,#onetrust-pc-sdk [type=checkbox]:disabled+label{pointer-events:none;opacity:.8}#onetrust-pc-sdk #vendor-list-content{transform:translate3d(0, 0, 0)}#onetrust-pc-sdk li input[type=checkbox]{z-index:1}#onetrust-pc-sdk li .ot-checkbox label{z-index:2}#onetrust-pc-sdk li .ot-checkbox input[type=checkbox]{height:auto;width:auto}#onetrust-pc-sdk li .host-title a,#onetrust-pc-sdk li .ot-host-name a,#onetrust-pc-sdk li .accordion-text,#onetrust-pc-sdk li .ot-acc-txt{z-index:2;position:relative}#onetrust-pc-sdk input{margin:3px .1ex}#onetrust-pc-sdk .pc-logo,#onetrust-pc-sdk .ot-pc-logo{height:60px;width:180px;background-position:center;background-size:contain;background-repeat:no-repeat;display:inline-flex;justify-content:center;align-items:center}#onetrust-pc-sdk .pc-logo img,#onetrust-pc-sdk .ot-pc-logo img{max-height:100%;max-width:100%}#onetrust-pc-sdk .screen-reader-only,#onetrust-pc-sdk .ot-scrn-rdr,.ot-sdk-cookie-policy .screen-reader-only,.ot-sdk-cookie-policy .ot-scrn-rdr{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}#onetrust-pc-sdk.ot-fade-in,.onetrust-pc-dark-filter.ot-fade-in,#onetrust-banner-sdk.ot-fade-in{animation-name:onetrust-fade-in;animation-duration:400ms;animation-timing-function:ease-in-out}#onetrust-pc-sdk.ot-hide{display:none !important}.onetrust-pc-dark-filter.ot-hide{display:none !important}#ot-sdk-btn.ot-sdk-show-settings,#ot-sdk-btn.optanon-show-settings{color:#fff;background-color:#468254;height:auto;white-space:normal;word-wrap:break-word;padding:.8em 2em;font-size:.8em;line-height:1.2;cursor:pointer;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease}#ot-sdk-btn.ot-sdk-show-settings:hover,#ot-sdk-btn.optanon-show-settings:hover{color:#fff;background-color:#2c6415}#ot-sdk-btn.ot-sdk-show-settings:active,#ot-sdk-btn.optanon-show-settings:active{color:#fff;background-color:#2c6415;border:1px solid rgba(162,192,169,.5)}.onetrust-pc-dark-filter{background:rgba(0,0,0,.5);z-index:2147483646;width:100%;height:100%;overflow:hidden;position:fixed;top:0;bottom:0;left:0}@keyframes onetrust-fade-in{0%{opacity:0}100%{opacity:1}}.ot-cookie-label{text-decoration:underline}@media only screen and (min-width: 426px)and (max-width: 896px)and (orientation: landscape){#onetrust-pc-sdk p{font-size:.75em}}#onetrust-banner-sdk .banner-option-input:focus+label{outline:1px solid #000;outline-style:auto}.category-vendors-list-handler+a:focus,.category-vendors-list-handler+a:focus-visible{outline:2px solid #000}#onetrust-pc-sdk .ot-userid-title{margin-top:10px}#onetrust-pc-sdk .ot-userid-title>span,#onetrust-pc-sdk .ot-userid-timestamp>span{font-weight:700}#onetrust-pc-sdk .ot-userid-desc{font-style:italic}#onetrust-pc-sdk .ot-host-desc a{pointer-events:initial}#onetrust-pc-sdk .ot-ven-hdr>p a{position:relative;z-index:2;pointer-events:initial}#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info a{margin-right:auto}#onetrust-pc-sdk .ot-pc-footer-logo img{width:136px;height:16px}#onetrust-pc-sdk .ot-pur-vdr-count{font-weight:400;font-size:.7rem;padding-top:3px;display:block}#onetrust-banner-sdk .ot-optout-signal,#onetrust-pc-sdk .ot-optout-signal{border:1px solid #32ae88;border-radius:3px;padding:5px;margin-bottom:10px;background-color:#f9fffa;font-size:.85rem;line-height:2}#onetrust-banner-sdk .ot-optout-signal .ot-optout-icon,#onetrust-pc-sdk .ot-optout-signal .ot-optout-icon{display:inline;margin-right:5px}#onetrust-banner-sdk .ot-optout-signal svg,#onetrust-pc-sdk .ot-optout-signal svg{height:20px;width:30px;transform:scale(0.5)}#onetrust-banner-sdk .ot-optout-signal svg path,#onetrust-pc-sdk .ot-optout-signal svg path{fill:#32ae88}#onetrust-consent-sdk .ot-general-modal{overflow:hidden;position:fixed;margin:0 auto;top:50%;left:50%;width:40%;padding:1.5rem;max-width:575px;min-width:575px;z-index:2147483647;border-radius:2.5px;transform:translate(-50%, -50%)}#onetrust-consent-sdk .ot-signature-health-group{margin-top:1rem;padding-left:1.25rem;padding-right:1.25rem;margin-bottom:.625rem;width:calc(100% - 2.5rem)}#onetrust-consent-sdk .ot-signature-health-group .ot-signature-health-form{gap:.5rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-health-form{width:70%;gap:.35rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-input{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-consent-sdk .ot-signature-health .ot-signature-subtitle{font-size:1.125rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-group-title{font-size:1.25rem;font-weight:bold}#onetrust-consent-sdk .ot-signature-health,#onetrust-consent-sdk .ot-signature-health-group{display:flex;flex-direction:column;gap:1rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-cont,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-cont{display:flex;flex-direction:column;gap:.25rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-paragraph,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-paragraph{margin:0;line-height:20px;font-size:max(14px,.875rem)}#onetrust-consent-sdk .ot-signature-health .ot-health-signature-error,#onetrust-consent-sdk .ot-signature-health-group .ot-health-signature-error{color:#4d4d4d;font-size:min(12px,.75rem)}#onetrust-consent-sdk .ot-signature-health .ot-signature-buttons-cont,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-buttons-cont{margin-top:max(.75rem,2%);gap:1rem;display:flex;justify-content:flex-end}#onetrust-consent-sdk .ot-signature-health .ot-signature-button,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-button{flex:1;height:auto;color:#fff;cursor:pointer;line-height:1.2;min-width:125px;font-weight:600;font-size:.813em;border-radius:2px;padding:12px 10px;white-space:normal;word-wrap:break-word;word-break:break-word;background-color:#68b631;border:2px solid #68b631}#onetrust-consent-sdk .ot-signature-health .ot-signature-button.reject,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-button.reject{background-color:#fff}#onetrust-consent-sdk .ot-input-field-cont{display:flex;flex-direction:column;gap:.5rem}#onetrust-consent-sdk .ot-input-field-cont .ot-signature-input{width:65%}#onetrust-consent-sdk .ot-signature-health-form{display:flex;flex-direction:column}#onetrust-consent-sdk .ot-signature-health-form .ot-signature-label{margin-bottom:0;line-height:20px;font-size:max(14px,.875rem)}@media only screen and (max-width: 600px){#onetrust-consent-sdk .ot-general-modal{min-width:100%}#onetrust-consent-sdk .ot-signature-health .ot-signature-health-form{width:100%}#onetrust-consent-sdk .ot-input-field-cont .ot-signature-input{width:100%}}#onetrust-banner-sdk,#onetrust-pc-sdk,#ot-sdk-cookie-policy,#ot-sync-ntfy{font-size:16px}#onetrust-banner-sdk *,#onetrust-banner-sdk ::after,#onetrust-banner-sdk ::before,#onetrust-pc-sdk *,#onetrust-pc-sdk ::after,#onetrust-pc-sdk ::before,#ot-sdk-cookie-policy *,#ot-sdk-cookie-policy ::after,#ot-sdk-cookie-policy ::before,#ot-sync-ntfy *,#ot-sync-ntfy ::after,#ot-sync-ntfy ::before{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}#onetrust-banner-sdk div,#onetrust-banner-sdk span,#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-banner-sdk p,#onetrust-banner-sdk img,#onetrust-banner-sdk svg,#onetrust-banner-sdk button,#onetrust-banner-sdk section,#onetrust-banner-sdk a,#onetrust-banner-sdk label,#onetrust-banner-sdk input,#onetrust-banner-sdk ul,#onetrust-banner-sdk li,#onetrust-banner-sdk nav,#onetrust-banner-sdk table,#onetrust-banner-sdk thead,#onetrust-banner-sdk tr,#onetrust-banner-sdk td,#onetrust-banner-sdk tbody,#onetrust-banner-sdk .ot-main-content,#onetrust-banner-sdk .ot-toggle,#onetrust-banner-sdk #ot-content,#onetrust-banner-sdk #ot-pc-content,#onetrust-banner-sdk .checkbox,#onetrust-pc-sdk div,#onetrust-pc-sdk span,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#onetrust-pc-sdk p,#onetrust-pc-sdk img,#onetrust-pc-sdk svg,#onetrust-pc-sdk button,#onetrust-pc-sdk section,#onetrust-pc-sdk a,#onetrust-pc-sdk label,#onetrust-pc-sdk input,#onetrust-pc-sdk ul,#onetrust-pc-sdk li,#onetrust-pc-sdk nav,#onetrust-pc-sdk table,#onetrust-pc-sdk thead,#onetrust-pc-sdk tr,#onetrust-pc-sdk td,#onetrust-pc-sdk tbody,#onetrust-pc-sdk .ot-main-content,#onetrust-pc-sdk .ot-toggle,#onetrust-pc-sdk #ot-content,#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk .checkbox,#ot-sdk-cookie-policy div,#ot-sdk-cookie-policy span,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy p,#ot-sdk-cookie-policy img,#ot-sdk-cookie-policy svg,#ot-sdk-cookie-policy button,#ot-sdk-cookie-policy section,#ot-sdk-cookie-policy a,#ot-sdk-cookie-policy label,#ot-sdk-cookie-policy input,#ot-sdk-cookie-policy ul,#ot-sdk-cookie-policy li,#ot-sdk-cookie-policy nav,#ot-sdk-cookie-policy table,#ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy tr,#ot-sdk-cookie-policy td,#ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy .ot-main-content,#ot-sdk-cookie-policy .ot-toggle,#ot-sdk-cookie-policy #ot-content,#ot-sdk-cookie-policy #ot-pc-content,#ot-sdk-cookie-policy .checkbox,#ot-sync-ntfy div,#ot-sync-ntfy span,#ot-sync-ntfy h1,#ot-sync-ntfy h2,#ot-sync-ntfy h3,#ot-sync-ntfy h4,#ot-sync-ntfy h5,#ot-sync-ntfy h6,#ot-sync-ntfy p,#ot-sync-ntfy img,#ot-sync-ntfy svg,#ot-sync-ntfy button,#ot-sync-ntfy section,#ot-sync-ntfy a,#ot-sync-ntfy label,#ot-sync-ntfy input,#ot-sync-ntfy ul,#ot-sync-ntfy li,#ot-sync-ntfy nav,#ot-sync-ntfy table,#ot-sync-ntfy thead,#ot-sync-ntfy tr,#ot-sync-ntfy td,#ot-sync-ntfy tbody,#ot-sync-ntfy .ot-main-content,#ot-sync-ntfy .ot-toggle,#ot-sync-ntfy #ot-content,#ot-sync-ntfy #ot-pc-content,#ot-sync-ntfy .checkbox{font-family:inherit;font-weight:normal;-webkit-font-smoothing:auto;letter-spacing:normal;line-height:normal;padding:0;margin:0;height:auto;min-height:0;max-height:none;width:auto;min-width:0;max-width:none;border-radius:0;border:none;clear:none;float:none;position:static;bottom:auto;left:auto;right:auto;top:auto;text-align:left;text-decoration:none;text-indent:0;text-shadow:none;text-transform:none;white-space:normal;background:none;overflow:visible;vertical-align:baseline;visibility:visible;z-index:auto;box-shadow:none}#onetrust-banner-sdk label:before,#onetrust-banner-sdk label:after,#onetrust-banner-sdk .checkbox:after,#onetrust-banner-sdk .checkbox:before,#onetrust-pc-sdk label:before,#onetrust-pc-sdk label:after,#onetrust-pc-sdk .checkbox:after,#onetrust-pc-sdk .checkbox:before,#ot-sdk-cookie-policy label:before,#ot-sdk-cookie-policy label:after,#ot-sdk-cookie-policy .checkbox:after,#ot-sdk-cookie-policy .checkbox:before,#ot-sync-ntfy label:before,#ot-sync-ntfy label:after,#ot-sync-ntfy .checkbox:after,#ot-sync-ntfy .checkbox:before{content:"";content:none}#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{position:relative;width:100%;max-width:100%;margin:0 auto;padding:0 20px;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{width:100%;float:left;box-sizing:border-box;padding:0;display:initial}@media(min-width: 400px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:90%;padding:0}}@media(min-width: 550px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:100%}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{margin-left:4%}#onetrust-banner-sdk .ot-sdk-column:first-child,#onetrust-banner-sdk .ot-sdk-columns:first-child,#onetrust-pc-sdk .ot-sdk-column:first-child,#onetrust-pc-sdk .ot-sdk-columns:first-child,#ot-sdk-cookie-policy .ot-sdk-column:first-child,#ot-sdk-cookie-policy .ot-sdk-columns:first-child{margin-left:0}#onetrust-banner-sdk .ot-sdk-two.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-two.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-two.ot-sdk-columns{width:13.3333333333%}#onetrust-banner-sdk .ot-sdk-three.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-three.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-three.ot-sdk-columns{width:22%}#onetrust-banner-sdk .ot-sdk-four.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-four.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-four.ot-sdk-columns{width:30.6666666667%}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eight.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eight.ot-sdk-columns{width:65.3333333333%}#onetrust-banner-sdk .ot-sdk-nine.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-nine.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-nine.ot-sdk-columns{width:74%}#onetrust-banner-sdk .ot-sdk-ten.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-ten.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-ten.ot-sdk-columns{width:82.6666666667%}#onetrust-banner-sdk .ot-sdk-eleven.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eleven.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eleven.ot-sdk-columns{width:91.3333333333%}#onetrust-banner-sdk .ot-sdk-twelve.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-twelve.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-twelve.ot-sdk-columns{width:100%;margin-left:0}}#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6{margin-top:0;font-weight:600;font-family:inherit}#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem;line-height:1.2}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem;line-height:1.25}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem;line-height:1.3}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem;line-height:1.35}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem;line-height:1.5}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem;line-height:1.6}@media(min-width: 550px){#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem}}#onetrust-banner-sdk p,#onetrust-pc-sdk p,#ot-sdk-cookie-policy p{margin:0 0 1em 0;font-family:inherit;line-height:normal}#onetrust-banner-sdk a,#onetrust-pc-sdk a,#ot-sdk-cookie-policy a{color:#565656;text-decoration:underline}#onetrust-banner-sdk a:hover,#onetrust-pc-sdk a:hover,#ot-sdk-cookie-policy a:hover{color:#565656;text-decoration:none}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{display:inline-block;height:38px;padding:0 30px;color:#555;text-align:center;font-size:.9em;font-weight:400;line-height:38px;letter-spacing:.01em;text-decoration:none;white-space:nowrap;background-color:rgba(0,0,0,0);border-radius:2px;border:1px solid #bbb;cursor:pointer;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-button:hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#onetrust-pc-sdk .ot-sdk-button:hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#ot-sdk-cookie-policy .ot-sdk-button:hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus{color:#333;border-color:#888;opacity:.9}#onetrust-banner-sdk .ot-sdk-button:focus,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:focus,#onetrust-pc-sdk .ot-sdk-button:focus,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:focus,#ot-sdk-cookie-policy .ot-sdk-button:focus,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:focus{outline:2px solid #000}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-banner-sdk button.ot-sdk-button-primary,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-pc-sdk button.ot-sdk-button-primary,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary,#ot-sdk-cookie-policy button.ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary{color:#fff;background-color:#33c3f0;border-color:#33c3f0}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-banner-sdk button.ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary:hover,#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-banner-sdk button.ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary:focus,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-pc-sdk button.ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary:hover,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-pc-sdk button.ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary:focus{color:#fff;background-color:#1eaedb;border-color:#1eaedb}#onetrust-banner-sdk input[type=text],#onetrust-pc-sdk input[type=text],#ot-sdk-cookie-policy input[type=text]{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-banner-sdk input[type=text],#onetrust-pc-sdk input[type=text],#ot-sdk-cookie-policy input[type=text]{-webkit-appearance:none;-moz-appearance:none;appearance:none}#onetrust-banner-sdk input[type=text]:focus,#onetrust-pc-sdk input[type=text]:focus,#ot-sdk-cookie-policy input[type=text]:focus{border:1px solid #000;outline:0}#onetrust-banner-sdk label,#onetrust-pc-sdk label,#ot-sdk-cookie-policy label{display:block;margin-bottom:.5rem;font-weight:600}#onetrust-banner-sdk input[type=checkbox],#onetrust-pc-sdk input[type=checkbox],#ot-sdk-cookie-policy input[type=checkbox]{display:inline}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{list-style:circle inside}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{padding-left:0;margin-top:0}#onetrust-banner-sdk ul ul,#onetrust-pc-sdk ul ul,#ot-sdk-cookie-policy ul ul{margin:1.5rem 0 1.5rem 3rem;font-size:90%}#onetrust-banner-sdk li,#onetrust-pc-sdk li,#ot-sdk-cookie-policy li{margin-bottom:1rem}#onetrust-banner-sdk th,#onetrust-banner-sdk td,#onetrust-pc-sdk th,#onetrust-pc-sdk td,#ot-sdk-cookie-policy th,#ot-sdk-cookie-policy td{padding:12px 15px;text-align:left;border-bottom:1px solid #e1e1e1}#onetrust-banner-sdk button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-container:after,#onetrust-banner-sdk .ot-sdk-row:after,#onetrust-pc-sdk .ot-sdk-container:after,#onetrust-pc-sdk .ot-sdk-row:after,#ot-sdk-cookie-policy .ot-sdk-container:after,#ot-sdk-cookie-policy .ot-sdk-row:after{content:"";display:table;clear:both}#onetrust-banner-sdk .ot-sdk-row,#onetrust-pc-sdk .ot-sdk-row,#ot-sdk-cookie-policy .ot-sdk-row{margin:0;max-width:none;display:block}#onetrust-banner-sdk{box-shadow:0 0 18px rgba(0,0,0,.2)}#onetrust-banner-sdk.otFlat{position:fixed;z-index:2147483645;bottom:0;right:0;left:0;background-color:#fff;max-height:90%;overflow-x:hidden;overflow-y:auto}#onetrust-banner-sdk.otFlat.top{top:0px;bottom:auto}#onetrust-banner-sdk.otRelFont{font-size:1rem}#onetrust-banner-sdk>.ot-sdk-container{overflow:hidden}#onetrust-banner-sdk::-webkit-scrollbar{width:11px}#onetrust-banner-sdk::-webkit-scrollbar-thumb{border-radius:10px;background:#c1c1c1}#onetrust-banner-sdk{scrollbar-arrow-color:#c1c1c1;scrollbar-darkshadow-color:#c1c1c1;scrollbar-face-color:#c1c1c1;scrollbar-shadow-color:#c1c1c1}#onetrust-banner-sdk #onetrust-policy{margin:1.25em 0 .625em 2em;overflow:hidden}#onetrust-banner-sdk #onetrust-policy .ot-gv-list-handler{float:left;font-size:.82em;padding:0;margin-bottom:0;border:0;line-height:normal;height:auto;width:auto}#onetrust-banner-sdk #onetrust-policy-title{font-size:1.2em;line-height:1.3;margin-bottom:10px}#onetrust-banner-sdk #onetrust-policy-text{clear:both;text-align:left;font-size:.88em;line-height:1.4}#onetrust-banner-sdk #onetrust-policy-text *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk #onetrust-policy-text a{font-weight:bold;margin-left:5px}#onetrust-banner-sdk #onetrust-policy-title,#onetrust-banner-sdk #onetrust-policy-text{color:dimgray;float:left}#onetrust-banner-sdk #onetrust-button-group-parent{min-height:1px;text-align:center}#onetrust-banner-sdk #onetrust-button-group{display:inline-block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{background-color:#68b631;color:#fff;border-color:#68b631;margin-right:1em;min-width:125px;height:auto;white-space:normal;word-break:break-word;word-wrap:break-word;padding:12px 10px;line-height:1.2;font-size:.813em;font-weight:600}#onetrust-banner-sdk #onetrust-pc-btn-handler.cookie-setting-link{background-color:#fff;border:none;color:#68b631;text-decoration:underline;padding-left:0;padding-right:0}#onetrust-banner-sdk .onetrust-close-btn-ui{width:44px;height:44px;background-size:12px;border:none;position:relative;margin:auto;padding:0}#onetrust-banner-sdk .banner_logo{display:none}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{position:absolute;top:50%;transform:translateY(-50%);left:0px}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-policy{margin-left:65px}#onetrust-banner-sdk .ot-b-addl-desc{clear:both;float:left;display:block}#onetrust-banner-sdk #banner-options{float:left;display:table;margin-right:0;margin-left:1em;width:calc(100% - 1em)}#onetrust-banner-sdk .banner-option-input{cursor:pointer;width:auto;height:auto;border:none;padding:0;padding-right:3px;margin:0 0 10px;font-size:.82em;line-height:1.4}#onetrust-banner-sdk .banner-option-input *{pointer-events:none;font-size:inherit;line-height:inherit}#onetrust-banner-sdk .banner-option-input[aria-expanded=true]~.banner-option-details{display:block;height:auto}#onetrust-banner-sdk .banner-option-input[aria-expanded=true] .ot-arrow-container{transform:rotate(90deg)}#onetrust-banner-sdk .banner-option{margin-bottom:12px;margin-left:0;border:none;float:left;padding:0}#onetrust-banner-sdk .banner-option:first-child{padding-left:2px}#onetrust-banner-sdk .banner-option:not(:first-child){padding:0;border:none}#onetrust-banner-sdk .banner-option-header{cursor:pointer;display:inline-block}#onetrust-banner-sdk .banner-option-header :first-child{color:dimgray;font-weight:bold;float:left}#onetrust-banner-sdk .banner-option-header .ot-arrow-container{display:inline-block;border-top:6px solid rgba(0,0,0,0);border-bottom:6px solid rgba(0,0,0,0);border-left:6px solid dimgray;margin-left:10px;vertical-align:middle}#onetrust-banner-sdk .banner-option-details{display:none;font-size:.83em;line-height:1.5;padding:10px 0px 5px 10px;margin-right:10px;height:0px}#onetrust-banner-sdk .banner-option-details *{font-size:inherit;line-height:inherit;color:dimgray}#onetrust-banner-sdk .ot-arrow-container,#onetrust-banner-sdk .banner-option-details{transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-banner-sdk .ot-dpd-container{float:left}#onetrust-banner-sdk .ot-dpd-title{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-title,#onetrust-banner-sdk .ot-dpd-desc{font-size:.88em;line-height:1.4;color:dimgray}#onetrust-banner-sdk .ot-dpd-title *,#onetrust-banner-sdk .ot-dpd-desc *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text *{margin-bottom:0}#onetrust-banner-sdk.ot-iab-2 .onetrust-vendors-list-handler{display:block;margin-left:0;margin-top:5px;clear:both;margin-bottom:0;padding:0;border:0;height:auto;width:auto}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk.ot-close-btn-link{padding-top:25px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container{top:15px;transform:none;right:15px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container button{padding:0;white-space:pre-wrap;border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em}#onetrust-banner-sdk #onetrust-policy-text,#onetrust-banner-sdk .ot-dpd-desc,#onetrust-banner-sdk .ot-b-addl-desc{font-size:.813em;line-height:1.5}#onetrust-banner-sdk .ot-dpd-desc{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-desc>.ot-b-addl-desc{margin-top:10px;margin-bottom:10px;font-size:1em}@media only screen and (max-width: 425px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:6px;right:2px}#onetrust-banner-sdk #onetrust-policy{margin-left:0;margin-top:3em}#onetrust-banner-sdk #onetrust-button-group{display:block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{width:100%}#onetrust-banner-sdk .onetrust-close-btn-ui{top:auto;transform:none}#onetrust-banner-sdk #onetrust-policy-title{display:inline;float:none}#onetrust-banner-sdk #banner-options{margin:0;padding:0;width:100%}}@media only screen and (min-width: 426px)and (max-width: 896px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:0;right:0}#onetrust-banner-sdk #onetrust-policy{margin-left:1em;margin-right:1em}#onetrust-banner-sdk .onetrust-close-btn-ui{top:10px;right:10px}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:95%}#onetrust-banner-sdk.ot-iab-2 #onetrust-group-container{width:100%}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-button-group-parent{padding-left:50px}#onetrust-banner-sdk #onetrust-button-group-parent{width:100%;position:relative;margin-left:0}#onetrust-banner-sdk #onetrust-button-group button{display:inline-block}#onetrust-banner-sdk #onetrust-button-group{margin-right:0;text-align:center}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler{float:left}#onetrust-banner-sdk .has-reject-all-button #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-accept-btn-handler{float:right}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group{width:calc(100% - 2em);margin-right:0}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler.cookie-setting-link{padding-left:0px;text-align:left}#onetrust-banner-sdk.ot-buttons-fw .ot-sdk-three button{width:100%;text-align:center}#onetrust-banner-sdk.ot-buttons-fw #onetrust-button-group-parent button{float:none}#onetrust-banner-sdk.ot-buttons-fw #onetrust-pc-btn-handler.cookie-setting-link{text-align:center}}@media only screen and (min-width: 550px){#onetrust-banner-sdk .banner-option:not(:first-child){border-left:1px solid #d8d8d8;padding-left:25px}}@media only screen and (min-width: 425px)and (max-width: 550px){#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group,#onetrust-banner-sdk.ot-iab-2 #onetrust-policy,#onetrust-banner-sdk.ot-iab-2 .banner-option{width:100%}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-accept-btn-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-reject-all-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-pc-btn-handler{width:100%}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-accept-btn-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-reject-all-handler{float:left}}@media only screen and (min-width: 769px){#onetrust-banner-sdk #onetrust-button-group{margin-right:30%}#onetrust-banner-sdk #banner-options{margin-left:2em;margin-right:5em;margin-bottom:1.25em;width:calc(100% - 7em)}}@media only screen and (min-width: 897px)and (max-width: 1023px){#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:75%;transform:translateY(-50%)}#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;padding:0;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{position:relative;margin:0;right:-22px;top:2px}}@media only screen and (min-width: 1024px){#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{right:-12px}#onetrust-banner-sdk #onetrust-policy{margin-left:2em}#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:60%;transform:translateY(-50%)}#onetrust-banner-sdk .ot-optout-signal{width:50%}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-title{width:50%}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text,#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:1em;width:50%;border-right:1px solid #d8d8d8;padding-right:1rem}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-container{width:45%;padding-left:1rem;display:inline-block;float:none}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-title{line-height:1.7}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group-parent{left:auto;right:4%;margin-left:0}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:auto;width:30%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:60%}#onetrust-banner-sdk #onetrust-button-group{margin-right:auto}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{margin-top:1em}}@media only screen and (min-width: 890px){#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group-parent{padding-left:3%;padding-right:4%;margin-left:0}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{margin-right:0;margin-top:1.25em;width:100%}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button{width:100%;margin-bottom:5px;margin-top:5px}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type{margin-bottom:20px}}@media only screen and (min-width: 1280px){#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:55%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{width:44%;padding-left:2%;padding-right:2%}#onetrust-banner-sdk:not(.ot-iab-2).vertical-align-content #onetrust-button-group-parent{position:absolute;left:55%}}
        #onetrust-consent-sdk #onetrust-banner-sdk {background-color: #FFF;}
            #onetrust-consent-sdk #onetrust-policy-title,
                    #onetrust-consent-sdk #onetrust-policy-text,
                    #onetrust-consent-sdk .ot-b-addl-desc,
                    #onetrust-consent-sdk .ot-dpd-desc,
                    #onetrust-consent-sdk .ot-dpd-title,
                    #onetrust-consent-sdk #onetrust-policy-text *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk .ot-dpd-desc *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk #onetrust-banner-sdk #banner-options *,
                    #onetrust-banner-sdk .ot-cat-header,
                    #onetrust-banner-sdk .ot-optout-signal
                    {
                        color: #2E2E2E;
                    }
            #onetrust-consent-sdk #onetrust-banner-sdk .banner-option-details {
                    background-color: #E9E9E9;}
             #onetrust-consent-sdk #onetrust-banner-sdk a[href],
                    #onetrust-consent-sdk #onetrust-banner-sdk a[href] font,
                    #onetrust-consent-sdk #onetrust-banner-sdk .ot-link-btn
                        {
                            color: #007398;
                        }#onetrust-consent-sdk #onetrust-accept-btn-handler,
                         #onetrust-banner-sdk #onetrust-reject-all-handler {
                            background-color: #007398;border-color: #007398;
                color: #FFF;
            }
            #onetrust-consent-sdk #onetrust-banner-sdk *:focus,
            #onetrust-consent-sdk #onetrust-banner-sdk:focus {
               outline-color: #000000;
               outline-width: 1px;
            }
            #onetrust-consent-sdk #onetrust-pc-btn-handler,
            #onetrust-consent-sdk #onetrust-pc-btn-handler.cookie-setting-link {
                color: #6CC04A; border-color: #6CC04A;
                background-color:
                #FFF;
            }/*! v6.10.0 2021-01-18 */
div#onetrust-consent-sdk #onetrust-banner-sdk{border-top:2px solid #d0d3d4!important;box-shadow:none;padding:24px}div#onetrust-consent-sdk button{border-radius:0!important;box-shadow:none!important;box-sizing:border-box!important;font-size:20px!important;font-weight:400!important;letter-spacing:0!important;max-width:none!important;white-space:nowrap!important}div#onetrust-consent-sdk button:not(.ot-link-btn){background-color:#007dbc!important;border:2px solid #007dbc!important;color:#fff!important;height:48px!important;padding:0 1em!important;width:auto!important}div#onetrust-consent-sdk button:hover{background-color:#fff!important;border-color:#949494!important;color:#2e2e2e!important}div#onetrust-consent-sdk button.ot-link-btn{color:#007dbc!important;font-size:16px!important;text-decoration:underline}div#onetrust-consent-sdk button.ot-link-btn:hover{color:inherit!important;text-decoration-color:#949494!important}div#onetrust-consent-sdk a,div#onetrust-pc-sdk a{color:#007dbc!important;text-decoration:underline!important}div#onetrust-consent-sdk a,div#onetrust-consent-sdk button,div#onetrust-consent-sdk p:hover{opacity:1!important}div#onetrust-consent-sdk a:focus,div#onetrust-consent-sdk button:focus,div#onetrust-consent-sdk input:focus{outline:2px solid #949494!important;outline-offset:1px!important}div#onetrust-banner-sdk .ot-sdk-container{padding:0;width:auto}div#onetrust-banner-sdk .ot-sdk-row{align-items:flex-start;box-sizing:border-box;display:flex;flex-direction:column;justify-content:space-between;margin:auto;max-width:1152px}div#onetrust-banner-sdk .ot-sdk-row:after{display:none}div#onetrust-banner-sdk #onetrust-group-container,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-group-container,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{flex-grow:1;width:auto}div#onetrust-banner-sdk #onetrust-policy,div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy{margin:0;overflow:visible}div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy-text,div#onetrust-consent-sdk #onetrust-policy-text{font-size:16px;line-height:24px;max-width:44em;margin:0}div#onetrust-consent-sdk #onetrust-policy-text a[href]{font-weight:400;margin-left:8px}div#onetrust-banner-sdk #onetrust-button-group-parent{flex:0 0 auto;margin:32px 0 0;width:100%}div#onetrust-banner-sdk #onetrust-button-group{display:flex;flex-direction:row;flex-wrap:wrap;justify-content:flex-end;margin:-8px}div#onetrust-banner-sdk .banner-actions-container{display:flex;flex:1 0 auto}div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type,div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto;margin:8px;width:auto}div#onetrust-consent-sdk #onetrust-pc-btn-handler{background-color:#fff!important;color:inherit!important}div#onetrust-banner-sdk #onetrust-close-btn-container{display:none}@media only screen and (min-width:556px){div#onetrust-consent-sdk #onetrust-banner-sdk{padding:40px}div#onetrust-banner-sdk #onetrust-policy{margin:0 40px 0 0}div#onetrust-banner-sdk .ot-sdk-row{align-items:center;flex-direction:row}div#onetrust-banner-sdk #onetrust-button-group-parent,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-button-group-parent,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:0;padding:0;width:auto}div#onetrust-banner-sdk #onetrust-button-group,div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{align-items:stretch;flex-direction:column-reverse;margin:0}div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto}}@media only screen and (min-width:768px){div#onetrust-banner-sdk #onetrust-policy{margin:0 48px 0 0}div#onetrust-consent-sdk #onetrust-banner-sdk{padding:48px}}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-size:16px;line-height:24px}div#onetrust-consent-sdk #onetrust-pc-sdk p,div#onetrust-pc-sdk #ot-pc-desc,div#onetrust-pc-sdk .category-host-list-handler,div#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{font-size:16px;font-weight:400;line-height:24px}div#onetrust-consent-sdk a:hover,div#onetrust-pc-sdk a:hover{color:inherit!important;text-decoration-color:#949494!important}div#onetrust-pc-sdk{border-radius:0;bottom:0;height:auto;left:0;margin:auto;max-width:100%;overflow:hidden;right:0;top:0;width:512px;max-height:800px}div#onetrust-pc-sdk .ot-pc-header{display:none}div#onetrust-pc-sdk #ot-pc-content{overscroll-behavior:contain;padding:0 12px 0 24px;margin:16px 4px 0 0;top:0;right:16px;left:0;width:auto}div#onetrust-pc-sdk #ot-category-title,div#onetrust-pc-sdk #ot-pc-title{font-size:24px;font-weight:400;line-height:32px;margin:0 0 16px}div#onetrust-pc-sdk #ot-pc-desc{padding:0}div#onetrust-pc-sdk #ot-pc-desc a{display:inline}div#onetrust-pc-sdk #accept-recommended-btn-handler{display:none!important}div#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:2px solid #007dbc;outline-offset:-1px;transition:none}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{border-width:0 0 2px}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{border-width:2px 0}div#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding:8px 0;width:100%}div#onetrust-pc-sdk .ot-plus-minus{transform:translateY(2px)}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button{background:0 0!important;border:0!important;height:44px!important;max-width:none!important;width:calc(100% - 48px)!important}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-weight:700}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding:0}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item .ot-acc-grpdesc{padding:0;width:100%}div#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border:0;padding:0}div#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp{margin:0}div#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:calc(100% - 160px)}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{width:calc(100% - 88px)}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{color:inherit;font-size:12px;font-weight:400;line-height:1.5;padding-right:48px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:before{border-radius:12px;position:absolute;right:0;top:0;content:'';background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:after{border-radius:50%;position:absolute;right:5px;top:4px;content:'';background-color:#007dbc;height:12px;width:12px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active,div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl{right:2px}div#onetrust-pc-sdk .ot-switch{display:block;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob,div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob:before{background-color:#737373;height:8px;left:4px;top:4px;width:8px}div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{background-color:#007dbc;height:12px;left:0;top:2px;width:12px}div#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch .ot-switch-nob{box-shadow:0 0;outline:2px solid #007dbc!important;outline-offset:1px;transition:none}div#onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt{background-color:transparent;padding-left:3px}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr,div#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr{overflow:visible;width:100%}div#onetrust-pc-sdk .ot-pc-footer{border-top:0 solid}div#onetrust-pc-sdk .ot-btn-container{padding-top:24px;text-align:center}div#onetrust-pc-sdk .ot-pc-footer button{margin:8px 0;background-color:#fff}div#onetrust-pc-sdk .ot-pc-footer-logo{background-color:#fff}div#onetrust-pc-sdk #ot-lst-title span{font-size:24px;font-weight:400;line-height:32px}div#onetrust-pc-sdk #ot-host-lst .ot-host-desc,div#onetrust-pc-sdk #ot-host-lst .ot-host-expand,div#onetrust-pc-sdk #ot-host-lst .ot-host-name,div#onetrust-pc-sdk #ot-host-lst .ot-host-name a,div#onetrust-pc-sdk .back-btn-handler,div#onetrust-pc-sdk .ot-host-opt li>div div{font-size:16px;font-weight:400;line-height:24px}div#onetrust-pc-sdk #ot-pc-lst{top:0}div#onetrust-pc-sdk .back-btn-handler{text-decoration:none!important}div#onetrust-pc-sdk #filter-btn-handler:hover svg{filter:invert(1)}div#onetrust-pc-sdk .back-btn-handler svg{width:16px;height:16px}div#onetrust-pc-sdk .ot-host-item>button{background:0 0!important;border:0!important;height:66px!important;max-width:none!important;width:calc(100% - 5px)!important;transform:translate(2px,2px)}div#onetrust-pc-sdk .ot-host-item{border-bottom:2px solid #b9b9b9;padding:0}div#onetrust-pc-sdk .ot-host-item .ot-acc-hdr{margin:0 0 -6px;padding:8px 0}div#onetrust-pc-sdk ul li:first-child{border-top:2px solid #b9b9b9}div#onetrust-pc-sdk .ot-host-item .ot-plus-minus{margin:0 8px 0 0}div#onetrust-pc-sdk .ot-search-cntr{width:calc(100% - 48px)}div#onetrust-pc-sdk .ot-host-opt .ot-host-info{background-color:transparent}div#onetrust-pc-sdk .ot-host-opt li>div div{padding:0}div#onetrust-pc-sdk #vendor-search-handler{border-radius:0;border-color:#939393;border-style:solid;border-width:2px 0 2px 2px;font-size:20px;height:48px;margin:0}div#onetrust-pc-sdk .ot-lst-subhdr svg{right:0;top:8px}div#onetrust-pc-sdk .ot-fltr-cntr{box-sizing:border-box;right:0;width:48px}div#onetrust-pc-sdk #filter-btn-handler{width:48px!important;padding:8px!important}div#onetrust-pc-sdk #ot-fltr-modal{max-height:400px}
#onetrust-pc-sdk.otPcCenter{overflow:hidden;position:fixed;margin:0 auto;top:5%;right:0;left:0;width:40%;max-width:575px;min-width:575px;border-radius:2.5px;z-index:2147483647;background-color:#fff;-webkit-box-shadow:0px 2px 10px -3px #999;-moz-box-shadow:0px 2px 10px -3px #999;box-shadow:0px 2px 10px -3px #999}#onetrust-pc-sdk.otPcCenter[dir=rtl]{right:0;left:0}#onetrust-pc-sdk.otRelFont{font-size:1rem}#onetrust-pc-sdk .ot-optout-signal{margin-top:.625rem}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus,#onetrust-pc-sdk .ot-hide-tgl{visibility:hidden}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr *,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus *,#onetrust-pc-sdk .ot-hide-tgl *{visibility:hidden}#onetrust-pc-sdk #ot-gn-venlst .ot-ven-item .ot-acc-hdr{min-height:40px}#onetrust-pc-sdk .ot-pc-header{height:39px;padding:10px 0 10px 30px;border-bottom:1px solid #e9e9e9}#onetrust-pc-sdk #ot-pc-title,#onetrust-pc-sdk #ot-category-title,#onetrust-pc-sdk .ot-cat-header,#onetrust-pc-sdk #ot-lst-title,#onetrust-pc-sdk .ot-ven-hdr .ot-ven-name,#onetrust-pc-sdk .ot-always-active{font-weight:bold;color:dimgray}#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:55%;font-weight:700}#onetrust-pc-sdk .ot-cat-item p{clear:both;float:left;margin-top:10px;margin-bottom:5px;line-height:1.5;font-size:.812em;color:dimgray}#onetrust-pc-sdk .ot-close-icon{height:44px;width:44px;background-size:10px}#onetrust-pc-sdk #ot-pc-title{float:left;font-size:1em;line-height:1.5;margin-bottom:10px;margin-top:10px;width:100%}#onetrust-pc-sdk #accept-recommended-btn-handler{margin-right:10px;margin-bottom:25px;outline-offset:-1px}#onetrust-pc-sdk #ot-pc-desc{clear:both;width:100%;font-size:.812em;line-height:1.5;margin-bottom:25px}#onetrust-pc-sdk #ot-pc-desc *{font-size:inherit;line-height:inherit}#onetrust-pc-sdk #ot-pc-desc ul li{padding:10px 0px}#onetrust-pc-sdk a{color:#656565;cursor:pointer}#onetrust-pc-sdk a:hover{color:#3860be}#onetrust-pc-sdk label{margin-bottom:0}#onetrust-pc-sdk #vdr-lst-dsc{font-size:.812em;line-height:1.5;padding:10px 15px 5px 15px}#onetrust-pc-sdk button{max-width:394px;padding:12px 30px;line-height:1;word-break:break-word;word-wrap:break-word;white-space:normal;font-weight:bold;height:auto}#onetrust-pc-sdk .ot-link-btn{padding:0;margin-bottom:0;border:0;font-weight:normal;line-height:normal;width:auto;height:auto}#onetrust-pc-sdk #ot-pc-content{position:absolute;overflow-y:scroll;padding-left:2px;padding-right:30px;top:60px;bottom:110px;margin:1px 3px 0 30px;width:calc(100% - 63px)}#onetrust-pc-sdk .ot-vs-list .ot-always-active,#onetrust-pc-sdk .ot-cat-grp .ot-always-active{float:right;clear:none;color:#3860be;margin:0;font-size:.813em;line-height:1.3}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-track{margin-right:20px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar{width:11px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-thumb{border-radius:10px;background:#d8d8d8}#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:#000 1px solid}#onetrust-pc-sdk .ot-pc-scrollbar{scrollbar-arrow-color:#d8d8d8;scrollbar-darkshadow-color:#d8d8d8;scrollbar-face-color:#d8d8d8;scrollbar-shadow-color:#d8d8d8}#onetrust-pc-sdk .save-preference-btn-handler{margin-right:20px}#onetrust-pc-sdk .ot-pc-refuse-all-handler{margin-right:10px}#onetrust-pc-sdk #ot-pc-desc .privacy-notice-link{margin-left:0;margin-right:8px}#onetrust-pc-sdk #ot-pc-desc .ot-imprint-handler{margin-left:0;margin-right:8px}#onetrust-pc-sdk .ot-subgrp-cntr{display:inline-block;clear:both;width:100%;padding-top:15px}#onetrust-pc-sdk .ot-switch+.ot-subgrp-cntr{padding-top:10px}#onetrust-pc-sdk ul.ot-subgrps{margin:0;font-size:initial}#onetrust-pc-sdk ul.ot-subgrps li p,#onetrust-pc-sdk ul.ot-subgrps li h5{font-size:.813em;line-height:1.4;color:dimgray}#onetrust-pc-sdk ul.ot-subgrps .ot-switch{min-height:auto}#onetrust-pc-sdk ul.ot-subgrps .ot-switch-nob{top:0}#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr{display:inline-block;width:100%}#onetrust-pc-sdk ul.ot-subgrps .ot-acc-txt{margin:0}#onetrust-pc-sdk ul.ot-subgrps li{padding:0;border:none}#onetrust-pc-sdk ul.ot-subgrps li h5{position:relative;top:5px;font-weight:bold;margin-bottom:0;float:left}#onetrust-pc-sdk li.ot-subgrp{margin-left:20px;overflow:auto}#onetrust-pc-sdk li.ot-subgrp>h5{width:calc(100% - 100px)}#onetrust-pc-sdk .ot-cat-item p>ul,#onetrust-pc-sdk li.ot-subgrp p>ul{margin:0px;list-style:disc;margin-left:15px;font-size:inherit}#onetrust-pc-sdk .ot-cat-item p>ul li,#onetrust-pc-sdk li.ot-subgrp p>ul li{font-size:inherit;padding-top:10px;padding-left:0px;padding-right:0px;border:none}#onetrust-pc-sdk .ot-cat-item p>ul li:last-child,#onetrust-pc-sdk li.ot-subgrp p>ul li:last-child{padding-bottom:10px}#onetrust-pc-sdk .ot-pc-logo{height:40px;width:120px}#onetrust-pc-sdk .ot-pc-footer{position:absolute;bottom:0px;width:100%;max-height:160px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-refuse-all-handler{margin-bottom:0px}#onetrust-pc-sdk.ot-ftr-stacked #ot-pc-content{bottom:160px}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-footer button{width:100%;max-width:none}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container{margin:0 30px;width:calc(100% - 60px);padding-right:0}#onetrust-pc-sdk .ot-pc-footer-logo{height:30px;width:100%;text-align:right;background:#f4f4f4}#onetrust-pc-sdk .ot-pc-footer-logo a{display:inline-block;margin-top:5px;margin-right:10px}#onetrust-pc-sdk[dir=rtl] .ot-pc-footer-logo{direction:rtl}#onetrust-pc-sdk[dir=rtl] .ot-pc-footer-logo a{margin-right:25px}#onetrust-pc-sdk .ot-tgl{float:right;position:relative;z-index:1}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background-color:#468254;border:1px solid #fff}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{-webkit-transform:translateX(20px);-ms-transform:translateX(20px);transform:translateX(20px);background-color:#fff;border-color:#fff}#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch{outline:#000 solid 1px}#onetrust-pc-sdk .ot-switch{position:relative;display:inline-block;width:45px;height:25px}#onetrust-pc-sdk .ot-switch-nob{position:absolute;cursor:pointer;top:0;left:0;right:0;bottom:0;background-color:#767676;border:1px solid #ddd;transition:all .2s ease-in 0s;-moz-transition:all .2s ease-in 0s;-o-transition:all .2s ease-in 0s;-webkit-transition:all .2s ease-in 0s;border-radius:20px}#onetrust-pc-sdk .ot-switch-nob:before{position:absolute;content:"";height:18px;width:18px;bottom:3px;left:3px;background-color:#fff;-webkit-transition:.4s;transition:.4s;border-radius:20px}#onetrust-pc-sdk .ot-chkbox input:checked~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input:checked+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk .ot-chkbox input[aria-checked=mixed]~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input[aria-checked=mixed]+label::after{content:""}#onetrust-pc-sdk .ot-chkbox label{position:relative;display:inline-block;padding-left:30px;cursor:pointer;font-weight:500}#onetrust-pc-sdk .ot-chkbox label::before,#onetrust-pc-sdk .ot-chkbox label::after{position:absolute;content:"";display:inline-block;border-radius:3px}#onetrust-pc-sdk .ot-chkbox label::before{height:18px;width:18px;border:1px solid #3860be;left:0px;top:auto}#onetrust-pc-sdk .ot-chkbox label::after{height:5px;width:9px;border-left:3px solid;border-bottom:3px solid;transform:rotate(-45deg);-o-transform:rotate(-45deg);-ms-transform:rotate(-45deg);-webkit-transform:rotate(-45deg);left:4px;top:5px}#onetrust-pc-sdk .ot-label-txt{display:none}#onetrust-pc-sdk .ot-chkbox input,#onetrust-pc-sdk .ot-tgl input{position:absolute;opacity:0;width:0;height:0}#onetrust-pc-sdk .ot-arw-cntr{float:right;position:relative;pointer-events:none}#onetrust-pc-sdk .ot-arw-cntr .ot-arw{width:16px;height:16px;margin-left:5px;color:dimgray;display:inline-block;vertical-align:middle;-webkit-transition:all 150ms ease-in 0s;-moz-transition:all 150ms ease-in 0s;-o-transition:all 150ms ease-in 0s;transition:all 150ms ease-in 0s}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw-cntr svg{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:#000 1px solid}#onetrust-pc-sdk .ot-tgl-cntr,#onetrust-pc-sdk .ot-arw-cntr{display:inline-block}#onetrust-pc-sdk .ot-tgl-cntr{width:45px;float:right;margin-top:2px}#onetrust-pc-sdk #ot-lst-cnt .ot-tgl-cntr{margin-top:10px}#onetrust-pc-sdk .ot-always-active-subgroup{width:auto;padding-left:0px !important;top:3px;position:relative}#onetrust-pc-sdk .ot-label-status{font-size:.75em;display:none;font-size:.75em;position:relative;top:2px;padding-right:5px;float:left}#onetrust-pc-sdk .ot-arw-cntr{margin-top:-1px}#onetrust-pc-sdk .ot-arw-cntr svg{-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s;transition:all 300ms ease-in 0s;height:10px;width:10px}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk .ot-arw{width:10px;margin-left:15px;transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-pc-sdk .ot-vlst-cntr{margin-bottom:0}#onetrust-pc-sdk .ot-hlst-cntr{margin-top:5px;display:inline-block;width:100%}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a,#onetrust-pc-sdk .category-host-list-handler{clear:both;color:#3860be;margin-left:0;font-size:.813em;text-decoration:none;float:left;overflow:hidden}#onetrust-pc-sdk .category-vendors-list-handler:hover,#onetrust-pc-sdk .category-vendors-list-handler+a:hover,#onetrust-pc-sdk .category-host-list-handler:hover{text-decoration-line:underline}#onetrust-pc-sdk .category-vendors-list-handler+a{clear:none}#onetrust-pc-sdk .ot-vlst-cntr .ot-ext-lnk,#onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{display:inline-block;height:13px;width:13px;background-repeat:no-repeat;margin-left:1px;margin-top:6px;cursor:pointer}#onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{margin-bottom:-1px}#onetrust-pc-sdk .back-btn-handler{font-size:1em;text-decoration:none}#onetrust-pc-sdk .back-btn-handler:hover{opacity:.6}#onetrust-pc-sdk #ot-lst-title h3{display:inline-block;word-break:break-word;word-wrap:break-word;margin-bottom:0;color:#656565;font-size:1em;font-weight:bold;margin-left:15px}#onetrust-pc-sdk #ot-lst-title{margin:10px 0 10px 0px;font-size:1em;text-align:left}#onetrust-pc-sdk #ot-pc-hdr{margin:0 0 0 30px;height:auto;width:auto}#onetrust-pc-sdk #ot-pc-hdr input::placeholder{color:#707070;font-style:italic}#onetrust-pc-sdk #vendor-search-handler{height:31px;width:100%;border-radius:50px;font-size:.8em;padding-right:35px;padding-left:15px;float:left;margin-left:15px}#onetrust-pc-sdk .ot-ven-name{display:block;width:auto;padding-right:5px}#onetrust-pc-sdk #ot-lst-cnt{overflow-y:auto;margin-left:20px;margin-right:7px;width:calc(100% - 27px);max-height:calc(100% - 80px);height:100%;transform:translate3d(0, 0, 0)}#onetrust-pc-sdk #ot-pc-lst{width:100%;bottom:100px;position:absolute;top:60px}#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr *{visibility:hidden}#onetrust-pc-sdk #ot-pc-lst .ot-tgl-cntr{right:12px;position:absolute}#onetrust-pc-sdk #ot-pc-lst .ot-arw-cntr{float:right;position:relative}#onetrust-pc-sdk #ot-pc-lst .ot-arw{margin-left:10px}#onetrust-pc-sdk #ot-pc-lst .ot-acc-hdr{overflow:hidden;cursor:pointer}#onetrust-pc-sdk .ot-vlst-cntr{overflow:hidden}#onetrust-pc-sdk #ot-sel-blk{overflow:hidden;width:100%;position:sticky;position:-webkit-sticky;top:0;z-index:3}#onetrust-pc-sdk #ot-back-arw{height:12px;width:12px}#onetrust-pc-sdk .ot-lst-subhdr{width:100%;display:inline-block}#onetrust-pc-sdk .ot-search-cntr{float:left;width:78%;position:relative}#onetrust-pc-sdk .ot-search-cntr>svg{width:30px;height:30px;position:absolute;float:left;right:-15px}#onetrust-pc-sdk .ot-fltr-cntr{float:right;right:50px;position:relative}#onetrust-pc-sdk #filter-btn-handler{background-color:#3860be;border-radius:17px;display:inline-block;position:relative;width:32px;height:32px;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease;padding:0;margin:0}#onetrust-pc-sdk #filter-btn-handler:hover{background-color:#3860be}#onetrust-pc-sdk #filter-btn-handler svg{width:12px;height:12px;margin:3px 10px 0 10px;display:block;position:static;right:auto;top:auto}#onetrust-pc-sdk .ot-ven-link,#onetrust-pc-sdk .ot-ven-legclaim-link{color:#3860be;text-decoration:none;font-weight:100;display:inline-block;padding-top:10px;transform:translate(0, 1%);-o-transform:translate(0, 1%);-ms-transform:translate(0, 1%);-webkit-transform:translate(0, 1%);position:relative;z-index:2}#onetrust-pc-sdk .ot-ven-link *,#onetrust-pc-sdk .ot-ven-legclaim-link *{font-size:inherit}#onetrust-pc-sdk .ot-ven-link:hover,#onetrust-pc-sdk .ot-ven-legclaim-link:hover{text-decoration:underline}#onetrust-pc-sdk .ot-ven-hdr{width:calc(100% - 160px);height:auto;float:left;word-break:break-word;word-wrap:break-word;vertical-align:middle;padding-bottom:3px}#onetrust-pc-sdk .ot-ven-link,#onetrust-pc-sdk .ot-ven-legclaim-link{letter-spacing:.03em;font-size:.75em;font-weight:400}#onetrust-pc-sdk .ot-ven-dets{border-radius:2px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-ven-dets li:first-child p:first-child{border-top:none}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:not(:first-child){border-top:1px solid #ddd !important}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(odd){width:30%}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(even){width:50%;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p,#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h5{padding-top:5px;padding-bottom:5px;display:block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h5{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p:nth-last-child(-n+1){padding-bottom:10px}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p:nth-child(-n+2):not(.disc-pur){padding-top:10px}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur-cont{display:inline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur{position:relative;width:50% !important;word-break:break-word;word-wrap:break-word;left:calc(30% + 17px)}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur:nth-child(-n+1){position:static}#onetrust-pc-sdk .ot-ven-dets p,#onetrust-pc-sdk .ot-ven-dets h5,#onetrust-pc-sdk .ot-ven-dets span{font-size:.69em;text-align:left;vertical-align:middle;word-break:break-word;word-wrap:break-word;margin:0;padding-bottom:10px;padding-left:15px;color:#2e3644}#onetrust-pc-sdk .ot-ven-dets h5{padding-top:5px}#onetrust-pc-sdk .ot-ven-dets span{color:dimgray;padding:0;vertical-align:baseline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-pur h5{border-top:1px solid #e9e9e9;border-bottom:1px solid #e9e9e9;padding-bottom:5px;margin-bottom:5px;font-weight:bold}#onetrust-pc-sdk #ot-host-lst .ot-sel-all{float:right;position:relative;margin-right:42px;top:10px}#onetrust-pc-sdk #ot-host-lst .ot-sel-all input[type=checkbox]{width:auto;height:auto}#onetrust-pc-sdk #ot-host-lst .ot-sel-all label{height:20px;width:20px;padding-left:0px}#onetrust-pc-sdk #ot-host-lst .ot-acc-txt{overflow:hidden;width:95%}#onetrust-pc-sdk .ot-host-hdr{position:relative;z-index:1;pointer-events:none;width:calc(100% - 125px);float:left}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-desc{display:inline-block;width:90%}#onetrust-pc-sdk .ot-host-name{pointer-events:none}#onetrust-pc-sdk .ot-host-hdr>a{text-decoration:underline;font-size:.82em;position:relative;z-index:2;float:left;margin-bottom:5px;pointer-events:initial}#onetrust-pc-sdk .ot-host-name+a{margin-top:5px}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-name a,#onetrust-pc-sdk .ot-host-desc,#onetrust-pc-sdk .ot-host-info{color:dimgray;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-name a{font-weight:bold;font-size:.82em;line-height:1.3}#onetrust-pc-sdk .ot-host-name a{font-size:1em}#onetrust-pc-sdk .ot-host-expand{margin-top:3px;margin-bottom:3px;clear:both;display:block;color:#3860be;font-size:.72em;font-weight:normal}#onetrust-pc-sdk .ot-host-expand *{font-size:inherit}#onetrust-pc-sdk .ot-host-desc,#onetrust-pc-sdk .ot-host-info{font-size:.688em;line-height:1.4;font-weight:normal}#onetrust-pc-sdk .ot-host-desc{margin-top:10px}#onetrust-pc-sdk .ot-host-opt{margin:0;font-size:inherit;display:inline-block;width:100%}#onetrust-pc-sdk .ot-host-opt li>div div{font-size:.8em;padding:5px 0}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(1){width:30%;float:left}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(2){width:70%;float:left;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-host-info{border:none;display:inline-block;width:calc(100% - 10px);padding:10px;margin-bottom:10px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-host-info>div{overflow:auto}#onetrust-pc-sdk #no-results{text-align:center;margin-top:30px}#onetrust-pc-sdk #no-results p{font-size:1em;color:#2e3644;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk #no-results p span{font-weight:bold}#onetrust-pc-sdk #ot-fltr-modal{width:100%;height:auto;display:none;-moz-transition:.2s ease;-o-transition:.2s ease;-webkit-transition:2s ease;transition:.2s ease;overflow:hidden;opacity:1;right:0}#onetrust-pc-sdk #ot-fltr-modal .ot-label-txt{display:inline-block;font-size:.85em;color:dimgray}#onetrust-pc-sdk #ot-fltr-cnt{z-index:2147483646;background-color:#fff;position:absolute;height:90%;max-height:300px;width:325px;left:210px;margin-top:10px;margin-bottom:20px;padding-right:10px;border-radius:3px;-webkit-box-shadow:0px 0px 12px 2px #c7c5c7;-moz-box-shadow:0px 0px 12px 2px #c7c5c7;box-shadow:0px 0px 12px 2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-scrlcnt{overflow-y:auto;overflow-x:hidden;clear:both;max-height:calc(100% - 60px)}#onetrust-pc-sdk #ot-anchor{border:12px solid rgba(0,0,0,0);display:none;position:absolute;z-index:2147483647;right:55px;top:75px;transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);-webkit-transform:rotate(45deg);background-color:#fff;-webkit-box-shadow:-3px -3px 5px -2px #c7c5c7;-moz-box-shadow:-3px -3px 5px -2px #c7c5c7;box-shadow:-3px -3px 5px -2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-btns{margin-left:15px}#onetrust-pc-sdk #filter-apply-handler{margin-right:15px}#onetrust-pc-sdk .ot-fltr-opt{margin-bottom:5px;margin-left:15px;min-height:20px;width:75%;position:relative}#onetrust-pc-sdk .ot-fltr-opt p{display:inline-block;margin:0;font-size:.9em;color:#2e3644}#onetrust-pc-sdk .ot-chkbox label span{font-size:.85em;color:dimgray}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]:checked+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input[type=checkbox][aria-checked=mixed]+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk #ot-selall-vencntr,#onetrust-pc-sdk #ot-selall-adtlvencntr,#onetrust-pc-sdk #ot-selall-hostcntr,#onetrust-pc-sdk #ot-selall-licntr,#onetrust-pc-sdk #ot-selall-gnvencntr{right:15px;position:relative;width:20px;height:20px;float:right}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label,#onetrust-pc-sdk #ot-selall-hostcntr label,#onetrust-pc-sdk #ot-selall-licntr label,#onetrust-pc-sdk #ot-selall-gnvencntr label{float:left;padding-left:0}#onetrust-pc-sdk #ot-ven-lst:first-child{border-top:1px solid #e2e2e2}#onetrust-pc-sdk ul{list-style:none;padding:0}#onetrust-pc-sdk ul li{position:relative;margin:0;padding:15px 15px 15px 10px;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk ul li h3,#onetrust-pc-sdk ul li h4{font-size:.75em;color:#656565;margin:0;display:inline-block;width:70%;height:auto;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk ul li p{margin:0;font-size:.7em}#onetrust-pc-sdk ul li input[type=checkbox]{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0}#onetrust-pc-sdk .ot-cat-item>button:focus,#onetrust-pc-sdk .ot-acc-cntr>button:focus,#onetrust-pc-sdk li>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-cat-item>button,#onetrust-pc-sdk .ot-acc-cntr>button,#onetrust-pc-sdk li>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk li>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk li>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=true]~.ot-acc-grpcntr,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-grpcntr,#onetrust-pc-sdk li>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-host-item>button:focus,#onetrust-pc-sdk .ot-ven-item>button:focus{outline:0;border:2px solid #000}#onetrust-pc-sdk .ot-hide-acc>button{pointer-events:none}#onetrust-pc-sdk .ot-hide-acc .ot-plus-minus>*,#onetrust-pc-sdk .ot-hide-acc .ot-arw-cntr>*{visibility:hidden}#onetrust-pc-sdk .ot-hide-acc .ot-acc-hdr{min-height:30px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt){padding-right:10px;width:calc(100% - 37px);margin-top:10px;max-height:calc(100% - 90px)}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk{background-color:#f9f9fc;border:1px solid #e2e2e2;width:calc(100% - 2px);padding-bottom:5px;padding-top:5px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt{border:unset;background-color:unset}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all-hdr{display:none}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all{padding-right:.5rem}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all .ot-chkbox{right:0}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all{padding-right:34px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all-chkbox{width:auto}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) ul li{border:1px solid #e2e2e2;margin-bottom:10px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-acc-cntr>.ot-acc-hdr{padding:10px 0 10px 15px}#onetrust-pc-sdk.ot-addtl-vendors .ot-sel-all-chkbox{float:right}#onetrust-pc-sdk.ot-addtl-vendors .ot-plus-minus~.ot-sel-all-chkbox{right:34px}#onetrust-pc-sdk.ot-addtl-vendors #ot-ven-lst:first-child{border-top:none}#onetrust-pc-sdk .ot-acc-cntr{position:relative;border-left:1px solid #e2e2e2;border-right:1px solid #e2e2e2;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr input{z-index:1}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr{background-color:#f9f9fc;padding:5px 0 5px 15px;width:auto}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-plus-minus{vertical-align:middle;top:auto}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-arw-cntr{right:10px}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr input{z-index:2}#onetrust-pc-sdk .ot-acc-cntr.ot-add-tech .ot-acc-hdr{padding:10px 0 10px 15px}#onetrust-pc-sdk .ot-acc-cntr>input[type=checkbox]:checked~.ot-acc-hdr{border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-txt{padding-left:10px;padding-right:10px}#onetrust-pc-sdk .ot-acc-cntr button[aria-expanded=true]~.ot-acc-txt{width:auto}#onetrust-pc-sdk .ot-acc-cntr .ot-addtl-venbox{display:none}#onetrust-pc-sdk .ot-vlst-cntr{margin-bottom:0;width:100%}#onetrust-pc-sdk .ot-vensec-title{font-size:.813em;vertical-align:middle;display:inline-block}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a{margin-left:0;margin-top:10px}#onetrust-pc-sdk #ot-selall-vencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-adtlvencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-licntr.line-through label::after,#onetrust-pc-sdk #ot-selall-hostcntr.line-through label::after,#onetrust-pc-sdk #ot-selall-gnvencntr.line-through label::after{height:auto;border-left:0;transform:none;-o-transform:none;-ms-transform:none;-webkit-transform:none;left:5px;top:9px}#onetrust-pc-sdk #ot-category-title{float:left;padding-bottom:10px;font-size:1em;width:100%}#onetrust-pc-sdk .ot-cat-grp{margin-top:10px}#onetrust-pc-sdk .ot-cat-item{line-height:1.1;margin-top:10px;display:inline-block;width:100%}#onetrust-pc-sdk .ot-btn-container{text-align:right}#onetrust-pc-sdk .ot-btn-container button{display:inline-block;font-size:.75em;letter-spacing:.08em;margin-top:19px}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon{position:absolute;top:10px;right:0;z-index:1;padding:0;background-color:rgba(0,0,0,0);border:none}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon svg{display:block;height:10px;width:10px}#onetrust-pc-sdk #clear-filters-handler{margin-top:20px;margin-bottom:10px;float:right;max-width:200px;text-decoration:none;color:#3860be;font-size:.9em;font-weight:bold;background-color:rgba(0,0,0,0);border-color:rgba(0,0,0,0);padding:1px}#onetrust-pc-sdk #clear-filters-handler:hover{color:#2285f7}#onetrust-pc-sdk #clear-filters-handler:focus{outline:#000 solid 1px}#onetrust-pc-sdk .ot-enbl-chr h4~.ot-tgl,#onetrust-pc-sdk .ot-enbl-chr h4~.ot-always-active{right:45px}#onetrust-pc-sdk .ot-enbl-chr h4~.ot-tgl+.ot-tgl{right:120px}#onetrust-pc-sdk .ot-enbl-chr .ot-pli-hdr.ot-leg-border-color span:first-child{width:90px}#onetrust-pc-sdk .ot-enbl-chr li.ot-subgrp>h5+.ot-tgl-cntr{padding-right:25px}#onetrust-pc-sdk .ot-plus-minus{width:20px;height:20px;font-size:1.5em;position:relative;display:inline-block;margin-right:5px;top:3px}#onetrust-pc-sdk .ot-plus-minus span{position:absolute;background:#27455c;border-radius:1px}#onetrust-pc-sdk .ot-plus-minus span:first-of-type{top:25%;bottom:25%;width:10%;left:45%}#onetrust-pc-sdk .ot-plus-minus span:last-of-type{left:25%;right:25%;height:10%;top:45%}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:first-of-type,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{transform:rotate(90deg)}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{left:50%;right:50%}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label,#onetrust-pc-sdk #ot-selall-hostcntr label,#onetrust-pc-sdk #ot-selall-licntr label{position:relative;display:inline-block;width:20px;height:20px}#onetrust-pc-sdk .ot-host-item .ot-plus-minus,#onetrust-pc-sdk .ot-ven-item .ot-plus-minus{float:left;margin-right:8px;top:10px}#onetrust-pc-sdk .ot-ven-item ul{list-style:none inside;font-size:100%;margin:0}#onetrust-pc-sdk .ot-ven-item ul li{margin:0 !important;padding:0;border:none !important}#onetrust-pc-sdk .ot-pli-hdr{color:#77808e;overflow:hidden;padding-top:7.5px;padding-bottom:7.5px;width:calc(100% - 2px);border-top-left-radius:3px;border-top-right-radius:3px}#onetrust-pc-sdk .ot-pli-hdr span:first-child{top:50%;transform:translateY(50%);max-width:90px}#onetrust-pc-sdk .ot-pli-hdr span:last-child{padding-right:10px;max-width:95px;text-align:center}#onetrust-pc-sdk .ot-li-title{float:right;font-size:.813em}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color{background-color:#f4f4f4;border:1px solid #d8d8d8}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color span:first-child{text-align:left;width:70px}#onetrust-pc-sdk li.ot-subgrp>h5,#onetrust-pc-sdk .ot-cat-header{width:calc(100% - 130px)}#onetrust-pc-sdk li.ot-subgrp>h5+.ot-tgl-cntr{padding-left:13px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-acc-grpdesc{margin-bottom:5px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-acc-grpcntr .ot-vlst-cntr+.ot-subgrp-cntr{border-top:none}#onetrust-pc-sdk .ot-acc-hdr .ot-arw-cntr+.ot-tgl-cntr,#onetrust-pc-sdk .ot-acc-txt h4+.ot-tgl-cntr{padding-left:13px}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-subgrp>h5,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header{width:calc(100% - 145px)}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item h5+.ot-tgl-cntr,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header+.ot-tgl{padding-left:28px}#onetrust-pc-sdk .ot-sel-all-hdr,#onetrust-pc-sdk .ot-sel-all-chkbox{display:inline-block;width:100%;position:relative}#onetrust-pc-sdk .ot-sel-all-chkbox{z-index:1}#onetrust-pc-sdk .ot-sel-all{margin:0;position:relative;padding-right:23px;float:right}#onetrust-pc-sdk .ot-consent-hdr,#onetrust-pc-sdk .ot-li-hdr{float:right;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-li-hdr{max-width:100px;padding-right:10px}#onetrust-pc-sdk .ot-consent-hdr{max-width:55px}#onetrust-pc-sdk #ot-selall-licntr{display:block;width:21px;height:auto;float:right;position:relative;right:80px}#onetrust-pc-sdk #ot-selall-licntr label{position:absolute}#onetrust-pc-sdk .ot-ven-ctgl{margin-left:66px}#onetrust-pc-sdk .ot-ven-litgl+.ot-arw-cntr{margin-left:81px}#onetrust-pc-sdk .ot-enbl-chr .ot-host-cnt .ot-tgl-cntr{width:auto}#onetrust-pc-sdk #ot-lst-cnt:not(.ot-host-cnt) .ot-tgl-cntr{width:auto;top:auto;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-chkbox{position:relative;display:inline-block;width:20px;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-chkbox label{position:absolute;padding:0;width:20px;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-acc-grpdesc+.ot-leg-btn-container{padding-left:20px;padding-right:20px;width:calc(100% - 40px);margin-bottom:5px}#onetrust-pc-sdk .ot-subgrp .ot-leg-btn-container{margin-bottom:5px}#onetrust-pc-sdk #ot-ven-lst .ot-leg-btn-container{margin-top:10px}#onetrust-pc-sdk .ot-leg-btn-container{display:inline-block;width:100%;margin-bottom:10px}#onetrust-pc-sdk .ot-leg-btn-container button{height:auto;padding:6.5px 8px;margin-bottom:0;letter-spacing:0;font-size:.75em;line-height:normal}#onetrust-pc-sdk .ot-leg-btn-container svg{display:none;height:14px;width:14px;padding-right:5px;vertical-align:sub}#onetrust-pc-sdk .ot-active-leg-btn{cursor:default;pointer-events:none}#onetrust-pc-sdk .ot-active-leg-btn svg{display:inline-block}#onetrust-pc-sdk .ot-remove-objection-handler{text-decoration:underline;padding:0;font-size:.75em;font-weight:600;line-height:1;padding-left:10px}#onetrust-pc-sdk .ot-obj-leg-btn-handler span{font-weight:bold;text-align:center;font-size:inherit;line-height:1.5}#onetrust-pc-sdk.ot-close-btn-link #close-pc-btn-handler{border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em;background:none;right:15px;top:15px;width:auto;font-weight:normal}#onetrust-pc-sdk .ot-pgph-link{font-size:.813em !important;margin-top:5px;position:relative}#onetrust-pc-sdk .ot-pgph-link.ot-pgph-link-subgroup{margin-bottom:1rem}#onetrust-pc-sdk .ot-pgph-contr{margin:0 2.5rem}#onetrust-pc-sdk .ot-pgph-title{font-size:1.18rem;margin-bottom:2rem}#onetrust-pc-sdk .ot-pgph-desc{font-size:1rem;font-weight:400;margin-bottom:2rem;line-height:1.5rem}#onetrust-pc-sdk .ot-pgph-desc:not(:last-child):after{content:"";width:96%;display:block;margin:0 auto;padding-bottom:2rem;border-bottom:1px solid #e9e9e9}#onetrust-pc-sdk .ot-cat-header{float:left;font-weight:600;font-size:.875em;line-height:1.5;max-width:90%;vertical-align:middle}#onetrust-pc-sdk .ot-vnd-item>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-vnd-item>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{position:relative;border-radius:2px;margin:0;padding:0;border:1px solid #d8d8d8;border-top:none;width:calc(100% - 2px);float:left}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{margin-top:10px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc{padding-left:20px;padding-right:20px;width:calc(100% - 40px);font-size:.812em;margin-bottom:10px;margin-top:15px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul{padding-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul li{padding-top:0;line-height:1.5;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout div+.ot-acc-grpdesc{margin-top:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:first-child{margin-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:last-child,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr:last-child{margin-bottom:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding-top:11.5px;padding-bottom:11.5px;padding-left:20px;padding-right:20px;width:calc(100% - 40px);display:inline-block}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-txt{width:100%;padding:0}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp-cntr{padding-left:20px;padding-right:15px;padding-bottom:0;width:calc(100% - 35px)}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp{padding-right:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpcntr{z-index:1;position:relative}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr{position:absolute;top:50%;transform:translateY(-50%);right:20px;margin-top:-2px}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr .ot-arw{width:15px;height:20px;margin-left:5px;color:dimgray}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{float:none;color:#2e3644;margin:0;display:inline-block;height:auto;word-wrap:break-word;min-height:inherit}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding-left:20px;width:calc(100% - 20px);display:inline-block;margin-top:0;padding-bottom:2px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{position:relative;min-height:25px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl,#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{position:absolute;top:50%;transform:translateY(-50%);right:20px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl+.ot-tgl{right:95px}#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler,#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler+a{margin-top:5px}#onetrust-pc-sdk #ot-lst-cnt{margin-top:1rem;max-height:calc(100% - 96px)}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list,#onetrust-pc-sdk .ot-vnd-serv{width:auto;padding:1rem 1.25rem;padding-bottom:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:600;font-size:.95em;line-height:2;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item{border:none;margin:0;padding:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button{outline:none;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button[aria-expanded=true],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button[aria-expanded=true]{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:first-child{margin-top:.25rem;border-top:unset}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child{margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child button{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 1.75rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-lbl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-cnt,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt{padding-left:40px}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-size:.8em}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-cat-header{font-size:.8em}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv{margin-bottom:1rem;padding:1rem .95rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:700;font-size:.8em;line-height:20px;margin-left:.82rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-cat-header{font-weight:700;font-size:.8em;line-height:20px}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-vnd-serv .ot-vnd-lst-cont .ot-accordion-layout .ot-acc-hdr div.ot-chkbox{margin-left:.82rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr{padding:.7rem 0;margin:0;display:flex;width:100%;align-items:center;justify-content:space-between}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:first-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:first-child{margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:last-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:last-child{margin-right:.5rem;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-always-active{position:relative;right:unset;top:unset;transform:unset}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-plus-minus{top:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-arw-cntr{float:none;top:unset;right:unset;transform:unset;margin-top:-2px;position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-cat-header{flex:1;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-tgl{position:relative;transform:none;right:0;top:0;float:none}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox{position:relative;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label{padding:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label::before{position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox input{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0;z-index:1}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h5.ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h4.ot-cat-header{margin:0}#onetrust-pc-sdk .ot-vs-config .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp h5{top:0;line-height:20px}#onetrust-pc-sdk .ot-vs-list{display:flex;flex-direction:column;padding:0;margin:.5rem 4px}#onetrust-pc-sdk .ot-vs-selc-all{display:flex;padding:0;float:unset;align-items:center;justify-content:flex-start}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf{justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf.ot-caret-conf .ot-sel-all-chkbox{margin-right:48px}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf .ot-sel-all-chkbox{margin:0;padding:0;margin-right:14px;justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-chkbox,#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-tgl{display:inline-block;right:unset;width:auto;height:auto;float:none}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr label{width:45px;height:25px}#onetrust-pc-sdk .ot-vs-selc-all .ot-sel-all-chkbox{margin-right:11px;margin-left:.75rem;display:flex;align-items:center}#onetrust-pc-sdk .ot-vs-selc-all .sel-all-hdr{margin:0 1.25rem;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-vnd-list-cnt #ot-selall-vencntr.ot-chkbox{float:unset;right:0}#onetrust-pc-sdk[dir=rtl] #ot-back-arw,#onetrust-pc-sdk[dir=rtl] input~.ot-acc-hdr .ot-arw{transform:rotate(180deg);-o-transform:rotate(180deg);-ms-transform:rotate(180deg);-webkit-transform:rotate(180deg)}#onetrust-pc-sdk[dir=rtl] input:checked~.ot-acc-hdr .ot-arw{transform:rotate(270deg);-o-transform:rotate(270deg);-ms-transform:rotate(270deg);-webkit-transform:rotate(270deg)}#onetrust-pc-sdk[dir=rtl] .ot-chkbox label::after{transform:rotate(45deg);-webkit-transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);border-left:0;border-right:3px solid}#onetrust-pc-sdk[dir=rtl] .ot-search-cntr>svg{right:0}@media only screen and (max-width: 600px){#onetrust-pc-sdk.otPcCenter{left:0;min-width:100%;height:100%;top:0;border-radius:0}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container{margin:1px 3px 0 10px;padding-right:10px;width:calc(100% - 23px)}#onetrust-pc-sdk .ot-btn-container button{max-width:none;letter-spacing:.01em}#onetrust-pc-sdk #close-pc-btn-handler{top:10px;right:17px}#onetrust-pc-sdk p{font-size:.7em}#onetrust-pc-sdk #ot-pc-hdr{margin:10px 10px 0 5px;width:calc(100% - 15px)}#onetrust-pc-sdk .vendor-search-handler{font-size:1em}#onetrust-pc-sdk #ot-back-arw{margin-left:12px}#onetrust-pc-sdk #ot-lst-cnt{margin:0;padding:0 5px 0 10px;min-width:95%}#onetrust-pc-sdk .switch+p{max-width:80%}#onetrust-pc-sdk .ot-ftr-stacked button{width:100%}#onetrust-pc-sdk #ot-fltr-cnt{max-width:320px;width:90%;border-top-right-radius:0;border-bottom-right-radius:0;margin:0;margin-left:15px;left:auto;right:40px;top:85px}#onetrust-pc-sdk .ot-fltr-opt{margin-left:25px;margin-bottom:10px}#onetrust-pc-sdk .ot-pc-refuse-all-handler{margin-bottom:0}#onetrust-pc-sdk #ot-fltr-cnt{right:40px}}@media only screen and (max-width: 476px){#onetrust-pc-sdk .ot-fltr-cntr,#onetrust-pc-sdk #ot-fltr-cnt{right:10px}#onetrust-pc-sdk #ot-anchor{right:25px}#onetrust-pc-sdk button{width:100%}#onetrust-pc-sdk:not(.ot-addtl-vendors) #ot-pc-lst:not(.ot-enbl-chr) .ot-sel-all{padding-right:9px}#onetrust-pc-sdk:not(.ot-addtl-vendors) #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr{right:0}}@media(min-width: 768px){#onetrust-pc-sdk.ot-tgl-with-label .ot-label-status{display:inline}#onetrust-pc-sdk.ot-tgl-with-label #ot-pc-lst .ot-label-status{display:none}}@media only screen and (max-width: 896px)and (max-height: 425px)and (orientation: landscape){#onetrust-pc-sdk.otPcCenter{left:0;top:0;min-width:100%;height:100%;border-radius:0}#onetrust-pc-sdk .ot-pc-header{height:auto;min-height:20px}#onetrust-pc-sdk .ot-pc-header .ot-pc-logo{max-height:30px}#onetrust-pc-sdk .ot-pc-footer{max-height:60px;overflow-y:auto}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk #ot-pc-lst{bottom:70px}#onetrust-pc-sdk.ot-ftr-stacked #ot-pc-content{bottom:70px}#onetrust-pc-sdk #ot-anchor{left:initial;right:50px}#onetrust-pc-sdk #ot-lst-title{margin-top:12px}#onetrust-pc-sdk #ot-lst-title *{font-size:inherit}#onetrust-pc-sdk #ot-pc-hdr input{margin-right:0;padding-right:45px}#onetrust-pc-sdk .switch+p{max-width:85%}#onetrust-pc-sdk #ot-sel-blk{position:static}#onetrust-pc-sdk #ot-pc-lst{overflow:auto}#onetrust-pc-sdk #ot-lst-cnt{max-height:none;overflow:initial}#onetrust-pc-sdk #ot-lst-cnt.no-results{height:auto}#onetrust-pc-sdk input{font-size:1em !important}#onetrust-pc-sdk p{font-size:.6em}#onetrust-pc-sdk #ot-fltr-modal{width:100%;top:0}#onetrust-pc-sdk ul li p,#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a,#onetrust-pc-sdk .category-host-list-handler{font-size:.6em}#onetrust-pc-sdk.ot-shw-fltr #ot-anchor{display:none !important}#onetrust-pc-sdk.ot-shw-fltr #ot-pc-lst{height:100% !important;overflow:hidden;top:0px}#onetrust-pc-sdk.ot-shw-fltr #ot-fltr-cnt{margin:0;height:100%;max-height:none;padding:10px;top:0;width:calc(100% - 20px);position:absolute;right:0;left:0;max-width:none}#onetrust-pc-sdk.ot-shw-fltr .ot-fltr-scrlcnt{max-height:calc(100% - 65px)}}
            #onetrust-consent-sdk #onetrust-pc-sdk,
                #onetrust-consent-sdk #ot-search-cntr,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-switch.ot-toggle,
                #onetrust-consent-sdk #onetrust-pc-sdk ot-grp-hdr1 .checkbox,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title:after
                ,#onetrust-consent-sdk #onetrust-pc-sdk #ot-sel-blk,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-cnt,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-anchor {
                    background-color: #FFF;
                }
               
            #onetrust-consent-sdk #onetrust-pc-sdk h3,
                #onetrust-consent-sdk #onetrust-pc-sdk h4,
                #onetrust-consent-sdk #onetrust-pc-sdk h5,
                #onetrust-consent-sdk #onetrust-pc-sdk h6,
                #onetrust-consent-sdk #onetrust-pc-sdk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-ven-lst .ot-ven-opts p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-desc,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-li-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-sel-all-hdr span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-modal #modal-header,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-checkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-sel-blk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-lst-title h3,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .back-btn-handler p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .ot-ven-name,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-ven-lst .consent-category,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-label-status,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-chkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #clear-filters-handler,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-optout-signal
                {
                    color: #2E2E2E;
                }
             #onetrust-consent-sdk #onetrust-pc-sdk .privacy-notice-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-pgph-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler + a,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-host-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-legclaim-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-name a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-acc-hdr .ot-host-expand,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-content #ot-pc-desc .ot-link-btn,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info a
                    {
                        color: #007398;
                    }
            #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler:hover { text-decoration: underline;}
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt,
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-subgrp-tgl .ot-switch.ot-toggle
             {
                background-color: #F8F8F8;
            }
             #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-ven-dets
                            {
                                background-color: #F8F8F8;
                            }
        #onetrust-consent-sdk #onetrust-pc-sdk
            button:not(#clear-filters-handler):not(.ot-close-icon):not(#filter-btn-handler):not(.ot-remove-objection-handler):not(.ot-obj-leg-btn-handler):not([aria-expanded]):not(.ot-link-btn),
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-active-leg-btn {
                background-color: #007398;border-color: #007398;
                color: #FFF;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu {
                border-color: #007398;
            }
            
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-remove-objection-handler{
                background-color: transparent;
                border: 1px solid transparent;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn {
                background-color: #FFFFFF;
                color: #4D4D4D; border-color: #4D4D4D;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-tgl input:focus + .ot-switch, .ot-switch .ot-switch-nob, .ot-switch .ot-switch-nob:before,
            #onetrust-pc-sdk .ot-checkbox input[type="checkbox"]:focus + label::before,
            #onetrust-pc-sdk .ot-chkbox input[type="checkbox"]:focus + label::before {
                outline-color: #000000;
                outline-width: 1px;
                outline-offset: 1px;
            }
            #onetrust-pc-sdk .ot-host-item > button:focus, #onetrust-pc-sdk .ot-ven-item > button:focus {
                border: 1px solid #000000;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk *:focus,
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-vlst-cntr > a:focus {
               outline: 1px solid #000000;
               outline-offset: 1px;
            }#onetrust-pc-sdk .ot-vlst-cntr .ot-ext-lnk,  #onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{
                    background-image: url('https://cdn.cookielaw.org/logos/static/ot_external_link.svg');
                }
            /*! v6.10.0 2021-01-18 */
div#onetrust-consent-sdk #onetrust-banner-sdk{border-top:2px solid #d0d3d4!important;box-shadow:none;padding:24px}div#onetrust-consent-sdk button{border-radius:0!important;box-shadow:none!important;box-sizing:border-box!important;font-size:20px!important;font-weight:400!important;letter-spacing:0!important;max-width:none!important;white-space:nowrap!important}div#onetrust-consent-sdk button:not(.ot-link-btn){background-color:#007dbc!important;border:2px solid #007dbc!important;color:#fff!important;height:48px!important;padding:0 1em!important;width:auto!important}div#onetrust-consent-sdk button:hover{background-color:#fff!important;border-color:#949494!important;color:#2e2e2e!important}div#onetrust-consent-sdk button.ot-link-btn{color:#007dbc!important;font-size:16px!important;text-decoration:underline}div#onetrust-consent-sdk button.ot-link-btn:hover{color:inherit!important;text-decoration-color:#949494!important}div#onetrust-consent-sdk a,div#onetrust-pc-sdk a{color:#007dbc!important;text-decoration:underline!important}div#onetrust-consent-sdk a,div#onetrust-consent-sdk button,div#onetrust-consent-sdk p:hover{opacity:1!important}div#onetrust-consent-sdk a:focus,div#onetrust-consent-sdk button:focus,div#onetrust-consent-sdk input:focus{outline:2px solid #949494!important;outline-offset:1px!important}div#onetrust-banner-sdk .ot-sdk-container{padding:0;width:auto}div#onetrust-banner-sdk .ot-sdk-row{align-items:flex-start;box-sizing:border-box;display:flex;flex-direction:column;justify-content:space-between;margin:auto;max-width:1152px}div#onetrust-banner-sdk .ot-sdk-row:after{display:none}div#onetrust-banner-sdk #onetrust-group-container,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-group-container,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{flex-grow:1;width:auto}div#onetrust-banner-sdk #onetrust-policy,div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy{margin:0;overflow:visible}div#onetrust-banner-sdk.ot-bnr-flift #onetrust-policy-text,div#onetrust-consent-sdk #onetrust-policy-text{font-size:16px;line-height:24px;max-width:44em;margin:0}div#onetrust-consent-sdk #onetrust-policy-text a[href]{font-weight:400;margin-left:8px}div#onetrust-banner-sdk #onetrust-button-group-parent{flex:0 0 auto;margin:32px 0 0;width:100%}div#onetrust-banner-sdk #onetrust-button-group{display:flex;flex-direction:row;flex-wrap:wrap;justify-content:flex-end;margin:-8px}div#onetrust-banner-sdk .banner-actions-container{display:flex;flex:1 0 auto}div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type,div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto;margin:8px;width:auto}div#onetrust-consent-sdk #onetrust-pc-btn-handler{background-color:#fff!important;color:inherit!important}div#onetrust-banner-sdk #onetrust-close-btn-container{display:none}@media only screen and (min-width:556px){div#onetrust-consent-sdk #onetrust-banner-sdk{padding:40px}div#onetrust-banner-sdk #onetrust-policy{margin:0 40px 0 0}div#onetrust-banner-sdk .ot-sdk-row{align-items:center;flex-direction:row}div#onetrust-banner-sdk #onetrust-button-group-parent,div#onetrust-banner-sdk.ot-bnr-flift:not(.ot-iab-2) #onetrust-button-group-parent,div#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:0;padding:0;width:auto}div#onetrust-banner-sdk #onetrust-button-group,div#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{align-items:stretch;flex-direction:column-reverse;margin:0}div#onetrust-consent-sdk #onetrust-accept-btn-handler,div#onetrust-consent-sdk #onetrust-pc-btn-handler{flex:1 0 auto}}@media only screen and (min-width:768px){div#onetrust-banner-sdk #onetrust-policy{margin:0 48px 0 0}div#onetrust-consent-sdk #onetrust-banner-sdk{padding:48px}}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-size:16px;line-height:24px}div#onetrust-consent-sdk #onetrust-pc-sdk p,div#onetrust-pc-sdk #ot-pc-desc,div#onetrust-pc-sdk .category-host-list-handler,div#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{font-size:16px;font-weight:400;line-height:24px}div#onetrust-consent-sdk a:hover,div#onetrust-pc-sdk a:hover{color:inherit!important;text-decoration-color:#949494!important}div#onetrust-pc-sdk{border-radius:0;bottom:0;height:auto;left:0;margin:auto;max-width:100%;overflow:hidden;right:0;top:0;width:512px;max-height:800px}div#onetrust-pc-sdk .ot-pc-header{display:none}div#onetrust-pc-sdk #ot-pc-content{overscroll-behavior:contain;padding:0 12px 0 24px;margin:16px 4px 0 0;top:0;right:16px;left:0;width:auto}div#onetrust-pc-sdk #ot-category-title,div#onetrust-pc-sdk #ot-pc-title{font-size:24px;font-weight:400;line-height:32px;margin:0 0 16px}div#onetrust-pc-sdk #ot-pc-desc{padding:0}div#onetrust-pc-sdk #ot-pc-desc a{display:inline}div#onetrust-pc-sdk #accept-recommended-btn-handler{display:none!important}div#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:2px solid #007dbc;outline-offset:-1px;transition:none}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{border-width:0 0 2px}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{border-width:2px 0}div#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding:8px 0;width:100%}div#onetrust-pc-sdk .ot-plus-minus{transform:translateY(2px)}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item>button{background:0 0!important;border:0!important;height:44px!important;max-width:none!important;width:calc(100% - 48px)!important}div#onetrust-consent-sdk #onetrust-pc-sdk h5{font-weight:700}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding:0}div#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item .ot-acc-grpdesc{padding:0;width:100%}div#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border:0;padding:0}div#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp{margin:0}div#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:calc(100% - 160px)}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{width:calc(100% - 88px)}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{color:inherit;font-size:12px;font-weight:400;line-height:1.5;padding-right:48px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:before{border-radius:12px;position:absolute;right:0;top:0;content:'';background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active:after{border-radius:50%;position:absolute;right:5px;top:4px;content:'';background-color:#007dbc;height:12px;width:12px}div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active,div#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl{right:2px}div#onetrust-pc-sdk .ot-switch{display:block;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob,div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background:#fff;border:2px solid #939393;box-sizing:border-box;height:20px;width:40px}div#onetrust-pc-sdk .ot-tgl input+.ot-switch .ot-switch-nob:before{background-color:#737373;height:8px;left:4px;top:4px;width:8px}div#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{background-color:#007dbc;height:12px;left:0;top:2px;width:12px}div#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch .ot-switch-nob{box-shadow:0 0;outline:2px solid #007dbc!important;outline-offset:1px;transition:none}div#onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt{background-color:transparent;padding-left:3px}div#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr,div#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr{overflow:visible;width:100%}div#onetrust-pc-sdk .ot-pc-footer{border-top:0 solid}div#onetrust-pc-sdk .ot-btn-container{padding-top:24px;text-align:center}div#onetrust-pc-sdk .ot-pc-footer button{margin:8px 0;background-color:#fff}div#onetrust-pc-sdk .ot-pc-footer-logo{background-color:#fff}div#onetrust-pc-sdk #ot-lst-title span{font-size:24px;font-weight:400;line-height:32px}div#onetrust-pc-sdk #ot-host-lst .ot-host-desc,div#onetrust-pc-sdk #ot-host-lst .ot-host-expand,div#onetrust-pc-sdk #ot-host-lst .ot-host-name,div#onetrust-pc-sdk #ot-host-lst .ot-host-name a,div#onetrust-pc-sdk .back-btn-handler,div#onetrust-pc-sdk .ot-host-opt li>div div{font-size:16px;font-weight:400;line-height:24px}div#onetrust-pc-sdk #ot-pc-lst{top:0}div#onetrust-pc-sdk .back-btn-handler{text-decoration:none!important}div#onetrust-pc-sdk #filter-btn-handler:hover svg{filter:invert(1)}div#onetrust-pc-sdk .back-btn-handler svg{width:16px;height:16px}div#onetrust-pc-sdk .ot-host-item>button{background:0 0!important;border:0!important;height:66px!important;max-width:none!important;width:calc(100% - 5px)!important;transform:translate(2px,2px)}div#onetrust-pc-sdk .ot-host-item{border-bottom:2px solid #b9b9b9;padding:0}div#onetrust-pc-sdk .ot-host-item .ot-acc-hdr{margin:0 0 -6px;padding:8px 0}div#onetrust-pc-sdk ul li:first-child{border-top:2px solid #b9b9b9}div#onetrust-pc-sdk .ot-host-item .ot-plus-minus{margin:0 8px 0 0}div#onetrust-pc-sdk .ot-search-cntr{width:calc(100% - 48px)}div#onetrust-pc-sdk .ot-host-opt .ot-host-info{background-color:transparent}div#onetrust-pc-sdk .ot-host-opt li>div div{padding:0}div#onetrust-pc-sdk #vendor-search-handler{border-radius:0;border-color:#939393;border-style:solid;border-width:2px 0 2px 2px;font-size:20px;height:48px;margin:0}div#onetrust-pc-sdk .ot-lst-subhdr svg{right:0;top:8px}div#onetrust-pc-sdk .ot-fltr-cntr{box-sizing:border-box;right:0;width:48px}div#onetrust-pc-sdk #filter-btn-handler{width:48px!important;padding:8px!important}div#onetrust-pc-sdk #ot-fltr-modal{max-height:400px}
.ot-sdk-cookie-policy{font-family:inherit;font-size:16px}.ot-sdk-cookie-policy.otRelFont{font-size:1rem}.ot-sdk-cookie-policy h3,.ot-sdk-cookie-policy h4,.ot-sdk-cookie-policy h6,.ot-sdk-cookie-policy p,.ot-sdk-cookie-policy li,.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy th,.ot-sdk-cookie-policy #cookie-policy-description,.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}.ot-sdk-cookie-policy h4{font-size:1.2em}.ot-sdk-cookie-policy h6{font-size:1em;margin-top:2em}.ot-sdk-cookie-policy th{min-width:75px}.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy a:hover{background:#fff}.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}.ot-sdk-cookie-policy .ot-mobile-border{display:none}.ot-sdk-cookie-policy section{margin-bottom:2em}.ot-sdk-cookie-policy table{border-collapse:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy{font-family:inherit;font-size:1rem}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup{margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group-desc,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-table-header,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td{font-size:.9em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td a{font-size:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group{font-size:1em;margin-bottom:.6em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-title{margin-bottom:1.2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy>section{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th{min-width:75px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a:hover{background:#fff}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-mobile-border{display:none}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy section{margin-bottom:2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li{list-style:disc;margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li h4{display:inline-block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{border-collapse:inherit;margin:auto;border:1px solid #d7d7d7;border-radius:5px;border-spacing:initial;width:100%;overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border-bottom:1px solid #d7d7d7;border-right:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr th:last-child,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr td:last-child{border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:25%}.ot-sdk-cookie-policy[dir=rtl]{text-align:left}#ot-sdk-cookie-policy h3{font-size:1.5em}@media only screen and (max-width: 530px){.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) table,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tbody,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) th,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{display:block}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead tr{position:absolute;top:-9999px;left:-9999px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{margin:0 0 1em 0}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd),.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd) a{background:#f6f6f4}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td{border:none;border-bottom:1px solid #eee;position:relative;padding-left:50%}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{position:absolute;height:100%;left:6px;width:40%;padding-right:10px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) .ot-mobile-border{display:inline-block;background-color:#e4e4e4;position:absolute;height:100%;top:0;left:45%;width:2px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{content:attr(data-label);font-weight:bold}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border:none;border-bottom:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{display:block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:auto}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{margin:0 0 1em 0}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{height:100%;width:40%;padding-right:10px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{content:attr(data-label);font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead tr{position:absolute;top:-9999px;left:-9999px;z-index:-9999}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:1px solid #d7d7d7;border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td:last-child{border-bottom:0px}}
                
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h5,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group {
                        color: #696969;
                    }
                    
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title {
                            color: #696969;
                        }
                    
            
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th {
                            background-color: #F8F8F8;
                        }
                    
            .ot-floating-button__front{background-image:url('https://cdn.cookielaw.org/logos/static/ot_persistent_cookie_icon.png')}</style><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><style></style><link href="https://crossmark-cdn.crossref.org/widget/v2.0/style.css" type="text/css" rel="stylesheet"></head>
<body class="pb-ui">
    <div class="skip">
        <a href="#page-body-id" id="skipNavigationLink" title="Skip to Main Content" tabindex="0" class="skipToContent">Skip to Main Content</a>
        <a href="#mega-menu-nav" id="skipToMainMenu" title="Skip to Main Menu" tabindex="0" class="skipToContent">Skip to Main Menu</a>
    </div>



    <div id="pb-page-content" data-ng-non-bindable="">
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="ux3-layout-widget" data-widget-id="832ad3f3-97ac-45ab-9af1-90c6f7bff54a" class="ux3">
        
    

        


    

            

            
                <div class="cell fonts-loaded">
            

            <div data-widget-id="832ad3f3-97ac-45ab-9af1-90c6f7bff54a" data-widget-name="ux3-layout-widget"><div>
    

        


    

            

            

            <div id="a1f1ba25-79af-4194-aaa9-66206104a800" class="widget loginPopup none widget-none widget-compact-all"><div class="wrapped"><div class="widget-body body body-none body-compact-all"><div role="dialog" aria-modal="true" aria-label="Login" class="popup login-popup hidden"><div class="content"><a href="#" aria-label="Close login popup" title="Close login popup" role="button" class="close"><i class="icon-close_thin"></i></a><h2 class="login-title">Login to your account</h2><div class="login-form"><p tabindex="-1" class="message error"></p><form action="/action/doLogin?redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" method="post"><input type="hidden" name="redirectUri" value="https://www.cell.com/cell/fulltext/S0092-8674(20)31141-7"><input type="hidden" name="referer" value="/cell/fulltext/S0092-8674(20)31141-7"><input type="hidden" name="ecommRedirect"><input type="hidden" name="code" value="cell-site"><input type="hidden" name="UX3LoginWidget" value="true"><input type="hidden" name="isPopup" value="true"><div class="input-group login-input--wrapper"><div class="label"><label for="login">Email/Username</label></div><input id="login" type="text" name="login" value="" size="15" class="login"><div role="alert" class="error-hint js--hidden"><div class="error-hint__text"><div class="error-text">Your email address is a required field.</div><div class="email-example">E.g., j.smith@mail.com</div></div></div></div><div class="input-group login-input--wrapper"><div class="label"><label for="password">Password</label></div><input id="password" type="password" name="password" value="" autocomplete="off" class="password"><a href="#" class="login__field__action js-show-password">Show</a><div role="alert" class="error-hint js--hidden"><span class="error-hint__text">Your password is a required field.</span></div><div class="actions"><a href="https://www.cell.com/action/requestResetPassword" class="link show-request-reset-password">Forgot password?</a></div></div><div class="remember"><input type="checkbox" name="savePassword" id="a1f1ba25-79af-4194-aaa9-66206104a800-remember" value="1" checked="checked"><label for="a1f1ba25-79af-4194-aaa9-66206104a800-remember">Remember me</label></div><div class="submit"><input type="submit" name="submit" value="Log in" class="button submit primary"></div></form></div><div class="create-account"><div>Don’t have an account?</div><a href="/action/registration?redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" class="show-registration">Create a Free Account</a></div></div></div></div></div></div>

            

        

    

        


    

            

            

            <div role="dialog" aria-modal="true" aria-label="Reset password" class="popup top-drawer request-reset-password-drawer hidden"><div class="content"><a href="#" aria-label="Close reset password popup" title="Close reset password popup" role="button" class="close"><i class="icon-close_thin"></i></a><div class="request-reset"><div class="form"><p class="sub">If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password</p><div tabindex="-1" class="message error"></div><form action="/action/requestResetPassword" method="post" class="request-reset-password-form"><input type="hidden" name="platform"><input type="hidden" name="requestResetPassword" value="true"><input type="hidden" name="codeSite" value="cell-site"><div class="input-group"><div class="label"><label for="reset-password-email">Email*</label></div><input id="reset-password-email" type="text" name="email" value="" size="15" class="email"></div><div class="submit" disabled="disabled"><input type="submit" name="submit" value="Submit" disabled="disabled" class="button primary submit"></div></form></div><div class="success-template hidden"><p>If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password</p></div></div><div class="request-reset-cancel"><a href="#" aria-label="Close reset password popup" title="Close reset password popup" class="cancel">Cancel</a></div></div></div>

            

        

    

        


    

            

            
                <div class="ux3-ads">
            

            <div class="pb-ad">
            <!-- Do Not Modify without contacting ELS-HSOnlineCampaign@elsevier.com -->
<!-- To be kept in sync with Global Commercial Publishing Operations-->
<!-- Start: GPT Async -->
<div id="gpt-Variables" data-adfile="CELLJOURNAL">
	<input type="hidden" id="gptSite" value="cell">
	<input type="hidden" id="gptLoggedIn" value="no">
	<input type="hidden" id="gptAccessType" value="ae:ANON_GUEST|ae:ANON_GUEST">
	<input type="hidden" id="gptDefaultSite" value="cell">
</div>
<div id="gpt-Interscroller" class="gpt-InScrollBox" style="display:none;">
	<div class="gpt-InScrollLabel">ADVERTISEMENT</div>
	<div class="gpt-InScrollContainer">
		<div class="gpt-InScrollWrapper">
			<div class="gpt-InScrollInner">
				<div class="gpt-adinterscroller" data-adsize="interscroller"></div>
			</div>
		</div>
	</div>
	<div class="gpt-InScrollLabel">SCROLL TO CONTINUE WITH CONTENT</div>
</div>
<div id="gpt-DebugDiv" class="gpt-DebugDiv" style="display:none;">
	<div style="width: 100%; display: table;">
		<div style="display: table-row">
			<div style="width: 200px; display: table-cell;">
				<button class="gpt-DebugBtn" onclick="gpt_ShowConsole()">Open GPT Console</button><br>
				<button id="gpt_GrapeShotDebugBtn" class="gpt-DebugBtn" onclick="gpt_GrapeShotDebug();">Open Oracle Keywords</button><br>
				<br>
				<button class="gpt-DebugBtn" onclick="gpt_LoadDebugValues()">Refresh Values</button>
			</div>
			<div style="display: table-cell;">
				<table class="gpt-DebugTable">
					<thead>
						<tr>
							<th>Property</th>
							<th>Value</th>
						</tr>
					</thead>
					<tbody>
						<tr><td class="gpt-DebugTitle">Status</td><td><div class="gptStatus_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Version</td><td><div class="gptVersion_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Ad File</td><td><div class="gptAdFile_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Disable Ads Flag</td><td><div class="gptDisableAds_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Environment</td><td><div class="gptTestENV_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Moat Init</td><td><div class="gptMoatInit_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Moat Ready</td><td><div class="gptMoatReady_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Contextual Ready</td><td><div class="gptContextualReady_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Contextual URL</td><td><div class="gptContextualURL_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Contextual Initial Segments</td><td><div class="gptContextualInit_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Contextual Used Segments</td><td><div class="gptContextualResult_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">AdUnit</td><td><div class="gptSite_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">SubAdUnit</td><td><div class="gptPage_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Custom Targeting</td><td><div class="gptCustomTargeting_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Ad Events</td><td><div class="gptEvent_Debug"></div></td></tr>
						<tr><td class="gpt-DebugTitle">Invalid Ad Sizes</td><td><div class="gptInvalidAdSize_Debug"></div></td></tr>
					</tbody>
				</table>
			</div>
		</div>
	</div>
</div>
<style type="text/css">
	.gpt-DebugBtn {
		display: inline-block;
		text-align: center;
		text-decoration: none;
		margin: 2px 0;
		border: solid 1px #122b40;
		border-radius: 0.4em;
		padding: 0.5em 1em;
		color: #ffffff;
		background-color: #204d74;
		font-weight: normal;
		font-size: 12px;
	}

	.gpt-DebugDiv {
		margin: 5px;
	}

	.gpt-DebugTitle {
		font-weight: bold;
	}

	.gpt-DebugTable {
		border: 1px solid #dddddd;
		border-collapse: collapse;
		margin: 5px;
		font-size: 0.9em;
		font-family: sans-serif;
		min-width: 400px;
		margin-bottom: 25px;
	}

		.gpt-DebugTable td:first-child {
			padding: 5px;
		}

		.gpt-DebugTable thead tr th {
			background-color: #d9edf7;
			color: #ffffff;
			text-align: left;
			padding: 5px;
			border-bottom: 2px solid #204d74;
		}

		.gpt-DebugTable th,
		.gpt-DebugTable td {
			padding: 5px;
		}

		.gpt-DebugTable tbody tr {
			border-bottom: 1px solid #dddddd;
		}

			.gpt-DebugTable tbody tr:nth-of-type(even) {
				background-color: #f3f3f3;
			}

			.gpt-DebugTable tbody tr:last-of-type {
				border-bottom: 2px solid #204d74;
			}

	.gpt-InScrollLabel {
		background-color: rgb(0, 0, 0);
		color: rgb(255, 255, 255);
		position: relative;
		max-width: 100vw;
		left: 50%;
		right: 50%;
		margin-left: -50vw;
		margin-right: -50vw;
		padding: 0;
		text-align: center;
		width: 100vw !important;
		font-size: 10px;
	}

	.gpt-InScrollBox {
		height: 100vh !important;
		width: 100vw;
		cursor: pointer;
		max-width: 100vw;
		position: relative;
		left: 50%;
		right: 50%;
		margin-left: -50vw;
		margin-right: -50vw;
		margin-bottom: 50px;
		padding-top: 5px;
		padding-bottom: 5px;
		z-index: 10001;
		background-color: white;
	}

		.gpt-InScrollBox .gpt-InScrollContainer {
			height: 95vh !important;
			position: relative;
		}

		.gpt-InScrollBox .gpt-InScrollWrapper {
			position: absolute !important;
			top: 0 !important;
			left: 0;
			width: 100%;
			height: 95vh !important;
			border: 0 !important;
			margin: 0 !important;
			padding: 0 !important;
			clip: rect(0, auto, auto, 0) !important;
			-webkit-clip-path: polygon(0px 0px, 100% 0px, 100% 100%, 0px 100%) !important;
			clip-path: polygon(0px 0px, 100% 0px, 100% 100%, 0px 100%) !important;
		}

		.gpt-InScrollBox .gpt-InScrollInner {
			position: fixed !important;
			top: 0 !important;
			left: 0 !important;
			bottom: 0;
			margin: auto;
			width: 100vw;
			height: 95vh;
			-webkit-transform: translateZ(0) !important;
			display: -webkit-box;
			display: -ms-flexbox;
			display: flex;
			-webkit-box-orient: vertical;
			-webkit-box-direction: normal;
			-ms-flex-direction: column;
			flex-direction: column;
			-webkit-box-align: center;
			-ms-flex-align: center;
			align-items: center;
			-webkit-box-pack: center;
			-ms-flex-pack: center;
			justify-content: center;
			text-align: center;
		}
</style>
<script class="optanon-category-4" type="text/plain">
	//--------------------------------------------------------------------------
	var gpt_Version = '04072023';
	var gpt_AdFile = $('#gpt-Variables').data('adfile');
	var gpt_MaxMOATInitAttempts = 11;
	var gpt_MaxMOATReadyAttempts = 11;
	var gpt_MaxContextualReadyAttempts = 21;
	var gpt_MOATInitAttempts = 0;
	var gpt_MOATReadyAttempts = 0;
	var gpt_ContextualReadyAttempts = 0;
	var gpt_IsProd = true;
	var gpt_StartTime;
	var gs_channels = 'DEFAULT';
	var gpt_ContextualReady = false;
	var gpt_ContextualURL = 'Not enabled outside of Production';
	var gpt_DisableAdsFlagFound = false;

	var gptEvent_Debug = '';
	var gptCustomTargeting_Debug = '';
	var gptSite_Debug = "";
	var gptPage_Debug = "";
	var gptContextualEnabled = false;
	var gptContextualResult_Debug = '';
	var gptContextualInit_Debug = '';
	var gptContextualURL_Debug = '';
	var gptContextualReady_Debug = '';
	var gptMoatReady_Debug = '';
	var gptMoatInit_Debug = '';
	var gptTestENV_Debug = '';
	var gptDisableAds_Debug = '';
	var gptStatus_Debug = 'GPT Still Loading - Refresh Values';
	var gptInvalidAdSize_Debug = '';
	//--------------------------------------------------------------------------
	$(document).ready(function () {
		//Check to see if we are on a development env
		gpt_CheckEnvironment();

		if (!gpt_DisableAdsFlagFound) {
			gpt_StartTime = new Date();
			if (gpt_AdFile !== "PU") {
				//Once the dom has loaded, begin the process to init the ads.
				gpt_InitScripts();
				gpt_CheckForMOATInit();
			}
		}
	});
</script>
<script type="text/javascript">
	function gpt_CheckEnvironment() {
		if ($('#gptDisableAds').length > 0) {
			gptDisableAds_Debug = 'Flag Detected - Ads Disabled';
			gpt_DisableAdsFlagFound = true;
		}
		else {
			gptDisableAds_Debug = 'Ads Enabled';
			gpt_DisableAdsFlagFound = false;
		}
		switch (gpt_AdFile) {
			case 'PU':
				gptContextualEnabled = true;
				if ($("#Environment").val() !== "Prod") {
					gpt_IsProd = false;
					gptTestENV_Debug = 'Test Environment Detected';
				}
				else {
					gptTestENV_Debug = 'Production Environment Detected';
				}
				break;
			case 'JBS':
			case 'LANCET':
				gptContextualEnabled = true;
				if ($(".gpt-ad").length > 0) {
					//Other ads exist, allow the Prestitial
					$(document.body).append("<div class='gpt-ad' data-adsize='prestitial'></div>");
				}
				if (window.location.hostname.toLowerCase().indexOf('.literatumonline.') >= 0) {
					gpt_IsProd = false;
					gptTestENV_Debug = 'Test Environment Detected';
				}
				else {
					gptTestENV_Debug = 'Production Environment Detected';
				}
				break;
			default:
				//Cell
				gptContextualEnabled = false;
				if (window.location.hostname.toLowerCase().indexOf('.literatumonline.') >= 0) {
					gpt_IsProd = false;
					gptTestENV_Debug = 'Test Environment Detected';
				}
				else {
					gptTestENV_Debug = 'Production Environment Detected';
				}
				break;
		}
	}
	//--------------------------------------------------------------------------
    function gpt_GetNonCMEArticle() {
        var url;
        $('.articleCitation').each(function (i, obj) {
            if ($(obj).find('.toc__item__detials').length > 0) {
                var itemDetails = $(obj).first().find('.toc__item__detials');
                var cmeFound = 0;
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='CME']").length; }
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='(CME)']").length; }
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='Education']").length; }
                if (cmeFound == 0) { cmeFound = $(itemDetails).find("img[title~='education']").length; }
                if (cmeFound == 0) {
                    var itemLink = $(itemDetails).first().find('.toc__item__title');
                    var linkCount = $(itemLink).first().find("a:contains('CME')").length;
                    if (linkCount == 0) {
                        url = $(itemLink).first().find('a').attr('href');
                        return false;   //Found a URL, break the loop
                    }
                }
            }
        });
        return url;
    }
	//--------------------------------------------------------------------------
	function gpt_GetElapsedTime() {
		var endTime = new Date();
		var timeDiff = endTime - gpt_StartTime; //in ms
		// strip the ms
		timeDiff /= 1000;

		// get seconds
		return seconds = Math.round(timeDiff) + " seconds";
	}
	//--------------------------------------------------------------------------
	function gpt_CheckSSC() {
		//Check for ScreenShot Client
		var gpt_SSC = gpt_GetQuerystring('gpt_ssc', '');
		if (gpt_SSC == '1') {
			//it's the ScreenShotClient, disable MOAT IVT Detection
			$('#gpt-Variables').append('<input type="hidden" id="gptm_data">');
			$('#gptm_data').val(0);
			gpt_Target("m_data");
		}
	}
	//--------------------------------------------------------------------------
	function gpt_LocalSS(adTypeId) {
		window.scrollTo(0, 0);
		gpt_Sleep(1000);
		gpt_ScrollToAd(adTypeId);
		gpt_PreTearsheet(adTypeId);
	}
	//--------------------------------------------------------------------------
	function gpt_InitScripts() {
		if (gpt_AdFile == "PU") {
			if (gpt_IsProd) {
				gpt_ContextualURL = gpt_CheckForNULL($('#canonicalurl').val());
				if (gpt_ContextualURL === null) {
					gpt_ContextualURL = window.location.href.split('?')[0].split('#')[0];
				}
				else {
					gpt_ContextualURL = window.location.origin + gpt_ContextualURL;
				}
				var useSSL = 'https:' == document.location.protocol;
				var gs = document.createElement('script');
				gs.async = true;
				gs.type = 'text/javascript';
				gs.src = (useSSL ? 'https:' : 'http:') + '//elsevier.gscontxt.net/multizone/channels.cgi?url=' + encodeURIComponent(gpt_ContextualURL);
				gs.onload = function () {
					gpt_ContextualReady = true;
				};
				document.head.appendChild(gs);
			}
		}
		else {
			//JBS-Cell-Lancet
			var useSSL = 'https:' == document.location.protocol;

			var gads = document.createElement('script');
			gads.async = true;
			gads.type = 'text/javascript';
			gads.src = (useSSL ? 'https:' : 'http:') + '//securepubads.g.doubleclick.net/tag/js/gpt.js';
			document.head.appendChild(gads);

			if (gpt_IsProd && gptContextualEnabled) {
				gpt_ContextualURL = window.location.href.split('?')[0].split('#')[0];
				var gs = document.createElement('script');
				gs.async = true;
				gs.type = 'text/javascript';
				gs.src = (useSSL ? 'https:' : 'http:') + '//elsevier.gscontxt.net/multizone/channels.cgi?url=' + encodeURIComponent(gpt_ContextualURL);
				gs.onload = function () {
					gpt_ContextualReady = true;
				};
				document.head.appendChild(gs);
			}

			var elsevierMoatHeader = document.createElement('link');
			elsevierMoatHeader.rel = 'preload';
			elsevierMoatHeader.as = 'script';
			elsevierMoatHeader.src = (useSSL ? 'https:' : 'http:') + '//z.moatads.com/elsevierheader150204004183/moatheader.js';
			document.head.appendChild(elsevierMoatHeader);

			var elsevierMoatAds = document.createElement('link');
			elsevierMoatAds.rel = 'preconnect';
			elsevierMoatAds.src = (useSSL ? 'https:' : 'http:') + '//mb.moatads.com';
			document.head.appendChild(elsevierMoatAds);

			var moatHeader = document.createElement('script');
			moatHeader.async = true; gads.type = 'text/javascript';
			moatHeader.src = (useSSL ? 'https:' : 'http:') + '//z.moatads.com/elsevierheader150204004183/moatheader.js';
			document.head.appendChild(moatHeader);
		}
	}
	//--------------------------------------------------------------------------
	async function gpt_CheckForMOATInit() {
		//Check every 1/10 of a second until MOAT is Loaded or 1 second timeout
		if (gpt_MOATInitAttempts < gpt_MaxMOATInitAttempts) {
			gpt_MOATInitAttempts += 1;
			if (typeof window.moatPrebidApi === "object") {
				//MOAT LOADED
				gptMoatInit_Debug = '0.0' + gpt_MOATInitAttempts + ' seconds';
				gpt_CheckForMOATReady();
			}
			else {
				setTimeout(() => { gpt_CheckForMOATInit(); }, 100);
			}
		}
		else {
			//TIMEOUT: MOAT Not LOADED
			gptMoatInit_Debug = 'Timeout Expired';
			var googletag = googletag || {};
			googletag.cmd = googletag.cmd || [];
			gpt_CheckForContextualReady();
		}
	}
	//--------------------------------------------------------------------------
	function gpt_CheckForMOATReady() {
		//Check every 1/10 of a second until MOAT is Ready or 1 second timeout
		if (gpt_MOATReadyAttempts < gpt_MaxMOATReadyAttempts) {
			gpt_MOATReadyAttempts += 1;
			if (window.moatPrebidApi.safetyDataAvailable()) {
				//MOAT Ready
				gptMoatReady_Debug = '0.0' + gpt_MOATReadyAttempts + " seconds";
				gpt_CheckForContextualReady();
			}
			else {
				setTimeout(() => { gpt_CheckForMOATReady(); }, 100);
			}
		}
		else {
			//TIMEOUT: MOAT Not Ready
			gptMoatReady_Debug = 'Timeout Expired';
			gpt_CheckForContextualReady();
		}
	}
	//--------------------------------------------------------------------------
	function gpt_CheckForContextualReady() {
		//Check every 1/10 of a second until Contextual is Ready or 2 second timeout
		if (gpt_IsProd && gptContextualEnabled) {
			//Enabled
			if (gpt_ContextualReadyAttempts < gpt_MaxContextualReadyAttempts) {
				gpt_ContextualReadyAttempts += 1;
				if (gpt_ContextualReady) {
					//Contextual Ready
					gptContextualURL_Debug = gpt_ContextualURL;
					gptContextualReady_Debug = '0.0' + gpt_ContextualReadyAttempts + " seconds";
					gptContextualInit_Debug = gs_channels;
					gpt_InitAds();
				}
				else {
					setTimeout(() => { gpt_CheckForContextualReady(); }, 100);
				}
			}
			else {
				//LOG TIMEOUT error
				//REMOVE FOR NOW (SHOULD LOG TO A DIFF LOCATION)
				//TIMEOUT: Contextual Not Ready
				$('#gpt_GrapeShotDebugBtn').remove();
				gptContextualURL_Debug = gpt_ContextualURL;
				gptContextualReady_Debug = 'Timeout Expired';
				gptContextualInit_Debug = "";
				gpt_InitAds();
			}
		}
		else {
			//Not Enabled
			$('#gpt_GrapeShotDebugBtn').remove();
			switch (gpt_AdFile) {
				case 'PU':
				case 'LANCET':
				case 'JBS':
					gptContextualURL_Debug = 'Not enabled outside of Production';
					gptContextualReady_Debug = 'Not enabled outside of Production';
					gptContextualInit_Debug = 'Not enabled outside of Production';
					break;
				case "CELLJOURNAL":
				case "CELLBUCKET":
					gptContextualReady_Debug = 'Not enabled on Cell';
					gptContextualInit_Debug = 'Not enabled on Cell';
					gptContextualURL_Debug = 'Not enabled on Cell';
					break;
			}
			gpt_InitAds();
		}
	}
	//--------------------------------------------------------------------------
	function GPT_GetPageByURL() {
		var host = window.location.host.toLocaleLowerCase()
		var localpath = window.location.pathname.toLocaleLowerCase();

		///Check for Cell.com
		if (host.indexOf('cell.com') >= 0) {
			return null;
		}

		///Check for Cell.com (marlin-stag)
		if (host.indexOf('www-cell-com') >= 0) {
			return null;
		}

		///Check for Lancet
		if (host.indexOf('thelancet') >= 0) {
			return null;
		}

		if (localpath.indexOf('/article/') >= 0) {
			return 'article.fulltext';
		}

		if (localpath.indexOf('/action/dosearch') >= 0) {
			return 'search.searchResults';
		}

		if (localpath.indexOf('/content/') >= 0) {
			return 'periodical.editorial';
		}

		return 'periodical.home';
	}
	//--------------------------------------------------------------------------
	function gpt_CheckForNULL(x, valueifnull) {
		if (typeof valueifnull == "undefined") {
			valueifnull = null;
		}

		if (typeof x == 'undefined') {
			return valueifnull;
		}
		if (x == null) {
			return valueifnull;
		}
		if (x == "null") {
			return valueifnull;
		}
		if ($.trim(x) == '') {
			return valueifnull;
		}

		return x;
	}
	//--------------------------------------------------------------------------
	function gpt_GetAdditionalTargeting() {
		//adds page level targeting of custom variables
		//the id (minus gpt) and the value will be used as a key-value pair
		//eg: <input type="hidden" id="gptissuepii" value="x" class="gpt-Target">
		//eg: target issuepii=x
		$(".gpt-Target").each(function (index) {
			var gptTargetId = $(this).attr('id');
			gptTargetId = gptTargetId.replace('gpt', '').toLowerCase();
			if (gptTargetId !== '') {
				gpt_Target(gptTargetId);
			}
		})
	}
	//--------------------------------------------------------------------------
	function gpt_GetQuerystring(key, default_) {
		//function to read querystring variables
		if (default_ === null) default_ = '';
		key = key.replace(/[\[]/, "\\\[").replace(/[\]]/, "\\\]");
		var regex = new RegExp("[\\?&]" + key + "=([^&#]*)");
		var qs = regex.exec(window.location.href);
		if (qs === null)
			return default_;
		else
			return qs[1];
	}
	//--------------------------------------------------------------------------
	function gpt_GetDFPTestId() {
		//Get any request for a test id from querystring and set custom targeting parameter
		var gptDFPTestId = gpt_GetQuerystring('dfptestid', '');
		if (gptDFPTestId !== '') {
			$('#gpt-Variables').append('<input type="hidden" id="gptDFPTestId">');
			$('#gptDFPTestId').val(gptDFPTestId);
			gpt_Target("DFPTestId");
		}
	}
	//--------------------------------------------------------------------------
	function gpt_Target(targetName) {
		//Set page level target if value is found
		if ($('#gpt' + targetName).length > 0) {
			var targetValue = $('#gpt' + targetName).val();

			if (targetValue !== '') {
				targetValue = targetValue.replace(/[^-a-z0-9]/ig, '');	//Only Allow a-z, 0-9
				googletag.pubads().setTargeting(targetName.toLowerCase(), targetValue.toLowerCase());
				gptCustomTargeting_Debug = gptCustomTargeting_Debug + targetName.toLowerCase() + ' = ' + targetValue.toLowerCase() + '<br>';
			}
		}
	}
	//--------------------------------------------------------------------------
	function gpt_TargetAccessType() {
		var currentAccessType = $('#gptAccessType').val();
		if (typeof currentAccessType == "undefined") {
			currentAccessType = "";
		}
		if (currentAccessType.indexOf('ANON_IP') >= 0) {
			googletag.pubads().setTargeting("loggedin", "yes");
		}
		else {
			gpt_Target("LoggedIn");
		}
	}
	//--------------------------------------------------------------------------
	async function gpt_PreTearsheet(adTypeId) {
		if (typeof adTypeId === "undefined") {
			adTypeId = 0;
		}
		//Remove Elsevier Cookie Policy Notice
		if ($("#onetrust-consent-sdk").length > 0) {
			$("#onetrust-consent-sdk").remove();
		}

        //Mobile Nav
        $('#skip').remove();
        $('skipNavigationLink').remove();

		//JBS Modals
		if ($('.leadinModal').length > 0) {
			$('.leadinModal').remove();
		}
		if ($('.leadinModal').length > 0) {
			$('.leadinModal').remove();
		}
		if ($('.usabilla__overlay').length > 0) {
			$('.usabilla__overlay').remove();
		}

		//Pendo
		if ($('._pendo-step-container').length > 0) {
			$('._pendo-step-container').remove();
		}
		if ($('._pendo-guide-tt_').length > 0) {
			$('._pendo-guide-tt_').remove();
		}
		if ($('._pendo-image').length > 0) {
			$('._pendo-image').remove();
		}
		if ($('._pendo-badge-image').length > 0) {
			$('._pendo-badge-image').remove();
		}

		switch (gpt_AdFile) {
			case "CELLJOURNAL":
			case "CELLBUCKET":
				//Mobile Bug Fix on Cell
				if (parseInt(adTypeId) == 5) {
					$('.widget-horizontalAd').css('position', 'static');
					$('.body-horizontalAd').css('display', 'block');
				}
				break;
			case "JBS":
			case "LANCET":
				objLeaderboard = ".container-leaderboard";
				offset = 53;
				switch (parseInt(adTypeId)) {
					case 3: //MPU
					case 4: //SkyScraper
						//BUGFIX: Show Sidebar ad for JBS
						//skyscraper & mpu
						if ($('.widget-verticalAd').length > 0) {
							$('.widget-verticalAd').css('display', 'block');
						}
						$('#backgroundLayer').css('display', 'none');   //Hide any Prestitial
						break;
					case 6:     //Prestitial
						$('#backgroundLayer').css('display', 'block');
						break;
					default:
						$('#backgroundLayer').css('display', 'none');   //Hide any Prestitial
						break;
				}
				break;
		}
	}
	//--------------------------------------------------------------------------
	function gpt_Sleep(ms) {
		return new Promise(resolve => setTimeout(resolve, ms));
	}
	//--------------------------------------------------------------------------
	async function gpt_ScrollToAd(adTypeId) {
		if (typeof adTypeId === "undefined") {
			adTypeId = 0;
		}
		var adId = "";
		var offset = 0;
		var objLeaderboard = "";
		var gpt_ScrollToAd = true;

		switch (gpt_AdFile) {
			case "PU": //PracticeUpdate
				var hideOtherAds = true;
				$('#modalPrestitial').modal('hide');
				$('.jumbotron-welcome').hide();
				objLeaderboard = ".container-leaderboard";
				offset = 53;
				switch (parseInt(adTypeId)) {
					case 2:
						//LeaderBoard, no Scroll Needed
						gpt_ScrollToAd = false;
						adId = "adSlot1";
						break;
					case 3:
						//MPU
						adId = "adSlot2";
						break;
					case 4:
						//SkyScraper
						adId = "adSlot3";
						$('.most-read').hide();
						break;
					case 5:
						//Mobile, no Scroll Needed
						gpt_ScrollToAd = false;
						adId = "adSlot1";
						break;
					case 6:
						//Interstitial
						gpt_ScrollToAd = false;
						adId = "adSlot15";
						await gpt_Sleep(1000);
						$(objLeaderboard).hide();
						$('#modalPrestitial').unbind();
						$('#modalPrestitial').modal();
						break;
					case 7:
						//Native Ad
						break;
					case 10:
						//Master Companion
						hideOtherAds = false;
						gpt_ScrollToAd = false;
						break;
					default:
						//Unknown Ad Type
						gpt_ScrollToAd = false;
						adId = "adSlot1";
						break;
				}
				if (hideOtherAds) {
					//Hide all other ads
					$('.ad-container').each(function (i, obj) {
						if (this.id !== adId) {
							var tempParent = this.id;
							tempParent = tempParent.replace("adSlot", "adParent");
							$("#" + tempParent).addClass('hide');
						}
					});
				}
				break;
			case "JBS":
				objLeaderboard = ".js__adToHide";
				offset = 80;
				switch (parseInt(adTypeId)) {
					case 2:
						//Leaderboard
						gpt_ScrollToAd = false;
						$(".widget-verticalAd").hide();
						break;
					case 5:
						//Mobile
						//Scroll to Top
						gpt_ScrollToAd = false;
						break;
					case 3: //MPU
					case 4: //SkyScraper
						$(objLeaderboard).hide();
						adId = $('.gpt-ad-defined[data-adsize="sidebar"').attr('id');
						break;
					case 10:
						//MasterCompanion
						gpt_ScrollToAd = false;
						break;
					case 13:	    //Phone - Portrait
					case 14:        //Phone - Landscape
						$(objLeaderboard).hide();
						offset = 60;
						adId = 'gpt-Interscroller';
						gpt_ScrollToAd = true;
						break;
					default:
						//Unknown Ad Type
						gpt_ScrollToAd = false;
						break;
				}
				break;
			case "CELLJOURNAL":
			case "CELLBUCKET":
				objLeaderboard = ".js__adToHide";
				offset = 260;
				switch (parseInt(adTypeId)) {
					case 2:
						//Leaderboard
						gpt_ScrollToAd = false;
						$('.body-verticalAd').hide();
						break;
					case 5:
						//Mobile
						//Scroll to Top
						gpt_ScrollToAd = false;
						break;
					case 3: //MPU
					case 4: //SkyScraper
						$(objLeaderboard).hide();
						adId = $('.gpt-ad-defined[data-adsize="boombox"').attr('id');
						break;
					case 10:
						//MasterCompanion
						gpt_ScrollToAd = false;
						break;
					default:
						//Unknown Ad Type
						gpt_ScrollToAd = false;
						break;
				}
				//Hide the second ad if found
				var tCount = 0;
				$(".widget.literatumAd.none.GPT-ad-placeholder.widget-horizontalAd.widget-compact-all").each(function (index) {
					tCount += 1;
					if (tCount !== 1) {
						$(this).hide();
					}
				});
				break;
			case "LANCET":
				objLeaderboard = ".js__adToHide";
				offset = 80;
				switch (parseInt(adTypeId)) {
					case 2:
						//Leaderboard
						gpt_ScrollToAd = false;
						$('.body-verticalAd').hide();
						break;
					case 5:
						//Mobile
						//Scroll to Top
						gpt_ScrollToAd = false;
						break;
					case 3: //MPU
					case 4: //SkyScraper
						$(objLeaderboard).hide();
						adId = $('.gpt-ad-defined[data-adsize="skyscraper"').attr('id');
						break;
					case 10:
						//MasterCompanion
						gpt_ScrollToAd = false;
						break;
					default:
						//Unknown Ad Type
						gpt_ScrollToAd = false;
						break;
				}
				break;
		}

		//Scroll to Top
		var gpt_container = $("html,body");
		gpt_container.animate({ scrollTop: 0, scrollLeft: 0 });

		if (gpt_ScrollToAd) {
			//If Adexists, scroll to it
			var gpt_scrollTo = $('#' + adId);
			if (gpt_scrollTo.length > 0) {
				//Scroll to the Ad
				var gpt_topPosition = gpt_scrollTo.offset().top - gpt_container.offset().top + gpt_container.scrollTop();
				if (gpt_topPosition > 0) {
					gpt_container.animate({ scrollTop: gpt_topPosition, scrollLeft: 0 });
					if (gpt_topPosition - offset > 0 && offset > 0) {
						gpt_container.animate({ scrollTop: gpt_topPosition - offset, scrollLeft: 0 });
					}
				}
			}
		}
	}
	//--------------------------------------------------------------------------
	async function gpt_CheckForCookiePolicy() {
		var returnVal = false;
		if ($('#onetrust-accept-btn-handler').length > 0) {
			$('#onetrust-accept-btn-handler').click();
			returnVal = true;
		}
		return returnVal;
	}
	//--------------------------------------------------------------------------
	function gpt_InitAds() {
		var gpt_ResponsiveHomepage = false;

		switch (gpt_AdFile) {
			case "JBS":
			case "CELLJOURNAL":
			case "CELLBUCKET":
				//Responsive Check
				if ($('#hdrHomeBrand').length > 0) {
					gpt_ResponsiveHomepage = true;
				}
				break;
		}

		//InterScroller Check
		if (gpt_AdFile === "JBS") {
			var gpt_InterScrollerEnabled = false;
			var gpt_InterScrollerInsertObj;

			if ($("#articleHeader").length > 0) {
				//It's an article Page
				if ($('.article__sections > section').length > 0) {
					gpt_InterScrollerEnabled = true;
					gpt_InterScrollerInsertObj = $(".article__sections > section");
				}
			}
			else {
				if ($('.toc__section').length > 0) {
					//It's a TOC Page
					gpt_InterScrollerEnabled = true;
					gpt_InterScrollerInsertObj = $(".toc__section").first();
				}
			}

			//Add the Interscroller
			if (gpt_InterScrollerEnabled) {
				gpt_InterScrollerInsertObj.first().append($("#gpt-Interscroller").clone());
				$("#gpt-Interscroller").remove();
				$(".gpt-adinterscroller").addClass("gpt-ad");
			}
		}

		googletag.cmd.push(function () {
			var gptBoomBoxSizeMapping;
			var gptFluidMapping;
			var gptHomePageSidebarMapping;
			var gptCellHomePageSidebarMapping;
			var gptInterscrollerMapping;
			var gptLeaderboardSizeMapping;
			var gptMobileSizeMapping;
			var gptPrestitialMapping;
			var gptRectangleShortSizeMapping;
			var gptRectangleSizeMapping;
			var gptSideBarSizeMapping;
			var gptTallSizeMapping;
			var gptWideSizeMapping;
			var gptWideRectangleSizeMapping;

			//***********************************************
			//Start Define Size mapping based on client Viewport
			//***********************************************
			if (gpt_AdFile === 'PU') {
				gptTallSizeMapping = googletag.sizeMapping().
					addSize([992, 0], [[300, 600], [160, 600], [120, 600]]).
					addSize([0, 0], []).
					build();

				gptRectangleSizeMapping = googletag.sizeMapping().
					addSize([992, 0], [[300, 250]]).
					addSize([0, 0], []).
					build();

				gptRectangleShortSizeMapping = googletag.sizeMapping().
					addSize([992, 0], [[300, 250], [320, 50], [300, 50]]).
					addSize([0, 0], [[300, 250], [320, 50], [300, 50]]).
					build();

				gptWideSizeMapping = googletag.sizeMapping().
					addSize([992, 0], [[728, 90]]).
					addSize([760, 0], [[728, 90], [320, 50], [300, 50]]).
					addSize([0, 0], [[320, 50], [300, 50]]).
					build();

				gptWideRectangleSizeMapping = googletag.sizeMapping().
					addSize([992, 0], []).
					addSize([760, 0], [[320, 50], [300, 50], [300, 250]]).
					addSize([0, 0], [[320, 50], [300, 50], [300, 250]]).
					build();

				gptMobileSizeMapping = googletag.sizeMapping().
					addSize([0, 0], [[320, 50], [300, 50]]).
					build();

				gptFluidMapping = googletag.sizeMapping().
					addSize([0, 0], ['fluid']).
					build();

				gptPrestitialMapping = googletag.sizeMapping().
					addSize([760, 0], [[1, 1]]).
					build();
			}
			else {
				//JBS-CELL-LANCET
				gptLeaderboardSizeMapping = googletag.sizeMapping().
					addSize([992, 0], [[728, 90]]).
					addSize([768, 0], [[728, 90]]).
					addSize([0, 0], [[320, 50], [300, 50]]).
					build();

				gptHomePageSidebarMapping = googletag.sizeMapping().
					addSize([2090, 795], [[300, 600], [300, 250], [160, 600], [120, 600]]).
					addSize([1910, 795], [[160, 600], [120, 600]]).
                    addSize([1740, 795], [[120, 600]]).
					addSize([0, 0], []).
					build();

				gptCellHomePageSidebarMapping = googletag.sizeMapping().
                    addSize([2180, 795], [[300, 600], [160, 600], [120, 600], [300, 250], [336, 280]]).
					addSize([2180, 445], [[336, 280]]).
                    addSize([2090, 795], [[300, 600], [160, 600], [120, 600], [300, 250]]).
                    addSize([2090, 445], [[300, 250]]).
					addSize([1830, 795], [[160, 600], [120, 600]]).
                    addSize([1740, 795], [[120, 600]]).
					addSize([0, 0], []).
					build();

				gptSideBarSizeMapping = googletag.sizeMapping().
					addSize([1140, 795], [[300, 600], [160, 600], [120, 600], [300, 250]]).
					addSize([1140, 445], [[300, 250]]).
					addSize([0, 0], []). 				
					build();

				gptBoomBoxSizeMapping = googletag.sizeMapping().
					addSize([768, 0], [[300, 250], [336, 280]]).
					addSize([0, 0], []). 						
					build();

				gptFluidMapping = googletag.sizeMapping().
					addSize([0, 0], ['fluid']).
					build();

				gptPrestitialMapping = googletag.sizeMapping().
					addSize([600, 700], [[1, 1]]).
					addSize([0, 0], []).
					build();

				gptInterscrollerMapping = googletag.sizeMapping().
					addSize([1140, 445], []).
					addSize([1024, 768], [[1024, 768]]).
					addSize([768, 1024], [[768, 1024]]).
					addSize([480, 320], [[480, 320]]).
					addSize([320, 480], [[320, 480]]).
					build();
			}
			//***********************************************
			//End Define Size mapping based on client Viewport
			//***********************************************

			//***********************************************
			//Start detection for ad slots on page
			//***********************************************
			var gptMasterPage = gpt_CheckForNULL($('#gptPage').val());
			var gptMasterSite;

			if (gpt_AdFile === 'PU') {
				gptMasterSite = $('#gptSite').val();
			}
			else {
				//JBS-CELL-LANCET
				gptMasterSite = "dev";

				if (gpt_IsProd) {
					gptMasterSite = gpt_CheckForNULL($('#gptSite').val());

					//If there is no master site, check for a defaultsite
					if (gptMasterSite == null) {
						gptMasterSite = gpt_CheckForNULL($('#gptDefaultSite').val());
					}
				}
				else {
					//Dev ENV
					//If the page has no gptSite Value, assume no value which will disable ads
					if (gpt_CheckForNULL($('#gptSite').val()) === null) {
						gptMasterSite = null;
					}
				}

				//If there is no master Page, check for a Page using the URL
				if (gptMasterPage === null) {
					gptMasterPage = GPT_GetPageByURL();
				}
			}

			$(".gpt-ad").each(function (index) {
				var gptPage = '';
				var adSizeMapping = '';
				var gptPOS;
				var gptTC;
				var gptNative;
				var adId;
				var gptSite;
				var tempSlot = null;


                if (gpt_IsProd) {
					if (gpt_AdFile !== "CELLJOURNAL") {
						//Check if the ad slot has it's own site defined
						if (typeof $(this).data('site') === 'undefined') {
							gptSite = gptMasterSite;
						}
						else {
							gptSite = gpt_CheckForNULL($(this).data('site'));
						}
					}
					else {
						gptSite = gptMasterSite;
					}
                }
                else {
					gptSite = gptMasterSite;
                }



				if (gpt_AdFile === 'PU') {
					adId = $(this).attr('id');
				}
				else {
					//JBS-CELL-LANCET
					adId = 'gpt-ad-' + index + 1;
				}

				if (gpt_CheckForNULL(gptSite) !== null) {
					gptSite_Debug = gptSite;

					gptPOS = parseInt($(this).data('pos')) || -1;
					if (gptPOS === -1) {
						gptPOS = index + 1;
					}

					//Check if the ad slot has it's own page defined
					gptPage = $(this).data('page');
					if (gpt_CheckForNULL(gptPage) == null) {
						//Use the Master Page
						gptPage = gptMasterPage;
					}

					//If the page is not null, preceed it with a slash
					if (gptPage !== null) {
						gptPage = '/' + gptPage;
					}
					else {
						gptPage = '';
					}
					gptPage_Debug = gptPage;


					gptTC = $(this).data('tc');
					if (typeof gptTC === "undefined") {
						gptTC = '';
					}

					gptNative = $(this).data('native');
					if (typeof gptNative === "undefined") {
						gptNative = '';
					}

					//Determine sizemapping based on data-adsize
					if (gpt_AdFile === 'PU') {
						switch ($(this).data('adsize')) {
							case 'tall':
								adSizeMapping = gptTallSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600]], adId);
								break;
							case 'rectangle':
								adSizeMapping = gptRectangleSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250]], adId);
								break;
							case 'rectangleshort':
								adSizeMapping = gptRectangleShortSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250], [320, 50], [300, 50]], adId);
								break;
							case 'wide':
								adSizeMapping = gptWideSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[728, 90], [320, 50], [300, 50]], adId);
								break;
							case 'widerectangle':
								adSizeMapping = gptWideRectangleSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[320, 50], [300, 50], [300, 250]], adId);
								break;
							case 'mobile':
								adSizeMapping = gptMobileSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[320, 50], [300, 50]], adId);
								break;
							case 'fluid':
								adSizeMapping = gptFluidMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, 'fluid', adId);
								break;
							case 'prestitial':
								adSizeMapping = gptPrestitialMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[1, 1]], adId);
								break;
						}
					}
					else {
						//JBS-CELL-LANCET
						switch ($(this).data('adsize')) {
							case 'cell-leaderboard':
							case 'leaderboard':
								adSizeMapping = gptLeaderboardSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[728, 90], [320, 50], [300, 50]], adId);
								break;
							case 'bottom':
								if (gpt_ResponsiveHomepage) {
									adSizeMapping = gptHomePageSidebarMapping;
									tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600], [300, 250]], adId);
								}
								else {
									adSizeMapping = gptBoomBoxSizeMapping;
									tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250]], adId);
								}
								break;
							case 'boombox':
								if (gpt_AdFile === "CELLJOURNAL" || gpt_AdFile == "CELLBUCKET") {
									if (gpt_ResponsiveHomepage) {
										adSizeMapping = gptCellHomePageSidebarMapping;
										tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600], [300, 250], [336, 280]], adId);
									}
									else {
										adSizeMapping = gptBoomBoxSizeMapping;
										tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250], [336, 280]], adId);
									}
								}
								else {
									adSizeMapping = gptBoomBoxSizeMapping;
									tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[300, 250]], adId);
								}
								break;
							case 'interscroller':
								adSizeMapping = gptInterscrollerMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[320, 480], [480, 320], [768, 1024], [1024, 768]], adId);
								break;
							case 'sidebar':
							case 'skyscraper':
								adSizeMapping = gptSideBarSizeMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, [[120, 600], [160, 600], [300, 600], [300, 250]], adId);
								break;
							case 'native':
							case 'fluid':
								adSizeMapping = gptFluidMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, 'fluid', adId);
								break;
							case 'prestitial':
								adSizeMapping = gptPrestitialMapping;
								tempSlot = googletag.defineSlot('/6053/els.' + gptSite + gptPage, 'fluid', adId);
								break;
						}
					}
				}

				//Ignore any invalid adsizes that could be on the page
				if (adSizeMapping !== '') {
					$(this).addClass('gpt-ad-defined');
					if (gpt_AdFile !== 'PU') {
						$(this).attr('id', adId);
					}
					tempSlot.defineSizeMapping(adSizeMapping).addService(googletag.pubads()).setTargeting("pos", gptPOS);

					if (gptTC !== '') {
						tempSlot.setTargeting("tc", gptTC);
					}
					if (gptNative !== '') {
						tempSlot.setTargeting("native", gptNative);
					}
					gptEvent_Debug = gptEvent_Debug + $(this).data('adsize') + ' Requested<br>';
				}
				else {
					gptInvalidAdSize_Debug = gptInvalidAdSize_Debug + "Invalid Size Found, Id: " + $(this).prop('id') + ', adSize: ' + $(this).data('adsize') + '<br>';
					$(this).remove();
				}
			});
			if (gpt_CheckForNULL(gptInvalidAdSize_Debug) === null) {
				gptInvalidAdSize_Debug = "None Detected";
			}
			//***********************************************
			//End detection for ad slots on page
			//***********************************************

			//***********************************************
			//Start page level targeting
			//***********************************************
			if (gpt_AdFile !== 'PU') {
				//Logged in or IP Access
				gpt_TargetAccessType();

				//Check for Screenshot Client
				gpt_CheckSSC();
			}

			//Check for DFP Test
			gpt_GetDFPTestId();

			//Check for Additional Targeting
			gpt_GetAdditionalTargeting();

			if (gpt_IsProd && gptContextualEnabled) {
				var gpt_ContextualRetry = false;
				//Check for Contextual Targeting
				if (gs_channels !== "DEFAULT") {
					var gpt_ContextualCategories = Array.from(gs_channels);
					for (var i = 0; i < gpt_ContextualCategories.length; i++) {
						if (gpt_ContextualCategories[i] == 'gx_retry') {
							gpt_ContextualRetry = true;
						}
						if (!gpt_ContextualCategories[i].startsWith("custom_")) {
							//Remove any tag that is not custom
							gpt_ContextualCategories.splice(i, 1);
							i--;
						}
						else {
							//Strip the 'custom_' from the tag
							gpt_ContextualCategories[i] = gpt_ContextualCategories[i].replace("custom_", "")
						}
					}
					if (gpt_ContextualCategories.length > 0) {
						googletag.pubads().setTargeting("gs_cat", gpt_ContextualCategories);
					}
					else {
						gpt_ContextualCategories = 'none';
					}
					if (gpt_ContextualRetry) {
						gpt_ContextualCategories = "*Indexing*";
					}
					gptContextualResult_Debug = gpt_ContextualCategories;
				}
				else {
					gptContextualResult_Debug = 'No segments found';
				}
			}
			else {
				//Not Prod || Contextual not enabled
				gptContextualResult_Debug = 'Not enabled';
				
				if (!gpt_IsProd) {
                    var gpt_DevSite = gpt_CheckForNULL($('#gptSite').val(), "dev");
                    $('#gpt-Variables').append('<input type="hidden" id="gptEnvironment" value="' + gpt_DevSite + '">');
                    gpt_Target("Environment");
                }

			}
			//***********************************************
			//End page level targeting
			//***********************************************

			//Enable google dfp services
			if (parseInt($('#gptLazyLoading').val()) === 1) {
				googletag.pubads().enableLazyLoad({
					fetchMarginPercent: 200,
					renderMarginPercent: 0,
					mobileScaling: 2.0
				});
			}
			else {
				googletag.pubads().enableSingleRequest();
			}

			//Add Listener for RenderEnded
			googletag.pubads().addEventListener('slotRenderEnded', function (event) {
				if (!event.isEmpty) {
					if (typeof LocalAdLoaded === "function") {
						LocalAdLoaded(event);
					}
					if (gpt_ResponsiveHomepage) {
						if (typeof positionAd === "function") {
							positionAd();
						}
					}
					if (event.size[0] == "480" || event.size[1] == "480") {
						$('.gpt-InScrollBox').css('display', 'block');
						gptEvent_Debug = gptEvent_Debug + 'Interscroller ' + event.size + ' rendered: ' + gpt_GetElapsedTime() + '<br>';
					}
					else {
						gptEvent_Debug = gptEvent_Debug + event.size + ' rendered: ' + gpt_GetElapsedTime() + '<br>';
					}

				}
			});

			if (gpt_AdFile !== 'PU') {
				googletag.pubads().collapseEmptyDivs();
			}
			googletag.enableServices();

			//Populate Defined Ad Slots
			$(".gpt-ad-defined").each(function (index) {
				var adId = $(this).attr('id');
				googletag.cmd.push(function () { googletag.display(adId); });
			});

			gptStatus_Debug = 'GPT Complete';
		});
	}
	//--------------------------------------------------------------------------
	function gpt_DisplayDebug() {
		//Clone the template and append to Body
		$(document.body).append($('#gpt-DebugDiv').clone());
		$('#gpt-DebugDiv').remove();

		//Populate the Values
		gpt_LoadDebugValues();

		//Display and scroll to debug section
		$('.gpt-DebugDiv').css('display', 'block');
		window.scrollTo(0, document.body.scrollHeight);
	}
	//--------------------------------------------------------------------------
	function gpt_LoadDebugValues() {
		$('.gpt-DebugBtn').blur();
		$('.gptVersion_Debug').text(gpt_Version);
		$('.gptAdFile_Debug').html(gpt_AdFile);
		$('.gptEvent_Debug').html(gptEvent_Debug);
		$('.gptCustomTargeting_Debug').html(gptCustomTargeting_Debug);
		$('.gptSite_Debug').text(gptSite_Debug);
		$('.gptContextualResult_Debug').text(gptContextualResult_Debug);
		$('.gptContextualInit_Debug').text(gptContextualInit_Debug);
		$('.gptContextualURL_Debug').text(gptContextualURL_Debug);
		$('.gptContextualReady_Debug').text(gptContextualReady_Debug);
		$('.gptMoatReady_Debug').text(gptMoatReady_Debug);
		$('.gptMoatInit_Debug').text(gptMoatInit_Debug);
		$('.gptTestENV_Debug').text(gptTestENV_Debug);
		$('.gptDisableAds_Debug').text(gptDisableAds_Debug);
		$('.gptStatus_Debug').text(gptStatus_Debug);
		$('.gptPage_Debug').text(gptPage_Debug);
		$('.gptInvalidAdSize_Debug').html(gptInvalidAdSize_Debug);
	}
	//--------------------------------------------------------------------------
	function gpt_GrapeShotDebug() {
		$('.gpt-DebugBtn').blur();
		window.open("http://admin-elsevier.grapeshot.co.uk/custom/bookmarklet.cgi?blocking=1&vn=2&url=" + encodeURIComponent(document.location), "GRAPESHOT_POPUP", "width=650,height=600,scrollbars=yes,screenX=40,screenY=50,menubar=no,toolbar=no,resizable=yes", "Custom").focus();
	}
	//--------------------------------------------------------------------------
	function gpt_ShowConsole() {
		$('.gpt-DebugBtn').blur();
		googletag.openConsole();
	}
	//--------------------------------------------------------------------------
</script>
        </div>

            
                </div>
            

        

    

        


    

            

            

            <div data-widget-id="912135d6-7135-4d45-b457-b503cacc3c8b" data-widget-name="ux3-layout-widget"><header class="header base fixed">
    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd none adplaceholder adplaceholder--header js__adToHide widget-horizontalAd" id="9d6062d7-fad6-4e64-81cc-7dd25d99b23d">
                
                

                <div class="wrapped ">
                    
                    <div class="widget-body body body-horizontalAd "><div class="horizontalAdContainer">
    <div class="horizontalAdLabelContainer">
        <div class="horizontalAdLabel">
                <img src="/templates/jsp/_style2/_marlin/images/bg_adHoriz.gif" alt="Advertisement">
        </div>
    </div>
    <div class="horizontalAd">
        





        <div class="pb-ad">
            <!-- Beginning Async AdSlot 1 for Ad unit els.cellpress/cell  ### size: [[728,90]] -->
<div class="gpt-ad" data-adsize="cell-leaderboard" data-page="" data-site="cell" data-pos="1"></div>
<!-- End AdSlot 1 -->
        </div>
    

    </div>
</div></div>
                </div>
                </div>

        










        <div data-widget-def="ux3-layout-widget" data-widget-id="3a83e2a6-2e7e-4931-892c-4ef43b6e3312" class="header__wrapper clearfix" data-db-parent-of="quickSearch"><div id="brandingRow"><a href="/" data-aa-name="science that inspires" data-aa-region="cp global header" title="Visit Cell.com">Science that inspires</a><p id="brandingRowRight"><a href="/" data-aa-name="cell press endorsement" data-aa-region="cp global header" title="Visit Cell.com">A Cell Press journal</a></p></div>
        
    

        


    

            

            

            <div data-widget-id="3a83e2a6-2e7e-4931-892c-4ef43b6e3312" data-widget-name="ux3-layout-widget"><div class="col-xs-6 header__left-side">
    

        


    

            

            
                <a href="/home" id="cpIconLnk" data-aa-name="cell press logo" data-aa-region="cp global header" title="Cell Press" target="_blank"><svg id="cp_logo" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 100 98.1" style="enable-background:new 0 0 100 98.1;" xml:space="preserve" height="100" width="98.1"><path style="fill:#FFFFFF;" d="M69.09,0.09c-4.01-0.6-7.83,1.94-8.78,5.89l-3.14,13.11c-0.76,3.19-3.44,5.56-6.7,5.93l-18.6,2.13          C11.83,29.31-2.53,47.66,0.37,67.78c2.3,15.96,15.18,27.77,30.54,30.08c4.01,0.6,7.83-1.94,8.78-5.89l3.14-13.11 c0.76-3.19,3.44-5.56,6.69-5.93l18.6-2.13c20.04-2.17,34.41-20.52,31.5-40.65C97.32,14.21,84.45,2.39,69.09,0.09z M65.06,47.2  l-11.75,1.4c-1.98,0.21-3.62,1.65-4.08,3.59l-3.43,14.3c-1.01,4.22-4.5,7.39-8.8,8c-6.66,0.72-12.63-4.2-13.15-10.92                c-0.51-6.5,4.6-12.11,11.08-12.81l11.75-1.39c1.98-0.22,3.62-1.65,4.08-3.59l3.43-14.3c1.01-4.22,4.5-7.39,8.8-8          c6.66-0.72,12.63,4.19,13.15,10.92C76.66,40.89,71.55,46.5,65.06,47.2z"></path></svg></a><div class="journal-logos">
            

            <span data-widget-id="35d8d734-3aa0-4ec8-9e2d-14babe803594" data-widget-name="ux3-general-image"><a href="/cell/home" title="Cell"><img alt="Cell" src="/pb-assets/ux3/logos/cell/Cell_white-1532516611593.svg"></a></span>

            
                </div>
            

        

    

        


    

            

            
                <div class="journal-logos">
            

            <span data-widget-id="3ffcbf1f-79fd-4ba3-85b5-bef10a63475f" data-widget-name="ux3-general-image"><a href="https://www.cell.com/open-access?utm_source=oa-label&amp;__hstc=109691226.e4e812b53ff324eccbdbdb2e4fb9a6ab.1644503737405.1644524234622.1644587109507.4&amp;__hssc=109691226.7.1644587109507&amp;__hsfp=3253153019" title="This journal offers authors two options (open access or subscription) to publish research"><img alt="This journal offers authors two options (open access or subscription) to publish research" src="/pb-assets/ux3/logos/cell/Supports_open_access_border-1645554937897.svg"></a></span>

            
                </div>
            

        
</div><div class="col-xs-6">
    

        


    

            

            

            <div data-widget-id="2555f6db-b333-4edb-8b15-ef9213f1f0a5" data-widget-name="ux3-layout-widget"><div class="header__nav row">
    

        


    

            

            

            <ul data-widget-id="52432d24-0331-4c9d-85f3-2033edc7208b" data-widget-name="UX3ProfileLinksWidget" class="rlist rlist--inline profile-links"><li class="profile-links__submit"><a data-adobe-name="Publish" class="profile-links__submit__btn" title="Submit" href="https://www.editorialmanager.com/cell" target="_self" data-aa-conversiondriver="jbs:global-header:submitpage" data-profile-link="true">Submit</a></li><li class="profile-links__login-dropdown"><div class="profile-links__user-list__wrapper"><button data-db-target-for="loginmenu-162876" aria-expanded="false" aria-controls="login-links-162876" title="Log in links dropdown" class="profile-links__username"><span>Log in</span></button><div data-db-target-of="loginmenu-162876" id="login-links--162876" class="profile-links__user-list__holder dropBlock__holder"><ul class="rlist profile-links__list"><li class="profile-links__login"><a data-adobe-name="Log In" class="profile-links__login__btn" title="Log in to Cell.com" href="https://www.cell.com/action/idLogin?type=login&amp;redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" target="_self" data-profile-link="true">Log in</a></li><li class="profile-links__institution"><a data-adobe-name="Get institutional access" class="profile-links__institution__btn" title="Institutional access" href="https://www.cell.com/action/idLogin?type=institution&amp;redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" target="_self" data-profile-link="true">Get Institutional Access</a></li></ul></div></div></li><li class="profile-links__register"><a data-adobe-name="Register" class="profile-links__register__btn" title="Register a username and password for free" href="https://www.cell.com/action/idLogin?type=registration&amp;redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" target="_self" data-profile-link="true">Register</a></li><li class="hidden-lg"> <div class="profile-links__controls"> <button aria-expanded="false" aria-controls="links-dialog-162876" data-opens="#links-dialog-162876" class="profile-links__btn--open"><span class="sr-only">open links dialog</span><i aria-hidden="true" class="icon-gizmo-person"></i></button></div><dialog id="links-dialog-162876" aria-modal="true"><button data-closes="#links-dialog-162876" class="profile-links__btn--close"><span class="sr-only">close links dialog</span><i aria-hidden="true" class="icon-close-solid"></i></button><ul>   <li class="profile-links__submit"><a data-adobe-name="Publish" class="profile-links__submit__btn" title="Submit" href="https://www.editorialmanager.com/cell" target="_self" data-aa-conversiondriver="jbs:global-header:submitpage" data-profile-link="true">Submit</a></li><li class="profile-links__login"><a data-adobe-name="Log In" class="profile-links__login__btn" title="Log in to Cell.com" href="https://www.cell.com/action/idLogin?type=login&amp;redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" target="_self" data-profile-link="true">Log in</a></li><li class="profile-links__institution"><a data-adobe-name="Get institutional access" class="profile-links__institution__btn" title="Institutional access" href="https://www.cell.com/action/idLogin?type=institution&amp;redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" target="_self" data-profile-link="true">Get Institutional Access</a></li><li class="profile-links__register"><a data-adobe-name="Register" class="profile-links__register__btn" title="Register a username and password for free" href="https://www.cell.com/action/idLogin?type=registration&amp;redirectUri=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2820%2931141-7" target="_self" data-profile-link="true">Register</a></li></ul></dialog></li></ul>

            

        
</div></div>

            

        
</div></div>

            

        

        </div>
    

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget csasInstitutionBanner none  widget-none" id="51b7fa33-2137-4f58-9e98-9746c4400513" style="display: none;">
                
                

                <div class="wrapped ">
                    
                    <div class="widget-body body body-none "><div class="ui-state-highlight ui-corner-all csas-institution-banner hidden" data-doi="10.1016/j.cell.2020.08.053">
    <span class="ui-icon ui-icon-close banner-close"></span>
    <p>
        Access provided by <span class="accountName"></span>
    </p>
</div>

<style>
    .csas-institution-banner {
        padding: 10px 0 0 10px;
        margin: 5px;
    }

    .csas-institution-banner.ui-state-highlight .ui-icon {
        background-image: url("/templates/jsp/css/jquery-ui-1.10.2/base/images/ui-icons_454545_256x240.png");
        margin-right: 5px;
        margin-top: -4px;
    }

    .csas-institution-banner .banner-close {
        float: right;
    }
</style>

<script>

    function resetBanner(doi) {
        $.get('/action/getAccount?doi=' + doi, function(data) {
            if (data) {
                $(".csas-institution-banner p .accountName").html(data);
                $(".csasInstitutionBanner").fadeIn();
                $(".csas-institution-banner").fadeIn();
            }
        });
    }

    var flag = 0;
    $(document).ready(function() {
        if(!$(".csas-institution-banner").is(":visible")){
            $(".csasInstitutionBanner").hide();
        }

        $(".banner-close").click(function() {
            $.get("/action/dismissBanner", function(data) {
                $(".csasInstitutionBanner").fadeOut(function () {
                    if(typeof UX !== 'undefined') {
                        UX.pageBody.init();
                    }
                });
            });
        });

        $(".articleContent .tabs li[role='tab'].showFullText").click(function() {
           flag = 1;
        });

        $(document).on("reloadTabsContent", function() {
            var isSelected = $(".articleContent .tabs li[role='tab'].showFullText").hasClass("active");
            if (isSelected) {
                var isHidden =  $(".csas-institution-banner").is(".hidden");
                if (!isHidden) {
                    resetBanner($(".csas-institution-banner").data("doi"));
                    console.log("fadeIn");
                }
            } else {
                $(".csas-institution-banner").fadeOut();
                console.log("fadeOut");
            }
            flag = 0;
        });

        $(document).on("click", ".articleContent .tabs li[role='tab']", function() {

        });
    });
</script></div>
                </div>
                </div>

        
</header></div>

            

        










        <div data-widget-def="graphQueryWidget" data-widget-id="2a125dae-6dbc-4e76-a75e-3e563f1d3a1d" class="ux3">
        
    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget graphQueryWidget none top-padding-handler noMargin axel-mega-menu widget-none widget-compact-all fonts-loaded" id="2a125dae-6dbc-4e76-a75e-3e563f1d3a1d" style="padding-top: 115.594px;">
                
                
                    
                

                <div class="wrapped " id="CP TOP LEVEL NAV MENU">
                    
                    <div class="widget-body body body-none  body-compact-all"><nav id="mega-menu-nav" role="navigation" class="mega-menu-nav">
  <!--.skip//a(href='#searchText' aria-label='Skip menu') Skip menu
  -->
  <div class="mega-menu-nav__wrapper">
    <button class="mega-menu__toggle"><span class="sr-only">Main menu</span><i aria-hidden="true" class="icon-gizmo-hamburger"></i></button>
    <ul role="menubar" class="mega-menu rlist">
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-1" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-1" data-item-link="main-menu-link-1" data-index="0" class="mega-menu__item-link menu-link"><span>This journal</span></a>
        <div id="main-menu-panel-1" aria-labelledby="main-menu-link-1" data-item-wrapper="main-menu-link-1" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <div aria-label="Menu dropzone section" tabindex="-1" class="listDropZone">
    

        


    

            

            

            <div class="cover-image"><div class="cover-image__thumb"><a href="/issue/S0092-8674(24)X0012-4" class="menu-link"><img src="/cms/asset/atypon:cms:attachment:img:d5e6:rev:1748270185670-389:pii:S0092867424X00124/cover.tif.jpg" alt="Cover Image - Cell, Volume 188, Issue 11"></a></div><div class="cover-image__meta"></div></div>

            

        
</div>
            </li>
            <li style="grid-column: 2/3" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-1-2" class="sub-menu__heading">Read
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/newarticles" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Online now</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/current" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Current issue</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/archive" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Archive</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/action/showPreferences?menuTab=Alerts" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Publication alerts</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/sneakpeek" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Sneak Peek - preprints</span></a></li>
              </ul>
            </li>
            <li style="grid-column: 3/5" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-1-3" class="sub-menu__heading">About
              </h4>
              <ul role="menubar" data-index="1" class="rlist heading-list col-count-2">
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/advisory-board" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Advisory board</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/aims" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Aims and scope</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/contact" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Contact</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/editors-and-staff" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Editors and staff</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/editorial-ethics" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Ethics</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/information-for-authors/permissions" data-index="5" role="menuitem" class="sub-menu__item-link menu-link"><span>Permissions</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/reviewers" data-index="6" role="menuitem" class="sub-menu__item-link menu-link"><span>Reviewer instructions</span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-2" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-2" data-item-link="main-menu-link-2" data-index="1" class="mega-menu__item-link menu-link"><span>Journals</span></a>
        <div id="main-menu-panel-2" aria-labelledby="main-menu-link-2" data-item-wrapper="main-menu-link-2" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/5" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-2-1" class="sub-menu__heading">Life &amp; medical sciences
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-4">
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/home" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cancer-cell/home" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Cancer Cell</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-chemical-biology" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Chemical Biology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-genomics/home" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Genomics</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-host-microbe/home" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Host &amp; Microbe</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-metabolism/home" data-index="5" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Metabolism</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-reports/home" data-index="6" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Reports</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-reports-medicine/home" data-index="7" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Reports Medicine</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-stem-cell/home" data-index="8" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Stem Cell</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-systems/home" data-index="9" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Systems</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/current-biology/home" data-index="10" role="menuitem" class="sub-menu__item-link menu-link"><span>Current Biology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/developmental-cell/home" data-index="11" role="menuitem" class="sub-menu__item-link menu-link"><span>Developmental Cell</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/immunity/home" data-index="12" role="menuitem" class="sub-menu__item-link menu-link"><span>Immunity</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/med/home" data-index="13" role="menuitem" class="sub-menu__item-link menu-link"><span>Med</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/molecular-cell/home" data-index="14" role="menuitem" class="sub-menu__item-link menu-link"><span>Molecular Cell</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/neuron/home" data-index="15" role="menuitem" class="sub-menu__item-link menu-link"><span>Neuron</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/structure/home" data-index="16" role="menuitem" class="sub-menu__item-link menu-link"><span>Structure</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/ajhg/home" data-index="17" role="menuitem" class="sub-menu__item-link menu-link"><span>American Journal of Human Genetics (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/biophysj/home" data-index="18" role="menuitem" class="sub-menu__item-link menu-link"><span>Biophysical Journal (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/biophysreports/home" data-index="19" role="menuitem" class="sub-menu__item-link menu-link"><span>Biophysical Reports (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/hgg-advances/home" data-index="20" role="menuitem" class="sub-menu__item-link menu-link"><span>Human Genetics and Genomics Advances (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/molecular-plant/home" data-index="21" role="menuitem" class="sub-menu__item-link menu-link"><span>Molecular Plant (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/molecular-therapy-family/molecular-therapy/home" data-index="22" role="menuitem" class="sub-menu__item-link menu-link"><span>Molecular Therapy (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/molecular-therapy-family/methods/home" data-index="23" role="menuitem" class="sub-menu__item-link menu-link"><span>Molecular Therapy Methods &amp; Clinical Development (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/molecular-therapy-family/nucleic-acids/home" data-index="24" role="menuitem" class="sub-menu__item-link menu-link"><span>Molecular Therapy Nucleic Acids (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/molecular-therapy-family/oncology/home" data-index="25" role="menuitem" class="sub-menu__item-link menu-link"><span>Molecular Therapy Oncology (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/plant-communications/home" data-index="26" role="menuitem" class="sub-menu__item-link menu-link"><span>Plant Communications (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/stem-cell-reports/home" data-index="27" role="menuitem" class="sub-menu__item-link menu-link"><span>Stem Cell Reports (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/biochemical-sciences/home" data-index="28" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Biochemical Sciences</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/cancer/home" data-index="29" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Cancer</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/cell-biology/home" data-index="30" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Cell Biology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/ecology-evolution/home" data-index="31" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Ecology &amp; Evolution</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/endocrinology-metabolism/home" data-index="32" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Endocrinology &amp; Metabolism</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/genetics/home" data-index="33" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Genetics</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/immunology/home" data-index="34" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Immunology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/microbiology/home" data-index="35" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Microbiology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/molecular-medicine/home" data-index="36" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Molecular Medicine</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/neurosciences/home" data-index="37" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Neurosciences</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/parasitology/home" data-index="38" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Parasitology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/pharmacological-sciences/home" data-index="39" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Pharmacological Sciences</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/plant-science/home" data-index="40" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Plant Science</span></a></li>
              </ul>
            </li>
            <li style="grid-column: 5/6" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-2-2" class="sub-menu__heading">Physical sciences &amp; engineering
              </h4>
              <ul role="menubar" data-index="1" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-biomaterials/home" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Biomaterials</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-reports-physical-science/home" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Reports Physical Science</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/chem/home" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Chem</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/chem-catalysis/home" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Chem Catalysis</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/device/home" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Device</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/joule/home" data-index="5" role="menuitem" class="sub-menu__item-link menu-link"><span>Joule</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/matter/home" data-index="6" role="menuitem" class="sub-menu__item-link menu-link"><span>Matter</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/newton/home" data-index="7" role="menuitem" class="sub-menu__item-link menu-link"><span>Newton</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/chemistry/home" data-index="8" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Chemistry</span></a></li>
              </ul>
            </li>
            <li style="grid-column: 6/7" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-2-3" class="sub-menu__heading">Multidisciplinary
              </h4>
              <ul role="menubar" data-index="2" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-reports-methods/home" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Reports Methods</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-reports-sustainability/home" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Reports Sustainability</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/heliyon/home" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Heliyon</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/iscience/home" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>iScience</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/one-earth/home" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>One Earth</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/patterns/home" data-index="5" role="menuitem" class="sub-menu__item-link menu-link"><span>Patterns</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/star-protocols/home" data-index="6" role="menuitem" class="sub-menu__item-link menu-link"><span>STAR Protocols</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/nexus/home" data-index="7" role="menuitem" class="sub-menu__item-link menu-link"><span>Nexus (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/the-innovation/home" data-index="8" role="menuitem" class="sub-menu__item-link menu-link"><span>The Innovation (<em>partner</em>)</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/biotechnology/home" data-index="9" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Biotechnology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/trends/cognitive-sciences/home" data-index="10" role="menuitem" class="sub-menu__item-link menu-link"><span>Trends in Cognitive Sciences</span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-3" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-3" data-item-link="main-menu-link-3" data-index="2" class="mega-menu__item-link menu-link"><span>Publish</span></a>
        <div id="main-menu-panel-3" aria-labelledby="main-menu-link-3" data-item-wrapper="main-menu-link-3" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-3-1" class="sub-menu__heading">Authors
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="https://www.editorialmanager.com/cell?__hstc=25856994.7201670a4397fa03148684920d4a8d38.1672762013831.1694716659709.1694718909620.146&amp;__hssc=25856994.15.1694718909620&amp;__hsfp=1366844671" data-index="0" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Submit article
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell/information-for-authors" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Information for authors</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/open-access" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Open access</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/multi-journal-submission" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Multi-Journal Submission</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/information-for-authors/star-authors-guide" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>STAR Methods</span></a></li>
              </ul>
            </li>
            <li style="grid-column: 2/3" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-3-2" class="sub-menu__heading">Reviewers
              </h4>
              <ul role="menubar" data-index="1" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/reviewers" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Information for reviewers</span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-4" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-4" data-item-link="main-menu-link-4" data-index="3" class="mega-menu__item-link menu-link"><span>News &amp; events</span></a>
        <div id="main-menu-panel-4" aria-labelledby="main-menu-link-4" data-item-wrapper="main-menu-link-4" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/newsroom" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Newsroom</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/events" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Events</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/symposia" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Symposia</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/webinars" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Webinars</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/consortia" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Consortia Hub</span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
      <li role="presentation" class="mega-menu__item"><a id="main-menu-link-5" aria-haspopup="true" href="javascript:void(0)" role="menuitem" aria-controls="main-menu-panel-5" data-item-link="main-menu-link-5" data-index="4" class="mega-menu__item-link menu-link"><span>About Cell Press</span></a>
        <div id="main-menu-panel-5" aria-labelledby="main-menu-link-5" data-item-wrapper="main-menu-link-5" aria-expanded="false" class="mega-menu__item-wrapper">
          <ul class="sub-menu rlist mega-menu__sub-menu-heading">
            <li style="grid-column: 1/2" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-5-1" class="sub-menu__heading">Cell Press
              </h4>
              <ul role="menubar" data-index="0" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/about" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>About Cell Press</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/contact" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Contact us</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="https://service.elsevier.com/app/overview/cell-press/" data-index="2" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Help &amp; support
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/open-access" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>Open access at Cell Press</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/diversity" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Inclusion and diversity</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-press-50" data-index="5" role="menuitem" class="sub-menu__item-link menu-link"><span>50th anniversary</span></a></li>
              </ul>
            </li>
            <li style="grid-column: 2/3" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-5-2" class="sub-menu__heading">Hubs
              </h4>
              <ul role="menubar" data-index="1" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="/biotechnology-bioengineering" data-index="0" role="menuitem" class="sub-menu__item-link menu-link"><span>Biotechnology and bioengineering</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/cell-press-chemistry" data-index="1" role="menuitem" class="sub-menu__item-link menu-link"><span>Chemistry</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/clinical-translational" data-index="2" role="menuitem" class="sub-menu__item-link menu-link"><span>Clinical and translational</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/covid-19" data-index="3" role="menuitem" class="sub-menu__item-link menu-link"><span>COVID-19</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/fundamental-biology" data-index="4" role="menuitem" class="sub-menu__item-link menu-link"><span>Fundamental biology</span></a></li>
                <li role="presentation" class="menu-link__wrapper"><a href="/sustainability" data-index="5" role="menuitem" class="sub-menu__item-link menu-link"><span>Sustainability</span></a></li>
              </ul>
            </li>
            <li style="grid-column: 3/4" class="double-width sub-menu__item">
              <h4 data-item-link="main-menu-link-5-3" class="sub-menu__heading">Careers
              </h4>
              <ul role="menubar" data-index="2" class="rlist heading-list col-count-1">
                <li role="presentation" class="menu-link__wrapper"><a href="https://relx.wd3.myworkdayjobs.com/en-US/ElsevierJobs" data-index="0" target="_blank" role="menuitem" class="sub-menu__item-link menu-link"><span>Cell Press careers
                      <div class="external-icon"></div><span class="sr-only">External Link</span></span></a></li>
              </ul>
            </li>
          </ul>
        </div>
      </li>
    </ul>
    <div class="mega-menu-nav__quick-search">
    

        


    

            

            

            <div data-widget-id="a1f05748-166f-41e0-b01a-ca8ac1cc95d4" data-widget-name="UX3QuickSearchWidget" class="quick-search"><div class="dropBlock"><form action="https://www.cell.com/action/doSearch?journalCode=cell" name="quickSearchBar" method="get" title="Quick Search"><input id="type" type="hidden" value="quicksearch" name="type"><div class="quick-search__toggle autoCompleteWrapper"><input id="searchText" type="text" name="text1" placeholder="Search for..." enterkeyhint="search" autocomplete="off" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" data-group-titles-conf="3" data-publication-items-conf="3" aria-label="Enter a search term" class="searchText searchText-autocomplete ui-autocomplete-input"><button type="submit" title="Search" aria-label="Submit the search form" class="btn quick-search__button icon-search"><span>Go search</span></button><a href="https://www.cell.com/search/advanced?SeriesKey=cell&amp;ISSN=0092-8674&amp;journalCode=cell" title="Advanced search" class="quick-search__advanced-link">Advanced search</a><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" unselectable="on" style="display: none;"></ul></div><div class="quick-search__box"><div class="quick-search__box-inner"><div class="quick-search__box-wrapper"><select name="field1" aria-label="Select a search area"><option value="AllField">All content</option><option value="Title">Article title</option><option value="Contrib">Authors</option><option value="Keyword">Keywords</option><option value="Abstract">Abstract</option><option value="AbstractTitleKeywordFilterField">Article title, abstract, keywords</option></select><input type="hidden" name="journalCode" value="cell"><div class="quick-search__scope-options"><span>Search within:</span><label title="This journal" class="radio--primary"><input type="radio" name="SeriesKey" id="searchScopeSeries-a1f05748-166f-41e0-b01a-ca8ac1cc95d4" title="This journal" value="cell" checked="checked" aria-label="Search within current journal"><span>This journal</span></label><label title="Full site" class="radio--primary"><input type="radio" name="SeriesKey" id="searchScopeFullSite-a1f05748-166f-41e0-b01a-ca8ac1cc95d4" value="" title="Full site" aria-label="Search within full site"><span>Full site</span></label></div><a href="https://www.cell.com/search/advanced?SeriesKey=cell&amp;ISSN=0092-8674&amp;journalCode=cell" title="Advanced search" class="quick-search__advanced-link">Advanced search</a></div><a href="javascript:void(0)" aria-label="Close search options" title="Close search options" class="quick-search__box-close"><i aria-hidden="true" class="icon-tools_close"></i></a></div></div><div class="quick-search__alert hidden"><p>Please enter a term before submitting your search.</p><a href="#" class="quick-search__alert--close"> Ok</a></div></form></div></div>

            

        
</div>
  </div>
</nav>
<div id="page-body-id" class="page-body-flag"></div></div>
                </div>
                </div>

        

        </div>
    

    

        


    

            

            

            <div data-widget-id="f8c6daf9-9df1-4fd9-ba3a-7f5d7b3d4466" data-widget-name="UX3HTMLWidget"><style>
.journal-logos:nth-of-type(2) img {
max-height: 30px !important;
}
.journal-logos:nth-of-type(3) img {
max-height: 30px !important;
}
.ux3 .journal-logos + .journal-logos {
margin-left: 30px;
}
.header__wrapper.clearfix .col-xs-6:first-of-type {
width: 55%;
}
.header__wrapper.clearfix .col-xs-6:nth-of-type(2) {
width: 45%;
}
@media screen and (max-width: 1000px) {
.ux3 .journal-logos + .journal-logos {
display: none;
}
.header__wrapper.clearfix .col-xs-6:first-of-type {
width: 50%;
}
.header__wrapper.clearfix .col-xs-6:nth-of-type(2) {
width: 50%;
}
}

.ux3 .journal-logos:first-of-type {
   max-width: 500px;
}

.profile-links {
   white-space: nowrap;
}

@media only screen and (min-width: 740px) and (max-width: 1600px) {
   .journal-logos:nth-of-type(2) img {
      max-width: 250px !important;
   }
}

@media only screen and (min-width: 1024px) and (max-width: 1600px) {
   .header__wrapper.clearfix .col-xs-6:first-of-type {
      width: 60% !important;
   }
   .header__wrapper.clearfix .col-xs-6:nth-of-type(2) {
      width: 40% !important;
   }
}

@media only screen and (max-width: 1240px) {
   .ux3 .journal-logos + .journal-logos {
      display: none !important;
   }
}

</style></div>

            

        
</div></div>

            
                </div>
            

        

        </div>
    

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget axelPublicationContent none  widget-none" id="cadc9b41-a542-448a-9de4-8d0803320174">
                
                

                <div class="wrapped ">
                    
                    <div class="widget-body body body-none "><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/marlin/cell/releasedAssets/css/build-article-b26f3342b722959c7931.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail long-title" vocab="http://schema.org/" typeof="ScholarlyArticle" data-pii="S0092-8674(20)31141-7" lang="en" dir="ltr"><div data-core-wrapper="header"><header data-extent="frontmatter"><div class="core-container"><div data-article-access="free" data-article-access-type="open" class="meta-panel"><span class="meta-panel__left-content"><span class="meta-panel__type"><span>Article</span></span></span><span class="meta-panel__middle-content"><span class="meta-panel__volumeIssue"><a href="/cell/issue?pii=S0092-8674(19)X0022-7"><span>Volume 183</span>, <span>Issue 2</span></a></span><span class="meta-panel__pages"><span>p347-362.e24</span></span><span class="meta-panel__onlineDate">October 15, 2020</span></span><span class="meta-panel__right-content"><span class="meta-panel__access meta-panel__access--archive"><span>Open Archive</span></span></span><div class="article-header__download-full-issue"><button title="Download full issue" type="submit" formaction="/action/downloadMultiplePdf?action=downloadIssuePdf&amp;journal=cell&amp;volume=183&amp;issue=2&amp;pii=S0092-8674%2819%29X0022-7" class="btn--download-issue btn--cancel download-full-issue"><i class="icon-download-new"></i><span>Download Full Issue</span></button><div class="table-of-content__alert table-of-content__alert--download"><p>Download started</p><a href="#" class="table-of-content__alert--close">Ok</a></div></div></div><h1 property="name">A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer</h1><div class="contributors"><span class="authors"><span role="list"><span property="author" typeof="Person" role="listitem" class="corresponding-author"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au1" aria-controls="axel_author_au1"><span property="givenName">Patrick A.</span> <span property="familyName">Ott</span></a><div id="au1" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Patrick A.</span> <span property="familyName">Ott</span> <a class="orcid-id" href="https://orcid.org/0000-0002-4253-943X" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-4253-943X</a></div><div class="content"><div class="core-author-emails"><div class="label">Correspondence</div><div>Corresponding author</div><div><a id="eadd00151" href="mailto:patrick_ott@dfci.harvard.edu" property="email" title="Send email to Patrick A. Ott">patrick_ott@dfci.harvard.edu</a></div></div><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Ott/Patrick+A" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">1</a></sup> <a id="eadd00151" href="mailto:patrick_ott@dfci.harvard.edu" property="email" title="Send email to Patrick A. Ott">patrick_ott@dfci.harvard.edu</a></span> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au2" aria-controls="axel_author_au2"><span property="givenName">Siwen</span> <span property="familyName">Hu-Lieskovan</span></a><div id="au2" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Siwen</span> <span property="familyName">Hu-Lieskovan</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Hu-Lieskovan/Siwen" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">2</a></sup></span> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au3" aria-controls="axel_author_au3"><span property="givenName">Bartosz</span> <span property="familyName">Chmielowski</span></a><div id="au3" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Bartosz</span> <span property="familyName">Chmielowski</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2374-3320" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-2374-3320</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Chmielowski/Bartosz" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">2</a></sup></span><span data-displayed-on="all"> ∙ … </span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au4" aria-controls="axel_author_au4"><span property="givenName">Ramaswamy</span> <span property="familyName">Govindan</span></a><div id="au4" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au4"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Ramaswamy</span> <span property="familyName">Govindan</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Washington University School of Medicine, St. Louis, MO, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Govindan/Ramaswamy" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">3</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au5" aria-controls="axel_author_au5"><span property="givenName">Aung</span> <span property="familyName">Naing</span></a><div id="au5" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au5"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Aung</span> <span property="familyName">Naing</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Naing/Aung" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">4</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au6" aria-controls="axel_author_au6"><span property="givenName">Nina</span> <span property="familyName">Bhardwaj</span></a><div id="au6" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au6"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Nina</span> <span property="familyName">Bhardwaj</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Tisch Cancer Institute, Icahn School of Medicine, New York, NY, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Bhardwaj/Nina" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">5</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au7" aria-controls="axel_author_au7"><span property="givenName">Kim</span> <span property="familyName">Margolin</span></a><div id="au7" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au7"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Kim</span> <span property="familyName">Margolin</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Margolin/Kim" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">6</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au8" aria-controls="axel_author_au8"><span property="givenName">Mark M.</span> <span property="familyName">Awad</span></a><div id="au8" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au8"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Mark M.</span> <span property="familyName">Awad</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0928-5244" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0003-0928-5244</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Awad/Mark+M" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">1</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au9" aria-controls="axel_author_au9"><span property="givenName">Matthew D.</span> <span property="familyName">Hellmann</span></a><div id="au9" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au9"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Matthew D.</span> <span property="familyName">Hellmann</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2670-9777" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-2670-9777</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Memorial Sloan Kettering Cancer Center, New York, NY, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Hellmann/Matthew+D" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">7</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au10" aria-controls="axel_author_au10"><span property="givenName">Jessica J.</span> <span property="familyName">Lin</span></a><div id="au10" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au10"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Jessica J.</span> <span property="familyName">Lin</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7373-3916" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0001-7373-3916</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Cancer Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Lin/Jessica+J" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">8</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au11" aria-controls="axel_author_au11"><span property="givenName">Terence</span> <span property="familyName">Friedlander</span></a><div id="au11" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au11"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Terence</span> <span property="familyName">Friedlander</span> <a class="orcid-id" href="https://orcid.org/0000-0002-3630-4941" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-3630-4941</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Friedlander/Terence" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">9</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au12" aria-controls="axel_author_au12"><span property="givenName">Meghan E.</span> <span property="familyName">Bushway</span></a><div id="au12" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au12"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Meghan E.</span> <span property="familyName">Bushway</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Bushway/Meghan+E" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au13" aria-controls="axel_author_au13"><span property="givenName">Kristen N.</span> <span property="familyName">Balogh</span></a><div id="au13" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au13"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Kristen N.</span> <span property="familyName">Balogh</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Balogh/Kristen+N" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au14" aria-controls="axel_author_au14"><span property="givenName">Tracey E.</span> <span property="familyName">Sciuto</span></a><div id="au14" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au14"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Tracey E.</span> <span property="familyName">Sciuto</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2985-9930" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-2985-9930</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Sciuto/Tracey+E" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au15" aria-controls="axel_author_au15"><span property="givenName">Victoria</span> <span property="familyName">Kohler</span></a><div id="au15" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au15"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Victoria</span> <span property="familyName">Kohler</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Kohler/Victoria" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au16" aria-controls="axel_author_au16"><span property="givenName">Samantha J.</span> <span property="familyName">Turnbull</span></a><div id="au16" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au16"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Samantha J.</span> <span property="familyName">Turnbull</span> <a class="orcid-id" href="https://orcid.org/0000-0002-2880-6677" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-2880-6677</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Turnbull/Samantha+J" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au17" aria-controls="axel_author_au17"><span property="givenName">Rana</span> <span property="familyName">Besada</span></a><div id="au17" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au17"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Rana</span> <span property="familyName">Besada</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7255-3435" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-7255-3435</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Besada/Rana" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au18" aria-controls="axel_author_au18"><span property="givenName">Riley R.</span> <span property="familyName">Curran</span></a><div id="au18" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au18"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Riley R.</span> <span property="familyName">Curran</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Curran/Riley+R" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au19" aria-controls="axel_author_au19"><span property="givenName">Benjamin</span> <span property="familyName">Trapp</span></a><div id="au19" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au19"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Benjamin</span> <span property="familyName">Trapp</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Trapp/Benjamin" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au20" aria-controls="axel_author_au20"><span property="givenName">Julian</span> <span property="familyName">Scherer</span></a><div id="au20" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au20"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Julian</span> <span property="familyName">Scherer</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Scherer/Julian" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au21" aria-controls="axel_author_au21"><span property="givenName">Asaf</span> <span property="familyName">Poran</span></a><div id="au21" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au21"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Asaf</span> <span property="familyName">Poran</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9118-1051" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0001-9118-1051</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Poran/Asaf" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au22" aria-controls="axel_author_au22"><span property="givenName">Dewi</span> <span property="familyName">Harjanto</span></a><div id="au22" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au22"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Dewi</span> <span property="familyName">Harjanto</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0754-4409" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0003-0754-4409</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Harjanto/Dewi" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au23" aria-controls="axel_author_au23"><span property="givenName">Dominik</span> <span property="familyName">Barthelme</span></a><div id="au23" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au23"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Dominik</span> <span property="familyName">Barthelme</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Barthelme/Dominik" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au24" aria-controls="axel_author_au24"><span property="givenName">Ying Sonia</span> <span property="familyName">Ting</span></a><div id="au24" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au24"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Ying Sonia</span> <span property="familyName">Ting</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Ting/Ying+Sonia" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au25" aria-controls="axel_author_au25"><span property="givenName">Jesse Z.</span> <span property="familyName">Dong</span></a><div id="au25" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au25"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Jesse Z.</span> <span property="familyName">Dong</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Dong/Jesse+Z" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au26" aria-controls="axel_author_au26"><span property="givenName">Yvonne</span> <span property="familyName">Ware</span></a><div id="au26" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au26"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Yvonne</span> <span property="familyName">Ware</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Ware/Yvonne" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au27" aria-controls="axel_author_au27"><span property="givenName">Yuting</span> <span property="familyName">Huang</span></a><div id="au27" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au27"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Yuting</span> <span property="familyName">Huang</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Huang/Yuting" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au28" aria-controls="axel_author_au28"><span property="givenName">Zhengping</span> <span property="familyName">Huang</span></a><div id="au28" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au28"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Zhengping</span> <span property="familyName">Huang</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0406-5421" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-0406-5421</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Huang/Zhengping" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au29" aria-controls="axel_author_au29"><span property="givenName">Amy</span> <span property="familyName">Wanamaker</span></a><div id="au29" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au29"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Amy</span> <span property="familyName">Wanamaker</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Wanamaker/Amy" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au30" aria-controls="axel_author_au30"><span property="givenName">Lisa D.</span> <span property="familyName">Cleary</span></a><div id="au30" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au30"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Lisa D.</span> <span property="familyName">Cleary</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Cleary/Lisa+D" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au31" aria-controls="axel_author_au31"><span property="givenName">Melissa A.</span> <span property="familyName">Moles</span></a><div id="au31" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au31"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Melissa A.</span> <span property="familyName">Moles</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Moles/Melissa+A" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au32" aria-controls="axel_author_au32"><span property="givenName">Kelledy</span> <span property="familyName">Manson</span></a><div id="au32" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au32"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Kelledy</span> <span property="familyName">Manson</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Manson/Kelledy" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au33" aria-controls="axel_author_au33"><span property="givenName">Joel</span> <span property="familyName">Greshock</span></a><div id="au33" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au33"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Joel</span> <span property="familyName">Greshock</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6567-4266" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0001-6567-4266</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Greshock/Joel" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au34" aria-controls="axel_author_au34"><span property="givenName">Zakaria S.</span> <span property="familyName">Khondker</span></a><div id="au34" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au34"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Zakaria S.</span> <span property="familyName">Khondker</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Khondker/Zakaria+S" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au35" aria-controls="axel_author_au35"><span property="givenName">Ed</span> <span property="familyName">Fritsch</span></a><div id="au35" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au35"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Ed</span> <span property="familyName">Fritsch</span> <a class="orcid-id" href="https://orcid.org/0000-0002-8412-5665" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-8412-5665</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Fritsch/Ed" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span><span data-hidden-on="all"> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au36" aria-controls="axel_author_au36"><span property="givenName">Michael S.</span> <span property="familyName">Rooney</span></a><div id="au36" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au36"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Michael S.</span> <span property="familyName">Rooney</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Rooney/Michael+S" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span></span> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au37" aria-controls="axel_author_au37"><span property="givenName">Mark</span> <span property="familyName">DeMario</span></a><div id="au37" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au37"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Mark</span> <span property="familyName">DeMario</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7368-9895" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0002-7368-9895</a></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/DeMario/Mark" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span> ∙ <span property="author" typeof="Person" role="listitem"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au38" aria-controls="axel_author_au38"><span property="givenName">Richard B.</span> <span property="familyName">Gaynor</span></a><div id="au38" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au38"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Richard B.</span> <span property="familyName">Gaynor</span></div><div class="content"><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Gaynor/Richard+B" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a></sup></span> ∙ <span property="author" typeof="Person" role="listitem" class="corresponding-author"><span class="dropBlock"><a href="#" aria-expanded="false" data-db-target-for="axel_author_au39" aria-controls="axel_author_au39"><span property="givenName">Lakshmi</span> <span property="familyName">Srinivasan</span></a><div id="au39" property="author" typeof="Person" class="dropBlock__holder" data-db-target-of="axel_author_au39"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="heading"><span property="givenName">Lakshmi</span> <span property="familyName">Srinivasan</span> <a class="orcid-id" href="https://orcid.org/0000-0003-1351-7407" property="identifier" aria-label="ORCID identifier" target="_blank">0000-0003-1351-7407</a></div><div class="content"><div class="core-author-emails"><div class="label">Correspondence</div><div>Corresponding author</div><div><a id="eadd0015" href="mailto:lakshmi.srinivasan@biontech.us" property="email" title="Send email to Lakshmi Srinivasan">lakshmi.srinivasan@biontech.us</a></div></div><div class="core-author-notes"><div class="label">Footnotes</div><div role="doc-footnote" data-has="label"><div class="label">11</div><div id="fn1"><div id="ntpara0010" role="paragraph">Lead Contact</div></div></div></div><div class="core-author-affiliations"><div class="label">Affiliations</div><div property="affiliation" typeof="Organization"><span property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-author-link"><a href="/authored-by/Srinivasan/Lakshmi" rel="nofollow" target="_blank">Search for articles by this author</a></div></div></div><button class="dropBlock__ctrl--close" title="Close contributor details" aria-label="Close contributor details"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span><sup class="xref"><a property="affiliation" typeof="Organization" role="doc-noteref">10</a>,<a role="doc-noteref">11</a></sup> <a id="eadd0015" href="mailto:lakshmi.srinivasan@biontech.us" property="email" title="Send email to Lakshmi Srinivasan">lakshmi.srinivasan@biontech.us</a></span><span data-displayed-on="all"> … <span><span data-action="reveal" tabindex="0" role="listitem">Show more</span></span> </span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">Show less</span></span></span></span></div><div class="core-self-citation"><div class="expandable-triggers"><button aria-controls="core-affiliations-notes" aria-expanded="false" tabindex="0" role="button"><span>Affiliations &amp; Notes</span><i class="icon-arrow_d_n" aria-hidden="true"></i></button><button aria-controls="core-content-info" aria-expanded="false" tabindex="0" role="button"><span>Article Info</span><i class="icon-arrow_d_n" aria-hidden="true"></i></button></div><div id="core-linked-content">
    

        

</div><div class="expandable-content"><div id="core-affiliations-notes" role="region" data-expandable="item" style="display: none;"><div class="affiliations"><div property="affiliation" typeof="Organization"><span class="label">1</span><span id="aff1" property="name">Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">2</span><span id="aff2" property="name">Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">3</span><span id="aff3" property="name">Washington University School of Medicine, St. Louis, MO, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">4</span><span id="aff4" property="name">Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">5</span><span id="aff5" property="name">Tisch Cancer Institute, Icahn School of Medicine, New York, NY, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">6</span><span id="aff6" property="name">Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">7</span><span id="aff7" property="name">Memorial Sloan Kettering Cancer Center, New York, NY, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">8</span><span id="aff8" property="name">Cancer Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">9</span><span id="aff9" property="name">Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA</span></div><div property="affiliation" typeof="Organization"><span class="label">10</span><span id="aff10" property="name">Neon Therapeutics/BioNTech US, Cambridge, MA, USA</span></div></div><div class="core-authors-notes"><div role="doc-footnote" data-has="label"><div class="label">11</div><div id="fn1"><div id="ntpara0010" role="paragraph">Lead Contact</div></div></div></div></div><div id="core-content-info" role="region" data-expandable="item" style="display: none;"><div class="history"><div>Publication History:</div><div><span>Received March 3, 2020</span>; <span>Revised May 8, 2020</span>; <span>Accepted August 28, 2020</span></div></div><div class="core-links"><span class="doi">DOI: <a href="https://doi.org/10.1016/j.cell.2020.08.053" property="sameAs" target="_blank">10.1016/j.cell.2020.08.053 <span class="sr-only">External Link</span></a></span><span class="science-direct">Also available on <a href="https://www.sciencedirect.com/science/article/pii/S0092867420311417" target="_blank">ScienceDirect <span class="sr-only">External Link</span></a></span></div><div role="paragraph">Copyright: © 2020 Elsevier Inc.</div><div class="core-links"><span>User License: <a href="http://www.elsevier.com/open-access/userlicense/1.0/" target="_blank">Elsevier user license</a> | <a href="https://www.elsevier.com/open-access" target="_blank">Elsevier's open access license policy</a></span></div><div class="core-crossmark-badge"><a data-target="crossmark" href="#" title="Check for updates on crossmark" data-doi="10.1016/j.cell.2020.08.053" data-id="article-info-crossmark" class="crossmark__link" style="cursor: pointer;"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 290 58" height="22px" role="presentation"><path fill="url(#horizontal_crossmark)" stroke="#948F8F" stroke-miterlimit="10" stroke-width=".75" d="M287 1H3a2 2 0 0 0-2 2v52a2 2 0 0 0 2 2h284a2 2 0 0 0 2-2V3a2 2 0 0 0-2-2Z"></path><path fill="#535353" d="M80.3 23.58a6.395 6.395 0 0 0-.55-1.43 3.92 3.92 0 0 0-2.19-1.86 5.099 5.099 0 0 0-1.71-.29 5 5 0 0 0-2.46.58 4.831 4.831 0 0 0-1.69 1.54 6.921 6.921 0 0 0-1 2.19 10.16 10.16 0 0 0 0 5 6.921 6.921 0 0 0 1 2.19 4.83 4.83 0 0 0 1.69 1.5 5 5 0 0 0 2.46.58 4.44 4.44 0 0 0 1.85-.36 4.12 4.12 0 0 0 1.38-1c.39-.436.695-.942.9-1.49A7.094 7.094 0 0 0 80.4 29h3a8.46 8.46 0 0 1-.69 2.92 7.179 7.179 0 0 1-1.59 2.29 7 7 0 0 1-2.35 1.49 8.14 8.14 0 0 1-3 .52 8.43 8.43 0 0 1-3.59-.74 7.88 7.88 0 0 1-2.69-2 9.001 9.001 0 0 1-1.69-3 11.41 11.41 0 0 1 0-7.23 9.001 9.001 0 0 1 1.69-3 8.001 8.001 0 0 1 2.69-2 8.3 8.3 0 0 1 3.59-.75 9.44 9.44 0 0 1 2.83.41c.866.242 1.68.642 2.4 1.18A6.229 6.229 0 0 1 82.65 21a6.66 6.66 0 0 1 .78 2.58H80.3ZM85.9 17.9h2.85v6.63h.05a4.15 4.15 0 0 1 1.56-1.46 4.61 4.61 0 0 1 2.31-.59 4.83 4.83 0 0 1 3.33 1.1 4.21 4.21 0 0 1 1.22 3.3v8.88H94.4v-8.13a3.51 3.51 0 0 0-.65-2.21 2.36 2.36 0 0 0-1.87-.69 3.1 3.1 0 0 0-1.3.26 2.821 2.821 0 0 0-1 .73A3.41 3.41 0 0 0 89 26.8a3.88 3.88 0 0 0-.23 1.33v7.63H85.9V17.9ZM102.47 30c-.002.491.069.98.21 1.45.131.448.348.866.64 1.23a3.08 3.08 0 0 0 1.08.84 3.543 3.543 0 0 0 1.55.31 3.431 3.431 0 0 0 2-.54c.541-.402.94-.966 1.14-1.61h2.7A5.349 5.349 0 0 1 109.7 35a5.715 5.715 0 0 1-1.74.85 7 7 0 0 1-2 .29 6.848 6.848 0 0 1-2.7-.5 5.577 5.577 0 0 1-2-1.4A5.953 5.953 0 0 1 100 32a8.748 8.748 0 0 1-.41-2.75 7.768 7.768 0 0 1 .44-2.61 6.67 6.67 0 0 1 1.25-2.17 5.863 5.863 0 0 1 4.56-2 5.79 5.79 0 0 1 2.74.64c.783.41 1.466.986 2 1.69a6.824 6.824 0 0 1 1.16 2.41c.264.905.352 1.852.26 2.79h-9.53Zm6.65-1.87a4.605 4.605 0 0 0-.29-1.3c-.148-.4-.368-.77-.65-1.09a3.22 3.22 0 0 0-1-.75 3 3 0 0 0-1.31-.29 3.431 3.431 0 0 0-1.36.26 3.108 3.108 0 0 0-1 .73 3.594 3.594 0 0 0-.7 1.09 3.798 3.798 0 0 0-.29 1.35h6.65-.05ZM122.88 27.15a2.666 2.666 0 0 0-1-1.81 3.14 3.14 0 0 0-2-.61c-.4.005-.798.07-1.18.19-.435.136-.83.376-1.15.7a3.92 3.92 0 0 0-.87 1.43 6.783 6.783 0 0 0-.35 2.39c.002.539.065 1.076.19 1.6.113.509.316.993.6 1.43.273.41.635.752 1.06 1a3 3 0 0 0 1.58.39 2.872 2.872 0 0 0 2.06-.77 3.596 3.596 0 0 0 1-2.18h2.85a6.26 6.26 0 0 1-1.91 3.86 5.83 5.83 0 0 1-4 1.34 6.61 6.61 0 0 1-2.69-.51 5.695 5.695 0 0 1-2-1.4 6.001 6.001 0 0 1-1.21-2.11 8.279 8.279 0 0 1-.41-2.65 8.987 8.987 0 0 1 .4-2.72 6.237 6.237 0 0 1 1.2-2.21 5.614 5.614 0 0 1 2-1.47 6.7 6.7 0 0 1 2.79-.54 7.801 7.801 0 0 1 2.14.29 5.634 5.634 0 0 1 1.8.86c.529.386.969.88 1.29 1.45a5 5 0 0 1 .6 2.07h-2.85l.06-.02ZM128.13 17.9H131V28l5.15-5.22h3.5l-5 4.75 5.42 8.17h-3.47l-4-6.27-1.6 1.7v4.63h-2.85V17.9h-.02ZM147.15 22.83h2.13v-1.08a5.505 5.505 0 0 1 .3-2c.161-.456.436-.862.8-1.18.33-.273.721-.462 1.14-.55.44-.094.89-.141 1.34-.14a8.158 8.158 0 0 1 2 .18v2.24a4.113 4.113 0 0 0-.59-.11 6.343 6.343 0 0 0-.74 0 1.74 1.74 0 0 0-1 .27 1.204 1.204 0 0 0-.41 1.08v1.33h2.42V25h-2.42v10.8h-2.85V25h-2.12v-2.17ZM162.23 36.1a6.999 6.999 0 0 1-2.76-.51 5.877 5.877 0 0 1-2-1.41 5.998 5.998 0 0 1-1.33-2.18 8.775 8.775 0 0 1 0-5.48 6.008 6.008 0 0 1 1.27-2.15 5.894 5.894 0 0 1 2-1.41A7.71 7.71 0 0 1 165 23a5.894 5.894 0 0 1 2 1.41 6.003 6.003 0 0 1 1.28 2.15c.585 1.78.585 3.7 0 5.48a5.99 5.99 0 0 1-3.28 3.54 7.002 7.002 0 0 1-2.77.52Zm0-2.25a3.268 3.268 0 0 0 1.65-.4c.447-.262.83-.621 1.12-1.05.304-.444.528-.938.66-1.46a6.581 6.581 0 0 0 0-3.31 4.416 4.416 0 0 0-.66-1.46 3.526 3.526 0 0 0-1.15-1 3.6 3.6 0 0 0-3.3 0 3.526 3.526 0 0 0-1.15 1 4.414 4.414 0 0 0-.66 1.46 6.558 6.558 0 0 0 0 3.31c.132.522.356 1.016.66 1.46a3.47 3.47 0 0 0 1.15 1.05 3.26 3.26 0 0 0 1.68.4ZM171.13 22.83h2.67v2.5c.097-.362.264-.701.49-1 .251-.341.547-.647.88-.91a4.404 4.404 0 0 1 1.14-.66 3.41 3.41 0 0 1 1.28-.25c.23-.013.46-.013.69 0h.39v2.79l-.61-.09a5.173 5.173 0 0 0-.61 0 3.278 3.278 0 0 0-1.36.29 3.131 3.131 0 0 0-1.11.85 4.171 4.171 0 0 0-.75 1.39 6 6 0 0 0-.28 1.9v6.15h-2.85V22.83h.03ZM198.22 35.75h-2.8V34a3.907 3.907 0 0 1-1.56 1.56 4.25 4.25 0 0 1-2.11.59 4.742 4.742 0 0 1-3.75-1.31 5.537 5.537 0 0 1-1.12-3.84v-8.2h2.85v7.92a3.503 3.503 0 0 0 .65 2.4 2.38 2.38 0 0 0 1.83.7 3.599 3.599 0 0 0 1.5-.27 2.66 2.66 0 0 0 1-.74c.259-.326.444-.705.54-1.11a5.79 5.79 0 0 0 .16-1.4v-7.5h2.85v12.95h-.04ZM201.3 22.83h2.7v1.75a3.523 3.523 0 0 1 1.72-1.58 5.568 5.568 0 0 1 2.33-.49 6.17 6.17 0 0 1 2.66.54 5.246 5.246 0 0 1 1.89 1.47c.515.65.899 1.394 1.13 2.19.257.87.385 1.773.38 2.68.001.851-.114 1.7-.34 2.52a6.568 6.568 0 0 1-1 2.16 5.002 5.002 0 0 1-4.21 2.06c-.419 0-.837-.036-1.25-.11a5.39 5.39 0 0 1-1.2-.36A4.737 4.737 0 0 1 205 35a3.567 3.567 0 0 1-.81-.91v6.45h-2.89V22.83Zm10 6.47c0-.574-.078-1.146-.23-1.7a4.606 4.606 0 0 0-.67-1.46 3.475 3.475 0 0 0-1.12-1 3.06 3.06 0 0 0-1.55-.39A3.141 3.141 0 0 0 205 26a5.518 5.518 0 0 0-1 3.3c-.004.611.077 1.22.24 1.81.138.523.38 1.012.71 1.44a3.55 3.55 0 0 0 1.14 1 3.242 3.242 0 0 0 1.54.35 3.18 3.18 0 0 0 1.65-.4c.438-.25.817-.59 1.11-1 .299-.44.513-.931.63-1.45a7.38 7.38 0 0 0 .23-1.75h.05ZM228.67 35.75H226V34a3.38 3.38 0 0 1-1.67 1.61 5.668 5.668 0 0 1-2.33.49 6.17 6.17 0 0 1-2.66-.54 5.307 5.307 0 0 1-1.89-1.46 6.254 6.254 0 0 1-1.12-2.19 9.48 9.48 0 0 1-.37-2.71 8.67 8.67 0 0 1 .47-3 6.058 6.058 0 0 1 1.26-2.1 4.89 4.89 0 0 1 1.8-1.21 5.738 5.738 0 0 1 2.06-.39c.412 0 .824.037 1.23.11.413.073.815.194 1.2.36.38.166.736.381 1.06.64.32.255.594.562.81.91V17.9h2.85v17.85h-.03Zm-10-6.33c-.001.55.069 1.098.21 1.63.13.511.35.996.65 1.43.288.414.668.757 1.11 1a3.241 3.241 0 0 0 1.6.38 3.199 3.199 0 0 0 1.64-.4 3.398 3.398 0 0 0 1.13-1.05c.297-.447.517-.94.65-1.46.14-.542.211-1.1.21-1.66a5.227 5.227 0 0 0-1-3.35 3.175 3.175 0 0 0-2.61-1.2 3.23 3.23 0 0 0-1.69.41 3.478 3.478 0 0 0-1.12 1.07 4.494 4.494 0 0 0-.62 1.5 7.871 7.871 0 0 0-.11 1.7h-.05ZM242.6 32.88c-.018.258.03.516.14.75a.577.577 0 0 0 .54.23h.3c.135-.002.269-.019.4-.05v2l-.39.11-.49.08-.5.08h-.42a2.75 2.75 0 0 1-1.45-.35 1.731 1.731 0 0 1-.75-1.23 4.998 4.998 0 0 1-2.09 1.2 8.224 8.224 0 0 1-2.39.38 5.861 5.861 0 0 1-1.67-.24 4.394 4.394 0 0 1-1.41-.7 3.35 3.35 0 0 1-1-1.18 3.624 3.624 0 0 1-.36-1.66 3.84 3.84 0 0 1 .44-2 3.246 3.246 0 0 1 1.15-1.17 5.195 5.195 0 0 1 1.6-.61c.593-.127 1.19-.223 1.79-.29a14.77 14.77 0 0 1 1.47-.21 6.896 6.896 0 0 0 1.24-.21c.318-.077.611-.236.85-.46a1.286 1.286 0 0 0 .31-.94 1.458 1.458 0 0 0-.26-.9A1.759 1.759 0 0 0 239 25a2.807 2.807 0 0 0-.86-.25 6.941 6.941 0 0 0-.9-.06 3.58 3.58 0 0 0-2 .5 2 2 0 0 0-.87 1.55h-2.85c.021-.73.227-1.442.6-2.07.338-.54.797-.996 1.34-1.33a5.475 5.475 0 0 1 1.84-.7c.692-.134 1.395-.2 2.1-.2.632 0 1.262.067 1.88.2a5.337 5.337 0 0 1 1.66.65 3.6 3.6 0 0 1 1.19 1.16c.314.525.47 1.129.45 1.74v6.65l.02.04Zm-2.85-3.6a3.45 3.45 0 0 1-1.6.51c-.667.06-1.3.147-1.9.26a6.137 6.137 0 0 0-.87.21 2.64 2.64 0 0 0-.75.38c-.22.164-.395.38-.51.63a2.129 2.129 0 0 0-.19.94c-.011.29.085.575.27.8.182.215.407.388.66.51.269.128.555.216.85.26.277.05.558.076.84.08a4.63 4.63 0 0 0 1-.12 3.418 3.418 0 0 0 1-.43 2.73 2.73 0 0 0 .81-.76 1.93 1.93 0 0 0 .32-1.14v-2.14l.07.01ZM244.37 22.83h2.15V19h2.85v3.88h2.58V25h-2.58v6.9a7.064 7.064 0 0 0 0 .77c.016.194.074.381.17.55a.84.84 0 0 0 .41.34 2 2 0 0 0 .75.11h.6c.203-.01.404-.04.6-.09v2.2l-.93.1a8.403 8.403 0 0 1-.92 0 6.33 6.33 0 0 1-1.81-.21 2.421 2.421 0 0 1-1.08-.62 2.15 2.15 0 0 1-.52-1 7.791 7.791 0 0 1-.16-1.42V25h-2.15v-2.17h.04ZM256.22 30c-.002.491.069.98.21 1.45.131.448.348.866.64 1.23a3.08 3.08 0 0 0 1.08.84 3.543 3.543 0 0 0 1.55.31 3.431 3.431 0 0 0 2-.54c.541-.402.94-.966 1.14-1.61h2.7a5.352 5.352 0 0 1-2.1 3.26 5.715 5.715 0 0 1-1.74.85 7 7 0 0 1-2 .29 6.848 6.848 0 0 1-2.7-.5 5.577 5.577 0 0 1-2-1.4 5.947 5.947 0 0 1-1.21-2.18 8.754 8.754 0 0 1-.41-2.75 7.758 7.758 0 0 1 .44-2.61 6.67 6.67 0 0 1 1.25-2.17 5.863 5.863 0 0 1 4.56-2 5.79 5.79 0 0 1 2.74.64c.783.41 1.466.986 2 1.69a6.824 6.824 0 0 1 1.16 2.41c.243.916.308 1.87.19 2.81h-9.5V30Zm6.65-1.87a4.605 4.605 0 0 0-.29-1.3c-.148-.4-.368-.77-.65-1.09a3.22 3.22 0 0 0-1-.75 3 3 0 0 0-1.31-.29 3.431 3.431 0 0 0-1.36.26 3.108 3.108 0 0 0-1 .73 3.575 3.575 0 0 0-.7 1.09 3.798 3.798 0 0 0-.29 1.35h6.65-.05ZM270 31.6a2.154 2.154 0 0 0 .95 1.75c.607.35 1.3.524 2 .5.304-.002.608-.022.91-.06a3.943 3.943 0 0 0 1-.24c.286-.105.54-.28.74-.51a1.23 1.23 0 0 0 .26-.89 1.261 1.261 0 0 0-.4-.9 2.779 2.779 0 0 0-1-.56 9.315 9.315 0 0 0-1.34-.36l-1.5-.33a14.219 14.219 0 0 1-1.54-.42 4.937 4.937 0 0 1-1.33-.68 3.12 3.12 0 0 1-.94-1.09 3.472 3.472 0 0 1-.35-1.64 2.94 2.94 0 0 1 .51-1.76 3.913 3.913 0 0 1 1.3-1.15 5.66 5.66 0 0 1 1.75-.61 10.316 10.316 0 0 1 1.84-.17 8.418 8.418 0 0 1 1.91.21 5.19 5.19 0 0 1 1.65.69c.496.318.916.741 1.23 1.24.341.559.55 1.188.61 1.84h-3a1.783 1.783 0 0 0-.94-1.37 3.892 3.892 0 0 0-1.69-.35 6.093 6.093 0 0 0-.71 0 3.327 3.327 0 0 0-.78.19 1.642 1.642 0 0 0-.61.4 1 1 0 0 0-.25.69 1.093 1.093 0 0 0 .36.85c.294.245.634.428 1 .54.437.153.885.274 1.34.36l1.55.33a20.9 20.9 0 0 1 1.53.42c.479.157.931.386 1.34.68.41.277.751.643 1 1.07.255.494.379 1.045.36 1.6a3.48 3.48 0 0 1-.52 2 4.15 4.15 0 0 1-1.36 1.3 6.19 6.19 0 0 1-1.86.73 9.435 9.435 0 0 1-2 .23 8.823 8.823 0 0 1-2.26-.27 5.265 5.265 0 0 1-1.8-.84 4 4 0 0 1-1.2-1.4 4.445 4.445 0 0 1-.46-2h2.7v-.02Z"></path><path fill="#C72914" d="m21.94 38.74 18.12-12.08v-14.5H21.94v26.58Z"></path><path fill="#EF3340" d="M40.06 38.74 21.94 26.66v-14.5h18.12v26.58Z"></path><path fill="#3EB1C8" d="M31 9a20 20 0 1 0 0 40 20 20 0 0 0 0-40Zm0 35.1a15.1 15.1 0 1 1 0-30.2 15.1 15.1 0 0 1 0 30.2Z"></path><path fill="#FFC72C" d="M42.09 39.23A15.09 15.09 0 0 1 17 23.38l-4.2-2.64a20 20 0 0 0 33.49 21.14l-4.2-2.65Z"></path><defs><linearGradient id="horizontal_crossmark" x1="145" x2="145" y1="7.33" y2="56.82" gradientUnits="userSpaceOnUse"><stop stop-color="#fff"></stop><stop offset="1" stop-color="#c4c4c4"></stop></linearGradient></defs></svg></a></div><div class="core-content-info"></div></div></div></div></div></header><div class="core-header-aside">
    

        


    

            

            

            <div class="cover-image cover-image--axel"><div class="cover-image__thumb"><a href="https://www.cell.com/cell/issue?pii=S0092-8674(19)X0022-7"><img src="/cms/asset/b4f16723-80d7-4141-83da-b7e3cbf3339a/cov200h.gif" alt="Cover Image - Cell, Volume 183, Issue 2"></a></div></div>

            

        
</div></div><div data-core-wrapper="content"><div id="dummy-sticky-observer"></div><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="navigation-menu-pdf">
    

        


    

            

            

            <div data-widget-id="ecff07e8-0bc4-4533-b1f1-49365e2ead20" data-widget-name="UX3ArticleToolsWidget" class="article-tools"><a href="/action/showPdf?pii=S0092-8674%2820%2931141-7" title="Standard PDF (opens in a new tab)" target="_blank" aria-hidden="false" role="menuitem" class="article-tools__item__pdf"><svg focusable="false" viewBox="0 0 32 32" width="20" height="20" title="PDF" class="pdf-icon"><path id="pdfwhite" d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path id="pdfda0000" d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path id="pdffff9f9" fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492 1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0 .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0 1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0 2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534 2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path id="pdff91d0a" d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317 2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32 24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153 1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306 2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047 1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="basic">Download PDF</span><span class="alternative">Download PDF</span></a></div>

            

        
</div><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-haspopup="true" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Outline</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><div class="heading">Outline<button aria-haspopup="true" aria-controls="article_sections_menu" title="Close outline menu"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div><ul><li><a href="#author-highlights-abstract">Highlights</a></li><li><a href="#author-abstract">Summary</a></li><li><a href="#graphical-abstract">Graphical Abstract</a></li><li><a href="#keywords">Keywords</a></li><li><a href="#sec-1">Introduction</a></li><li><a href="#sec-2">Results</a></li><li><a href="#sec-3">Discussion</a></li><li><a href="#sec-4">STAR★Methods</a></li><li><a href="#acknowledgments">Acknowledgments</a></li><li><a href="#supplementary-material">Supplemental Information (2)</a></li><li><a href="#references">References</a></li><li role="none" class="mobile-only"><a role="menuitem" href="#core-collateral-metrics">Article metrics</a></li><li role="none" class="mobile-only"><a role="menuitem" href="#core-collateral-relatedArticles">Related Articles</a></li></ul></nav></div><div class="navigation-menu-share">
    

        


    

            

            

            <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js"></script><script type="text/javascript">var a2a_config = a2a_config || {};
a2a_config.thanks = {
    postShare: false,
    ad: false,
};</script><script>var a2a_config = a2a_config || {};
let res = window.location.href.replace(/\(/g, "%28").replace(/\)/g, "%29");
a2a_config.templates = a2a_config.templates || {};

a2a_config.templates.email = {
    body: res
};
</script><div data-widget-id="5f978446-c80a-450c-a185-94d633df2db2" data-widget-name="UX3share" aria-hidden="false" role="group" class="article-tools__dropblock article-tools__share"><button aria-label="Toggle share menu" aria-expanded="false" aria-haspopup="true" role="menuitem" aria-controls="navigation_menu_share_block" aria-labelledby="share-label" class="article-tools__item__share"><i aria-hidden="true" class="icon-article-share"></i><span id="share-label">Share</span></button><div id="navigation_menu_share_block" role="menu" class="share__block axel-share article-tools__dropblock__holder"><h4 class="axel-share__title heading">Share<button title="Close share menu" aria-expanded="false" aria-haspopup="true" aria-controls="navigation_menu_share_block"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></h4><div class="axel-share__inner"><span class="sr-only">Share on</span><ul class="a2a__share-list rlist w-slide--list a2a a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-url="https://www.cell.com/cell/fulltext/S0092-8674%2820%2931141-7" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Email" class="a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><i aria-hidden="true" class="at-icon-wrapper icon-gizmo-email-plus"></i><span>Email</span></a></li><li class="a2a_listitem_custom"><a role="link" title="formerly known as Twitter" class="a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><i aria-hidden="true" class="at-icon-wrapper icon-x-default"></i><span>X</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Facebook" class="a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook-square-2"></i><span>Facebook</span></a></li><li class="a2a_listitem_custom"><a role="link" title="LinkedIn" class="a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin-square"></i><span>LinkedIn</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Sina Weibo" class="a2a_button_sina_weibo" target="_blank" rel="nofollow noopener" href="/#sina_weibo"><i aria-hidden="true" class="at-icon-wrapper icon-weibo"></i><span>Sina Weibo</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Mendeley" class="a2a_button_mendeley" target="_blank" rel="nofollow noopener" href="/#mendeley"><i aria-hidden="true" class="at-icon-wrapper icon-mendeley-2"></i><span>Mendeley</span></a></li><li class="a2a_listitem_custom"><a role="link" title="bluesky" class="a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><i aria-hidden="true" class="at-icon-wrapper icon-bluesky-logo"></i><span>bluesky</span></a></li><div style="clear: both;"></div></ul><div class="extra-links-drop-zone">
    

        


    

            

            

            <div data-widget-id="f1a208d3-ac5e-4db2-9c3a-40ef97ddfa10" data-widget-name="UX3HTMLWidget"><a class="axel-share__extra" target="_blank" href="/personalize/addFavoritePublication?doi=10.1016/j.cell.2020.08.053">
	<i class="icon-reading-list" aria-hidden="true"></i>
	<span>Add to my reading list</span>
</a></div>

            

        
</div></div></div></div>

            

        
</div><div><button data-id="article-nav-menubar-more" aria-controls="article_more_menu" aria-expanded="false" aria-haspopup="true" aria-label="Toggle more menu"><i aria-hidden="true" class="icon-more-mobile"></i><span>More</span></button><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__article_tools info-panel__item"><div id="article_more_menu" aria-label="More menu" data-core-nav="more"><div class="heading">More<button title="Close more menu" aria-controls="article_more_menu" aria-haspopup="true"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div>
    

        


    

            

            

            <ul data-widget-id="183a17a2-87b5-4e6f-bb85-6b5cda068c89" data-widget-name="UX3ArticleToolsWidget" class="article-tools"><li class="article-tools__item article-tools__pdf"><a href="/action/showPdf?pii=S0092-8674%2820%2931141-7" title="Standard PDF (opens in a new tab)" target="_blank" aria-hidden="false" class="article-tools__ctrl article-tools__item__pdf"><svg focusable="false" viewBox="0 0 32 32" width="20" height="20" title="PDF" class="pdf-icon"><path id="pdfwhite" d="M7 .362h17.875l6.763 6.1V31.64H6.948V16z" stroke="#000" stroke-width=".703" fill="#fff"></path><path id="pdfda0000" d="M.167 2.592H22.39V9.72H.166z" fill="#da0000"></path><path id="pdffff9f9" fill="#fff9f9" d="M5.97 3.638h1.62c1.053 0 1.483.677 1.488 1.564.008.96-.6 1.564-1.492 1.564h-.644v1.66h-.977V3.64m.977.897v1.34h.542c.27 0 .596-.068.596-.673-.002-.6-.32-.667-.596-.667h-.542m3.8.036v2.92h.35c.933 0 1.223-.448 1.228-1.462.008-1.06-.316-1.45-1.23-1.45h-.347m-.977-.94h1.03c1.68 0 2.523.586 2.534 2.39.01 1.688-.607 2.4-2.534 2.4h-1.03V3.64m4.305 0h2.63v.934h-1.657v.894H16.6V6.4h-1.56v2.026h-.97V3.638"></path><path id="pdff91d0a" d="M19.462 13.46c.348 4.274-6.59 16.72-8.508 15.792-1.82-.85 1.53-3.317 2.92-4.366-2.864.894-5.394 3.252-3.837 3.93 2.113.895 7.048-9.25 9.41-15.394zM14.32 24.874c4.767-1.526 14.735-2.974 15.152-1.407.824-3.157-13.72-.37-15.153 1.407zm5.28-5.043c2.31 3.237 9.816 7.498 9.788 3.82-.306 2.046-6.66-1.097-8.925-4.164-4.087-5.534-2.39-8.772-1.682-8.732.917.047 1.074 1.307.67 2.442-.173-1.406-.58-2.44-1.224-2.415-1.835.067-1.905 4.46 1.37 9.065z" fill="#f91d0a"></path></svg><span class="basic">Download PDF</span><span class="alternative">Download PDF</span></a></li><li><a href="https://www.cell.com/action/showCitFormats?doi=10.1016%2Fj.cell.2020.08.053&amp;pii=S0092-8674%2820%2931141-7" title="Cite" target="_blank" aria-label="Open Cite in new tab" class="article-tools__item__displayExportCitation"><i aria-hidden="true" class="icon-export-Citation"></i><span>Cite</span></a></li><li id="article_tools_share">
    

        


    

            

            

            <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js"></script><script type="text/javascript">var a2a_config = a2a_config || {};
a2a_config.thanks = {
    postShare: false,
    ad: false,
};</script><script>var a2a_config = a2a_config || {};
let res = window.location.href.replace(/\(/g, "%28").replace(/\)/g, "%29");
a2a_config.templates = a2a_config.templates || {};

a2a_config.templates.email = {
    body: res
};
</script><div data-widget-id="c3faf0bb-84d9-4c61-a6d8-93bfc77be8da" data-widget-name="UX3share" class="dropBlock article-tools__dropblock article-tools__share"><button data-db-target-for="c3faf0bb-84d9-4c61-a6d8-93bfc77be8da" aria-expanded="false" title="open Share menu" class="article-tools__ctrl share__ctrl"><i aria-hidden="true" class="icon-article-share"></i><span>Share</span></button><div data-db-target-of="c3faf0bb-84d9-4c61-a6d8-93bfc77be8da" id="c3faf0bb-84d9-4c61-a6d8-93bfc77be8da_Pop" class="share__block axel-share dropBlock__holder article-tools__dropblock__holder"><h4 class="axel-share__title">Share</h4><div class="axel-share__inner"><span class="sr-only">Share on</span><ul class="a2a__share-list rlist w-slide--list a2a a2a_kit a2a_kit_size_32 a2a_default_style" data-a2a-url="https://www.cell.com/cell/fulltext/S0092-8674%2820%2931141-7" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Email" class="a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><i aria-hidden="true" class="at-icon-wrapper icon-gizmo-email-plus"></i><span>Email</span></a></li><li class="a2a_listitem_custom"><a role="link" title="formerly known as Twitter" class="a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><i aria-hidden="true" class="at-icon-wrapper icon-x-default"></i><span>X</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Facebook" class="a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook-square-2"></i><span>Facebook</span></a></li><li class="a2a_listitem_custom"><a role="link" title="LinkedIn" class="a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin-square"></i><span>LinkedIn</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Sina Weibo" class="a2a_button_sina_weibo" target="_blank" rel="nofollow noopener" href="/#sina_weibo"><i aria-hidden="true" class="at-icon-wrapper icon-weibo"></i><span>Sina Weibo</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Mendeley" class="a2a_button_mendeley" target="_blank" rel="nofollow noopener" href="/#mendeley"><i aria-hidden="true" class="at-icon-wrapper icon-mendeley-2"></i><span>Mendeley</span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" class="a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><i aria-hidden="true" class="at-icon-wrapper icon-bluesky-logo"></i><span>Bluesky</span></a></li><div style="clear: both;"></div></ul><div class="extra-links-drop-zone">
    

        


    

            

            

            <div data-widget-id="ae9bf5c5-a2ee-4f5c-8e41-9b21638b1a9f" data-widget-name="UX3HTMLWidget"><a class="axel-share__extra" target="_blank" href="/personalize/addFavoritePublication?doi=10.1016/j.cell.2020.08.053">
	<i class="icon-reading-list" aria-hidden="true"></i>
	<span>Add to my reading list</span>
</a></div>

            

        
</div></div></div></div>

            

        
</li><li><a href="https://www.cell.com/action/addCitationAlert?doi=10.1016%2Fj.cell.2020.08.053" title="Set Alert" target="_blank" aria-label="Open Set Alert in new tab" class="article-tools__item__displayCreateCitationAlert"><i aria-hidden="true" class="icon-set-alert"></i><span>Set Alert</span></a></li><li><a href="https://s100.copyright.com/AppDispatchServlet?publisherName=ELS&amp;contentID=S0092867420311417&amp;orderBeanReset=true&amp;orderSource=Phoenix" title="Get Rights" target="_blank" aria-label="Open Get Rights in new tab" class="article-tools__item__request"><i aria-hidden="true" class="icon-get-rights"></i><span>Get Rights</span></a></li><li><a href="https://www.contentednet.com/salesforce-form/?pii=S0092867420311417&amp;issn=00928674&amp;source=jbs" title="Reprints" target="_blank" aria-label="Open Reprints in new tab" class="article-tools__item__reprints"><i aria-hidden="true" class="icon-article-reprints"></i><span>Reprints</span></a></li></ul>

            

        
</div></div><div class="info-panel__download-issue info-panel__item"><div class="article-header__download-full-issue"><button title="Download full issue" type="submit" formaction="/action/downloadMultiplePdf?action=downloadIssuePdf&amp;journal=cell&amp;volume=183&amp;issue=2&amp;pii=S0092-8674%2819%29X0022-7" class="btn--download-issue btn--cancel download-full-issue"><i class="icon-download-new"></i><span>Download Full Issue</span></button><div class="table-of-content__alert table-of-content__alert--download"><p>Download started</p><a href="#" class="table-of-content__alert--close">Ok</a></div></div></div></div><div class="info-panel__right-content"><div class="info-panel__navigation info-panel__item"><div class="content-navigation"><a href="/cell/fulltext/S0092-8674(20)31138-7" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><i aria-hidden="true" class="icon-arrow_l"></i><span>Previous article</span></a><a href="/cell/fulltext/S0092-8674(20)31142-9" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><span>Next article</span><i aria-hidden="true" class="icon-arrow_r"></i></a></div></div></div></div></div></div></div><div class="core-sections-menu-outer"><div class="core-sections-menu"><button aria-controls="article_sections_menu-desktop" aria-haspopup="true" aria-expanded="false" aria-label="Toggle sections menu" data-id="article-toolbar-showhide"><i class="icon-show-outline" aria-hidden="true"></i><span>Show Outline</span></button><nav id="article_sections_menu-desktop" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><button aria-controls="article_sections_menu-desktop" aria-haspopup="true" aria-expanded="false" aria-label="Toggle sections menu" data-id="article-toolbar-showhide"><i class="icon-hide-outline" aria-hidden="true"></i><span>Hide Outline</span></button><ul><li><a href="#author-highlights-abstract">Highlights</a></li><li><a href="#author-abstract">Summary</a></li><li><a href="#graphical-abstract">Graphical Abstract</a></li><li><a href="#keywords">Keywords</a></li><li><a href="#sec-1">Introduction</a></li><li><a href="#sec-2">Results</a></li><li><a href="#sec-3">Discussion</a></li><li><a href="#sec-4">STAR★Methods</a></li><li><a href="#acknowledgments">Acknowledgments</a></li><li><a href="#supplementary-material">Supplemental Information (2)</a></li><li><a href="#references">References</a></li><li role="none" class="mobile-only"><a role="menuitem" href="#core-collateral-metrics">Article metrics</a></li><li role="none" class="mobile-only"><a role="menuitem" href="#core-collateral-relatedArticles">Related Articles</a></li></ul></nav></div></div><div><div class="core-content-inner"><div class="core-linked-content"></div><div id="abstracts" data-extent="frontmatter"><div class="core-container"><section id="author-highlights-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Highlights</h2><div id="abspara0020" role="paragraph"><div id="ulist0010" role="list"><div id="u0010" role="listitem"><div class="label">•</div><div class="content"><div id="p0010" role="paragraph">The personalized neoantigen vaccine Neo-PV-01 plus nivolumab is feasible and safe</div></div></div><div id="u0015" role="listitem"><div class="label">•</div><div class="content"><div id="p0015" role="paragraph">NEO-PV-01 plus nivolumab stimulates durable neoantigen-specific T&nbsp;cell reactivity</div></div></div><div id="u0020" role="listitem"><div class="label">•</div><div class="content"><div id="p0020" role="paragraph">NEO-PV-01-specific T&nbsp;cells have cytotoxic potential and can traffic to the tumor</div></div></div><div id="u0025" role="listitem"><div class="label">•</div><div class="content"><div id="p0025" role="paragraph">NEO-PV-01 induces epitope spreading consistent with vaccine-mediated tumor cytotoxicity</div></div></div></div></div></section><section id="author-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Summary</h2><div id="abspara0010" role="paragraph">Neoantigens arise from mutations in cancer cells and are important targets of T&nbsp;cell-mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed. <i>De novo</i> neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cell responses were observed post-vaccination in all of the patients. The vaccine-induced T cells had a cytotoxic phenotype and were capable of trafficking to the tumor and mediating cell killing. In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination. These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors (Clinicaltrials.gov: <a id="intref0010" href="https://clinicaltrials.gov/show/NCT02897765" target="_blank">NCT02897765</a>).</div></section><section id="graphical-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Graphical Abstract</h2><div id="abspara0015" role="paragraph"><div class="figure-wrap"><figure id="undfig1" class="graphic" data-figureviewer-ignore="true"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/8037754b-4b6a-4321-9506-f531dd68496d/main.assets/fx1_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="fx1" alt="Graphical abstract undfig1" src="/cms/10.1016/j.cell.2020.08.053/asset/02e87db8-65c7-4733-a607-6997fd7749aa/main.assets/fx1.jpg" height="375" width="375" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/8037754b-4b6a-4321-9506-f531dd68496d/main.assets/fx1_lrg.jpg" loading="lazy"></a></figure></div></div></section></div></div><div class="core-linked-content"></div><section id="keywords" property="keywords"><h2>Keywords</h2><ol><li><a href="/action/doSearch?AllField=&quot;immunotherapy&quot;" alt="Search on this keyword" rel="nofollow">immunotherapy</a></li><li><a href="/action/doSearch?AllField=&quot;epitope+spread&quot;" alt="Search on this keyword" rel="nofollow">epitope spread</a></li><li><a href="/action/doSearch?AllField=&quot;metastatic+cancer&quot;" alt="Search on this keyword" rel="nofollow">metastatic cancer</a></li><li><a href="/action/doSearch?AllField=&quot;NEO-PV-01&quot;" alt="Search on this keyword" rel="nofollow">NEO-PV-01</a></li><li><a href="/action/doSearch?AllField=&quot;cancer+vaccine&quot;" alt="Search on this keyword" rel="nofollow">cancer vaccine</a></li><li><a href="/action/doSearch?AllField=&quot;T+cell&quot;" alt="Search on this keyword" rel="nofollow">T cell</a></li><li><a href="/action/doSearch?AllField=&quot;neoantigen&quot;" alt="Search on this keyword" rel="nofollow">neoantigen</a></li><li><a href="/action/doSearch?AllField=&quot;personalized+vaccine&quot;" alt="Search on this keyword" rel="nofollow">personalized vaccine</a></li><li><a href="/action/doSearch?AllField=&quot;checkpoint+inhibitor&quot;" alt="Search on this keyword" rel="nofollow">checkpoint inhibitor</a></li><li><a href="/action/doSearch?AllField=&quot;anti-PD-1&quot;" alt="Search on this keyword" rel="nofollow">anti-PD-1</a></li></ol></section><div class="core-linked-content"></div><div class="core-linked-content"></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text"><div class="core-container"><section id="sec-1"><h2>Introduction</h2><div id="p0030" role="paragraph">The repertoire of tumor-specific T&nbsp;cells in cancer patients is shaped by interactions between the tumor and the host’s immune response. Neoantigens, encoded by mutations that are unique to a patient’s tumors, are key targets of effective anti-tumor immune responses (<span class="dropBlock reference-citations"><a id="body-ref-sref35" href="#" role="doc-biblioref" data-xml-rid="bib35" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref35" aria-controls="sref35">Hu et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref35"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">35.</div><div>Hu, Z. ∙ Ott, P.A. ∙ Wu, C.J.</div><div><strong>Towards personalized, tumour-specific, therapeutic vaccines for cancer</strong></div><div><em>Nat. Rev. Immunol.</em> 2018; <strong>18</strong>:168-182</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nri.2017.131" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_35_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85041594324" target="_blank" aria-label="Open Scopus in new tab">Scopus (704)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29226910/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnri.2017.131&amp;pmid=29226910" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref62-1" href="#" role="doc-biblioref" data-xml-rid="bib62" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref62-1" aria-controls="sref62-1">Schumacher and Schreiber, 2015</a><div class="dropBlock__holder" data-db-target-of="sref62-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">64.</div><div>Schumacher, T.N. ∙ Schreiber, R.D.</div><div><strong>Neoantigens in cancer immunotherapy</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:69-74</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa4971" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_64_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928770388" target="_blank" aria-label="Open Scopus in new tab">Scopus (3509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25838375/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa4971&amp;pmid=25838375" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Recent first-in-human clinical trials, harnessing the ability to identify neoantigens in real time using next-generation sequencing technology and computational pipelines, have demonstrated that personalized neoantigen vaccines are feasible, safe, and immunogenic in cancer patients (<span class="dropBlock reference-citations"><a id="body-ref-sref16-1" href="#" role="doc-biblioref" data-xml-rid="bib16" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref16-1" aria-controls="sref16-1">Carreno et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref16-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">16.</div><div>Carreno, B.M. ∙ Magrini, V. ∙ Becker-Hapak, M. ...</div><div><strong>Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T&nbsp;cells</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:803-808</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa3828" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928195112" target="_blank" aria-label="Open Scopus in new tab">Scopus (966)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25837513/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa3828&amp;pmid=25837513" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref32-1" href="#" role="doc-biblioref" data-xml-rid="bib32" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref32-1" aria-controls="sref32-1">Hilf et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref32-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">32.</div><div>Hilf, N. ∙ Kuttruff-Coqui, S. ∙ Frenzel, K. ...</div><div><strong>Actively personalized vaccination trial for newly diagnosed glioblastoma</strong></div><div><em>Nature.</em> 2019; <strong>565</strong>:240-245</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-018-0810-y" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_32_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85059762738" target="_blank" aria-label="Open Scopus in new tab">Scopus (603)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30568303/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-018-0810-y&amp;pmid=30568303" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref38-1" href="#" role="doc-biblioref" data-xml-rid="bib38" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref38-1" aria-controls="sref38-1">Keskin et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref38-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">38.</div><div>Keskin, D.B. ∙ Anandappa, A.J. ∙ Sun, J. ...</div><div><strong>Neoantigen vaccine generates intratumoral T&nbsp;cell responses in phase Ib glioblastoma trial</strong></div><div><em>Nature.</em> 2019; <strong>565</strong>:234-239</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-018-0792-9" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_38_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85059785792" target="_blank" aria-label="Open Scopus in new tab">Scopus (901)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30568305/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-018-0792-9&amp;pmid=30568305" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref52-1" href="#" role="doc-biblioref" data-xml-rid="bib52" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref52-1" aria-controls="sref52-1">Ott et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref52-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">53.</div><div>Ott, P.A. ∙ Hu, Z. ∙ Keskin, D.B. ...</div><div><strong>An immunogenic personal neoantigen vaccine for patients with melanoma</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:217-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature22991" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_53_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024377220" target="_blank" aria-label="Open Scopus in new tab">Scopus (1897)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678778/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature22991&amp;pmid=28678778" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref59-1" href="#" role="doc-biblioref" data-xml-rid="bib59" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref59-1" aria-controls="sref59-1">Sahin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref59-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">60.</div><div>Sahin, U. ∙ Derhovanessian, E. ∙ Miller, M. ...</div><div><strong>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:222-226</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature23003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_60_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024396858" target="_blank" aria-label="Open Scopus in new tab">Scopus (11)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678784/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature23003&amp;pmid=28678784" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>).</div><div id="p0035" role="paragraph">Immune checkpoint inhibition (ICI) has revolutionized the treatment of cancer patients over the past decade. Treatment with anti-programmed cell death 1 (PD-1) and anti-PD-1 ligand 1 (PD-L1) antibodies have demonstrated substantial anti-tumor activity in multiple tumor types (<span class="dropBlock reference-citations"><a id="body-ref-sref29" href="#" role="doc-biblioref" data-xml-rid="bib29" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref29" aria-controls="sref29">Havel et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref29"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">29.</div><div>Havel, J.J. ∙ Chowell, D. ∙ Chan, T.A.</div><div><strong>The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy</strong></div><div><em>Nat. Rev. Cancer.</em> 2019; <strong>19</strong>:133-150</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41568-019-0116-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_29_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85061498033" target="_blank" aria-label="Open Scopus in new tab">Scopus (1509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30755690/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41568-019-0116-x&amp;pmid=30755690" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref76" href="#" role="doc-biblioref" data-xml-rid="bib76" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref76" aria-controls="sref76">Yarchoan et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref76"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">79.</div><div>Yarchoan, M. ∙ Hopkins, A. ∙ Jaffee, E.M.</div><div><strong>Tumor Mutational Burden and Response Rate to PD-1 Inhibition</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>377</strong>:2500-2501</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMc1713444" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_79_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85039783649" target="_blank" aria-label="Open Scopus in new tab">Scopus (2210)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29262275/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMc1713444&amp;pmid=29262275" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Despite the success of anti-PD-1 therapy across a wide range of tumor types, only a subset of patients receives long-term clinical benefit from the treatment (<span class="dropBlock reference-citations"><a id="body-ref-sref63" href="#" role="doc-biblioref" data-xml-rid="bib63" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref63" aria-controls="sref63">Sharma and Allison, 2015</a><div class="dropBlock__holder" data-db-target-of="sref63"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">65.</div><div>Sharma, P. ∙ Allison, J.P.</div><div><strong>The future of immune checkpoint therapy</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:56-61</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa8172" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_65_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928774156" target="_blank" aria-label="Open Scopus in new tab">Scopus (3539)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25838373/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa8172&amp;pmid=25838373" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Consequently, there has been a great deal of interest in combination therapies to improve the efficacy of ICI and ultimately patient outcomes.</div><div id="p0040" role="paragraph">Neoantigens arise from mutations in cancer cells and are&nbsp;important targets of T&nbsp;cell-mediated immunity. A high neoantigen burden in tumors is associated with favorable clinical response and improved progression-free survival (PFS) in patients with multiple tumor types treated with anti-PD-1 (<span class="dropBlock reference-citations"><a id="body-ref-sref47-1" href="#" role="doc-biblioref" data-xml-rid="bib47" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref47-1" aria-controls="sref47-1">Łuksza et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref47-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">48.</div><div>Łuksza, M. ∙ Riaz, N. ∙ Makarov, V. ...</div><div><strong>A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy</strong></div><div><em>Nature.</em> 2017; <strong>551</strong>:517-520</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature24473" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_48_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85034865728" target="_blank" aria-label="Open Scopus in new tab">Scopus (454)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29132144/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature24473&amp;pmid=29132144" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref48-1" href="#" role="doc-biblioref" data-xml-rid="bib48" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref48-1" aria-controls="sref48-1">McGranahan et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref48-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">49.</div><div>McGranahan, N. ∙ Furness, A.J. ∙ Rosenthal, R. ...</div><div><strong>Clonal neoantigens elicit T&nbsp;cell immunoreactivity and sensitivity to immune checkpoint blockade</strong></div><div><em>Science.</em> 2016; <strong>351</strong>:1463-1469</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaf1490" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_49_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962301577" target="_blank" aria-label="Open Scopus in new tab">Scopus (2240)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26940869/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaf1490&amp;pmid=26940869" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref55" href="#" role="doc-biblioref" data-xml-rid="bib55" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref55" aria-controls="sref55">Rizvi et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref55"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">56.</div><div>Rizvi, N.A. ∙ Hellmann, M.D. ∙ Snyder, A. ...</div><div><strong>Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:124-128</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa1348" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_56_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928761118" target="_blank" aria-label="Open Scopus in new tab">Scopus (6221)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25765070/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa1348&amp;pmid=25765070" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref72-1" href="#" role="doc-biblioref" data-xml-rid="bib72" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref72-1" aria-controls="sref72-1">Van Allen et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref72-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">75.</div><div>Van Allen, E.M. ∙ Miao, D. ∙ Schilling, B. ...</div><div><strong>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</strong></div><div><em>Science.</em> 2015; <strong>350</strong>:207-211</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aad0095" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_75_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84943516465" target="_blank" aria-label="Open Scopus in new tab">Scopus (1998)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26359337/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aad0095&amp;pmid=26359337" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Given the early promise of personalized neoantigen vaccines in the adjuvant setting (<span class="dropBlock reference-citations"><a id="body-ref-sref52-2" href="#" role="doc-biblioref" data-xml-rid="bib52" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref52-2" aria-controls="sref52-2">Ott et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref52-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">53.</div><div>Ott, P.A. ∙ Hu, Z. ∙ Keskin, D.B. ...</div><div><strong>An immunogenic personal neoantigen vaccine for patients with melanoma</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:217-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature22991" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_53_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024377220" target="_blank" aria-label="Open Scopus in new tab">Scopus (1897)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678778/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature22991&amp;pmid=28678778" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref59-2" href="#" role="doc-biblioref" data-xml-rid="bib59" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref59-2" aria-controls="sref59-2">Sahin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref59-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">60.</div><div>Sahin, U. ∙ Derhovanessian, E. ∙ Miller, M. ...</div><div><strong>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:222-226</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature23003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_60_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024396858" target="_blank" aria-label="Open Scopus in new tab">Scopus (11)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678784/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature23003&amp;pmid=28678784" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), coupled with the observation that the anti-tumor activity of PD-1 inhibition in melanoma is largely limited to patients with tumors exhibiting a preexisting T&nbsp;cell infiltrate (<span class="dropBlock reference-citations"><a id="body-ref-sref70" href="#" role="doc-biblioref" data-xml-rid="bib70" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref70" aria-controls="sref70">Tumeh et&nbsp;al., 2014</a><div class="dropBlock__holder" data-db-target-of="sref70"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">73.</div><div>Tumeh, P.C. ∙ Harview, C.L. ∙ Yearley, J.H. ...</div><div><strong>PD-1 blockade induces responses by inhibiting adaptive immune resistance</strong></div><div><em>Nature.</em> 2014; <strong>515</strong>:568-571</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature13954" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_73_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84920956732" target="_blank" aria-label="Open Scopus in new tab">Scopus (5059)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25428505/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature13954&amp;pmid=25428505" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), there is a strong rationale for combining these modalities in the metastatic setting. We reasoned that this strategy could augment the response rates and durability of responses over the results of PD-1 inhibition alone by inducing, expanding, and broadening the tumor-directed T&nbsp;cell repertoire.</div><div id="p0045" role="paragraph">We report here the first clinical trial combining a personalized neoantigen vaccine (NEO-PV-01) with PD-1 inhibition, in patients with high TMB metastatic tumors including melanoma, non-small cell lung cancer (NSCLC), and urothelial carcinoma (TCC) of the bladder (NCT02897765). In addition to addressing the feasibility and safety of this combination in a large phase Ib study, we performed comprehensive molecular and immune analyses to define the parameters associated with progression-free survival. These analyses revealed that there were few preexisting neoantigen responses. However, following vaccination, there was induction of neoantigen-specific cytotoxic T&nbsp;cells that can traffic to the tumor. In addition, epitope spread to non-vaccinating epitopes and major pathological responses were seen post-vaccination. The approach described here presents a treatment strategy for metastatic tumors based on increasing the frequencies of neoantigen-specific T&nbsp;cells to control tumor growth and spread.</div></section><section id="sec-2"><h2>Results</h2><section id="sec-2-1"><h3>Treatment with NEO-PV-01 Plus Anti-PD-1 Is Feasible and Safe in Metastatic Cancer Patients</h3><div id="p0050" role="paragraph">The study was open to patients with unresectable or metastatic melanoma, smoking-associated NSCLC, and TCC of the bladder, who were enrolled at nine major cancer centers in the United States. The protocol specified at most one prior regimen for metastatic disease and no prior immunotherapy with anti-PD-1/PD-L1, although at the start of the study, nivolumab monotherapy was not approved for the first-line treatment of NSCLC or TCC. Enrollment was not restricted based on PD-L1 status. The major study endpoints included evaluations for safety, objective response, progression-free survival, and comprehensive immune analysis in blood and tumor (<a id="crosref0305" href="#sec-4-4">Method Details</a>, study protocol).</div><div id="p0055" role="paragraph">To produce the personalized neoantigen vaccine NEO-PV-01, tumor mutations were first identified by whole exome and RNA sequencing of each patient’s formalin-fixed tumor and matched normal cells from blood as outlined in the vaccine manufacturing schema (<a id="crosref0310" href="#fig1">Figure&nbsp;1</a>A). High-quality neoepitopes encoded by somatic mutations were then selected using bioinformatics algorithms, as previously described (<span class="dropBlock reference-citations"><a id="body-ref-sref1-1" href="#" role="doc-biblioref" data-xml-rid="bib1" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref1-1" aria-controls="sref1-1">Abelin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref1-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">1.</div><div>Abelin, J.G. ∙ Keskin, D.B. ∙ Sarkizova, S. ...</div><div><strong>Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction</strong></div><div><em>Immunity.</em> 2017; <strong>46</strong>:315-326</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85013878753" target="_blank" aria-label="Open Scopus in new tab">Scopus (408)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28228285/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2017.02.007&amp;pmid=28228285" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref50-1" href="#" role="doc-biblioref" data-xml-rid="bib50" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref50-1" aria-controls="sref50-1">Nielsen and Andreatta, 2016</a><div class="dropBlock__holder" data-db-target-of="sref50-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">51.</div><div>Nielsen, M. ∙ Andreatta, M.</div><div><strong>NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets</strong></div><div><em>Genome Med.</em> 2016; <strong>8</strong>:33</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13073-016-0288-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_51_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962905590" target="_blank" aria-label="Open Scopus in new tab">Scopus (364)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27029192/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2Fs13073-016-0288-x&amp;pmid=27029192" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Neoepitopes were prioritized based on the expression of mutated alleles by RNA sequencing, binding to autologous human leukocyte antigen A (HLA-A) and HLA-B, and additional variables. Details of the production, including the selection of vaccine peptides, are provided in <a id="crosref0325" href="#sec-4-4">Method Details</a>. Each neoantigen vaccine consisted of up to 20 unique peptides, 14–35 amino acids in length, and was formulated in up to 4 distinct pools and mixed with the adjuvant poly-ICLC for administration. Patients were treated with nivolumab for 12&nbsp;weeks while the vaccines were generated (<a id="crosref0330" href="#fig1">Figure&nbsp;1</a>B, study schema). Starting at week 12, 1.5&nbsp;mL NEO-PV-01 was administered subcutaneously into each of 4 separate, non-rotating anatomical sites per administration. Five priming and 2 booster vaccinations were administered within a 3-month period, which made up a full NEO-PV-01 course. Nivolumab was continued during both the vaccine and post-vaccine time periods.</div><div class="figure-wrap"><figure id="fig1" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/7b80dff1-32bc-4774-8fb3-57c1835cde22/main.assets/gr1_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="gr1" src="/cms/10.1016/j.cell.2020.08.053/asset/65d86592-5420-43b2-aa15-d8ba1e4e222b/main.assets/gr1.jpg" height="613" width="759" aria-labelledby="fig1-title fig1-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/7b80dff1-32bc-4774-8fb3-57c1835cde22/main.assets/gr1_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="fig1-title" class="figure__title"><span class="label figure__label">Figure&nbsp;1</span> <span class="figure__title__text">NEO-PV-01 Vaccine Generation, Clinical Study Design, and Patient Disposition</span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="fig1-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0016" role="paragraph">(A) Schematic for the sequencing of patients’ tumors, prediction of neoantigens bound to class I MHC, and generation of synthetic long peptides for the personalized neoantigen vaccines.</div><div id="fspara0015" role="paragraph">(B) Treatment with nivolumab was initiated at week 0, NEO-PV-01 was administered between weeks 12 and 24, and nivolumab was continued for up to 2 years. Tumor biopsies and radiographic imaging were performed at weeks 0, 12, and 24 and leukaphereses were performed at the indicated time points.</div><div id="fspara0020" role="paragraph">(C) Study patient disposition.</div></div></div></div></figcaption></figure></div><div id="p0060" role="paragraph">Between November 2016 and August 2018, 82 patients were enrolled across 9 clinical sites and received at least 1 dose of nivolumab. This set was defined as the intention-to-treat (ITT) set (<a id="crosref0335" href="#fig1">Figure&nbsp;1</a>C). Among these patients, 41% of melanoma, 67% of NSCLC, and 71% of bladder cancer patients had prior therapy (<a id="crosref0340" href="#tbl1">Table 1</a>). Thirty-eight percent of melanoma patients had received prior immunotherapy, including ipilimumab (29%) and interferon-α (9%). Nineteen percent of bladder cancer patients had received prior immunotherapy, in all cases Bacillus Calmette-Guerin (BCG).</div><div class="figure-wrap"><figure id="tbl1" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true" tabindex="0"><thead><tr class="rowsep"><td rowspan="2">&nbsp;</td><th colspan="2"><span>Melanoma</span></th><th colspan="2"><span>NSCLC</span></th><th colspan="2"><span>Bladder Cancer</span></th></tr><tr class="rowsep"><th>ITT Set (N&nbsp;= 34)</th><th>Vaccinated Set (N&nbsp;= 27)</th><th>ITT Set (N&nbsp;= 27)</th><th>Vaccinated Set (N&nbsp;= 18)</th><th>ITT Set (N&nbsp;= 21)</th><th>Vaccinated Set (N&nbsp;= 15)</th></tr></thead><tbody><tr><td>Male sex, %</td><td>68</td><td>70</td><td>44</td><td>39</td><td>71</td><td>67</td></tr><tr class="rowsep"><td>Median age, y</td><td>60</td><td>62</td><td>66</td><td>66</td><td>67</td><td>67</td></tr><tr class="rowsep"><td colspan="7"><b>M-stage, %</b></td></tr><tr><td>M0</td><td>3</td><td>4</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>M1a</td><td>24</td><td>22</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>M1b</td><td>29</td><td>33</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr class="rowsep"><td>M1c</td><td>44</td><td>41</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr class="rowsep"><td colspan="7"><b>AJCC stage, %</b></td></tr><tr><td>III</td><td>3</td><td>4</td><td>7</td><td>6</td><td>29</td><td>33</td></tr><tr><td>IV</td><td>97</td><td>96</td><td>93</td><td>94</td><td>71</td><td>67</td></tr><tr><td>Elevated LDH, %</td><td>38</td><td>41</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Median TMB (TMB range)</td><td>267 (20–8,431)</td><td>363 (50–8,431)</td><td>185 (65–760)</td><td>221 (109–760)</td><td>142 (42–1,447)</td><td>194 (48–1,447)</td></tr><tr><td>PD-L1&nbsp;&lt; 1%</td><td>29</td><td>20</td><td>41</td><td>27</td><td>61</td><td>57</td></tr><tr><td>PD-L1&nbsp;&lt; 50%</td><td>92</td><td>90</td><td>71</td><td>64</td><td>94</td><td>93</td></tr><tr class="rowsep"><td>Median tumor size (cm)</td><td>5.3</td><td>5.2</td><td>7.2</td><td>6.8</td><td>5.2</td><td>4.7</td></tr><tr class="rowsep"><td colspan="7"><b>ECOG, %</b></td></tr><tr><td>0</td><td>82</td><td>89</td><td>41</td><td>50</td><td>48</td><td>60</td></tr><tr><td>1</td><td>18</td><td>11</td><td>59</td><td>50</td><td>48</td><td>40</td></tr><tr><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td><td>5</td><td>0</td></tr><tr><td>Prior therapy</td><td>41</td><td>30</td><td>67</td><td>61</td><td>71</td><td>73</td></tr><tr><td>Prior chemotherapy</td><td>0</td><td>0</td><td>67</td><td>61</td><td>67</td><td>67</td></tr><tr><td>Prior platinum</td><td>NA</td><td>NA</td><td>63</td><td>61</td><td>57</td><td>53</td></tr><tr><td>Prior immune therapy</td><td>38</td><td>30</td><td>0</td><td>0</td><td>19</td><td>20</td></tr><tr><td>Prior ipilimumab</td><td>29</td><td>22</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr></tbody></table></div><figcaption><div class="caption"><span class="heading">Table 1</span><div id="tspara0010" role="paragraph">Demographics and Baseline Disease Characteristics by Cancer Type</div></div><div class="notes"><div id="tspara0015" role="paragraph">In the NSCLC cohort, all of the patients had a history of smoking, 67% of NSCLC patients in the ITT and 61% of NSCLC patients in the NEO-PV-01 sets, respectively, had adenocarcinoma; the remaining NSCLC patients had squamous cell carcinoma. Among the melanoma patients, 9% of ITT and 8% of vaccinated patients previously received interferon-α. Prior immune therapy for bladder cancer patients was BCG in all cases. One bladder cancer patient was ECOG 2 at baseline, while all others were either ECOG 0 or 1. LDH levels were available from 21 and 17 patients in the ITT and vaccinated melanoma cohorts, respectively. Tumor PD-L1 levels were available from 24 and 20, 17 and 11, and 18 and 14 of the ITT and vaccinated sets in the melanoma, NSCLC, and bladder cancer cohorts, respectively. In the melanoma and bladder cohorts there were 29% and 48% smokers, respectively. AJCC, American Joint Committee on Cancer; BCG, Bacillus Calmette-Guerin; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NA, not applicable.</div></div><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=tbl1&amp;pii=S0092-8674%2820%2931141-7" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div><div id="p0065" role="paragraph">Of the 82 patients in the ITT set, 22 (27%) were not vaccinated for reasons that included radiographic or clinical progression (N&nbsp;= 11), insufficient tumor cellularity or low tumor mutational burden (N&nbsp;= 4), and other reasons (N&nbsp;= 7) (<a id="crosref0345" href="#fig1">Figure&nbsp;1</a>C). Therefore, the vaccinated set included 60 patients, each of whom received at least 1 dose of vaccine (27 melanoma, 18 NSCLC, 15 bladder cancer). Of the 60 patients, 14 (23%) received the vaccine after radiographic progression on nivolumab by RECIST 1.1 criteria (6 melanoma, 4 NSCLC, and 4 bladder cancer). Although the role of pseudo-progression was considered in progressors, this is a relatively rare phenomenon with anti-PD-1 therapy alone (<span class="dropBlock reference-citations"><a id="body-ref-sref33" href="#" role="doc-biblioref" data-xml-rid="bib33" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref33" aria-controls="sref33">Hodi et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref33"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">33.</div><div>Hodi, F.S. ∙ Ballinger, M. ∙ Lyons, B. ...</div><div><strong>Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy</strong></div><div><em>J.&nbsp;Clin. Oncol.</em> 2018; <strong>36</strong>:850-858</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2017.75.1644" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_33_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85044243593" target="_blank" aria-label="Open Scopus in new tab">Scopus (264)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29341833/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2017.75.1644&amp;pmid=29341833" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref51" href="#" role="doc-biblioref" data-xml-rid="bib51" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref51" aria-controls="sref51">Ott, 2018</a><div class="dropBlock__holder" data-db-target-of="sref51"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">52.</div><div>Ott, P.A.</div><div><strong>Immunotherapy: Immune-modified response criteria - an iterative learning process?</strong></div><div><em>Nat. Rev. Clin. Oncol.</em> 2018; <strong>15</strong>:267-268</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrclinonc.2018.36" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_52_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85045538104" target="_blank" aria-label="Open Scopus in new tab">Scopus (4)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29532797/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnrclinonc.2018.36&amp;pmid=29532797" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). In the vaccinated set, 30% of melanoma, 61% of NSCLC, and 73% of bladder cancer patients had prior therapy (<a id="crosref0360" href="#tbl1">Table 1</a>). Eleven of the vaccinated patients had BRAF mutations (2 NSCLC and 9 melanoma) and 3 had KRAS mutations (all codon 12 and all in NSCLC). No other specific mutations (same amino acid change in the same gene) occurred in&nbsp;≥5 patients in the study.</div><div id="p0070" role="paragraph">The primary objective of the study was to evaluate the safety and tolerability of NEO-PV-01 in combination with nivolumab (<a id="crosref0365" href="#mmc1">Tables S1–S3</a>). The most common adverse events in vaccinated patients were injection-site reactions and influenza-like illness (52% and 35% of the patients, respectively). Injection site reactions typically manifested as transient, localized warmth and erythema. These events were mild (Common Terminology Criteria for Adverse Events [CTCAE] grade 1) in all cases except in 1 patient, who had a grade 2 injection site erythema. Injection site-related adverse events did not lead to NEO-PV-01 dose interruption or discontinuation for any patient (<a id="crosref0370" href="#mmc1">Table S2</a>). Treatment-related events of grade ≥3 severity were noted for only 2 patients in the vaccinated group, with 1 case each of hypokalemia and rash, and 1 patient in the vaccinated group discontinued treatment for grade 2 gastritis (<a id="crosref0375" href="#mmc1">Table S3</a>). No treatment-related serious adverse events were observed.</div><div id="p0075" role="paragraph">The objective response rates (ORRs, RECIST version 1.1), PFS and overall survival (OS) were analyzed with a minimum follow-up of 12&nbsp;months as of the August 2019 data cutoff. <a id="crosref0380" href="#fig2">Figure&nbsp;2</a> summarizes the radiographic response profiles (RECIST 1.1) for each patient by tumor type (change in sum of target lesions) who received anti-PD-1 alone or in combination with NEO-PV-01. The pair of bar plots (top panel) for the vaccinated patients allow for the comparison of the best response before vaccine initiation (dark shade) and the best response overall (light shade). The difference indicates a further reduction in tumor size following the start of the vaccine. The PD-L1 status of the vaccinated patients did not correlate with the ORR in any of the three cohorts (<a id="crosref0385" href="#figs1">Figure&nbsp;S1</a>A). We note that the further tumor regression observed after vaccination could reflect delayed responses following nivolumab monotherapy, although vaccine-induced anti-tumor T&nbsp;cell responses may be a component of these responses. Among the vaccinated patients (N&nbsp;= 60), ORRs (95% confidence interval [CI]) were 59% (39%–78%), 39% (17%–64%), and 27% (8%–55%) for melanoma, NSCLC, and bladder cancer patients, respectively. The median duration of response was not reached for any of the three cohorts. Efficacy data for the ITT and the vaccinated sets are included in <a id="crosref0390" href="#mmc1">Table S4</a>. Overall, 8 of 60 vaccinated patients met the criteria for tumor response conversions, for a response conversion rate (RCR) of 13%. The RCRs for the melanoma, NSCLC, and bladder cancer patient cohorts were 15%, 17%, and 7%, respectively. Among the 14 patients who had progressive disease before vaccination, 1 patient with NSCLC had a partial response and 1 patient with bladder cancer experienced stable disease after vaccination.</div><div class="figure-wrap"><figure id="fig2" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/d5528583-3934-4805-b87a-cfb6a702fa8a/main.assets/gr2_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="gr2" src="/cms/10.1016/j.cell.2020.08.053/asset/ef9d342e-3fbb-44c3-af23-edb565aeee00/main.assets/gr2.jpg" height="274" width="753" aria-labelledby="fig2-title fig2-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/d5528583-3934-4805-b87a-cfb6a702fa8a/main.assets/gr2_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="fig2-title" class="figure__title"><span class="label figure__label">Figure&nbsp;2</span> <span class="figure__title__text">Rates and Durability of Responses Following Treatment with NEO-PV-01 Plus Anti-PD-1</span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="fig2-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0030" role="paragraph">Top: best radiographic change (%) in sum of target lesions for each patient. The dark shade narrow bars represent best change pre-NEO-PV-01; the light shade wide bars represent the overall best change in study for patients who received at least 1 dose of NEO-PV-01 plus anti-PD-1. Red indicates progressive disease, blue indicates partial response, and green indicates complete response. Bottom: radiographic changes (%) in target lesions from the initiation of nivolumab treatment for each patient. The colors are the same as in the top panel.</div></div></div></div></figcaption></figure></div><div class="figure-wrap"><figure id="figs1" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/e047e0fd-9fd8-4ddd-80aa-a6d405c0e4c4/main.assets/figs1_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs1" src="/cms/10.1016/j.cell.2020.08.053/asset/81daa4d3-7623-4bb7-b858-5b65f08ae185/main.assets/figs1.jpg" height="941" width="743" aria-labelledby="figs1-title figs1-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/e047e0fd-9fd8-4ddd-80aa-a6d405c0e4c4/main.assets/figs1_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="figs1-title" class="figure__title"><span class="label figure__label">Figure&nbsp;S1</span> <span class="figure__title__text">Radiographic Responses with Pre-treatment Tumor PD-L1 Levels in Vaccinated Patients and OS/PFS by Tumor Type; Additional Data Related to <a id="crosref1215" href="#fig2">Figure&nbsp;2</a></span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="figs1-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0130" role="paragraph">(A): Radiographic responses with pre-treatment PD-L1 levels in tumors of patients who received at least one dose of NEO-PV-01. PD-L1 levels are indicated below the bars in the waterfall plots for the three tumor cohorts. Scoring was based on percent PD-L1 on tumor cells as follows:&nbsp;&lt; 1% is indicated as -, ≥ 1% as&nbsp;+, ≥ 5% as&nbsp;++ and ≥ 50% as&nbsp;+++. NA: data not available. (B and C): Kaplan-Meier estimates of PFS (top panel) and OS (bottom panel) for all three tumor types in patients who received &gt;&nbsp;= 1 dose of vaccine (B) and in all patients who received at least one dose of nivolumab (ITT, C).</div></div></div></div></figcaption></figure></div><div id="p0080" role="paragraph">Kaplan-Meier estimates for PFS and OS in both the ITT and vaccinated cohorts for the melanoma, NSCLC, and bladder cancer patients are shown in <a id="crosref0395" href="#figs1">Figures S1</a>B and S1C, respectively. The median PFS (95% CI) among vaccinated patients was 23.5&nbsp;months (6.6, NE), 8.5&nbsp;months (3.9, NE), and 5.8&nbsp;months (2.8, 12.7) in the melanoma, NSCLC, and bladder cancer cohorts, respectively. The median OS for vaccinated patients was not reached in the melanoma and NSCLC cohorts, while for the bladder cancer cohort, the median OS was 20.7&nbsp;months (4.8, NE). The 1-year OS rates were 96% (76%–99%), 83% (57%–94%) and 67% (38%–85%) for melanoma, NSCLC, and bladder cancer patients, respectively (<a id="crosref0400" href="#mmc1">Table S4</a>). These data compare favorably with historical data for anti-PD-1 monotherapy (<span class="dropBlock reference-citations"><a id="body-ref-sref7-1" href="#" role="doc-biblioref" data-xml-rid="bib7" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref7-1" aria-controls="sref7-1">Balar et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref7-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">6.</div><div>Balar, A.V. ∙ Galsky, M.D. ∙ Rosenberg, J.E. ..., IMvigor210 Study Group</div><div><strong>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial</strong></div><div><em>Lancet.</em> 2017; <strong>389</strong>:67-76</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2816%2932455-2&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2816%2932455-2&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85007564166" target="_blank" aria-label="Open Scopus in new tab">Scopus (1629)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27939400/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2816%2932455-2&amp;pmid=27939400" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref9-1" href="#" role="doc-biblioref" data-xml-rid="bib9" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref9-1" aria-controls="sref9-1">Bellmunt et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref9-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">8.</div><div>Bellmunt, J. ∙ de Wit, R. ∙ Vaughn, D.J. ..., KEYNOTE-045 Investigators</div><div><strong>Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>376</strong>:1015-1026</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1613683" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85015755043" target="_blank" aria-label="Open Scopus in new tab">Scopus (2522)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28212060/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1613683&amp;pmid=28212060" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref13-1" href="#" role="doc-biblioref" data-xml-rid="bib13" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref13-1" aria-controls="sref13-1">Borghaei et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref13-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">13.</div><div>Borghaei, H. ∙ Paz-Ares, L. ∙ Horn, L. ...</div><div><strong>Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2015; <strong>373</strong>:1627-1639</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1507643" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_13_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84944937210" target="_blank" aria-label="Open Scopus in new tab">Scopus (7626)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref15-1" href="#" role="doc-biblioref" data-xml-rid="bib15" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref15-1" aria-controls="sref15-1">Carbone et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref15-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">15.</div><div>Carbone, D.P. ∙ Reck, M. ∙ Paz-Ares, L. ..., CheckMate 026 Investigators</div><div><strong>First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>376</strong>:2415-2426</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1613493" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85020964772" target="_blank" aria-label="Open Scopus in new tab">Scopus (1990)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28636851/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1613493&amp;pmid=28636851" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref31-1" href="#" role="doc-biblioref" data-xml-rid="bib31" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref31-1" aria-controls="sref31-1">Herbst et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref31-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">31.</div><div>Herbst, R.S. ∙ Baas, P. ∙ Kim, D.W. ...</div><div><strong>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</strong></div><div><em>Lancet.</em> 2016; <strong>387</strong>:1540-1550</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84950117835" target="_blank" aria-label="Open Scopus in new tab">Scopus (5239)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref44-1" href="#" role="doc-biblioref" data-xml-rid="bib44" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref44-1" aria-controls="sref44-1">Larkin et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref44-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">44.</div><div>Larkin, J. ∙ Minor, D. ∙ D’Angelo, S. ...</div><div><strong>Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial</strong></div><div><em>J.&nbsp;Clin. Oncol.</em> 2018; <strong>36</strong>:383-390</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.8023" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_44_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85041205158" target="_blank" aria-label="Open Scopus in new tab">Scopus (384)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28671856/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2016.71.8023&amp;pmid=28671856" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref61-1" href="#" role="doc-biblioref" data-xml-rid="bib61" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref61-1" aria-controls="sref61-1">Schachter et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref61-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">62.</div><div>Schachter, J. ∙ Ribas, A. ∙ Long, G.V. ...</div><div><strong>Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)</strong></div><div><em>Lancet.</em> 2017; <strong>390</strong>:1853-1862</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2817%2931601-X&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2817%2931601-X&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85027501801" target="_blank" aria-label="Open Scopus in new tab">Scopus (934)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28822576/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2817%2931601-X&amp;pmid=28822576" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref64-1" href="#" role="doc-biblioref" data-xml-rid="bib64" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref64-1" aria-controls="sref64-1">Sharma et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref64-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">66.</div><div>Sharma, P. ∙ Callahan, M.K. ∙ Bono, P. ...</div><div><strong>Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial</strong></div><div><em>Lancet Oncol.</em> 2016; <strong>17</strong>:1590-1598</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS1470-2045%2816%2930496-X&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS1470-2045%2816%2930496-X&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84990852158" target="_blank" aria-label="Open Scopus in new tab">Scopus (565)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27733243/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2816%2930496-X&amp;pmid=27733243" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref75-1" href="#" role="doc-biblioref" data-xml-rid="bib75" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref75-1" aria-controls="sref75-1">Wolchok et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref75-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">78.</div><div>Wolchok, J.D. ∙ Chiarion-Sileni, V. ∙ Gonzalez, R. ...</div><div><strong>Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>377</strong>:1345-1356</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1709684" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_78_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85030460514" target="_blank" aria-label="Open Scopus in new tab">Scopus (2658)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28889792/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1709684&amp;pmid=28889792" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Patients with prior treatment tended to have worse PFS, as has been demonstrated with other trials testing checkpoint therapy (<span class="dropBlock reference-citations"><a id="body-ref-sref13-2" href="#" role="doc-biblioref" data-xml-rid="bib13" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref13-2" aria-controls="sref13-2">Borghaei et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref13-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">13.</div><div>Borghaei, H. ∙ Paz-Ares, L. ∙ Horn, L. ...</div><div><strong>Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2015; <strong>373</strong>:1627-1639</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1507643" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_13_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84944937210" target="_blank" aria-label="Open Scopus in new tab">Scopus (7626)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref31-2" href="#" role="doc-biblioref" data-xml-rid="bib31" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref31-2" aria-controls="sref31-2">Herbst et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref31-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">31.</div><div>Herbst, R.S. ∙ Baas, P. ∙ Kim, D.W. ...</div><div><strong>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</strong></div><div><em>Lancet.</em> 2016; <strong>387</strong>:1540-1550</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84950117835" target="_blank" aria-label="Open Scopus in new tab">Scopus (5239)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref44-2" href="#" role="doc-biblioref" data-xml-rid="bib44" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref44-2" aria-controls="sref44-2">Larkin et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref44-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">44.</div><div>Larkin, J. ∙ Minor, D. ∙ D’Angelo, S. ...</div><div><strong>Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial</strong></div><div><em>J.&nbsp;Clin. Oncol.</em> 2018; <strong>36</strong>:383-390</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.8023" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_44_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85041205158" target="_blank" aria-label="Open Scopus in new tab">Scopus (384)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28671856/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2016.71.8023&amp;pmid=28671856" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The clinical data indicate that vaccination with personalized neoantigens is feasible and safe in multiple solid tumor types when co-administered with anti-PD-1 therapy. The single-arm design of the trial does not allow attribution of responses specifically to the vaccine since it was administered in combination with anti-PD-1.</div></section><section id="sec-2-2"><h3>Distinct Immune and Molecular Features Are Associated with PFS across the Three Tumor Cohorts</h3><div id="p0085" role="paragraph">We next investigated the presence of biomarkers that could correlate with PFS across all three tumor cohorts. For this post hoc analysis, we introduced an exploratory endpoint defined by lack of progression at 9&nbsp;months (PFS-9) post-initiation of nivolumab therapy for the melanoma and the NSCLC cohorts and lack of progression at 6&nbsp;months (PFS-6) for the bladder cancer cohort. Patients were classified into two groups who either did or did not achieve PFS-9 or PFS-6, respectively. The time point for bladder cancer was set at 6&nbsp;months to ensure sufficient patient numbers in both groups (PFS-6 or no PFS-6, respectively) due to higher dropout in this cohort. Previous ICI monotherapy studies have investigated clinical outcomes with a variety of different markers, including tumor mutation burden (TMB) (<span class="dropBlock reference-citations"><a id="body-ref-sref25" href="#" role="doc-biblioref" data-xml-rid="bib25" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref25" aria-controls="sref25">Cristescu et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref25"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">25.</div><div>Cristescu, R. ∙ Mogg, R. ∙ Ayers, M. ...</div><div><strong>Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy</strong></div><div><em>Science.</em> 2018; <strong>362</strong>:eaar3593</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aar3593" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_25_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85054777584" target="_blank" aria-label="Open Scopus in new tab">Scopus (1457)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30309915/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aar3593&amp;pmid=30309915" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref72-2" href="#" role="doc-biblioref" data-xml-rid="bib72" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref72-2" aria-controls="sref72-2">Van Allen et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref72-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">75.</div><div>Van Allen, E.M. ∙ Miao, D. ∙ Schilling, B. ...</div><div><strong>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</strong></div><div><em>Science.</em> 2015; <strong>350</strong>:207-211</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aad0095" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_75_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84943516465" target="_blank" aria-label="Open Scopus in new tab">Scopus (1998)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26359337/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aad0095&amp;pmid=26359337" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), immunological gene expression signatures in the tumor microenvironment (TME) (<span class="dropBlock reference-citations"><a id="body-ref-sref6-1" href="#" role="doc-biblioref" data-xml-rid="bib6" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref6-1" aria-controls="sref6-1">Ayers et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref6-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">5.</div><div>Ayers, M. ∙ Lunceford, J. ∙ Nebozhyn, M. ...</div><div><strong>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</strong></div><div><em>J.&nbsp;Clin. Invest.</em> 2017; <strong>127</strong>:2930-2940</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI91190" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85026675148" target="_blank" aria-label="Open Scopus in new tab">Scopus (2322)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28650338/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1172%2FJCI91190&amp;pmid=28650338" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), expression of genes in the antigen presentation pathway, including β2&nbsp;m (<span class="dropBlock reference-citations"><a id="body-ref-sref28" href="#" role="doc-biblioref" data-xml-rid="bib28" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref28" aria-controls="sref28">Gettinger et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref28"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">28.</div><div>Gettinger, S.N. ∙ Choi, J. ∙ Mani, N. ...</div><div><strong>A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers</strong></div><div><em>Nat. Commun.</em> 2018; <strong>9</strong>:3196</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-018-05032-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_28_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85051529355" target="_blank" aria-label="Open Scopus in new tab">Scopus (131)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30097571/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41467-018-05032-8&amp;pmid=30097571" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref57" href="#" role="doc-biblioref" data-xml-rid="bib57" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref57" aria-controls="sref57">Sade-Feldman et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref57"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">58.</div><div>Sade-Feldman, M. ∙ Jiao, Y.J. ∙ Chen, J.H. ...</div><div><strong>Resistance to checkpoint blockade therapy through inactivation of antigen presentation</strong></div><div><em>Nat. Commun.</em> 2017; <strong>8</strong>:1136</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-017-01062-w" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_58_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85032288210" target="_blank" aria-label="Open Scopus in new tab">Scopus (627)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29070816/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41467-017-01062-w&amp;pmid=29070816" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), and the presence of B cells and tertiary lymphoid structures in the TME (<span class="dropBlock reference-citations"><a id="body-ref-sref30" href="#" role="doc-biblioref" data-xml-rid="bib30" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref30" aria-controls="sref30">Helmink et&nbsp;al., 2020</a><div class="dropBlock__holder" data-db-target-of="sref30"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">30.</div><div>Helmink, B.A. ∙ Reddy, S.M. ∙ Gao, J. ...</div><div><strong>B cells and tertiary lymphoid structures promote immunotherapy response</strong></div><div><em>Nature.</em> 2020; <strong>577</strong>:549-555</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1922-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_30_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85078126241" target="_blank" aria-label="Open Scopus in new tab">Scopus (1307)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31942075/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1922-8&amp;pmid=31942075" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref53" href="#" role="doc-biblioref" data-xml-rid="bib53" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref53" aria-controls="sref53">Petitprez et&nbsp;al., 2020</a><div class="dropBlock__holder" data-db-target-of="sref53"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">54.</div><div>Petitprez, F. ∙ de Reyniès, A. ∙ Keung, E.Z. ...</div><div><strong>B cells are associated with survival and immunotherapy response in sarcoma</strong></div><div><em>Nature.</em> 2020; <strong>577</strong>:556-560</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1906-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_54_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85078153209" target="_blank" aria-label="Open Scopus in new tab">Scopus (1057)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31942077/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1906-8&amp;pmid=31942077" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>).</div><div id="p0090" role="paragraph">Mutational profiling of tumor by whole-exome sequencing in all ITT patients revealed a median of 215 non-silent somatic variants (<a id="crosref0500" href="#tbl1">Table 1</a>). Since class I MHC expression on tumors is critical for neoepitope presentation, we also addressed the presence of β2&nbsp;m mutations in tumor biopsies. There were only two patients from the ITT population who had non-silent somatic mutations in the β2&nbsp;m gene, with both patients being positive for HLA class I expression on tumor cells by immunohistochemistry (IHC) (data not shown). Thus, the presence of these types of mutations was rare in the study.</div><div id="p0095" role="paragraph">With respect to TMB, we observed a significant positive correlation with PFS-9 in the melanoma cohort and a positive trend in the NSCLC cohort (<a id="crosref0505" href="#figs2">Figure&nbsp;S2</a>A, I). Data for the bladder cancer cohort, which had limited variability in TMB, revealed no such trend (<a id="crosref0510" href="#figs2">Figure&nbsp;S2</a>A, I). The epitope quality score, a unique score assigned to each candidate epitope based on its binding affinity, allele-specific expression, and proteasomal cleavage potential (<span class="dropBlock reference-citations"><a id="body-ref-sref1-2" href="#" role="doc-biblioref" data-xml-rid="bib1" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref1-2" aria-controls="sref1-2">Abelin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref1-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">1.</div><div>Abelin, J.G. ∙ Keskin, D.B. ∙ Sarkizova, S. ...</div><div><strong>Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction</strong></div><div><em>Immunity.</em> 2017; <strong>46</strong>:315-326</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85013878753" target="_blank" aria-label="Open Scopus in new tab">Scopus (408)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28228285/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2017.02.007&amp;pmid=28228285" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), falls on a 0–1 scale, with higher scores corresponding to the increased likelihood of presentation. Epitope quality scores of the vaccine peptides (sum of all HLA class I epitopes in the vaccine peptides), which were correlated with overall TMB, likewise showed positive associations with PFS-9 in the melanoma and NSCLC cohorts, but only reached statistical significance for the melanoma cohort (<a id="crosref0520" href="#figs2">Figure&nbsp;S2</a>A, II). No association with PFS-6 was observed for the bladder cancer cohort (<a id="crosref0525" href="#figs2">Figure&nbsp;S2</a>A, II). Evaluation of intra-tumoral gene expression for markers of inflammation (<span class="dropBlock reference-citations"><a id="body-ref-sref6-2" href="#" role="doc-biblioref" data-xml-rid="bib6" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref6-2" aria-controls="sref6-2">Ayers et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref6-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">5.</div><div>Ayers, M. ∙ Lunceford, J. ∙ Nebozhyn, M. ...</div><div><strong>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</strong></div><div><em>J.&nbsp;Clin. Invest.</em> 2017; <strong>127</strong>:2930-2940</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI91190" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85026675148" target="_blank" aria-label="Open Scopus in new tab">Scopus (2322)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28650338/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1172%2FJCI91190&amp;pmid=28650338" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) at the pre-treatment time point revealed a positive trend for the melanoma and bladder cancer cohorts, but not for the NSCLC cohort (<a id="crosref0535" href="#figs2">Figure&nbsp;S2</a>A, III). Data for the vaccinated set are shown in <a id="crosref0540" href="#figs2">Figure&nbsp;S2</a>A, panels IV, V, and VI, and, similar to the ITT set, we observed a significant positive correlation in the melanoma cohort for the epitope quality score and a trend toward positive correlation for TMB. Whole-exome sequencing of additional biopsies taken later in the treatment course showed only minor changes in the mutational landscape and TMB. Overall, these data suggest that both TMB and epitope quality are important determinants of response to the combination of the neoantigen vaccine and anti-PD-1 therapy.</div><div class="figure-wrap"><figure id="figs2" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/accc0a4f-0870-4188-9353-4d1af89f534d/main.assets/figs2_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs2" src="/cms/10.1016/j.cell.2020.08.053/asset/4c785364-ff9d-4ce6-ae9c-688d65554174/main.assets/figs2.jpg" height="941" width="659" aria-labelledby="figs2-title figs2-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/accc0a4f-0870-4188-9353-4d1af89f534d/main.assets/figs2_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="figs2-title" class="figure__title"><span class="label figure__label">Figure&nbsp;S2</span> <span class="figure__title__text">Distinct Molecular and Immune Features Are Associated with PFS across the 3 Tumor Cohorts; Additional Data Related to <a id="crosref1220" href="#fig3">Figure&nbsp;3</a></span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="figs2-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0140" role="paragraph">A: Tumor mutation burden, epitope quality score, and gene expression with PFS; Molecular correlations of PFS-9 in the melanoma and NSCLC and PFS-6 in the bladder cancer cohorts. PFS-9/6 is defined as lack of disease progression at nine months post-initiation of anti-PD-1 therapy for the melanoma and NSCLC cohorts, respectively, and lack of disease progression at six months for the bladder cancer cohort. Panels i, ii, and iii include patients in the ITT set and panels iv, v&nbsp;and vi include patients who received at least one dose of NEO-PV-01 (vaccinated set). I and IV) Each dot depicts tumor mutation burden (total number of non-silent mutations) of individual melanoma patients with PFS-9 (green) and without PFS-9 (blue). Gray boxes indicate interquartile ranges; p values are calculated using Wilcoxon rank-sum test. II and V) Analogous plots for the HLA class I epitope quality scores of vaccinating epitopes for melanoma patients. The epitope quality score of each candidate epitope falls on a 0-1 scale with higher scores corresponding to increased likelihood of presentation. Values are summed across the potential HLA-I epitopes for all vaccinating peptides per patient. III and VI) Analogous plots for T&nbsp;cell inflammation score (TIS) at the pre-treatment time point as assessed by gene expression analysis on the NanoString™ platform. TIS score was calculated as previously described. Lymph-node derived biopsies were excluded from this analysis. B: Peripheral immune phenotypes correlate with PFS-9 in NSCLC patients and PFS-6 in bladder cancer patients; I) Identification of plasmacytoid dendritic cells in the NSCLC cohort and correlation with PFS-9. PBMCs from pre-treatment, pre-vaccine and post-vaccine time points were analyzed using flow cytometry to quantify plasmacytoid DCs based on expression of CD123 and CD303. II) Identification of memory and naive CD8<sup>+</sup> T&nbsp;cells in the bladder cancer cohort and correlation with PFS-6. PBMCs from pre-treatment, pre-vaccine and post-vaccine time points were analyzed using flow cytometry to quantify memory CD8<sup>+</sup> T&nbsp;cell subsets based on expression of CD45RA and CD45RO. Data are presented as box and whisker plot with the box representing the 25th to 75th percentile, whiskers representing the min and max value and the horizontal line representingt the median. Statistical significance was determined using an unpaired t test. C: Presence of APOE4 genetic variant correlates with PFS-9 in melanoma, but not with PFS-9 in NSCLC or PFS-6 in bladder cancer; Patients with PFS-6/9 (green) and without PFS-6/9 (blue) in relation to presence or absence of an APOE4 germline genetic variant. Values are shown for the melanoma, NSCLC, and bladder cancer cohorts according to achieving 9-month month PFS for melanoma and NSCLC and 6&nbsp;months PFS for bladder cancer, respectively. P values are calculated using Fisher’s exact test. The numbers in each bar plot represents the number of patients.</div></div></div></div></figcaption></figure></div><div id="p0100" role="paragraph">To characterize potential biomarkers outside the tumor microenvironment, we evaluated distinct immune cell phenotypes including T, B, natural killer (NK), and myeloid cells in peripheral blood mononuclear cells (PBMCs) obtained at week 0 (pre-treatment), week 10 (pre-vaccine), and week 20 (post-vaccine) in patients from all 3 cohorts. Melanoma patients who achieved PFS-9 had a higher percentage of peripheral effector memory CD8<sup>+</sup> T&nbsp;cells compared to patients with progression before the 9-month mark, with significant differences observed at both the pre-vaccine and post-vaccine time points (<a id="crosref0545" href="#fig3">Figure&nbsp;3</a>A). Conversely, the percentage of naive CD8<sup>+</sup> T&nbsp;cells was higher in melanoma patients with progression, with significant differences observed at all three time points (<a id="crosref0550" href="#fig3">Figure&nbsp;3</a>A). Consistent with the observation of increased effector memory CD8<sup>+</sup> T&nbsp;cells, melanoma patients with PFS-9 had a more restricted and less diverse circulating T&nbsp;cell receptor (TCR) repertoire than patients who progressed (<a id="crosref0555" href="#fig3">Figure&nbsp;3</a>B) (<span class="dropBlock reference-citations"><a id="body-ref-sref26" href="#" role="doc-biblioref" data-xml-rid="bib26" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref26" aria-controls="sref26">Fairfax et&nbsp;al., 2020</a><div class="dropBlock__holder" data-db-target-of="sref26"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">26.</div><div>Fairfax, B.P. ∙ Taylor, C.A. ∙ Watson, R.A. ...</div><div><strong>Peripheral CD8<sup>+</sup> T&nbsp;cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma</strong></div><div><em>Nat. Med.</em> 2020; <strong>26</strong>:193-199</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-019-0734-6" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_26_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85079320198" target="_blank" aria-label="Open Scopus in new tab">Scopus (184)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32042196/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-019-0734-6&amp;pmid=32042196" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref34" href="#" role="doc-biblioref" data-xml-rid="bib34" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref34" aria-controls="sref34">Hosoi et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref34"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">34.</div><div>Hosoi, A. ∙ Takeda, K. ∙ Nagaoka, K. ...</div><div><strong>Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy</strong></div><div><em>Sci. Rep.</em> 2018; <strong>8</strong>:1058</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-018-19548-y" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85040863881" target="_blank" aria-label="Open Scopus in new tab">Scopus (47)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29348598/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41598-018-19548-y&amp;pmid=29348598" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref39" href="#" role="doc-biblioref" data-xml-rid="bib39" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref39" aria-controls="sref39">Kirsch et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref39"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">39.</div><div>Kirsch, I. ∙ Vignali, M. ∙ Robins, H.</div><div><strong>T-cell receptor profiling in cancer</strong></div><div><em>Mol. Oncol.</em> 2015; <strong>9</strong>:2063-2070</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molonc.2015.09.003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_39_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84952637397" target="_blank" aria-label="Open Scopus in new tab">Scopus (107)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26404496/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.molonc.2015.09.003&amp;pmid=26404496" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref66" href="#" role="doc-biblioref" data-xml-rid="bib66" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref66" aria-controls="sref66">Thomas et&nbsp;al., 2013</a><div class="dropBlock__holder" data-db-target-of="sref66"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">69.</div><div>Thomas, P.G. ∙ Handel, A. ∙ Doherty, P.C. ...</div><div><strong>Ecological analysis of antigen-specific CTL repertoires defines the relationship between naive and immune T-cell populations</strong></div><div><em>Proc. Natl. Acad. Sci. USA.</em> 2013; <strong>110</strong>:1839-1844</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.1222149110" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_69_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84873184482" target="_blank" aria-label="Open Scopus in new tab">Scopus (43)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23319654/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.1222149110&amp;pmid=23319654" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref71" href="#" role="doc-biblioref" data-xml-rid="bib71" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref71" aria-controls="sref71">Valpione et&nbsp;al., 2020</a><div class="dropBlock__holder" data-db-target-of="sref71"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">74.</div><div>Valpione, S. ∙ Galvani, E. ∙ Tweedy, J. ...</div><div><strong>Immune-awakening revealed by peripheral T&nbsp;cell dynamics after one cycle of immunotherapy</strong></div><div><em>Nat. Can.</em> 2020; <strong>1</strong>:210-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s43018-019-0022-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_74_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85082765119" target="_blank" aria-label="Open Scopus in new tab">Scopus (129)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32110781/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs43018-019-0022-x&amp;pmid=32110781" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>).</div><div class="figure-wrap"><figure id="fig3" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/6b0df645-307d-4627-bd9a-3858e1aea668/main.assets/gr3_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="gr3" src="/cms/10.1016/j.cell.2020.08.053/asset/e8af6642-db73-4973-a221-2dcdad1d684b/main.assets/gr3.jpg" height="758" width="657" aria-labelledby="fig3-title fig3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/6b0df645-307d-4627-bd9a-3858e1aea668/main.assets/gr3_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="fig3-title" class="figure__title"><span class="label figure__label">Figure&nbsp;3</span> <span class="figure__title__text">Increased Frequencies of Effector Memory T Cells, Increased TCR Clonality, and Presence of Tumor-Infiltrating TCF7<sup>+</sup>CD8<sup>+</sup> T Cells Correlate with PFS-9 in the Melanoma Cohort</span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="fig3-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0040" role="paragraph">(A) Identification of peripheral effector memory and naive CD8<sup>+</sup> T&nbsp;cells in the melanoma cohort and correlation with PFS-9. Circulating PBMCs from pre-treatment, pre-vaccine, and post-vaccine time points were analyzed using flow cytometry to quantify effector memory and naive CD8<sup>+</sup> T&nbsp;cell subsets based on the expression of CD45RA and CD62L. The data are presented as box and whisker plots, with the box representing the 25th–75th percentiles, whiskers representing the minimum and maximum values, and the line represents the median. Statistical significance was determined using an unpaired t test.</div><div id="fspara0045" role="paragraph">(B) Measures of TCR-β diversity as observed in the PBMCs of patients with PFS-9 (green) and without PFS-9 (blue). Each dot represents 1 patient; the black horizontal bars indicate mean values. A higher Gini coefficient indicates greater skewness in clonal frequencies (i.e., higher clonality). Diversity evenness 50 (DE 50) is an alternative metric with opposite directionality.</div><div id="fspara0050" role="paragraph">(C) Top: expression of TCF7<sup>+</sup>CD8<sup>+</sup> T&nbsp;cell genes in metastatic tumor biopsies of melanoma patients at pre-treatment, pre-vaccine, or post-vaccine time points using the NanoString platform. Each point represents the calculated TCF7<sup>+</sup>CD8<sup>+</sup> T&nbsp;cell gene signature score for 1 patient. The data are presented as box and whisker plots, with the box representing the 25th–75th percentiles, the whiskers representing 1.5 times the length of the box, and the line represents the median. Statistical significance was determined using an unpaired t test. Bottom: representative images showing multiplex immunofluorescence of pre-treatment formalin-fixed paraffin-embedded (FFPE) tumor biopsies in 2 melanoma patients, 1 with PFS-9 (M7) and the other with no PFS-9 (M11), stained with DAPI (blue), CD8 (yellow), TCF7 (red), and S100 (green). The white arrows show TCF7<sup>+</sup>CD8<sup>+</sup> T&nbsp;cell infiltrates. Scale bar, 50&nbsp;μm.</div></div></div></div></figcaption></figure></div><div id="p0105" role="paragraph">Distinct immune phenotypes in the peripheral blood were also observed in the NSCLC and bladder cancer cohorts correlating with PFS-9 and PFS-6, respectively, although the number of samples available in these cohorts was limited. NSCLC patients who achieved PFS-9 had a lower percentage of plasmacytoid DCs than patients who progressed (<a id="crosref0585" href="#figs2">Figure&nbsp;S2</a>B, I). Significant correlation to plasmacytoid DCs was not seen in the melanoma or bladder cancer cohorts. Bladder cancer patients who achieved PFS-6 had a significantly higher percentage of memory CD8<sup>+</sup> T&nbsp;cells that was observed only at the post-vaccine time point when compared to bladder cancer patients who progressed (<a id="crosref0590" href="#figs2">Figure&nbsp;S2</a>B, II).</div><div id="p0110" role="paragraph">We further evaluated the presence of stem-like memory T&nbsp;cells in the tumor using a gene signature analysis based on recently defined genes that includes TCF7, a critical transcription factor defining stem-like T&nbsp;cells (<span class="dropBlock reference-citations"><a id="body-ref-sref37" href="#" role="doc-biblioref" data-xml-rid="bib37" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref37" aria-controls="sref37">Jansen et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref37"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">37.</div><div>Jansen, C.S. ∙ Prokhnevska, N. ∙ Master, V.A. ...</div><div><strong>An intra-tumoral niche maintains and differentiates stem-like CD8 T&nbsp;cells</strong></div><div><em>Nature.</em> 2019; <strong>576</strong>:465-470</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1836-5" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_37_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85076588925" target="_blank" aria-label="Open Scopus in new tab">Scopus (450)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31827286/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1836-5&amp;pmid=31827286" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref58" href="#" role="doc-biblioref" data-xml-rid="bib58" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref58" aria-controls="sref58">Sade-Feldman et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref58"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">59.</div><div>Sade-Feldman, M. ∙ Yizhak, K. ∙ Bjorgaard, S.L. ...</div><div><strong>Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma</strong></div><div><em>Cell.</em> 2018; <strong>175</strong>:998-1013.e20</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_59_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2018.10.038&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_59_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2018.10.038&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_59_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85055560004" target="_blank" aria-label="Open Scopus in new tab">Scopus (1016)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30388456/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.cell.2018.10.038&amp;pmid=30388456" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). In agreement with the memory phenotype observed in peripheral CD8<sup>+</sup> T&nbsp;cells of melanoma patients who had PFS-9, higher levels of stem-like memory T&nbsp;cell gene signatures were also seen in tumor biopsies from patients with PFS-9 compared to patients with progression (<a id="crosref0605" href="#fig3">Figure&nbsp;3</a>C, upper panel). This was further corroborated by the presence of increased CD8<sup>+</sup> TCF7<sup>+</sup> T&nbsp;cells in the TME of patients with PFS-9 (<a id="crosref0610" href="#fig3">Figure&nbsp;3</a>C, lower panel). Both the peripheral and tumor markers described above did not show changes when comparing pre-vaccine to pre-treatment samples or post-vaccine to pre-vaccine samples in patients with or without PFS-9.</div><div id="p0115" role="paragraph">We also investigated whether any germline markers correlated with PFS in each of the tumor cohorts. Notably, more melanoma patients with PFS-9 had at least one germline copy of the APOE4 genetic variant compared to patients with progression before the 9-month mark (<a id="crosref0615" href="#figs2">Figure&nbsp;S2</a>C) (<span class="dropBlock reference-citations"><a id="body-ref-sref65" href="#" role="doc-biblioref" data-xml-rid="bib65" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref65" aria-controls="sref65">Tavazoie et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref65"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">68.</div><div>Tavazoie, M.F. ∙ Pollack, I. ∙ Tanqueco, R. ...</div><div><strong>LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer</strong></div><div><em>Cell.</em> 2018; <strong>172</strong>:825-840.e18</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_68_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2017.12.026&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_68_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2017.12.026&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_68_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85040446099" target="_blank" aria-label="Open Scopus in new tab">Scopus (311)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29336888/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.cell.2017.12.026&amp;pmid=29336888" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). In contrast, an opposite correlation to the presence of the APOE4 genetic variant was seen in the NSCLC cohort and no correlation was seen in the bladder cancer patients. Further validation of these observations should be addressed in future trials.</div></section><section id="sec-2-3"><h3>NEO-PV-01 Plus Anti-PD1 Induces Specific and Durable T Cell Reactivity against Neoantigen Epitopes in All Tumor Cohorts</h3><div id="p0120" role="paragraph">The immunogenicity of NEO-PV-01 plus nivolumab was evaluated in the peripheral blood by interferon γ (IFN-γ) ELISpot assay. Analysis of 570 vaccinating peptides across 34 patients with sufficient peripheral leukapheresis samples across all 3 time points (18 melanoma, 7 NSCLC, and 9 bladder cancer) revealed robust <i>de novo</i> immune responses to multiple vaccinating peptides in all of the patients (melanoma 52%, NSCLC 47%, and bladder cancer 52%; <a id="crosref0625" href="#fig4">Figure&nbsp;4</a>A). Of these, 42% were <i>ex&nbsp;vivo</i> responses detected in an overnight assay with added peptide and the remainder were detected after peptide stimulation in a 5-day assay, both without added cytokines (see <a id="crosref0630" href="#sec-4-4">Method Details</a>). Minimal neoantigen-specific T&nbsp;cell responses were detected at the pre-treatment and pre-vaccine time points, respectively (<a id="crosref0635" href="#fig4">Figures 4</a>A and <a id="crosref0640" href="#figs3">S3</a>A–S3C). These data are consistent with previous studies indicating that preexisting responses to neoantigens in the periphery are rarely detected (<span class="dropBlock reference-citations"><a id="body-ref-sref52-3" href="#" role="doc-biblioref" data-xml-rid="bib52" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref52-3" aria-controls="sref52-3">Ott et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref52-3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">53.</div><div>Ott, P.A. ∙ Hu, Z. ∙ Keskin, D.B. ...</div><div><strong>An immunogenic personal neoantigen vaccine for patients with melanoma</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:217-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature22991" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_53_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024377220" target="_blank" aria-label="Open Scopus in new tab">Scopus (1897)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678778/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature22991&amp;pmid=28678778" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>).</div><div class="figure-wrap"><figure id="fig4" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/037b9bd9-6d5b-42cb-b977-103f76f7b9c1/main.assets/gr4_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="gr4" src="/cms/10.1016/j.cell.2020.08.053/asset/1661b6d1-7375-4b97-b614-ba5e66176f87/main.assets/gr4.jpg" height="690" width="753" aria-labelledby="fig4-title fig4-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/037b9bd9-6d5b-42cb-b977-103f76f7b9c1/main.assets/gr4_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="fig4-title" class="figure__title"><span class="label figure__label">Figure&nbsp;4</span> <span class="figure__title__text">NEO-PV-01 Plus Anti-PD-1 Induces T Cell Reactivity against Neoantigen Epitopes That Are Mutant Specific and Persistent over Time</span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="fig4-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0060" role="paragraph">(A) I: percentage of all NEO-PV-01 vaccinating peptides per tumor cohort that elicited IFN-γ responses in serial PBMCs at the indicated time points as measured by IFN-γ ELISpot assay. II: percentage of CD4<sup>+</sup> versus CD8<sup>+</sup> T&nbsp;cell responses generated at the post-vaccine time point across all 3 tumor cohorts. III–V: deconvolution of PBMC responses to specific vaccinating peptides (immunizing [IM]) peptide measured by IFN-γ ELISpot assay in representative patients from each of the 3 tumor cohorts. Only the positive responses after background subtraction are shown. Deconvolution was done using a series of overlapping peptides for each IM peptide (<a id="crosref1210" href="#sec-4-4">Method Details</a>). Each bar corresponds to an IM peptide and the assay peptide that generates the maximal response in either of the 2 assay formats (<i>ex&nbsp;vivo</i> assay or in a 5-day assay) for that IM peptide is shown. IM peptides that generated an <i>ex&nbsp;vivo</i> response were as follows: for melanoma patient M1—IM01, -02, -08, -18, and -24; for NSCLC patient L1—IM20, -25, -28, and -29; for bladder cancer patient B1—IM02, -07, and -28. IM peptides labeled on the x axis in blue elicited a pre-vaccine response.</div><div id="fspara0065" role="paragraph">(B) Specificity of immune responses as measured by <i>ex&nbsp;vivo</i> IFN-γ ELISpot assay to mutant peptides (red) versus wild type (blue) across a range of peptide concentrations. Representative responses from melanoma patients (IM24, IM02, and IM01) and a NSCLC (IM29) patient are depicted.</div><div id="fspara0070" role="paragraph">(C) Persistence of immune responses induced by IM peptides, as measured by IFN-γ ELISpot assay in PBMCs collected at week 52 after initiation of anti-PD-1 therapy. Depending on sample availability at the 52-week time point, a range of 1–20 NEO-PV-01 peptides were tested. The data are represented as stacked columns for individual patients, with responses detected at both weeks 20 and 52 (blue) and responses detected only at week 20 (green).</div><div id="fspara0075" role="paragraph">Aggregate data in (A) and (B) are represented as means ± SEMs.</div></div></div></div></figcaption></figure></div><div class="figure-wrap"><figure id="figs3" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/68e18bdb-a097-419f-a124-9e68eeac2ad3/main.assets/figs3a1_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs3-part-1" src="/cms/10.1016/j.cell.2020.08.053/asset/b0eaac5e-c130-4043-9fa6-b9758b5721c5/main.assets/figs3a1.jpg" height="707" width="770" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/68e18bdb-a097-419f-a124-9e68eeac2ad3/main.assets/figs3a1_lrg.jpg" loading="lazy"></a><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/2ed3fe98-a10d-4740-a2aa-20d0677d6dd7/main.assets/figs3a2_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs3-part-2" src="/cms/10.1016/j.cell.2020.08.053/asset/3c3f2ae9-eae4-463a-9ac2-aadf32a889cf/main.assets/figs3a2.jpg" height="699" width="762" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/2ed3fe98-a10d-4740-a2aa-20d0677d6dd7/main.assets/figs3a2_lrg.jpg" loading="lazy"></a><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/7693ef18-c728-4f8c-ae1a-5a76a06d0292/main.assets/figs3b_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs3-part-3" src="/cms/10.1016/j.cell.2020.08.053/asset/3336825f-f1fe-4aa3-a533-938c0763bb07/main.assets/figs3b.jpg" height="697" width="753" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/7693ef18-c728-4f8c-ae1a-5a76a06d0292/main.assets/figs3b_lrg.jpg" loading="lazy"></a><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/a31c6432-a875-4de7-a158-8c11f8e12ad6/main.assets/figs3c_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs3-part-4" src="/cms/10.1016/j.cell.2020.08.053/asset/c6becb5f-b57a-4afa-a8b4-8dcba9c40f23/main.assets/figs3c.jpg" height="687" width="750" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/a31c6432-a875-4de7-a158-8c11f8e12ad6/main.assets/figs3c_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="figs3-title" class="figure__title"><span class="label figure__label">Figure&nbsp;S3</span> <span class="figure__title__text">NEO-PV-01 Plus Anti-PD-1 Induces T Cell Reactivity against Multiple Vaccine Neoepitopes; Additional Data Related to <a id="crosref1225" href="#fig4">Figure&nbsp;4</a></span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="figs3-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0150" role="paragraph">A-C) T&nbsp;cell responses to individual immunizing (IM) peptides across 18 melanoma (A), 7 NSCLC (B) and 9 bladder (C) cancer patients are shown. Details of the assay are provided in the <a id="crosref1230" href="#sec-4-4">Method Details</a> section. Immunizing peptides that did not elicit reactivity are not shown. Each IM peptide was tested for generation of an immune response using a series of overlapping peptides (<a id="crosref1235" href="#sec-4-4">Method Details</a>) and the assay peptide generating the maximum response for each IM peptide are shown across the three time points. Each bar corresponds to an IM peptide and the assay peptide that generates the maximal response in either of the two assay formats (<i>ex&nbsp;vivo</i> assay or 5-day assay) for that IM peptide is shown. Immunizing peptides labeled in red on the x axis were not tested at the indicated time point due to limited sample availability whereas IM peptides labeled in blue on the x axis elicited pre-vaccine responses. Forty two percent of the neoantigen-specific responses detected were seen in an <i>ex&nbsp;vivo</i> assay and the remainder were detected in a 5-day assay with the neoantigen peptide in the absence of serum and cytokines. Vaccine response plots for patients M1, L1 and B1 are also depicted in the main <a id="crosref1240" href="#fig4">Figure&nbsp;4</a>A. Aggregate data are represented as mean ± SEM.</div></div></div></div></figcaption></figure></div><div id="p0125" role="paragraph">Similar proportions of both CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cell responses were detected in all 3 cohorts, with an average of 42% and 24% of vaccinating peptides generating CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cell responses, respectively (<a id="crosref0650" href="#fig4">Figure&nbsp;4</a>A). Specificity of the vaccine-generated immune responses to the mutant epitope versus the wild-type epitope was tested using an IFN-γ ELISpot assay across a wide range of peptide concentrations. Reactivity of the mutant versus the wild-type epitope was seen preferentially in 12 (92%) of the 13 mutant epitopes tested (<a id="crosref0655" href="#fig4">Figure&nbsp;4</a>B; <a id="crosref0660" href="#mmc1">Table S5</a>). Persistence of these vaccine-induced responses was tested in blood samples obtained at week 52 after the start of the anti-PD-1 treatment, or ∼29&nbsp;weeks after the last vaccine dose. Among the 193 neoepitopes tested in 12 melanoma, 4 NSCLC, and 4 bladder cancer patients, persistent immune responses were detected for 58% of the neoepitopes (<a id="crosref0665" href="#fig4">Figure&nbsp;4</a>C). These responses included both CD4<sup>+</sup> and CD8<sup>+</sup> epitopes based on their detection in earlier (week 20) analyses. These data demonstrate that vaccination with NEO-PV-01 results in the generation of T&nbsp;cell responses that are specific and durable.</div></section><section id="sec-2-4"><h3>Neoantigen Vaccine-Specific T Cells Have Cytotoxic Potential, Migrate to the Tumor, and Can Kill Cancer Cells</h3><div id="p0130" role="paragraph">Detailed phenotypic analysis of neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cell responses from selected patients with available samples revealed an activated and effector memory phenotype of these cells (<a id="crosref0670" href="#figs4">Figure&nbsp;S4</a>). In addition, neoantigen-specific CD8<sup>+</sup> T&nbsp;cells from a patient who progressed on study had higher expression of multiple co-inhibitory receptors that was not seen in the neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cells from patients who achieved PFS-9 (<a id="crosref0675" href="#figs4">Figure&nbsp;S4</a>). The cytotoxic phenotype of neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cells in the peripheral blood was determined by the surface expression of CD107a, a marker for T&nbsp;cell degranulation (<span class="dropBlock reference-citations"><a id="body-ref-sref10" href="#" role="doc-biblioref" data-xml-rid="bib10" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref10" aria-controls="sref10">Betts et&nbsp;al., 2003</a><div class="dropBlock__holder" data-db-target-of="sref10"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">9.</div><div>Betts, M.R. ∙ Brenchley, J.M. ∙ Price, D.A. ...</div><div><strong>Sensitive and viable identification of antigen-specific CD8+ T&nbsp;cells by a flow cytometric assay for degranulation</strong></div><div><em>J.&nbsp;Immunol. Methods.</em> 2003; <strong>281</strong>:65-78</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0022-1759(03)00265-5" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-0142185336" target="_blank" aria-label="Open Scopus in new tab">Scopus (1341)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14580882/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0022-1759%2803%2900265-5&amp;pmid=14580882" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), when assayed in the presence of the neoantigen peptide. Among the 71 CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cell epitopes tested across 21 patients (13 melanoma, 3 NSCLC, and 5 bladder), the surface expression of CD107a was detected in the presence of 58% of the epitopes at the post-vaccine time point (<a id="crosref0685" href="#fig5">Figures 5</a>A and <a id="crosref0690" href="#figs5">S5</a>).</div><div class="figure-wrap"><figure id="fig5" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/9248d812-1240-4453-8b29-cbc42e37080f/main.assets/gr5_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="gr5" src="/cms/10.1016/j.cell.2020.08.053/asset/c5814439-cf3e-40c1-a791-13cd8be4aec2/main.assets/gr5.jpg" height="941" width="493" aria-labelledby="fig5-title fig5-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/9248d812-1240-4453-8b29-cbc42e37080f/main.assets/gr5_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="fig5-title" class="figure__title"><span class="label figure__label">Figure&nbsp;5</span> <span class="figure__title__text">NEO-PV-01 Plus Anti-PD-1 Generates Cytotoxic T Cells That Can Traffic to Metastatic Tumors and Induce Epitope Spreading</span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="fig5-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0085" role="paragraph">(A) Cytotoxic potential of NEO-PV-01-generated immune responses as measured by the surface expression of the marker CD107a at the post-vaccine time point. A range of 1–10 NEO-PV-01 peptides were tested per patient. The data are represented as stacked columns for individual patients, with CD107a-positive responses represented in blue and CD107a-negative responses represented in red.</div><div id="fspara0090" role="paragraph">(B) NEO-PV-01 induced neoantigen-specific CD8<sup>+</sup> T&nbsp;cells are present in post-vaccine tumors of melanoma patient M1. (I) Sorting gate of IM24-tetramer<sup>+</sup> CD8<sup>+</sup> T&nbsp;cells present in post-vaccine PBMCs. (II) Cytotoxic potential of IM24-specific CD8<sup>+</sup> T&nbsp;cells as measured by the surface expression of CD107a at week 20. (III) Identification of neoantigen epitope IM24-specific TCR in the post-vaccine tumor biopsy. (IV) Cytotoxicity assay based on cleaved caspase-3 expression of A375 targets cells expressing HLA-B51:01 co-cultured with pre-treatment patient PBMCs transduced with IM24-specific TCR in the presence of mutant or wild-type IM24 peptide, respectively.</div><div id="fspara0095" role="paragraph">(C) Identification of neoantigen epitope IM07-specific CD4<sup>+</sup> T&nbsp;cells in the post-vaccine tumor of melanoma patient M13. (I) IM07-reactive CD4<sup>+</sup> T&nbsp;cells present in post-vaccine PBMCs. (II) Identification of IM07-specific TCRs (TCR1 and TCR3) in the post-vaccine tumor biopsy. (III) Jurkat T&nbsp;cells expressing the IM07-specific TCRs were co-cultured with patient antigen-presenting cells (CD3<sup>+</sup> depleted PBMCs) from the pre-treatment time point in an IL-2 secretion assay.</div><div id="fspara0100" role="paragraph">(D) I: Epitope spread was tested in 25 patients across all 3 tumor cohorts. Reactivity of post-vaccine PBMCs against a range of 10–19 predicted neoantigen peptides that were not included in the vaccine were tested by IFN-γ ELISpot assay in each patient. The data are presented as the percentage of non-vaccine peptides that elicited a response; each dot represents 1 patient. These responses were detected only at the post-vaccine time point. II: Kaplan-Meier plot of progression-free survival (months) by epitope spread yes (≥1) versus no (= 0); p value from log-rank test; hazard ratio from Cox model. The aggregate data are represented as means ± SEMs.</div></div></div></div></figcaption></figure></div><div class="figure-wrap"><figure id="figs4" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/443c0e86-cf4f-498d-be96-25a4dfa84248/main.assets/figs4_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs4" src="/cms/10.1016/j.cell.2020.08.053/asset/e14ad1de-f2c4-4095-8017-e927d4cbc10a/main.assets/figs4.jpg" height="941" width="753" aria-labelledby="figs4-title figs4-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/443c0e86-cf4f-498d-be96-25a4dfa84248/main.assets/figs4_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="figs4-title" class="figure__title"><span class="label figure__label">Figure&nbsp;S4</span> <span class="figure__title__text">Phenotypic Analysis of CD4<sup>+</sup> and CD8<sup>+</sup> T Cells Induced by NEO-PV-01 Plus Anti-PD-1; Additional Data Related to <a id="crosref1245" href="#fig4">Figure&nbsp;4</a></span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="figs4-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0160" role="paragraph">Phenotypic analysis of neoantigen specific T&nbsp;cells by FACS for patients M3 (A) and (B), L7 (C), M1 (D) and M10 (E). Each row depicts phenotyping of an individual IM peptide. The left panel in each row depicts the FACS plot to identify the neoantigen specific T&nbsp;cell either by tetramer analysis (for CD8<sup>+</sup> T&nbsp;cell responses, A-D) or by a functional IFNγ assay (for CD4<sup>+</sup> T&nbsp;cell responses, E). The histogram plots in each row show the relative levels of the indicated marker between tetramer/ IFNγ positive T&nbsp;cells (orange) to the corresponding negative population (blue). Quantitation of the histogram plots are shown in the right panel. Tetramers used in this analysis are HLA- A11:01 (A), HLA-A68:01 (B), HLA-B81:01 (C) and HLA-B51:01 (D).</div></div></div></div></figcaption></figure></div><div class="figure-wrap"><figure id="figs5" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/d8276e66-9f0d-486c-b0a2-54ed8c20ab6c/main.assets/figs5_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs5" src="/cms/10.1016/j.cell.2020.08.053/asset/3c014e66-dcab-41a1-a509-b7cfdd736172/main.assets/figs5.jpg" height="940" width="629" aria-labelledby="figs5-title figs5-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/d8276e66-9f0d-486c-b0a2-54ed8c20ab6c/main.assets/figs5_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="figs5-title" class="figure__title"><span class="label figure__label">Figure&nbsp;S5</span> <span class="figure__title__text">NEO-PV-01 Plus Anti-PD-1 Induces Cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T Cell Responses; Additional Data Related to <a id="crosref1250" href="#fig5">Figure&nbsp;5</a></span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="figs5-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0170" role="paragraph">Surface expression of the cytolytic marker CD107a (x axis) and intracellular expression of IFNγ (y axis) is shown by FACS for 40 IM peptides across 19 patients. Individual plots depict control (DMSO) on the left and IM peptide on the right. Only IM peptides that were positive in this assay (&gt; 1.5-fold stimulation over DMSO control in the CD107a positive or CD107a and IFNγ double positive gate are shown. Parent gates are indicated below each pair of FACS plots. <sup>∗</sup>analysis done at the week 52 time point. Plot for patient M1 is also depicted in the main <a id="crosref1255" href="#fig5">Figure&nbsp;5</a>B II.</div></div></div></div></figcaption></figure></div><div id="p0135" role="paragraph">To further elucidate the role of the vaccine-induced cytolytic T&nbsp;cell responses in anti-tumor responses, the presence of NEO-PV-01-specific T&nbsp;cells was assessed by TCR sequencing in both the peripheral blood and in serial tumor biopsies from 3 melanoma patients who achieved PFS-9. Patient M1 was a 67-year-old female metastatic melanoma patient who had liver and pre-sacral metastases and experienced stable disease for 24&nbsp;months on the study. A CD8<sup>+</sup> T&nbsp;cell response specific to a neoepitope in the RICTOR gene (IM24) was detected by tetramer analysis in PBMCs of this patient. IM24-specific CD8<sup>+</sup> T&nbsp;cells represented ∼0.17% of all circulating CD8<sup>+</sup> T&nbsp;cells post-vaccine and were not present pre-vaccination (<a id="crosref0695" href="#fig5">Figure&nbsp;5</a>B, I). CD8<sup>+</sup> T&nbsp;cells reactive to a control EBV epitope from the viral LMP2A protein were detected at all 3 time points at similar levels (∼0.04% CD8<sup>+</sup> T&nbsp;cells; <a id="crosref0700" href="#figs6">Figure&nbsp;S6</a>A). Further characterization of RICTOR mutant-specific CD8<sup>+</sup> T&nbsp;cells revealed a memory phenotype, polyfunctionality, and cytolytic potential (<a id="crosref0705" href="#fig5">Figures 5</a>B, II, and <a id="crosref0710" href="#figs6">S6</a>B). Single-cell sequencing of the TCR α and β chain loci was performed to identify the paired complementarity determining region 3 (CDR3) regions and revealed 3 major clones (<a id="crosref0715" href="#figs6">Figure&nbsp;S6</a>C). We compared the CDR3β sequences of these clones to CDR3β sequences identified by targeted sequencing of bulk RNA from serial metastatic tumors. One of these three major clones (M1TCR3) was found to be enriched in the post-vaccine tumor and was absent at the pre-treatment or pre-vaccine time points (<a id="crosref0720" href="#fig5">Figure&nbsp;5</a>B, III). The sequences from M1TCR3 were cloned and expressed in the patient’s pre-treatment CD8<sup>+</sup> T&nbsp;cells. These transduced CD8<sup>+</sup> T&nbsp;cells were assessed for killing of the cancer cell line A375 expressing the patient HLA allele when pulsed with either the wild-type or mutant neoepitope. Specific killing of the cancer cell line, as assessed by cleaved caspase-3 upregulation, was seen only in the presence of the mutant, but not the wild-type peptide (<a id="crosref0725" href="#fig5">Figure&nbsp;5</a>B, IV).</div><div class="figure-wrap"><figure id="figs6" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/f9964748-62d4-46b0-a6f4-ae5e110fe365/main.assets/figs6_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="figs6" src="/cms/10.1016/j.cell.2020.08.053/asset/3a56cbc2-c389-43c6-b8c5-0975c9a1ee71/main.assets/figs6.jpg" height="745" width="753" aria-labelledby="figs6-title figs6-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/f9964748-62d4-46b0-a6f4-ae5e110fe365/main.assets/figs6_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="figs6-title" class="figure__title"><span class="label figure__label">Figure&nbsp;S6</span> <span class="figure__title__text">NEO-PV-01 Plus Anti-PD-1 Induces T Cells That Exhibit a Memory Phenotype, Are Polyfunctional, and Result in Epitope Spread; Additional Data Related to <a id="crosref1260" href="#fig5">Figure&nbsp;5</a></span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="figs6-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0180" role="paragraph">(A) Tetramer analysis of LMP2A-specific epitope in PBMCs of patient M1. B and C) Phenotype, function, and TCR clonotype of IM24-specific CD8<sup>+</sup> T&nbsp;cells from patient M1 at the post-vaccine time point. (B) Left panel: Overlaid histogram plot for CD45RO expression in IM24 tetramer positive and negative CD8<sup>+</sup> T&nbsp;cells. Right panel: Expression of cytokines as assessed by intracellular cytokine staining upon control (DMSO) and IM24 stimulation for 6 hours in IM24 tetramer positive CD8<sup>+</sup> T&nbsp;cells. (C) TCR clones identified by single cell TCR sequencing of IM24 tetramer-sorted T&nbsp;cells. D and E) Phenotype, function, and TCR clonotypes of IM07-specific CD4<sup>+</sup> T&nbsp;cells from patient M13 at the post-vaccine time point. (D) Left panel: Overlaid histogram plot for CD45RO expression in PD-1 positive and PD-1 negative T&nbsp;cells upon stimulation with IM07. Right panel: Cytokine secretion after 40h as assessed by ELISA. (E) TCR clones identified by single cell TCR sequencing of IM07-specific sorted T&nbsp;cells. (F) Identities of three additional validated neoantigen-specific TCRs from two melanoma patients (M13 and M14) and their frequencies in PBMC and tumor biopsy. (G) Epitope spread in melanoma patients M1 (left panel) and M13 (right panel). Reactivity of post-vaccine PBMCs against predicted neoantigen peptides that were not included in the vaccine were tested by IFNγ ELISpot assay at the three indicated time points. (H) Epitope spread in melanoma patient M2 who had a CR, across 4 time points. Only peptides that elicited responses are shown. NIM: Non-immunizing neoepitope. Aggregate data are represented as mean ± SEM.</div></div></div></div></figcaption></figure></div><div id="p0140" role="paragraph">Similarly, in patient M13, a 60-year-old male melanoma patient with lymph node metastases, who had a partial radiographic response to treatment, a functional cytolytic peripheral CD4<sup>+</sup> T&nbsp;cell response specific to the immunizing peptide IM07 (frameshift mutation in the gene LGALS3BP) was detected following vaccination (<a id="crosref0730" href="#fig5">Figure&nbsp;5</a>C, I). Further phenotypic analysis of IM07-specific T&nbsp;cells demonstrated that these cells were of the memory phenotype and could secrete multiple cytokines upon stimulation with the IM07 peptide (<a id="crosref0735" href="#figs6">Figure&nbsp;S6</a>D). Single-cell CDR3 TCR sequence analysis of these cells revealed multiple clones (<a id="crosref0740" href="#figs6">Figure&nbsp;S6</a>E), of which two were detected exclusively in the post-vaccine biopsy (<a id="crosref0745" href="#fig5">Figure&nbsp;5</a>C, II). Subsequent expression of M13TCRs in TCR-deficient Jurkat T&nbsp;cells confirmed the specificity of these TCRs for IM07 in an interleukin-2 (IL-2) secretion assay (<a id="crosref0750" href="#fig5">Figure&nbsp;5</a>C, III). Cytotoxicity analysis of these IM07-specific CD4<sup>+</sup> TCRs was limited because the MHC class II restriction of these TCRs was unknown. Additional neoantigen-specific TCRs were found in the biopsies at multiple time points in 2 patients (M13 and M14) who achieved PFS-9 (<a id="crosref0755" href="#figs6">Figure&nbsp;S6</a>F). These data demonstrate trafficking of neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cells into the tumor.</div></section><section id="sec-2-5"><h3>Epitope Spread Occurs after Vaccination with NEO-PV-01 and Associates with PFS</h3><div id="p0145" role="paragraph">Given the detection of memory and potentially cytolytic T&nbsp;cells in the tumor, we reasoned that the killing of tumor cells by neoantigen-specific T&nbsp;cells could release additional epitopes resulting in the generation of a broadened neoantigen-specific immune response. This phenomenon, known as epitope spreading, has been previously reported to be important for expanding the T&nbsp;cell responses to vaccines (<span class="dropBlock reference-citations"><a id="body-ref-sref23-1" href="#" role="doc-biblioref" data-xml-rid="bib23" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref23-1" aria-controls="sref23-1">Corbière et&nbsp;al., 2011</a><div class="dropBlock__holder" data-db-target-of="sref23-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">23.</div><div>Corbière, V. ∙ Chapiro, J. ∙ Stroobant, V. ...</div><div><strong>Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases</strong></div><div><em>Cancer Res.</em> 2011; <strong>71</strong>:1253-1262</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/0008-5472.CAN-10-2693" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_23_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-79951848084" target="_blank" aria-label="Open Scopus in new tab">Scopus (152)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21216894/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1158%2F0008-5472.CAN-10-2693&amp;pmid=21216894" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref41-1" href="#" role="doc-biblioref" data-xml-rid="bib41" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref41-1" aria-controls="sref41-1">Kreiter et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref41-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">41.</div><div>Kreiter, S. ∙ Vormehr, M. ∙ van de Roemer, N. ...</div><div><strong>Mutant MHC class II epitopes drive therapeutic immune responses to cancer</strong></div><div><em>Nature.</em> 2015; <strong>520</strong>:692-696</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature14426" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_41_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928811341" target="_blank" aria-label="Open Scopus in new tab">Scopus (910)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25901682/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature14426&amp;pmid=25901682" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). To assess whether epitope spread occurred after vaccination, we screened for the presence of peripheral T&nbsp;cell responses against epitopes that were highly ranked but were not included in the vaccine (referred to as “non-immunizing neoepitopes”). We assessed epitope spread in the two melanoma patients (patients M1 and M13) whose tumors were infiltrated with vaccine-induced neoantigen-specific T&nbsp;cells as assessed by single-cell TCR sequencing. Peripheral immune responses reactive against 4 of 15 and 3 of 13 non-immunizing neoepitopes were detected post-vaccination in patients M1 and M13, respectively (<a id="crosref0770" href="#figs6">Figure&nbsp;S6</a>G). Of note, these responses were not present pre-treatment or pre-vaccine, suggesting that the presence of epitope spread could be a surrogate marker for tumor cell killing by neoantigen-specific T&nbsp;cells induced by vaccination.</div><div id="p0150" role="paragraph">The presence of epitope spread was then evaluated across multiple patients with sufficient samples available for analysis. Among 330 non-immunizing neoepitopes tested across 13 melanoma, 5 NSCLC, and 7 bladder cancer patients, post-vaccine-specific immune responses were detected for 33 non-immunizing neoepitopes (<a id="crosref0775" href="#mmc1">Table S6</a>). These immune responses were not detected in the pre-vaccine or pre-treatment PBMCs. Notably, the extent of epitope spread responses was higher in patients who achieved PFS-9 or PFS-6, respectively, and correlated with longer PFS across all 3 cohorts (<a id="crosref0780" href="#fig5">Figure&nbsp;5</a>D). It is possible that epitope spread could be a self-amplifying process, wherein dying tumor cells can trigger additional neoantigen-specific immune responses during the course of the treatment. This was indeed the case in patient M2, a 65-year-old male melanoma patient with gastric metastases, who experienced a clinical complete response at 66&nbsp;weeks from the start of treatment. An expansion of epitope spread to 3 additional non-immunizing neoepitopes was detected at 52&nbsp;weeks post-initiation of anti-PD-1 therapy (<a id="crosref0785" href="#figs6">Figure&nbsp;S6</a>H). Thus, the observation of epitope spread suggests that NEO-PV-01-induced T&nbsp;cells could be cytotoxic to tumor cells and thus expand the repertoire of T&nbsp;cell responses against tumor neoantigens.</div></section><section id="sec-2-6"><h3>Major Pathological Responses (MPRs) Are Observed Post-vaccination with NEO-PV-01 in the Melanoma Cohort</h3><div id="p0155" role="paragraph">The observation of epitope spread suggested that vaccination with NEO-PV-01 could lead to major changes in tumor cellularity post-vaccination. We were able to address this question in the melanoma cohort, where there were sufficient numbers of serial tumor samples available for this analysis. Tumor cellularity was evaluated in multiple longitudinal core biopsies by a blinded independent pathologist, and the highest percentage of tumor at each time point was recorded. Assessment of residual viable tumor (RVT) across the 3 longitudinal biopsies obtained from the same gastric lesion in patient M2 described above revealed the presence of considerable tumor at the pre-treatment (95%) and pre-vaccine (40%) biopsies (<a id="crosref0790" href="#fig6">Figure&nbsp;6</a>A). However, there was no evidence of RVT in any of the 5 core biopsies obtained at the post-vaccine time point. Notably, increased infiltration of the tumor with CD3<sup>+</sup> T&nbsp;cells was seen at the pre-vaccine and post-vaccine time points (<a id="crosref0795" href="#fig6">Figure&nbsp;6</a>A).</div><div class="figure-wrap"><figure id="fig6" class="graphic"><a class="icon-full-screen" href="/cms/10.1016/j.cell.2020.08.053/asset/4361eece-8ecd-4d95-89f7-4815d01df842/main.assets/gr6_lrg.jpg" target="_blank" title="View full size image in a new tab"><img id="gr6" src="/cms/10.1016/j.cell.2020.08.053/asset/bab1776c-dcf4-4067-b8b3-8ae9ad1f476a/main.assets/gr6.jpg" height="860" width="657" aria-labelledby="fig6-title fig6-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/4361eece-8ecd-4d95-89f7-4815d01df842/main.assets/gr6_lrg.jpg" loading="lazy"></a><figcaption class="figure__caption__body"><div id="fig6-title" class="figure__title"><span class="label figure__label">Figure&nbsp;6</span> <span class="figure__title__text">NEO-PV-01 Plus Anti-PD-1 Induces Major Pathological Responses (MPRs) in Patients with Residual Tumor after Initial Treatment with Anti-PD-1</span></div><div class="accordion"><div><button class="accordion__control" aria-expanded="false" title="Expand"><span>Show full caption</span><i class="icon-section_arrow_d"></i></button><button class="figure__open__ctrl">Figure viewer</button></div><div id="fig6-content" class="accordion__content" style="display: none;"><div class="figure__caption__text__content"><div id="fspara0110" role="paragraph">(A) Representative images of H&amp;E analysis of tumor content (top row) and anti-CD3 IHC (bottom row) from melanoma patient M2 at the indicated time points (scale bar, 50&nbsp;μm).</div><div id="fspara0115" role="paragraph">(B) H&amp;E analysis of tumor content from 14 of the 19 melanoma patients who had MPR with biopsies from the same anatomical site at all 3 time points. The maximum tumor percentage seen in up to 5 cores from each biopsy site at each time point evaluated by blinded independent pathologic examination is plotted. The blue lines (left panel) illustrate MPRs at the pre-vaccine time point (n&nbsp;= 5). The green lines (right panel) illustrate MPRs at the post-vaccine time point (n&nbsp;= 9).</div><div id="fspara0120" role="paragraph">(C) Left panel: PFS of patients with (n&nbsp;= 14) or without (n&nbsp;= 5) MPRs at any time point by Kaplan-Meier analysis. Right panel: PFS of patients with MPRs only at the post-vaccine time point (n&nbsp;= 9) or without MPR (n&nbsp;= 5) by Kaplan-Meier analysis.</div></div></div></div></figcaption></figure></div><div id="p0160" role="paragraph">Serial tumor biopsies from 19 melanoma patients who had tumor biopsies at all 3 time points from the same anatomical site were then assessed for pathological response in relation to treatment. Of the 19 patients, 5 had tumor present at all time points. At 12&nbsp;weeks after initiation of nivolumab monotherapy (pre-vaccination), 5 of 19 patients (26%) achieved MPR (RVT&nbsp;&lt; 5% in all of the biopsy cores), indicating response to nivolumab monotherapy in these patients (<a id="crosref0800" href="#fig6">Figure&nbsp;6</a>B, left). At 12&nbsp;weeks post-initiation of vaccine, 9 melanoma patients who had not achieved an MPR with nivolumab exhibited a post-vaccine MPR (<a id="crosref0805" href="#fig6">Figure&nbsp;6</a>B, right; <a id="crosref0810" href="#mmc1">Table S7</a>). Three of these patients had &gt;80% tumor pre-vaccination. We note that the MPRs seen after vaccination could also represent delayed responses to nivolumab monotherapy. In addition, epitope spread data for 6 of the post-vaccine MPR patients were available, and 5 of them had epitope spread. Although these data are from a limited number of patients, they suggest an association of epitope spread with decreased tumor cellularity post-vaccine. Notably, all of the patients who exhibited MPR still had evidence of residual tumors by radiographic measurements, suggesting a disconnect between these measurements (3 SD, 10 PR, and 1 PD); there was no statistically significant correlation between MPR and best overall response by RESIST (p&nbsp;= 0.2098). However, the presence of MPR at any time point (n&nbsp;= 14) or seen only at the post-vaccine time point (n&nbsp;= 9) correlated with prolonged PFS compared to patients without MPR (n&nbsp;= 5; <a id="crosref0815" href="#fig6">Figure&nbsp;6</a>C).</div></section></section><section id="sec-3"><h2>Discussion</h2><div id="p0165" role="paragraph">Since neoantigens are specific for tumors versus normal tissues and thus are not subject to central tolerance, they provide excellent targets for the generation and amplification of immune responses to synergize with ICI therapy (<span class="dropBlock reference-citations"><a id="body-ref-sref48-2" href="#" role="doc-biblioref" data-xml-rid="bib48" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref48-2" aria-controls="sref48-2">McGranahan et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref48-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">49.</div><div>McGranahan, N. ∙ Furness, A.J. ∙ Rosenthal, R. ...</div><div><strong>Clonal neoantigens elicit T&nbsp;cell immunoreactivity and sensitivity to immune checkpoint blockade</strong></div><div><em>Science.</em> 2016; <strong>351</strong>:1463-1469</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaf1490" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_49_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962301577" target="_blank" aria-label="Open Scopus in new tab">Scopus (2240)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26940869/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaf1490&amp;pmid=26940869" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref62-2" href="#" role="doc-biblioref" data-xml-rid="bib62" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref62-2" aria-controls="sref62-2">Schumacher and Schreiber, 2015</a><div class="dropBlock__holder" data-db-target-of="sref62-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">64.</div><div>Schumacher, T.N. ∙ Schreiber, R.D.</div><div><strong>Neoantigens in cancer immunotherapy</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:69-74</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa4971" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_64_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928770388" target="_blank" aria-label="Open Scopus in new tab">Scopus (3509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25838375/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa4971&amp;pmid=25838375" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). In the phase Ib trial reported here, we extend earlier studies testing personalized vaccines as monotherapy in patients with melanoma and glioblastoma multiforme (GBM) (<span class="dropBlock reference-citations"><a id="body-ref-sref16-2" href="#" role="doc-biblioref" data-xml-rid="bib16" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref16-2" aria-controls="sref16-2">Carreno et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref16-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">16.</div><div>Carreno, B.M. ∙ Magrini, V. ∙ Becker-Hapak, M. ...</div><div><strong>Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T&nbsp;cells</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:803-808</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa3828" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928195112" target="_blank" aria-label="Open Scopus in new tab">Scopus (966)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25837513/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa3828&amp;pmid=25837513" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref32-2" href="#" role="doc-biblioref" data-xml-rid="bib32" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref32-2" aria-controls="sref32-2">Hilf et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref32-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">32.</div><div>Hilf, N. ∙ Kuttruff-Coqui, S. ∙ Frenzel, K. ...</div><div><strong>Actively personalized vaccination trial for newly diagnosed glioblastoma</strong></div><div><em>Nature.</em> 2019; <strong>565</strong>:240-245</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-018-0810-y" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_32_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85059762738" target="_blank" aria-label="Open Scopus in new tab">Scopus (603)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30568303/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-018-0810-y&amp;pmid=30568303" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref38-2" href="#" role="doc-biblioref" data-xml-rid="bib38" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref38-2" aria-controls="sref38-2">Keskin et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref38-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">38.</div><div>Keskin, D.B. ∙ Anandappa, A.J. ∙ Sun, J. ...</div><div><strong>Neoantigen vaccine generates intratumoral T&nbsp;cell responses in phase Ib glioblastoma trial</strong></div><div><em>Nature.</em> 2019; <strong>565</strong>:234-239</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-018-0792-9" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_38_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85059785792" target="_blank" aria-label="Open Scopus in new tab">Scopus (901)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30568305/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-018-0792-9&amp;pmid=30568305" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref52-4" href="#" role="doc-biblioref" data-xml-rid="bib52" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref52-4" aria-controls="sref52-4">Ott et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref52-4"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">53.</div><div>Ott, P.A. ∙ Hu, Z. ∙ Keskin, D.B. ...</div><div><strong>An immunogenic personal neoantigen vaccine for patients with melanoma</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:217-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature22991" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_53_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024377220" target="_blank" aria-label="Open Scopus in new tab">Scopus (1897)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678778/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature22991&amp;pmid=28678778" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref59-3" href="#" role="doc-biblioref" data-xml-rid="bib59" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref59-3" aria-controls="sref59-3">Sahin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref59-3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">60.</div><div>Sahin, U. ∙ Derhovanessian, E. ∙ Miller, M. ...</div><div><strong>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:222-226</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature23003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_60_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024396858" target="_blank" aria-label="Open Scopus in new tab">Scopus (11)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678784/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature23003&amp;pmid=28678784" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) by assessing the safety and feasibility of personalized neoantigen therapy in combination with anti-PD-1 therapy in the metastatic solid tumor setting. Furthermore, by studying serial tumor biopsies and PBMCs obtained pre-treatment, pre-vaccine, and post-vaccine, we were able to investigate the clinical, immune, and pathologic responses to this therapy.</div><div id="p0170" role="paragraph">We observed that radiographic responses deepened following treatment with the vaccine and were durable across all three cohorts. Of note, deepening of radiographic responses over time can be seen with nivolumab monotherapy. Comparison of all three cohorts treated with the combination of anti-PD-1 and NEO-PV-01 to historical data of anti-PD-1 monotherapy showed similar response rates, PFS, and OS (<span class="dropBlock reference-citations"><a id="body-ref-sref7-2" href="#" role="doc-biblioref" data-xml-rid="bib7" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref7-2" aria-controls="sref7-2">Balar et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref7-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">6.</div><div>Balar, A.V. ∙ Galsky, M.D. ∙ Rosenberg, J.E. ..., IMvigor210 Study Group</div><div><strong>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial</strong></div><div><em>Lancet.</em> 2017; <strong>389</strong>:67-76</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2816%2932455-2&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2816%2932455-2&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85007564166" target="_blank" aria-label="Open Scopus in new tab">Scopus (1629)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27939400/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2816%2932455-2&amp;pmid=27939400" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref9-2" href="#" role="doc-biblioref" data-xml-rid="bib9" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref9-2" aria-controls="sref9-2">Bellmunt et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref9-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">8.</div><div>Bellmunt, J. ∙ de Wit, R. ∙ Vaughn, D.J. ..., KEYNOTE-045 Investigators</div><div><strong>Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>376</strong>:1015-1026</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1613683" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85015755043" target="_blank" aria-label="Open Scopus in new tab">Scopus (2522)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28212060/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1613683&amp;pmid=28212060" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref13-3" href="#" role="doc-biblioref" data-xml-rid="bib13" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref13-3" aria-controls="sref13-3">Borghaei et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref13-3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">13.</div><div>Borghaei, H. ∙ Paz-Ares, L. ∙ Horn, L. ...</div><div><strong>Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2015; <strong>373</strong>:1627-1639</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1507643" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_13_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84944937210" target="_blank" aria-label="Open Scopus in new tab">Scopus (7626)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref15-2" href="#" role="doc-biblioref" data-xml-rid="bib15" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref15-2" aria-controls="sref15-2">Carbone et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref15-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">15.</div><div>Carbone, D.P. ∙ Reck, M. ∙ Paz-Ares, L. ..., CheckMate 026 Investigators</div><div><strong>First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>376</strong>:2415-2426</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1613493" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85020964772" target="_blank" aria-label="Open Scopus in new tab">Scopus (1990)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28636851/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1613493&amp;pmid=28636851" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref31-3" href="#" role="doc-biblioref" data-xml-rid="bib31" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref31-3" aria-controls="sref31-3">Herbst et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref31-3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">31.</div><div>Herbst, R.S. ∙ Baas, P. ∙ Kim, D.W. ...</div><div><strong>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</strong></div><div><em>Lancet.</em> 2016; <strong>387</strong>:1540-1550</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84950117835" target="_blank" aria-label="Open Scopus in new tab">Scopus (5239)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref44-3" href="#" role="doc-biblioref" data-xml-rid="bib44" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref44-3" aria-controls="sref44-3">Larkin et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref44-3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">44.</div><div>Larkin, J. ∙ Minor, D. ∙ D’Angelo, S. ...</div><div><strong>Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial</strong></div><div><em>J.&nbsp;Clin. Oncol.</em> 2018; <strong>36</strong>:383-390</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.8023" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_44_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85041205158" target="_blank" aria-label="Open Scopus in new tab">Scopus (384)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28671856/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2016.71.8023&amp;pmid=28671856" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref61-2" href="#" role="doc-biblioref" data-xml-rid="bib61" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref61-2" aria-controls="sref61-2">Schachter et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref61-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">62.</div><div>Schachter, J. ∙ Ribas, A. ∙ Long, G.V. ...</div><div><strong>Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)</strong></div><div><em>Lancet.</em> 2017; <strong>390</strong>:1853-1862</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2817%2931601-X&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2817%2931601-X&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85027501801" target="_blank" aria-label="Open Scopus in new tab">Scopus (934)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28822576/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2817%2931601-X&amp;pmid=28822576" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref64-2" href="#" role="doc-biblioref" data-xml-rid="bib64" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref64-2" aria-controls="sref64-2">Sharma et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref64-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">66.</div><div>Sharma, P. ∙ Callahan, M.K. ∙ Bono, P. ...</div><div><strong>Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial</strong></div><div><em>Lancet Oncol.</em> 2016; <strong>17</strong>:1590-1598</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS1470-2045%2816%2930496-X&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS1470-2045%2816%2930496-X&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84990852158" target="_blank" aria-label="Open Scopus in new tab">Scopus (565)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27733243/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2816%2930496-X&amp;pmid=27733243" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref75-2" href="#" role="doc-biblioref" data-xml-rid="bib75" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref75-2" aria-controls="sref75-2">Wolchok et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref75-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">78.</div><div>Wolchok, J.D. ∙ Chiarion-Sileni, V. ∙ Gonzalez, R. ...</div><div><strong>Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>377</strong>:1345-1356</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1709684" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_78_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85030460514" target="_blank" aria-label="Open Scopus in new tab">Scopus (2658)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28889792/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1709684&amp;pmid=28889792" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The relevance of such comparisons with considerably larger randomized historical clinical studies remains to be determined, as does the role of the vaccine alone.</div><div id="p0175" role="paragraph">Approximately 25% of enrolled patients were unable to proceed to vaccination, the majority due to either disease progression or inability to generate vaccines because of low tumor content in the biopsy samples or a low number of mutations. Opportunities to mitigate this issue include acceleration of vaccine production timelines and the incorporation of potentially higher-yield tumor sampling approaches. Furthermore, the selection of alternative clinical settings can be envisioned, such as the adjuvant or minimal residual disease setting or a strategy that uses pre-manufacturing of personalized vaccines at an&nbsp;earlier point in the disease for use during a later line of treatment.</div><div id="p0180" role="paragraph">The ability to design effective neoantigen vaccines is dependent on having a rapid computational pipeline for DNA and RNA sequence analysis and epitope scoring and prioritization. In this study, we used a mass spectrometry-based predictor (<span class="dropBlock reference-citations"><a id="body-ref-sref1-3" href="#" role="doc-biblioref" data-xml-rid="bib1" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref1-3" aria-controls="sref1-3">Abelin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref1-3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">1.</div><div>Abelin, J.G. ∙ Keskin, D.B. ∙ Sarkizova, S. ...</div><div><strong>Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction</strong></div><div><em>Immunity.</em> 2017; <strong>46</strong>:315-326</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85013878753" target="_blank" aria-label="Open Scopus in new tab">Scopus (408)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28228285/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2017.02.007&amp;pmid=28228285" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) to generate epitope rankings that jointly considers expression, proteasomal processing potential, and HLA-I binding affinity (<span class="dropBlock reference-citations"><a id="body-ref-sref50-2" href="#" role="doc-biblioref" data-xml-rid="bib50" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref50-2" aria-controls="sref50-2">Nielsen and Andreatta, 2016</a><div class="dropBlock__holder" data-db-target-of="sref50-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">51.</div><div>Nielsen, M. ∙ Andreatta, M.</div><div><strong>NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets</strong></div><div><em>Genome Med.</em> 2016; <strong>8</strong>:33</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13073-016-0288-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_51_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962905590" target="_blank" aria-label="Open Scopus in new tab">Scopus (364)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27029192/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2Fs13073-016-0288-x&amp;pmid=27029192" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). This strategy yielded multiple CD8<sup>+</sup> T&nbsp;cell responses in the majority of the patients, but, interestingly, it also yielded frequent CD4<sup>+</sup> T&nbsp;cell responses despite the absence of the HLA-II binding prediction in the selection scheme. Similar observations have been made with previous neoantigen vaccines (<span class="dropBlock reference-citations"><a id="body-ref-sref52-5" href="#" role="doc-biblioref" data-xml-rid="bib52" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref52-5" aria-controls="sref52-5">Ott et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref52-5"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">53.</div><div>Ott, P.A. ∙ Hu, Z. ∙ Keskin, D.B. ...</div><div><strong>An immunogenic personal neoantigen vaccine for patients with melanoma</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:217-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature22991" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_53_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024377220" target="_blank" aria-label="Open Scopus in new tab">Scopus (1897)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678778/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature22991&amp;pmid=28678778" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref59-4" href="#" role="doc-biblioref" data-xml-rid="bib59" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref59-4" aria-controls="sref59-4">Sahin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref59-4"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">60.</div><div>Sahin, U. ∙ Derhovanessian, E. ∙ Miller, M. ...</div><div><strong>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:222-226</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature23003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_60_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024396858" target="_blank" aria-label="Open Scopus in new tab">Scopus (11)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678784/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature23003&amp;pmid=28678784" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>).</div><div id="p0185" role="paragraph">A recent study by our group indicated that class II presentation is mainly dependent on the presentation of these epitopes by dendritic cells (<span class="dropBlock reference-citations"><a id="body-ref-sref2-1" href="#" role="doc-biblioref" data-xml-rid="bib2" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref2-1" aria-controls="sref2-1">Abelin et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref2-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">2.</div><div>Abelin, J.G. ∙ Harjanto, D. ∙ Malloy, M. ...</div><div><strong>Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction</strong></div><div><em>Immunity.</em> 2019; <strong>51</strong>:766-779.e17</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2019.08.012&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2019.08.012&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85073037953" target="_blank" aria-label="Open Scopus in new tab">Scopus (154)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31495665/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2019.08.012&amp;pmid=31495665" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). In this study, the generation of CD4<sup>+</sup> T&nbsp;cells is likely due to exogenous loading of peptides used in the vaccine since their size ranged from 14 to 35 amino acids, which is consistent with the length distribution of presented class II epitopes. Recent data suggest a critical role for CD4<sup>+</sup> T&nbsp;cells in tumor control in pre-clinical tumor models (<span class="dropBlock reference-citations"><a id="body-ref-sref3" href="#" role="doc-biblioref" data-xml-rid="bib3" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref3" aria-controls="sref3">Alspach et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">3.</div><div>Alspach, E. ∙ Lussier, D.M. ∙ Miceli, A.P. ...</div><div><strong>MHC-II neoantigens shape tumour immunity and response to immunotherapy</strong></div><div><em>Nature.</em> 2019; <strong>574</strong>:696-701</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1671-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85074223743" target="_blank" aria-label="Open Scopus in new tab">Scopus (490)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31645760/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1671-8&amp;pmid=31645760" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref41-2" href="#" role="doc-biblioref" data-xml-rid="bib41" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref41-2" aria-controls="sref41-2">Kreiter et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref41-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">41.</div><div>Kreiter, S. ∙ Vormehr, M. ∙ van de Roemer, N. ...</div><div><strong>Mutant MHC class II epitopes drive therapeutic immune responses to cancer</strong></div><div><em>Nature.</em> 2015; <strong>520</strong>:692-696</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature14426" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_41_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928811341" target="_blank" aria-label="Open Scopus in new tab">Scopus (910)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25901682/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature14426&amp;pmid=25901682" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Endogenous CD4<sup>+</sup> T&nbsp;cell responses against neoantigens have been observed previously in patients with melanoma, and neoantigen-reactive CD4<sup>+</sup> T&nbsp;cells have been shown to mediate clinical regression of tumor lesions upon adoptive transfer in a patient with cholangiocarcinoma (<span class="dropBlock reference-citations"><a id="body-ref-sref69" href="#" role="doc-biblioref" data-xml-rid="bib69" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref69" aria-controls="sref69">Tran et&nbsp;al., 2014</a><div class="dropBlock__holder" data-db-target-of="sref69"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">72.</div><div>Tran, E. ∙ Turcotte, S. ∙ Gros, A. ...</div><div><strong>Cancer immunotherapy based on mutation-specific CD4+ T&nbsp;cells in a patient with epithelial cancer</strong></div><div><em>Science.</em> 2014; <strong>344</strong>:641-645</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1251102" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_72_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84900301377" target="_blank" aria-label="Open Scopus in new tab">Scopus (1322)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24812403/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.1251102&amp;pmid=24812403" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). In our study, we observed that post-vaccine peripheral CD4<sup>+</sup> T&nbsp;cells upregulated CD107a in response to stimulation with many of the vaccine neoantigen peptides, indicating their cytolytic capacity.</div><div id="p0190" role="paragraph">Another aspect of the immune responses generated by NEO-PV-01 was their phenotype and specificity. T&nbsp;cells generated by the vaccines exhibited a memory phenotype, had cytotoxic potential, were mutant specific and durable, and could migrate to the tumor. An interesting observation was the differential expression of co-inhibitory receptors in neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cells induced by the vaccine in patients who achieved PFS-9 or PFS-6, respectively, versus those who did not, and will require further validation. In summary, our data suggest that vaccine-induced T&nbsp;cells exhibited properties that would be expected in a T&nbsp;cell population that could mediate tumor-specific immune killing.</div><div id="p0195" role="paragraph">Epitope spread was correlated with PFS in patients across all three tumors. This observation is important for several reasons. First, it suggests that the neoantigen-induced T&nbsp;cells generated by NEO-PV-01 are not only capable of trafficking to the tumor but also are potentially able to kill tumor cells, leading to the release of additional neoantigens that become targets for additional T&nbsp;cells. The data suggest that it may only be necessary to target a subset of neoantigens expressed by the tumor to generate a broad immune response against the expressed neoantigens (<span class="dropBlock reference-citations"><a id="body-ref-sref23-2" href="#" role="doc-biblioref" data-xml-rid="bib23" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref23-2" aria-controls="sref23-2">Corbière et&nbsp;al., 2011</a><div class="dropBlock__holder" data-db-target-of="sref23-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">23.</div><div>Corbière, V. ∙ Chapiro, J. ∙ Stroobant, V. ...</div><div><strong>Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases</strong></div><div><em>Cancer Res.</em> 2011; <strong>71</strong>:1253-1262</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/0008-5472.CAN-10-2693" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_23_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-79951848084" target="_blank" aria-label="Open Scopus in new tab">Scopus (152)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21216894/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1158%2F0008-5472.CAN-10-2693&amp;pmid=21216894" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The generation of epitope spread may help to control tumor cells that do not express truncal neoantigens and thus could be a mechanism to control tumor heterogeneity.</div><div id="p0200" role="paragraph">Finally, we addressed the ability of the combination of NEO-PV-01 and anti-PD-1 to induce MPR in melanoma patients. Two patterns of MPR were noted in this analysis of 19 melanoma patients, all of whom had biopsies from the same site at all 3 time points. One group of patients (n&nbsp;= 5) had MPR after initial therapy with nivolumab alone. A second group of patients (n&nbsp;= 9) who had no or only partial pathologic responses after nivolumab, achieved MPR post-vaccination. While not directly comparable to the metastatic disease setting, given that in our study only core biopsies were examined rather than completely surgically resected disease, it is also worth noting that major or complete pathological responses were recently found to be strongly associated with superior clinical outcomes in patients with resectable stage III melanoma who received PD-1 inhibitors (<span class="dropBlock reference-citations"><a id="body-ref-sref24" href="#" role="doc-biblioref" data-xml-rid="bib24" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref24" aria-controls="sref24">Cottrell et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref24"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">24.</div><div>Cottrell, T.R. ∙ Thompson, E.D. ∙ Forde, P.M. ...</div><div><strong>Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)</strong></div><div><em>Ann. Oncol.</em> 2018; <strong>29</strong>:1853-1860</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_24_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1093%2Fannonc%2Fmdy218&amp;cf=fulltext&amp;site=annonc-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_24_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1093%2Fannonc%2Fmdy218&amp;cf=pdf&amp;site=annonc-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_24_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85055516713" target="_blank" aria-label="Open Scopus in new tab">Scopus (310)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29982279/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmdy218&amp;pmid=29982279" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref36" href="#" role="doc-biblioref" data-xml-rid="bib36" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref36" aria-controls="sref36">Huang et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref36"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">36.</div><div>Huang, A.C. ∙ Orlowski, R.J. ∙ Xu, X. ...</div><div><strong>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma</strong></div><div><em>Nat. Med.</em> 2019; <strong>25</strong>:454-461</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-019-0357-y" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_36_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85062071459" target="_blank" aria-label="Open Scopus in new tab">Scopus (436)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30804515/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-019-0357-y&amp;pmid=30804515" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref68" href="#" role="doc-biblioref" data-xml-rid="bib68" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref68" aria-controls="sref68">Topalian et&nbsp;al., 2020</a><div class="dropBlock__holder" data-db-target-of="sref68"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">71.</div><div>Topalian, S.L. ∙ Taube, J.M. ∙ Pardoll, D.M.</div><div><strong>Neoadjuvant checkpoint blockade for cancer immunotherapy</strong></div><div><em>Science.</em> 2020; <strong>367</strong>:eaax0182</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aax0182" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_71_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85078710390" target="_blank" aria-label="Open Scopus in new tab">Scopus (526)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32001626/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aax0182&amp;pmid=32001626" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) or combined PD-1 and CTLA-4 inhibitors in the neoadjuvant setting (<span class="dropBlock reference-citations"><a id="body-ref-sref11" href="#" role="doc-biblioref" data-xml-rid="bib11" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref11" aria-controls="sref11">Blank et&nbsp;al., 2018</a><div class="dropBlock__holder" data-db-target-of="sref11"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">11.</div><div>Blank, C.U. ∙ Rozeman, E.A. ∙ Fanchi, L.F. ...</div><div><strong>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</strong></div><div><em>Nat. Med.</em> 2018; <strong>24</strong>:1655-1661</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0198-0" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_11_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85054564616" target="_blank" aria-label="Open Scopus in new tab">Scopus (582)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30297911/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-018-0198-0&amp;pmid=30297911" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>).</div><div id="p0205" role="paragraph">A limitation of our study is its single-arm design. Since the treatment was a combination of the neoantigen vaccine and anti-PD-1 and there was no nivolumab monotherapy comparator cohort, the deepening of radiographic responses, epitope spread, and major pathologic responses observed after vaccination cannot definitively be linked to the vaccine. Randomized trials of neoantigen-directed therapy plus anti-PD-1 versus anti-PD-1 monotherapy will be necessary to confirm these findings and determine the specific contribution of the personalized neoantigen vaccine.</div><div id="p0210" role="paragraph">In summary, we demonstrate the feasibility and safety of this personalized neoantigen-based vaccine in combination with anti-PD-1 to generate <i>de novo</i> neoantigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T&nbsp;cells that have a cytotoxic phenotype and are capable of trafficking to the tumor. We also observed epitope spread and evidence for major pathological responses in post-vaccination tumor biopsies. The potential to use peripheral blood and tumor biomarkers to select patients for the design of future randomized studies holds promise. These additional studies will be needed to better refine this approach and determine whether personalized neoantigen vaccines in combination with anti-PD-1 may play a role in the therapy of cancer patients.</div></section><section id="sec-4"><h2>STAR★Methods</h2><section id="sec-4-1"><h3>Key Resources Table</h3><div id="p0215" role="paragraph"><div class="figure-wrap"><figure id="undtbl1" class="table" data-figureviewer-ignore="true"><div class="table-wrap"><table data-figureviewer-ignore="true" tabindex="0"><thead><tr class="rowsep"><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr class="rowsep"><td colspan="3"><b>Antibodies</b></td></tr><tr><td>Active-caspase 3-BV650</td><td>BD Biosciences</td><td>Cat # 564096; RRID:<a id="interref70" href="https://antibodyregistry.org/AB_2738589" target="_blank">AB_2738589</a></td></tr><tr><td>Arginase-PE</td><td>R&amp;D Systems</td><td>Cat # IC5868P</td></tr><tr><td>CD107a-BV786</td><td>BD Biosciences</td><td>Cat # 563869; RRID:<a id="interref75" href="https://antibodyregistry.org/AB_2738458" target="_blank">AB_2738458</a></td></tr><tr><td>CD11b-PerCPCy5.5</td><td>BioLegend</td><td>Cat # 301328; RRID:<a id="interref80" href="https://antibodyregistry.org/AB_10933428" target="_blank">AB_10933428</a></td></tr><tr><td>CD11c-BV510</td><td>BD Biosciences</td><td>Cat # 563026; RRID:<a id="interref85" href="https://antibodyregistry.org/AB_2737960" target="_blank">AB_2737960</a></td></tr><tr><td>CD123-BV786</td><td>BD Biosciences</td><td>Cat # 564196; RRID:<a id="interref90" href="https://antibodyregistry.org/AB_2738662" target="_blank">AB_2738662</a></td></tr><tr><td>CD137-BV650</td><td>BD Biosciences</td><td>Cat # 564092; RRID:<a id="interref95" href="https://antibodyregistry.org/AB_2738586" target="_blank">AB_2738586</a></td></tr><tr><td>CD14-BUV805</td><td>BD Biosciences</td><td>Cat # 565780</td></tr><tr><td>CD14-FITC</td><td>BD Biosciences</td><td>Cat # 340682; RRID:<a id="interref100" href="https://antibodyregistry.org/AB_400086" target="_blank">AB_400086</a></td></tr><tr><td>CD141-BV711</td><td>BD Biosciences</td><td>Cat # 563155; RRID:<a id="interref105" href="https://antibodyregistry.org/AB_2738033" target="_blank">AB_2738033</a></td></tr><tr><td>CD15-BUV396</td><td>BD Biosciences</td><td>Cat # 563872; RRID:<a id="interref110" href="https://antibodyregistry.org/AB_2738461" target="_blank">AB_2738461</a></td></tr><tr><td>CD152 (CTLA-4)-BV421</td><td>BD Biosciences</td><td>Cat # 562743; RRID:<a id="interref115" href="https://antibodyregistry.org/AB_2737762" target="_blank">AB_2737762</a></td></tr><tr><td>CD152 (CTLA-4)-PE Cy5</td><td>BD Biosciences</td><td>Cat # 555854; RRID:<a id="interref120" href="https://antibodyregistry.org/AB_396177" target="_blank">AB_396177</a></td></tr><tr><td>CD154 (CD40L)-FITC</td><td>BD Biosciences</td><td>Cat # 555699; RRID:<a id="interref125" href="https://antibodyregistry.org/AB_396049" target="_blank">AB_396049</a></td></tr><tr><td>CD16-FITC</td><td>BD Biosciences</td><td>Cat # 340704; RRID:<a id="interref130" href="https://antibodyregistry.org/AB_400104" target="_blank">AB_400104</a></td></tr><tr><td>CD16-PECy7</td><td>BD Biosciences</td><td>Cat # 557744; RRID:<a id="interref135" href="https://antibodyregistry.org/AB_396850" target="_blank">AB_396850</a></td></tr><tr><td>CD19-BUV496</td><td>BD Biosciences</td><td>Cat # 564655; RRID:<a id="interref140" href="https://antibodyregistry.org/AB_2744311" target="_blank">AB_2744311</a></td></tr><tr><td>CD19-FITC</td><td>BioLegend</td><td>Cat # 555412; RRID:<a id="interref145" href="https://antibodyregistry.org/AB_395812" target="_blank">AB_395812</a></td></tr><tr><td>CD19-FITC</td><td>BD Biosciences</td><td>Cat # 340864; RRID:<a id="interref150" href="https://antibodyregistry.org/AB_400152" target="_blank">AB_400152</a></td></tr><tr><td>CD19-APCCy7</td><td>BD Biosciences</td><td>Cat # 557791; RRID:<a id="interref155" href="https://antibodyregistry.org/AB_396873" target="_blank">AB_396873</a></td></tr><tr><td>CD1c-BV421</td><td>BD Biosciences</td><td>Cat # 565050; RRID:<a id="interref160" href="https://antibodyregistry.org/AB_2744319" target="_blank">AB_2744319</a></td></tr><tr><td>CD223 (LAG-3)-BV786</td><td>BioLegend</td><td>Cat # 369322; RRID:<a id="interref165" href="https://antibodyregistry.org/AB_2716127" target="_blank">AB_2716127</a></td></tr><tr><td>CD25-BV605</td><td>BD Biosciences</td><td>Cat # 562660; RRID:<a id="interref170" href="https://antibodyregistry.org/AB_2744343" target="_blank">AB_2744343</a></td></tr><tr><td>CD25-PerCPCy5.5</td><td>BD Biosciences</td><td>Cat # 560503; RRID:<a id="interref175" href="https://antibodyregistry.org/AB_1727453" target="_blank">AB_1727453</a></td></tr><tr><td>CD26-APC</td><td>BioLegend</td><td>Cat # 302710; RRID:<a id="interref180" href="https://antibodyregistry.org/AB_10916120" target="_blank">AB_10916120</a></td></tr><tr><td>CD26-PECF594</td><td>BD Biosciences</td><td>Cat # 565158; RRID:<a id="interref185" href="https://antibodyregistry.org/AB_2739085" target="_blank">AB_2739085</a></td></tr><tr><td>CD27-BV605</td><td>BD Biosciences</td><td>Cat # 562655; RRID:<a id="interref190" href="https://antibodyregistry.org/AB_2744351" target="_blank">AB_2744351</a></td></tr><tr><td>CD27-BV711</td><td>BD Biosciences</td><td>Cat # 356430; RRID:<a id="interref195" href="https://antibodyregistry.org/AB_2650751" target="_blank">AB_2650751</a></td></tr><tr><td>CD3</td><td>Biocare Medical</td><td>Cat # ACI 3152A</td></tr><tr><td>CD3-BUV805</td><td>BD Biosciences</td><td>Cat # 565511; RRID:<a id="interref200" href="https://antibodyregistry.org/AB_2739275" target="_blank">AB_2739275</a></td></tr><tr><td>CD3-FITC</td><td>BioLegend</td><td>Cat # 300306; RRID:<a id="interref205" href="https://antibodyregistry.org/AB_314042" target="_blank">AB_314042</a></td></tr><tr><td>CD3-BV421</td><td>BD Biosciences</td><td>Cat # 563797; RRID:<a id="interref210" href="https://antibodyregistry.org/AB_2744383" target="_blank">AB_2744383</a></td></tr><tr><td>CD303-AF700</td><td>BioLegend</td><td>Cat # 354228; RRID:<a id="interref215" href="https://antibodyregistry.org/AB_2629744" target="_blank">AB_2629744</a></td></tr><tr><td>CD33-PECy5</td><td>BD Biosciences</td><td>Cat # 551377; RRID:<a id="interref220" href="https://antibodyregistry.org/AB_394173" target="_blank">AB_394173</a></td></tr><tr><td>CD366 (Tim-3)-BV510</td><td>BioLegend</td><td>Cat # 345030; RRID:<a id="interref225" href="https://antibodyregistry.org/AB_2565831" target="_blank">AB_2565831</a></td></tr><tr><td>CD4-BV711</td><td>BD Biosciences</td><td>Cat # 563028; RRID:<a id="interref230" href="https://antibodyregistry.org/AB_2737961" target="_blank">AB_2737961</a></td></tr><tr><td>CD4-FITC</td><td>BD Biosciences</td><td>Cat # 347413; RRID:<a id="interref235" href="https://antibodyregistry.org/AB_400297" target="_blank">AB_400297</a></td></tr><tr><td>CD4-BV510</td><td>BD Biosciences</td><td>Cat # 562971; RRID:<a id="interref240" href="https://antibodyregistry.org/AB_2744424" target="_blank">AB_2744424</a></td></tr><tr><td>CD4-BUV496</td><td>BD Biosciences</td><td>Cat # 564652; RRID:<a id="interref245" href="https://antibodyregistry.org/AB_2744422" target="_blank">AB_2744422</a></td></tr><tr><td>CD45RA-Alexa Fluor 700</td><td>BD Biosciences</td><td>Cat # 560673; RRID:<a id="interref250" href="https://antibodyregistry.org/AB_1727496" target="_blank">AB_1727496</a></td></tr><tr><td>CD45RO-PerCP Cy5.5</td><td>BD Biosciences</td><td>Cat # 560607; RRID:<a id="interref255" href="https://antibodyregistry.org/AB_1727500" target="_blank">AB_1727500</a></td></tr><tr><td>CD45RO-BV605</td><td>BD Biosciences</td><td>Cat # 562791; RRID:<a id="interref260" href="https://antibodyregistry.org/AB_2744411" target="_blank">AB_2744411</a></td></tr><tr><td>CD56-FITC</td><td>BioLegend</td><td>Cat # 362546; RRID:<a id="interref265" href="https://antibodyregistry.org/AB_2565964" target="_blank">AB_2565964</a></td></tr><tr><td>CD62L-FITC</td><td>BD Biosciences</td><td>Cat # 555543; RRID:<a id="interref270" href="https://antibodyregistry.org/AB_395927" target="_blank">AB_395927</a></td></tr><tr><td>CD69-PE Cy7</td><td>BD Biosciences</td><td>Cat # 557745; RRID:<a id="interref275" href="https://antibodyregistry.org/AB_396851" target="_blank">AB_396851</a></td></tr><tr><td>CD69-BV786</td><td>BD Biosciences</td><td>Cat # 563834; RRID:<a id="interref280" href="https://antibodyregistry.org/AB_2738441" target="_blank">AB_2738441</a></td></tr><tr><td>CD8-PE Cy5</td><td>BD Biosciences</td><td>Cat # 555636; RRID:<a id="interref285" href="https://antibodyregistry.org/AB_395998" target="_blank">AB_395998</a></td></tr><tr><td>CD8-Alexa Fluor 700</td><td>BioLegend</td><td>Cat # 344724; RRID:<a id="interref290" href="https://antibodyregistry.org/AB_2562790" target="_blank">AB_2562790</a></td></tr><tr><td>CD8-BUV805</td><td>BD Biosciences</td><td>Cat # 564912; RRID:<a id="interref295" href="https://antibodyregistry.org/AB_2744465" target="_blank">AB_2744465</a></td></tr><tr><td>CD8</td><td>Biocare Medical</td><td>Cat # CRM311A</td></tr><tr><td>CLEC9A-AF647</td><td>BD Biosciences</td><td>Cat # 564267; RRID:<a id="interref300" href="https://antibodyregistry.org/AB_2738717" target="_blank">AB_2738717</a></td></tr><tr><td>CTLA-4-PECy5</td><td>BD Biosciences</td><td>Cat # 555854; RRID:<a id="interref305" href="https://antibodyregistry.org/AB_396177" target="_blank">AB_396177</a></td></tr><tr><td>Foxp3-PE Cy7</td><td>Life Technologies</td><td>Cat # 25-4776-42; RRID:<a id="interref310" href="https://antibodyregistry.org/AB_10804638" target="_blank">AB_10804638</a></td></tr><tr><td>Gamma-9-APC</td><td>BioLegend</td><td>Cat # 331310; RRID:<a id="interref315" href="https://antibodyregistry.org/AB_2057504" target="_blank">AB_2057504</a></td></tr><tr><td>HLA-DR-BV650</td><td>BD Biosciences</td><td>Cat # 564231; RRID:<a id="interref320" href="https://antibodyregistry.org/AB_2738685" target="_blank">AB_2738685</a></td></tr><tr><td>HLA-DR-BV711</td><td>BD Biosciences</td><td>Cat # 563696; RRID:<a id="interref325" href="https://antibodyregistry.org/AB_2738378" target="_blank">AB_2738378</a></td></tr><tr><td>HLA-DR-BV650</td><td>BioLegend</td><td>Cat # 307650; RRID:<a id="interref330" href="https://antibodyregistry.org/AB_2563828" target="_blank">AB_2563828</a></td></tr><tr><td>ICOS-BUV395</td><td>BD Biosciences</td><td>Cat # 564777; RRID:<a id="interref335" href="https://antibodyregistry.org/AB_2738946" target="_blank">AB_2738946</a></td></tr><tr><td>IFNγ-PE</td><td>Life Technologies</td><td>Cat # 12-7319-42; RRID:<a id="interref340" href="https://antibodyregistry.org/AB_1311247" target="_blank">AB_1311247</a></td></tr><tr><td>IFNγ-Alexa Fluor 700</td><td>eBioscience</td><td>Cat # 56-7319-42; RRID:<a id="interref345" href="https://antibodyregistry.org/AB_2574509" target="_blank">AB_2574509</a></td></tr><tr><td>IL-10-PE-Cy7</td><td>eBioscience</td><td>Cat # 25-7108-42; RRID:<a id="interref350" href="https://antibodyregistry.org/AB_2573524" target="_blank">AB_2573524</a></td></tr><tr><td>IL-12-BV421</td><td>BD Biosciences</td><td>Cat # 565023; RRID:<a id="interref355" href="https://antibodyregistry.org/AB_2739045" target="_blank">AB_2739045</a></td></tr><tr><td>IL-2-PE-CF495</td><td>BD Biosciences</td><td>Cat # 562384; RRID:<a id="interref360" href="https://antibodyregistry.org/AB_11154601" target="_blank">AB_11154601</a></td></tr><tr><td>IL-4-BV711</td><td>BD Biosciences</td><td>Cat # 564112; RRID:<a id="interref365" href="https://antibodyregistry.org/AB_2738600" target="_blank">AB_2738600</a></td></tr><tr><td>IL-6-PerCP-e710</td><td>eBioscience</td><td>Cat # 46-7069-42; RRID:<a id="interref370" href="https://antibodyregistry.org/AB_11151511" target="_blank">AB_11151511</a></td></tr><tr><td>LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit</td><td>ThermoFisher</td><td>Cat # L10119</td></tr><tr><td>PD-1-PE-CF594</td><td>Invitrogen</td><td>Cat # 61-2799-42; RRID:<a id="interref375" href="https://antibodyregistry.org/AB_2574598" target="_blank">AB_2574598</a></td></tr><tr><td>PD-1-BV510</td><td>BD Biosciences</td><td>Cat # 563076; RRID:<a id="interref380" href="https://antibodyregistry.org/AB_2737990" target="_blank">AB_2737990</a></td></tr><tr><td>S100</td><td>Biocare Medical</td><td>Cat # CM089A</td></tr><tr><td>TCF7</td><td>Cell Signal Technology</td><td>Cat # 2203T</td></tr><tr><td>TCF7-PE</td><td>BD Biosciences</td><td>Cat # 564217; RRID:<a id="interref385" href="https://antibodyregistry.org/AB_2687845" target="_blank">AB_2687845</a></td></tr><tr><td>TNFα-BUV395</td><td>BD Biosciences</td><td>Cat # 563996; RRID:<a id="interref390" href="https://antibodyregistry.org/AB_2738533" target="_blank">AB_2738533</a></td></tr><tr><td>Streptavidin-PE</td><td>BioLegend</td><td>Cat # 405203</td></tr><tr><td>Streptavidin-BUV395</td><td>BD Biosciences</td><td>Cat # 564176</td></tr><tr><td>Streptavidin-APC</td><td>BioLegend</td><td>Cat # 405207</td></tr><tr><td>Streptavidin-BV421</td><td>BioLegend</td><td>Cat # 405225</td></tr><tr><td>Streptavidin-BV650</td><td>BD Biosciences</td><td>Cat # 563855</td></tr><tr><td>Streptavidin-Qdot 605</td><td>Life Technologies</td><td>Cat # Q10101MP</td></tr><tr><td>Streptavidin-Qdot 705</td><td>Life Technologies</td><td>Cat # Q10161MP</td></tr><tr><td>TSA-Cy3</td><td>Akoya Biosciences</td><td>Cat # NEL744001KT</td></tr><tr><td>TSA-Cy5</td><td>Akoya Biosciences</td><td>Cat # NEL745001KT</td></tr><tr><td>TSA-Fluorescein</td><td>Akoya Biosciences</td><td>Cat # NEL741001KT</td></tr><tr><td>ImPRESS HRP Anti-Mouse IgG (Peroxidase) Polymer Detection Kit</td><td>Vector Laboratories</td><td>Cat # MP-7402</td></tr><tr class="rowsep"><td>ImPRESS HRP Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit</td><td>Vector Laboratories</td><td>Cat # ML-7401</td></tr><tr class="rowsep"><td colspan="3"><b>Bacterial and Virus Strains</b></td></tr><tr class="rowsep"><td>BL21 (DE3) Competent <i>E.&nbsp;coli</i></td><td>NEB</td><td>Cat # C2527I</td></tr><tr class="rowsep"><td colspan="3"><b>Biological Samples</b></td></tr><tr><td>Patient PBMCs from NT-001 trial</td><td>This manuscript</td><td>N/A</td></tr><tr><td>Patient Tumor Biopsies from NT-001 trial</td><td>This manuscript</td><td>N/A</td></tr><tr><td>Healthy Donor PBMCs</td><td>Precision for Medicine</td><td>Cat # 93000-10M</td></tr><tr class="rowsep"><td>Healthy Donor PBMCs</td><td>StemExpress</td><td>Cat # LE010F</td></tr><tr class="rowsep"><td colspan="3"><b>Chemicals, Peptides, and Recombinant Proteins</b></td></tr><tr><td>CEF viral peptide pool</td><td>JPT</td><td>Cat # PM-CEF-E</td></tr><tr><td>Cell Stimulation Cocktail</td><td>Life Technologies</td><td>Cat # 00-4970-93</td></tr><tr><td>Dasatinib</td><td>Sigma-Aldrich</td><td>Cat # CDS023389</td></tr><tr><td>Benzonase</td><td>Millipore Sigma</td><td>Cat # 70746</td></tr><tr><td>d-biotin solution</td><td>AVIDITY</td><td>Cat # BIO200</td></tr><tr><td>Assay peptides used in Immune Analysis</td><td>This manuscript</td><td><a id="crosref0965" href="#mmc2">Table S8</a></td></tr><tr class="rowsep"><td>MHC class I tetramers</td><td>This manuscript</td><td>N/A</td></tr><tr class="rowsep"><td colspan="3"><b>Critical Commercial Assays</b></td></tr><tr><td>AEC substrate-chromogen</td><td>BD Biosciences</td><td>Cat # 551951</td></tr><tr><td>AllPrep DNA/RNA FFPE kit</td><td>QIAGEN</td><td>Cat # 80234</td></tr><tr><td>Fixation/Permeabilization Solution Kit</td><td>BD Biosciences</td><td>Cat # 554714</td></tr><tr><td>Foxp3/Transcription Factor Staining Buffer Set</td><td>eBioscience</td><td>Cat # 00-5523-00</td></tr><tr><td>Intracellular Fixation and Permeabilization Buffer Set</td><td>eBioscience</td><td>Cat # 88-8824-00</td></tr><tr><td>GolgiStop</td><td>BD Biosciences</td><td>Cat # 554724</td></tr><tr><td>GolgiPlug</td><td>BD Biosciences</td><td>Cat # 555029</td></tr><tr><td>IFN gamma Human ELISPOT Kit</td><td>Invitrogen</td><td>Cat # 88-7386-88</td></tr><tr><td>U-Plex development pack, 10-assay sector plate</td><td>Meso Scale Discovery</td><td>Cat # K15235N</td></tr><tr><td>Meso Scale Discovery (MSD) Read Buffer T (4x)</td><td>Meso Scale Discovery</td><td>Cat # R92TC</td></tr><tr><td>Meso Scale Discovery (MSD) U-Plex System</td><td>Meso Scale Discovery</td><td>Cat # K15067L</td></tr><tr><td>Qubit RNA HS Assay Kit</td><td>ThermoFisher</td><td>Cat # Q32855</td></tr><tr><td>RNA 6000 Nano Kit</td><td>Agilent</td><td>Cat # 5067-1511</td></tr><tr><td>RNA 6000 Pico Kit</td><td>Agilent</td><td>Cat # 5067-1513</td></tr><tr><td>RNeasy Plus Micro Kit</td><td>QIAGEN</td><td>Cat # 74034</td></tr><tr><td>RNeasy Plus Mini Kit</td><td>QIAGEN</td><td>Cat # 74134</td></tr><tr><td>Fixation/Permeabilization Solution Kit</td><td>BD Biosciences</td><td>Cat # 554714</td></tr><tr><td>Foxp3/Transcription Factor Staining Buffer Set</td><td>eBioscience</td><td>Cat # 00-5523-00</td></tr><tr><td>CD3 MicroBeads, human</td><td>Miltenyi Biotec</td><td>Cat # 130-050-101</td></tr><tr><td>CD4 MicroBeads, human</td><td>Miltenyi Biotec</td><td>Cat # 130-045-101</td></tr><tr><td>Pan T&nbsp;cell Isolation Kit, human</td><td>Miltenyi Biotec</td><td>Cat # 130-096-535</td></tr><tr><td>Opal 7-Color Manual IHC Kit</td><td>PerkinElmer</td><td>Cat # NEL811001KT</td></tr><tr class="rowsep"><td>TSA Plus Fluorescence kit</td><td>PerkinElmer</td><td>Cat # NEL741001KT</td></tr><tr class="rowsep"><td colspan="3"><b>Experimental Models: Cell Lines</b></td></tr><tr><td>Jurkat, Clone E6-1</td><td>ATCC</td><td>Cat # ATCC-TIB-152</td></tr><tr><td>A375</td><td>ATCC</td><td>Cat # ATCC-CRL-1619</td></tr><tr class="rowsep"><td>293FT Cell Line</td><td>Thermo Fisher</td><td>Cat # R70007</td></tr><tr class="rowsep"><td colspan="3"><b>Recombinant DNA</b></td></tr><tr class="rowsep"><td>pET-22b(+) DNA - Novagen</td><td>Millipore Sigma</td><td>Cat # 69744-3</td></tr><tr class="rowsep"><td colspan="3"><b>Software and Algorithms</b></td></tr><tr><td>R (version 3.5.1)</td><td>CRAN</td><td><a id="intref0015" href="https://www.r-project.org/" target="_blank">https://www.r-project.org/</a></td></tr><tr><td>ImageJ</td><td><span class="dropBlock reference-citations"><a id="body-ref-optLpDVvQM84K" href="#" role="doc-biblioref" data-xml-rid="bib79" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="optLpDVvQM84K" aria-controls="optLpDVvQM84K">Schneider et al., 2012</a><div class="dropBlock__holder" data-db-target-of="optLpDVvQM84K"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">63.</div><div>Schneider, C.A. ∙ Rasband, W.S. ∙ Eliceiri, K.W.</div><div><strong>NIH Image to ImageJ: 25 years of image analysis</strong></div><div><em>Nature Methods.</em> 2012; <strong>9</strong>:671-675</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nmeth.2089" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_63_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84863205849" target="_blank" aria-label="Open Scopus in new tab">Scopus (42378)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22930834/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnmeth.2089&amp;pmid=22930834" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td><a id="intref0020" href="https://imagej.nih.gov/ij/" target="_blank">https://imagej.nih.gov/ij/</a></td></tr><tr><td>FlowJo (version 10)</td><td>FlowJo Software (for Windows) Version 10. Becton, Dickinson and Company; 2019.</td><td><a id="intref0025" href="https://www.flowjo.com/" target="_blank">https://www.flowjo.com/</a></td></tr><tr><td>IPD-IMGT/HLA</td><td>N/A</td><td><a id="intref0030" href="https://www.ebi.ac.uk/ipd/imgt/hla" target="_blank">https://www.ebi.ac.uk/ipd/imgt/hla</a></td></tr><tr><td>GraphPad Prism (version 7.01)</td><td>GraphPad Software, La Jolla California, USA</td><td><a id="intref0035" href="https://www.graphpad.com:443" target="_blank">https://www.graphpad.com:443</a></td></tr><tr><td>BWA-MEM (version 0.7.13)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref46-1" href="#" role="doc-biblioref" data-xml-rid="bib46" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref46-1" aria-controls="sref46-1">Li and Durbin, 2009</a><div class="dropBlock__holder" data-db-target-of="sref46-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">46.</div><div>Li, H. ∙ Durbin, R.</div><div><strong>Fast and accurate short read alignment with Burrows-Wheeler transform</strong></div><div><em>Bioinformatics.</em> 2009; <strong>25</strong>:1754-1760</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btp324" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_46_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-67649884743" target="_blank" aria-label="Open Scopus in new tab">Scopus (31658)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19451168/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtp324&amp;pmid=19451168" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>STAR-Fusion (version 2.5.1.b)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref14-1" href="#" role="doc-biblioref" data-xml-rid="bib14" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref14-1" aria-controls="sref14-1">Haas et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref14-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">14.</div><div>Haas, B.J. ∙ Dobin, A. ∙ Stransky, N. ...</div><div><strong>STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq</strong></div><div><em>bioRxiv.</em> 2017;</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/120295" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85095631683" target="_blank" aria-label="Open Scopus in new tab">Scopus (0)</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2F120295" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>GATK 3.5 workflow</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref49-1" href="#" role="doc-biblioref" data-xml-rid="bib49" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref49-1" aria-controls="sref49-1">McKenna et&nbsp;al., 2010</a><div class="dropBlock__holder" data-db-target-of="sref49-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">50.</div><div>McKenna, A. ∙ Hanna, M. ∙ Banks, E. ...</div><div><strong>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</strong></div><div><em>Genome Res.</em> 2010; <strong>20</strong>:1297-1303</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/gr.107524.110" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_50_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-77956295988" target="_blank" aria-label="Open Scopus in new tab">Scopus (17473)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20644199/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2Fgr.107524.110&amp;pmid=20644199" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>ConTest</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref20-1" href="#" role="doc-biblioref" data-xml-rid="bib20" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref20-1" aria-controls="sref20-1">Cibulskis et&nbsp;al., 2011</a><div class="dropBlock__holder" data-db-target-of="sref20-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">20.</div><div>Cibulskis, K. ∙ McKenna, A. ∙ Fennell, T. ...</div><div><strong>ContEst: estimating cross-contamination of human samples in next-generation sequencing data</strong></div><div><em>Bioinformatics.</em> 2011; <strong>27</strong>:2601-2602</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btr446" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_20_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-80052707308" target="_blank" aria-label="Open Scopus in new tab">Scopus (191)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21803805/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtr446&amp;pmid=21803805" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>VarDict (version 1.4.6)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref43-1" href="#" role="doc-biblioref" data-xml-rid="bib43" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref43-1" aria-controls="sref43-1">Lai et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref43-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">43.</div><div>Lai, Z. ∙ Markovets, A. ∙ Ahdesmaki, M. ...</div><div><strong>VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research</strong></div><div><em>Nucleic Acids Res.</em> 2016; <strong>44</strong>:e108</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nar/gkw227" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_43_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84976448371" target="_blank" aria-label="Open Scopus in new tab">Scopus (509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27060149/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fnar%2Fgkw227&amp;pmid=27060149" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>Strelka (version 1.0.15)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref60-1" href="#" role="doc-biblioref" data-xml-rid="bib60" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref60-1" aria-controls="sref60-1">Saunders et&nbsp;al., 2012</a><div class="dropBlock__holder" data-db-target-of="sref60-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">61.</div><div>Saunders, C.T. ∙ Wong, W.S. ∙ Swamy, S. ...</div><div><strong>Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs</strong></div><div><em>Bioinformatics.</em> 2012; <strong>28</strong>:1811-1817</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/bts271" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_61_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84864153492" target="_blank" aria-label="Open Scopus in new tab">Scopus (1123)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22581179/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbts271&amp;pmid=22581179" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>VarScan2 (version 2.3.9)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref40-1" href="#" role="doc-biblioref" data-xml-rid="bib40" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref40-1" aria-controls="sref40-1">Koboldt et&nbsp;al., 2012</a><div class="dropBlock__holder" data-db-target-of="sref40-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">40.</div><div>Koboldt, D.C. ∙ Zhang, Q. ∙ Larson, D.E. ...</div><div><strong>VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing</strong></div><div><em>Genome Res.</em> 2012; <strong>22</strong>:568-576</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/gr.129684.111" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_40_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84863229597" target="_blank" aria-label="Open Scopus in new tab">Scopus (3360)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22300766/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2Fgr.129684.111&amp;pmid=22300766" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>Atlas Indel2 (version 1.4.3)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref18-1" href="#" role="doc-biblioref" data-xml-rid="bib18" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref18-1" aria-controls="sref18-1">Challis et&nbsp;al., 2012</a><div class="dropBlock__holder" data-db-target-of="sref18-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">18.</div><div>Challis, D. ∙ Yu, J. ∙ Evani, U.S. ...</div><div><strong>An integrative variant analysis suite for whole exome next-generation sequencing data</strong></div><div><em>BMC Bioinformatics.</em> 2012; <strong>13</strong>:8</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2105-13-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_18_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84855593661" target="_blank" aria-label="Open Scopus in new tab">Scopus (206)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22239737/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2105-13-8&amp;pmid=22239737" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>Seurat (version 2.6)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref19-1" href="#" role="doc-biblioref" data-xml-rid="bib19" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref19-1" aria-controls="sref19-1">Christoforides et&nbsp;al., 2013</a><div class="dropBlock__holder" data-db-target-of="sref19-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">19.</div><div>Christoforides, A. ∙ Carpten, J.D. ∙ Weiss, G.J. ...</div><div><strong>Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs</strong></div><div><em>BMC Genomics.</em> 2013; <strong>14</strong>:302</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2164-14-302" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_19_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84876963318" target="_blank" aria-label="Open Scopus in new tab">Scopus (65)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23642077/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2164-14-302&amp;pmid=23642077" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>Platypus (version 0.8.1)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref54-1" href="#" role="doc-biblioref" data-xml-rid="bib54" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref54-1" aria-controls="sref54-1">Rimmer et&nbsp;al., 2014</a><div class="dropBlock__holder" data-db-target-of="sref54-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">55.</div><div>Rimmer, A. ∙ Phan, H. ∙ Mathieson, I. ..., WGS500 Consortium</div><div><strong>Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications</strong></div><div><em>Nat. Genet.</em> 2014; <strong>46</strong>:912-918</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ng.3036" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_55_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84905576523" target="_blank" aria-label="Open Scopus in new tab">Scopus (702)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25017105/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fng.3036&amp;pmid=25017105" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>RSEM (version 1.2.31)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref45-1" href="#" role="doc-biblioref" data-xml-rid="bib45" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref45-1" aria-controls="sref45-1">Li and Dewey, 2011</a><div class="dropBlock__holder" data-db-target-of="sref45-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">45.</div><div>Li, B. ∙ Dewey, C.N.</div><div><strong>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</strong></div><div><em>BMC Bioinformatics.</em> 2011; <strong>12</strong>:323</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2105-12-323" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_45_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-79961123152" target="_blank" aria-label="Open Scopus in new tab">Scopus (13399)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21816040/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2105-12-323&amp;pmid=21816040" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>NetMHCpan (version 3.0)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref50-3" href="#" role="doc-biblioref" data-xml-rid="bib50" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref50-3" aria-controls="sref50-3">Nielsen and Andreatta, 2016</a><div class="dropBlock__holder" data-db-target-of="sref50-3"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">51.</div><div>Nielsen, M. ∙ Andreatta, M.</div><div><strong>NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets</strong></div><div><em>Genome Med.</em> 2016; <strong>8</strong>:33</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13073-016-0288-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_51_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962905590" target="_blank" aria-label="Open Scopus in new tab">Scopus (364)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27029192/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2Fs13073-016-0288-x&amp;pmid=27029192" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>MiXCR (version 3.0.12)</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref12-1" href="#" role="doc-biblioref" data-xml-rid="bib12" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref12-1" aria-controls="sref12-1">Bolotin et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref12-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">12.</div><div>Bolotin, D.A. ∙ Poslavsky, S. ∙ Mitrophanov, I. ...</div><div><strong>MiXCR: software for comprehensive adaptive immunity profiling</strong></div><div><em>Nat. Methods.</em> 2015; <strong>12</strong>:380-381</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nmeth.3364" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_12_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928898852" target="_blank" aria-label="Open Scopus in new tab">Scopus (979)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25924071/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnmeth.3364&amp;pmid=25924071" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>DescTools package</td><td><span class="dropBlock reference-citations"><a id="body-ref-sref4-1" href="#" role="doc-biblioref" data-xml-rid="bib4" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref4-1" aria-controls="sref4-1">Signorell et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref4-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">67.</div><div>Signorell, A. ∙ Aho, K.A. ∙ Alfons, A. ...</div><div><strong>DescTools: tools for descriptive statistics</strong></div><div>2016</div><div><a id="intref0065" href="https://rdrr.io/cran/DescTools/man/DescTools-package.html" target="_blank">https://rdrr.io/cran/DescTools/man/DescTools-package.html</a></div></div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=A.SignorellK.A.AhoA.AlfonsN.AndereggT.AragonA.ArppeA.BaddeleyK.BartonB.BolkerH.W.BorchersDescTools%3A+tools+for+descriptive+statistics2016https%3A%2F%2Frdrr.io%2Fcran%2FDescTools%2Fman%2FDescTools-package.html" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span></td><td>N/A</td></tr><tr><td>nSolver Analysis Software (version 3.0)</td><td>NanoString</td><td><a id="intref0040" href="https://www.nanostring.com/products/analysis-software/nsolver" target="_blank">https://www.nanostring.com/products/analysis-software/nsolver</a></td></tr></tbody></table></div><figcaption><div class="core-table-tools"><ul><li><a class="core-table-show-action" href="/action/showFullTableHTML?isHtml=true&amp;tableId=undtbl1&amp;pii=S0092-8674%2820%2931141-7" target="_blank">Open table in a new tab</a></li></ul></div></figcaption></figure></div></div></section><section id="sec-4-2"><h3>Resource Availability</h3><section id="sec-4-2-1"><h4>Lead Contact</h4><div id="p0220" role="paragraph">Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lakshmi Srinivasan (<a id="intref0045" href="mailto:lakshmi.srinivasan@biontech.us">lakshmi.srinivasan@biontech.us</a>).</div></section><section id="sec-4-2-2"><h4>Materials Availability</h4><div id="p0225" role="paragraph">All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.</div></section><section id="sec-4-2-3"><h4>Data and Code Availability</h4><div id="p0230" role="paragraph">All vaccine peptide and immune assay peptide sequences are provided in <a id="crosref1035" href="#mmc2">Table S8</a>. Patient sequencing information will be provided for patients consistent with their institutional informed consent. Epitope selection utilized previously published algorithms and methods as described in the <a id="crosref1040" href="#sec-4">STAR Methods</a>.</div></section></section><section id="sec-4-3"><h3>Experimental Model and Subject Details</h3><section id="sec-4-3-1"><h4>Study design</h4><div id="p0235" role="paragraph">Details of the study can be found in the attached clinical study protocol NT-001 and patient demographics can be found in <a id="crosref1045" href="#tbl1">Table 1</a>. Nine clinical sites enrolled patients including Dana Farber Cancer Institute, City of Hope National Medical Center, Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, University of California San Francisco, University of Texas MD Anderson Cancer Center and Washington University School of Medicine. Patients who were 18 years of age or older with histologically or cytologically confirmed unresectable or metastatic melanoma, NSCLC or UC of the bladder, urethra, ureter or renal pelvis were eligible for enrollment in this multicenter phase I clinical trial (NCT02897765, also known as NT001). No statistical methods were used to pre-determine the sample size for each of the three tumor cohorts. The study was conducted in accordance with the Declaration of Helsinki and with approval by the Institutional Review Board at each participating site and written informed consent was obtained for all patients. Key eligibility criteria included an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and life expectancy of at least 6&nbsp;months. Excluded from the study were patients with untreated central nervous system (CNS) metastases, active or history of autoimmune disease, and patients who had received previous therapy with ICI other than cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibition for melanoma and intra-vesical BCG for urothelial carcinoma.</div><div id="p0240" role="paragraph">The primary objective of the study was to evaluate safety of administering NEO-PV-01&nbsp;+ adjuvant (poly-ICLC) with nivolumab. The relationship of an adverse event to study treatments was determined according to clinical judgement of the clinical investigators. The secondary objective was to determine the anti-tumor activity of the combination as assessed by objective response rate and the exploratory objective was to determine the vaccine induced immune responses. The clinical characteristics for these patients are included in <a id="crosref1050" href="#tbl1">Table 1</a>. NEO-PV-01 is a personalized vaccine composed of up to 20 synthesized peptides that are between 14 and 35 amino acids in length. The peptides are divided into up to four individual pools, each pool consisting of 1 to 5 peptides. On the day of vaccination, each pool of NEO-PV-01 was mixed with the adjuvant polyinosinic polycytidylic acid polylysine carboxymethylcellulose (poly ICLC; Hiltonol®) for a concentration of 300&nbsp;μg/mL of each peptide. Each patient was scheduled to receive 5 doses of vaccination during the priming phase (on days 1 and 4 of week 12) and then weekly for 3&nbsp;weeks (weeks 13, 14, and 15), followed by 2 booster vaccinations at weeks 19 and 23. Each pool was administered by subcutaneous injection in one of the four limbs or left or right midriff as alternative anatomical locations. The anatomical site of injection for each pool was constant through the vaccination regimen. Patients were allowed to start vaccination with NEO-PV-01&nbsp;+ adjuvant poly-ICLC regardless of disease status. Nivolumab at 240&nbsp;mg flat dose was administered i.v. every 2&nbsp;weeks starting on study day 1.</div></section><section id="sec-4-3-2"><h4>Clinical assessments</h4><div id="p0245" role="paragraph">Adverse events, laboratory values, ECG, and vital signs were assessed regularly and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Response was assessed at weeks 8 and 12 and subsequently every 12&nbsp;weeks according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 based on investigator assessment.</div></section><section id="sec-4-3-3"><h4>Patient samples</h4><div id="p0250" role="paragraph">Eighty-two patients were enrolled on the study. These included 34 patients with melanoma (68% male), 27 patients with NSCLC (44% male), and 21 patients with bladder cancer (71% male). Leukaphereses, blood, and serum samples were obtained from study participants throughout treatment. Leukaphereses were obtained at pre-treatment, pre-vaccine (week 10-12) and post-vaccine (week 20). Blood and plasma samples were obtained at weeks 6, 14, 16 and 24. Patient PBMCs were isolated within 4h after blood collection using Ficoll-paque (GE Healthcare) density-gradient centrifugation and cryopreserved in Recovery Cell Culture Freezing Medium (Invitrogen). PBMCs were stored in vapor-phase liquid nitrogen and plasma samples were stored at −80°C until time of analysis.</div><div id="p0255" role="paragraph">Tumor samples (surgical and core-needle biopsies) were obtained at pre-treatment, pre-vaccine (week 10-12) and post-vaccine (week 24). Samples were fixed in 10% neutral-buffered formalin for at least 18 and no more than 30h and then processed and embedded in paraffin by traditional vacuum infiltration tissue processing techniques. Pre-treatment biopsies were used for generation of NEO-PV-01 and were advanced for DNA and RNA sequencing only if 5 cores or 100mm<sup>3</sup> were available and if pathology review indicated a tumor cellularity ≥ 30%. If none of the core biopsies met the minimum 30% tumor cellularity, enrichment by macro-dissection may have been performed. In several instances, archival biopsies were permitted, if they had been obtained within 180&nbsp;days of patient consent and if there had been no intercurrent therapy.</div></section></section><section id="sec-4-4"><h3>Method Details</h3><section id="sec-4-4-1"><h4>Generation of NEO-PV-01</h4><section id="sec-4-4-1-1"><h5>Whole exome sequencing</h5><div id="p0260" role="paragraph">WES (library protocol: ACE(TM) Cancer Research Exome, Personalis, Menlo Park, CA) and RNA-Seq (library protocol: ACE(TM) Cancer Research Transcriptome, Personalis, Menlo Park, CA) libraries were sequenced using Illumina HiSeq in a CLIA/CAP accredited laboratory (Personalis, Menlo Park, CA). WES was conducted on a tumor sample and a normal blood sample per patient (depths: 158-347 reads and 65-289 reads, respectively); RNA-Seq was conducted on tumor samples only (depth: 94-547 reads).</div><div id="p0265" role="paragraph">The HLA-A and HLA-B genotype of each patient was determined by amplifying informative exons by polymerase chain reaction (PCR) using locus-specific primers. Dye-terminator sequencing fragments from the PCR fragments were analyzed on a capillary sequencer to determine nucleotide sequences for each haplotype (BloodCenter of Wisconsin, Milwaukee, WI).</div></section></section><section id="sec-4-4-2"><h4>Alignment and mutation calling</h4><div id="p0270" role="paragraph">All computational analysis steps were conducted using an automated analysis pipeline hosted on a cloud computing platform (Seven Bridges Genomics, Charlestown, MA).</div><div id="p0275" role="paragraph">Tumor and germline WES and tumor RNA-Seq FASTQs were aligned to the human genome (Gencode V19) using the BWA-MEM (version 0.7.13) (<span class="dropBlock reference-citations"><a id="body-ref-sref46-2" href="#" role="doc-biblioref" data-xml-rid="bib46" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref46-2" aria-controls="sref46-2">Li and Durbin, 2009</a><div class="dropBlock__holder" data-db-target-of="sref46-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">46.</div><div>Li, H. ∙ Durbin, R.</div><div><strong>Fast and accurate short read alignment with Burrows-Wheeler transform</strong></div><div><em>Bioinformatics.</em> 2009; <strong>25</strong>:1754-1760</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btp324" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_46_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-67649884743" target="_blank" aria-label="Open Scopus in new tab">Scopus (31658)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19451168/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtp324&amp;pmid=19451168" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) and STAR (version 2.5.1.b), respectively. All alignments were post-processed with the GATK 3.5 workflow (<span class="dropBlock reference-citations"><a id="body-ref-sref49-2" href="#" role="doc-biblioref" data-xml-rid="bib49" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref49-2" aria-controls="sref49-2">McKenna et&nbsp;al., 2010</a><div class="dropBlock__holder" data-db-target-of="sref49-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">50.</div><div>McKenna, A. ∙ Hanna, M. ∙ Banks, E. ...</div><div><strong>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</strong></div><div><em>Genome Res.</em> 2010; <strong>20</strong>:1297-1303</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/gr.107524.110" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_50_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-77956295988" target="_blank" aria-label="Open Scopus in new tab">Scopus (17473)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20644199/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2Fgr.107524.110&amp;pmid=20644199" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) including GATK Indel Realigner, GATK Base Recalibrator, and Picard Mark Duplicates (version 1.140). ConTest (<span class="dropBlock reference-citations"><a id="body-ref-sref20-2" href="#" role="doc-biblioref" data-xml-rid="bib20" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref20-2" aria-controls="sref20-2">Cibulskis et&nbsp;al., 2011</a><div class="dropBlock__holder" data-db-target-of="sref20-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">20.</div><div>Cibulskis, K. ∙ McKenna, A. ∙ Fennell, T. ...</div><div><strong>ContEst: estimating cross-contamination of human samples in next-generation sequencing data</strong></div><div><em>Bioinformatics.</em> 2011; <strong>27</strong>:2601-2602</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btr446" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_20_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-80052707308" target="_blank" aria-label="Open Scopus in new tab">Scopus (191)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21803805/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtr446&amp;pmid=21803805" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) was used to confirm that all three samples originated from the same individual.</div><div id="p0280" role="paragraph">Somatic variants were called on the basis of tumor and normal WES using an ensemble of seven different mutation calling algorithms: VarDict (version 1.4.6) (<span class="dropBlock reference-citations"><a id="body-ref-sref43-2" href="#" role="doc-biblioref" data-xml-rid="bib43" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref43-2" aria-controls="sref43-2">Lai et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref43-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">43.</div><div>Lai, Z. ∙ Markovets, A. ∙ Ahdesmaki, M. ...</div><div><strong>VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research</strong></div><div><em>Nucleic Acids Res.</em> 2016; <strong>44</strong>:e108</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nar/gkw227" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_43_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84976448371" target="_blank" aria-label="Open Scopus in new tab">Scopus (509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27060149/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fnar%2Fgkw227&amp;pmid=27060149" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), Strelka (version 1.0.15) (<span class="dropBlock reference-citations"><a id="body-ref-sref60-2" href="#" role="doc-biblioref" data-xml-rid="bib60" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref60-2" aria-controls="sref60-2">Saunders et&nbsp;al., 2012</a><div class="dropBlock__holder" data-db-target-of="sref60-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">61.</div><div>Saunders, C.T. ∙ Wong, W.S. ∙ Swamy, S. ...</div><div><strong>Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs</strong></div><div><em>Bioinformatics.</em> 2012; <strong>28</strong>:1811-1817</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/bts271" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_61_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84864153492" target="_blank" aria-label="Open Scopus in new tab">Scopus (1123)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22581179/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbts271&amp;pmid=22581179" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), VarScan2 (version 2.3.9) (<span class="dropBlock reference-citations"><a id="body-ref-sref40-2" href="#" role="doc-biblioref" data-xml-rid="bib40" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref40-2" aria-controls="sref40-2">Koboldt et&nbsp;al., 2012</a><div class="dropBlock__holder" data-db-target-of="sref40-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">40.</div><div>Koboldt, D.C. ∙ Zhang, Q. ∙ Larson, D.E. ...</div><div><strong>VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing</strong></div><div><em>Genome Res.</em> 2012; <strong>22</strong>:568-576</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/gr.129684.111" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_40_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84863229597" target="_blank" aria-label="Open Scopus in new tab">Scopus (3360)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22300766/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2Fgr.129684.111&amp;pmid=22300766" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), Mutect2 (from the GATK version 3.5 bundle) (<span class="dropBlock reference-citations"><a id="body-ref-sref21" href="#" role="doc-biblioref" data-xml-rid="bib21" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref21" aria-controls="sref21">Cibulskis et&nbsp;al., 2013</a><div class="dropBlock__holder" data-db-target-of="sref21"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">21.</div><div>Cibulskis, K. ∙ Lawrence, M.S. ∙ Carter, S.L. ...</div><div><strong>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</strong></div><div><em>Nat. Biotechnol.</em> 2013; <strong>31</strong>:213-219</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nbt.2514" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_21_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84874025843" target="_blank" aria-label="Open Scopus in new tab">Scopus (3317)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23396013/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnbt.2514&amp;pmid=23396013" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), Atlas Indel2 (version 1.4.3) (<span class="dropBlock reference-citations"><a id="body-ref-sref18-2" href="#" role="doc-biblioref" data-xml-rid="bib18" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref18-2" aria-controls="sref18-2">Challis et&nbsp;al., 2012</a><div class="dropBlock__holder" data-db-target-of="sref18-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">18.</div><div>Challis, D. ∙ Yu, J. ∙ Evani, U.S. ...</div><div><strong>An integrative variant analysis suite for whole exome next-generation sequencing data</strong></div><div><em>BMC Bioinformatics.</em> 2012; <strong>13</strong>:8</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2105-13-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_18_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84855593661" target="_blank" aria-label="Open Scopus in new tab">Scopus (206)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22239737/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2105-13-8&amp;pmid=22239737" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), Seurat (version 2.6) (<span class="dropBlock reference-citations"><a id="body-ref-sref19-2" href="#" role="doc-biblioref" data-xml-rid="bib19" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref19-2" aria-controls="sref19-2">Christoforides et&nbsp;al., 2013</a><div class="dropBlock__holder" data-db-target-of="sref19-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">19.</div><div>Christoforides, A. ∙ Carpten, J.D. ∙ Weiss, G.J. ...</div><div><strong>Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs</strong></div><div><em>BMC Genomics.</em> 2013; <strong>14</strong>:302</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2164-14-302" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_19_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84876963318" target="_blank" aria-label="Open Scopus in new tab">Scopus (65)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23642077/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2164-14-302&amp;pmid=23642077" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), and Platypus (version 0.8.1) (<span class="dropBlock reference-citations"><a id="body-ref-sref54-2" href="#" role="doc-biblioref" data-xml-rid="bib54" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref54-2" aria-controls="sref54-2">Rimmer et&nbsp;al., 2014</a><div class="dropBlock__holder" data-db-target-of="sref54-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">55.</div><div>Rimmer, A. ∙ Phan, H. ∙ Mathieson, I. ..., WGS500 Consortium</div><div><strong>Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications</strong></div><div><em>Nat. Genet.</em> 2014; <strong>46</strong>:912-918</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ng.3036" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_55_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84905576523" target="_blank" aria-label="Open Scopus in new tab">Scopus (702)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25017105/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fng.3036&amp;pmid=25017105" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The three sequencing datasets were then realigned using HaplotypeCaller (from the GATK version 3.5 bundle), specifying the candidate mutations (union of the seven call sets) as known variants. Finally, the variants were filtered according the following features: the level of read support in the tumor WES data, the presence of variant reads in the normal WES data, read orientation bias, adequacy of coverage in the normal WES sample, the presence of neighboring (+/−30nt) variants (somatic or germline), and read quality bias observed in mutation-supporting reads.</div><div id="p0285" role="paragraph">RNA-Seq expression levels of all genes and transcripts were quantified in transcripts per million (TPM) using RSEM (version 1.2.31) (<span class="dropBlock reference-citations"><a id="body-ref-sref45-2" href="#" role="doc-biblioref" data-xml-rid="bib45" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref45-2" aria-controls="sref45-2">Li and Dewey, 2011</a><div class="dropBlock__holder" data-db-target-of="sref45-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">45.</div><div>Li, B. ∙ Dewey, C.N.</div><div><strong>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</strong></div><div><em>BMC Bioinformatics.</em> 2011; <strong>12</strong>:323</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2105-12-323" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_45_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-79961123152" target="_blank" aria-label="Open Scopus in new tab">Scopus (13399)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21816040/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2105-12-323&amp;pmid=21816040" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The overall expression of each somatic variant was calculated as the product of the RSEM-derived transcript expression (summing across all overlapping protein-coding transcripts) and the fraction of RNA-Seq reads supporting the variant. Variants with zero supporting RNA reads were still considered as valid mutations (and counted toward tumor mutation burden) but were not considered for inclusion in vaccine. RNA-Seq was additionally processed using STAR-Fusion (version 2.5.1.b) (<span class="dropBlock reference-citations"><a id="body-ref-sref14-2" href="#" role="doc-biblioref" data-xml-rid="bib14" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref14-2" aria-controls="sref14-2">Haas et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref14-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">14.</div><div>Haas, B.J. ∙ Dobin, A. ∙ Stransky, N. ...</div><div><strong>STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq</strong></div><div><em>bioRxiv.</em> 2017;</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/120295" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85095631683" target="_blank" aria-label="Open Scopus in new tab">Scopus (0)</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2F120295" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) to identify transcript fusions (requiring both junction support and spanning read pairs).</div><div id="p0290" role="paragraph">In the event that an adequate RNA library could not be prepared (patients: B9 and M17), fusion calling was skipped and reference expression was obtained from TCGA samples with high tumor purity (as assessed by Absolute; five samples per tumor type) (<span class="dropBlock reference-citations"><a id="body-ref-sref17" href="#" role="doc-biblioref" data-xml-rid="bib17" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref17" aria-controls="sref17">Carter et&nbsp;al., 2012</a><div class="dropBlock__holder" data-db-target-of="sref17"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">17.</div><div>Carter, S.L. ∙ Cibulskis, K. ∙ Helman, E. ...</div><div><strong>Absolute quantification of somatic DNA alterations in human cancer</strong></div><div><em>Nat. Biotechnol.</em> 2012; <strong>30</strong>:413-421</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nbt.2203" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_17_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84860782006" target="_blank" aria-label="Open Scopus in new tab">Scopus (1404)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22544022/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnbt.2203&amp;pmid=22544022" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Since these patients lacked RNA-Seq as a filter against false positive mutation calls, their somatic variants were required to have a higher level of read support in the tumor WES and to have been identified by more than one mutation caller.</div></section><section id="sec-4-4-3"><h4>Vaccine peptide selection</h4><div id="p0295" role="paragraph">Patients with at least 50 non-synonymous point mutations and/or gene fusions were advanced to the vaccine design step. The vaccine peptides, also referred to as immunizing (IM) peptides, were identified by selecting 6 peptides on the basis of HLA-I presentation scores (also referred to as epitope quality scores, see below), 2 peptides based on high expression, and 2 peptides based on highly expressed frameshifts, iteratively until the full roster of 30 peptides was completed. HLA-I epitopes were required to have a NetMHCpan (version 3.0) percent rank lower than 2%, and the latter two epitope classes were required to have expression levels &gt; 10 TPM and &gt; 5 TPM, respectively (if none were available, the slots were ceded to HLA-I selections). Generally, each mutation was targeted by only one vaccine peptide and excluded from subsequent selections unless the span of novel sequence generated could not be covered by a single peptide (as can happen with frameshifts) or if the likelihood of manufacturing success was questionable for the first peptide per known synthesis constraints. The trade-off between synthesis constraints and immune-related scoring further dictated the relative length of the vaccine peptides (allowable range: 14-35 amino acids) and whether they were centered or shifted with respect to the site of mutation.</div><div id="p0300" role="paragraph">HLA-I presentation scores were determined based on a logistic regression that considered binding affinity (NetMHCpan-3.0 percent rank) (<span class="dropBlock reference-citations"><a id="body-ref-sref50-4" href="#" role="doc-biblioref" data-xml-rid="bib50" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref50-4" aria-controls="sref50-4">Nielsen and Andreatta, 2016</a><div class="dropBlock__holder" data-db-target-of="sref50-4"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">51.</div><div>Nielsen, M. ∙ Andreatta, M.</div><div><strong>NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets</strong></div><div><em>Genome Med.</em> 2016; <strong>8</strong>:33</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13073-016-0288-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_51_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962905590" target="_blank" aria-label="Open Scopus in new tab">Scopus (364)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27029192/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2Fs13073-016-0288-x&amp;pmid=27029192" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), allele-specific expression, and proteasomal cleavage potential (using a previously described prediction approach); the weights of the logistic regression were optimized according to mass spectrometry data as previously described (<span class="dropBlock reference-citations"><a id="body-ref-sref1-4" href="#" role="doc-biblioref" data-xml-rid="bib1" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref1-4" aria-controls="sref1-4">Abelin et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref1-4"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">1.</div><div>Abelin, J.G. ∙ Keskin, D.B. ∙ Sarkizova, S. ...</div><div><strong>Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction</strong></div><div><em>Immunity.</em> 2017; <strong>46</strong>:315-326</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85013878753" target="_blank" aria-label="Open Scopus in new tab">Scopus (408)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28228285/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2017.02.007&amp;pmid=28228285" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The score of a candidate vaccine peptide was determined by summing all the relevant peptide-allele combinations (epitopes lengths 8-11; HLA-A and HLA-B alleles only).</div><div id="p0305" role="paragraph">Secondary characteristics were used to up-weight and down-weight candidate epitopes but were purposely tuned to have less importance than the above-mentioned factors. Thus, all other parameters being equal, the selection algorithm favored more clonal epitopes (higher mutant allele fraction) over sub-clonal epitopes, frameshifts over point mutations, oncogenes over passenger genes, and peptides with good manufacturing scores over those with poor predicted manufacturability. Our scoring system did not consider the relative binding scores of wild-type peptides or similarity to known pathogen sequences (<span class="dropBlock reference-citations"><a id="body-ref-sref47-2" href="#" role="doc-biblioref" data-xml-rid="bib47" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref47-2" aria-controls="sref47-2">Łuksza et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref47-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">48.</div><div>Łuksza, M. ∙ Riaz, N. ∙ Makarov, V. ...</div><div><strong>A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy</strong></div><div><em>Nature.</em> 2017; <strong>551</strong>:517-520</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature24473" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_48_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85034865728" target="_blank" aria-label="Open Scopus in new tab">Scopus (454)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29132144/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature24473&amp;pmid=29132144" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) .</div></section><section id="sec-4-4-4"><h4>GMP peptide manufacturing</h4><div id="p0310" role="paragraph">The GMP grade peptides of NEO-PV-01 were synthesized using solid-phase peptide synthesis (SPPS) on automated parallel peptide synthesizers. 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry was employed. After the assembly of the peptide chains, the peptides were removed from the resins using cleavage cocktails containing trifluoroacetic acid and scavengers. The peptides were precipitated and washed with ether. After drying, the crude peptides were purified on automated preparative high-performance liquid chromatography (prep HPLC) systems with ultraviolet (UV) and mass spectrometry (MS) detectors. The prep HPLC fractions were analyzed using ultra-performance liquid chromatography (UPLC)-UV/MS systems to determine molecular weights (MW) and purities. The fractions containing the target peptides and desired purities were lyophilized to solid powders with the final purities equal to or higher than 95%. Up to 20 peptides per vaccine were formulated in a buffered aqueous solution containing 4% DMSO in isotonic dextrose and mixed into up to four pools, each containing up to five peptides. The pooled peptide solutions were filtered through 0.22&nbsp;μm filters for sterilization. The vaccines were analyzed for identity (molecular weights based on UPLC-UV/MS analysis), sterility, endotoxin, and strength before their releases from the GMP manufacturing site. The amino- and carboxyl-termini of the peptides are free amines and carboxylic acids respectively, without structural modifications.</div></section><section id="sec-4-4-5"><h4>Peptide synthesis for immunological assays</h4><div id="p0315" role="paragraph">The peptides for <i>in&nbsp;vitro</i> immune response studies were synthesized using SPPS on computer-controlled high-throughput peptide synthesizers. The peptides were assembled on resins by employing Fmoc-chemistry. The chemical cleavages of peptides from the resins were performed by using TFA solution containing scavengers followed by peptide precipitation and washes with diethyl ether. The assay peptides (ASP) were purified on automated prep HPLC systems equipped with UV and MS detectors. The prep HPLC fractions of each peptide that met the molecular weight (MW) and purity criteria based on UPLC-UV/MS analysis were pooled and dried using either parallel centrifugal evaporators or lyophilizers. The epitope peptides (EPT) were resuspended in acetonitrile and water and dried on a lyophilizer after diethyl ether washes and analyzed for required purity and MW by using UPLC-UV/MS. Assay peptides (ASP) were 13-15 amino acids and overlapped by at least 9 amino acids to cover the immunizing peptide (IM) sequence or were 8-11 amino acids and predicted to bind class I (<span class="dropBlock reference-citations"><a id="body-ref-sref52-6" href="#" role="doc-biblioref" data-xml-rid="bib52" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref52-6" aria-controls="sref52-6">Ott et&nbsp;al., 2017</a><div class="dropBlock__holder" data-db-target-of="sref52-6"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">53.</div><div>Ott, P.A. ∙ Hu, Z. ∙ Keskin, D.B. ...</div><div><strong>An immunogenic personal neoantigen vaccine for patients with melanoma</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:217-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature22991" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_53_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024377220" target="_blank" aria-label="Open Scopus in new tab">Scopus (1897)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678778/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature22991&amp;pmid=28678778" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). All assay peptide sequences are provided in <a id="crosref1140" href="#mmc2">Table S8</a>.</div></section><section id="sec-4-4-6"><h4>Detection of neoantigen-specific immune responses</h4><div id="p0320" role="paragraph">For <i>ex&nbsp;vivo</i> assays, patient PBMCs were rested overnight at 2&nbsp;× 10<sup>6</sup> cells/mL in X-Vivo media (Lonza) supplemented with 1% penicillin/streptomycin (GIBCO). For neoantigen pre-exposure assays, patient PBMCs were rested overnight and cultured with individual peptides (2&nbsp;μM) or pooled peptides (2&nbsp;μM per peptide) for 5&nbsp;days at a density of 5x10<sup>6</sup> cells/ml in a 24-well plate. On day 3 of culture, half the well volume was replaced with fresh media. All immunizing peptides were tested in both the <i>ex&nbsp;vivo</i> as well as in the 5-day stimulation with the neoantigen peptide assay formats. Immunizing peptides are referred to as IM followed by the peptide number.</div></section><section id="sec-4-4-7"><h4>IFN−γ ELISpot assay</h4><div id="p0325" role="paragraph">IFN-γ ELISpot assays were performed using 96-well MultiScreen Filter Plates (Millipore) and the Ready-Set-Go! Human IFN-γ ELISpot Kit (Invitrogen) according to manufacturer’s instructions. Plates were coated overnight at 4°C with anti-IFNγ Capture Antibody diluted in 1X Coating Buffer, washed with 1X Coating Buffer and blocked with X-Vivo media (Lonza) containing 1% penicillin/streptomycin (GIBCO) for 1h. For <i>ex&nbsp;vivo</i> ELISpots, PBMCs were plated in triplicate with 1&nbsp;× 10<sup>6</sup> cells per well. For cells that were pre-exposed to peptide, cells were washed and plated in triplicate with 1&nbsp;× 10<sup>5</sup> cells per well. Peptides were added to ELISpot wells at 2&nbsp;μM per peptide. Each plate included a healthy donor positive and negative control with the CEF viral peptide pool (JPT) and Cell Stimulation Cocktail (Life Technologies) to confirm reagent performance. Plates were incubated overnight at 37°C. Plates were washed 3 times using PBS with 0.05% Tween-20 and detection antibody diluted in 1X ELISpot diluent was added to wells for 2h. After washing 3 times with PBS with 0.05% Tween-20, Avidin-HRP was diluted in 1X ELISpot diluent and added to wells for 45&nbsp;min. Plates were washed with both PBS with Tween-20 and PBS 3 times. AEC substrate-chromogen (BD Biosciences) was then added for 20&nbsp;min. Plates were rinsed with deionized water 3 times and allowed to dry at room temperature overnight. Spots were imaged and enumerated using an Immunospot analyzer (Cellular Technology Limited). Responses were characterized as positive if spot-forming cell count detected was at least 10 spots over the DMSO control and&nbsp;+3 standard deviations and confirmed in repeat experiments.</div></section><section id="sec-4-4-8"><h4>Characterization of CD4<sup>+</sup>/ CD8<sup>+</sup> T&nbsp;cell responses</h4><div id="p0330" role="paragraph">CD3<sup>+</sup> T&nbsp;cells were isolated from patient PBMCs by negative selection using the Pan T&nbsp;cell isolation kit (Miltenyi). Both the CD3<sup>+</sup> and CD3<sup>-</sup> populations were collected, washed, and counted after isolation. The CD3- population was used as APCs (antigen presenting cells) for this assay. The CD3<sup>+</sup> population then underwent CD4<sup>+</sup> positive isolation using CD4<sup>+</sup> microbeads (Miltenyi). Both the CD4<sup>+</sup> (positive-selection) and CD8<sup>+</sup> (negative-selection) T&nbsp;cells were collected, washed, and counted. A co-culture containing APCs and either CD4<sup>+</sup> or CD8<sup>+</sup> cells at a ratio of 3:1, 2:1, or 1:1 were plated in a 96-well flat bottom polystyrene plate for 24-48h. Peptide was added directly to wells, in triplicate, at 2&nbsp;μM per peptide. If the T&nbsp;cells were pre-exposed to neoantigen peptide for 5-6&nbsp;days, CD3<sup>-</sup> APCs were isolated from fresh patient PBMCs using CD3 microbeads (Miltenyi). Supernatants were collected at the end of the coculture and frozen at −80°C until use.</div><div id="p0335" role="paragraph">The Meso Scale Discovery (MSD) U-Plex system was used to detect 10 distinct analytes from the coculture supernatants. The analytes measured were: IL-1β, IL-2, IL-6, IL-9, IL-13, IL-15, IL-17a, IFN-γ, and TNF-α. MSD 10-plex plates were coated with the linker-antibody solution for 1h with shaking at room temperature. The plates were then washed 3 times with PBS with 0.05% Tween-20 on a BioTek plate washer. Supernatant and standards were diluted 1:2 and added to the plate for 1h with shaking at room temperature. Plates were washed again with PBS with 0.05% Tween-20 before the addition of the detection antibody solution for 1h. Plates were washed with PBS with 0.05% Tween-20 and 2X Read Buffer (MSD) was added to the plates for detection on the MSD SECTOR S 600 instrument. Concentration in pg/mL was calculated by the MSD Discovery Workbench software by comparing luminescent signal of the patient samples against the known standard curve. CD4<sup>+</sup> and CD8<sup>+</sup> positive responses were determined separately based on the corresponding DMSO controls. A positive signal was determined by an IFN-γ signal 1.5-fold higher than the DMSO control.</div></section><section id="sec-4-4-9"><h4>MHC class I tetramer production and staining</h4><div id="p0340" role="paragraph">Recombinant pMHC-I monomers with UV cleavable conditional ligands were prepared for analysis of vaccine-induced neoantigen-specific CD8+ T&nbsp;cells. The gene sequences of the human class I HLA heavy chains were identified from the IPD-IMGT/HLA webpage (<a id="intref0050" href="https://www.ebi.ac.uk/ipd/imgt/hla" target="_blank">https://www.ebi.ac.uk/ipd/imgt/hla</a>) and codon-optimized for expression in <i>E.&nbsp;coli</i> using commercially available algorithms (Genewiz). The extracellular domain of class I heavy chain (amino acid residues 1-276) was fused to a C-terminal GSGGSGGSAGG linker and a GLNDIFEAQKIEWH biotinylation tag and cloned via the NdeI and BamHI restriction sites into the bacterial expression vector pET22b (Millipore Sigma). The human β2&nbsp;m sequence (amino acid residues 1-99) was cloned into pET22b via the NdeI and BamHI restriction sites.</div><div id="p0345" role="paragraph">The HLA heavy chains were expressed in BL21 (DE3) cells (NEB) grown in LB media at 37°C to an OD600 of 0.8 followed by induction with 1&nbsp;mM Isopropyl-β-D-1-thiogalactopyranoside for 4h. The human β2&nbsp;m protein was expressed in BL21 (DE3) cells grown in Studier ZYM-5052 auto-induction medium at 37°C to an OD600 of 0.8 followed by a temperature shift to 20°C for overnight growth. Both proteins accumulate in inclusion bodies which were isolated from the <i>E.&nbsp;coli</i> cells using a previously described protocol and solubilized in 100&nbsp;mM Tris-HCl, pH8.0, 8M Urea for subsequent refolding (<span class="dropBlock reference-citations"><a id="body-ref-sref56-1" href="#" role="doc-biblioref" data-xml-rid="bib56" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref56-1" aria-controls="sref56-1">Rodenko et&nbsp;al., 2006</a><div class="dropBlock__holder" data-db-target-of="sref56-1"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">57.</div><div>Rodenko, B. ∙ Toebes, M. ∙ Hadrup, S.R. ...</div><div><strong>Generation of peptide-MHC class I complexes through UV-mediated ligand exchange</strong></div><div><em>Nat. Protoc.</em> 2006; <strong>1</strong>:1120-1132</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nprot.2006.121" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_57_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-34347266953" target="_blank" aria-label="Open Scopus in new tab">Scopus (245)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17406393/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnprot.2006.121&amp;pmid=17406393" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). UV conditional ligand (CL) peptide-loaded pMHC-I monomers were refolded by mixing 3&nbsp;μM class I heavy chain with 6&nbsp;μM β2&nbsp;m and 10&nbsp;μM CL peptide in refolding buffer (100&nbsp;mM Tris-HCl pH8, 400&nbsp;mM L-arginine, 2&nbsp;mM EDTA, 5&nbsp;mM reduced glutathione, 0.5&nbsp;mM oxidized glutathione, 15% glycerol, 3&nbsp;mM PMSF and 1X CompleteTM EDTA free-protease Inhibitor Cocktail (Roche)) and incubated at 4°C for 5&nbsp;days (<span class="dropBlock reference-citations"><a id="body-ref-sref27" href="#" role="doc-biblioref" data-xml-rid="bib27" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref27" aria-controls="sref27">Garboczi et&nbsp;al., 1992</a><div class="dropBlock__holder" data-db-target-of="sref27"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">27.</div><div>Garboczi, D.N. ∙ Hung, D.T. ∙ Wiley, D.C.</div><div><strong>HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides</strong></div><div><em>Proc. Natl. Acad. Sci. USA.</em> 1992; <strong>89</strong>:3429-3433</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.89.8.3429" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_27_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-0026529908" target="_blank" aria-label="Open Scopus in new tab">Scopus (579)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1565634/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.89.8.3429&amp;pmid=1565634" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref56-2" href="#" role="doc-biblioref" data-xml-rid="bib56" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref56-2" aria-controls="sref56-2">Rodenko et&nbsp;al., 2006</a><div class="dropBlock__holder" data-db-target-of="sref56-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">57.</div><div>Rodenko, B. ∙ Toebes, M. ∙ Hadrup, S.R. ...</div><div><strong>Generation of peptide-MHC class I complexes through UV-mediated ligand exchange</strong></div><div><em>Nat. Protoc.</em> 2006; <strong>1</strong>:1120-1132</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nprot.2006.121" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_57_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-34347266953" target="_blank" aria-label="Open Scopus in new tab">Scopus (245)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17406393/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnprot.2006.121&amp;pmid=17406393" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref67" href="#" role="doc-biblioref" data-xml-rid="bib67" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref67" aria-controls="sref67">Toebes et&nbsp;al., 2006</a><div class="dropBlock__holder" data-db-target-of="sref67"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">70.</div><div>Toebes, M. ∙ Coccoris, M. ∙ Bins, A. ...</div><div><strong>Design and use of conditional MHC class I ligands</strong></div><div><em>Nat. Med.</em> 2006; <strong>12</strong>:246-251</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm1360" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_70_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-32244442535" target="_blank" aria-label="Open Scopus in new tab">Scopus (277)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16462803/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnm1360&amp;pmid=16462803" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The refolded trimetric HLA complex was subsequently buffer exchanged on a SARTOFLOW-R (Sartorius) crossflow system against 20&nbsp;mM Tris-HCl pH8, 25&nbsp;mM NaCl, 15% glycerol and loaded on a HiTrap Q HP anion exchange chromatography column followed by elution with a continuous salt gradient elution to 500&nbsp;mM NaCl on a ÄKTAPurifier system (GE Healthcare). Fractions containing refolded pMHC-I monomers were identified, pooled and concentrated to 60&nbsp;μM in 500&nbsp;mM Bicine, pH 8.3. 100&nbsp;mM ATP, 100&nbsp;mM MgOAc, 1&nbsp;mM biotin for biotinylation for 3h at 30°C with 1&nbsp;μM recombinant BirA (<span class="dropBlock reference-citations"><a id="body-ref-sref2-2" href="#" role="doc-biblioref" data-xml-rid="bib2" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref2-2" aria-controls="sref2-2">Abelin et&nbsp;al., 2019</a><div class="dropBlock__holder" data-db-target-of="sref2-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">2.</div><div>Abelin, J.G. ∙ Harjanto, D. ∙ Malloy, M. ...</div><div><strong>Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction</strong></div><div><em>Immunity.</em> 2019; <strong>51</strong>:766-779.e17</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2019.08.012&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2019.08.012&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85073037953" target="_blank" aria-label="Open Scopus in new tab">Scopus (154)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31495665/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2019.08.012&amp;pmid=31495665" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). The reaction mixture was then concentrated to 5&nbsp;mL and loaded on a Yarra S2000 (Phenomenex) column equilibrated in 1xPBS+16% (v/v) glycerol to separate the biotinylated pMHC-I monomers from other components of the biotinylation reaction by size exclusion chromatography on a ÄKTAPurifier system (GE Healthcare). The pMHC-I monomer product was flash-frozen in liquid nitrogen at a concentration of 2&nbsp;mg/mL and stored at −80°C until further use.</div></section><section id="sec-4-4-10"><h4>Tetramer preparation for PBMC staining</h4><div id="p0350" role="paragraph">Peptide MHC multimers were generated by irradiating UV-cleavable monomers (0.1mg/mL) in the presence of EPT (9-12 amino acids) peptides (10mM in DMSO) at a 1:50 ratio under UV light (365&nbsp;nm) at 4°C for 1h, followed by a 1h incubation at 37°C. Exchanged monomers were centrifuged at 3600RPM for 10&nbsp;min. The exchanged monomer supernatant was incubated with fluorochrome conjugated streptavidin antibodies on ice for 30&nbsp;min in the dark. Excess biotin (1:20 dilution) was added after incubation and exchanged fluorochrome-conjugated multimers were stored at 4°C until staining.</div><div id="p0355" role="paragraph">Patient PBMCs were treated with benzonase and dasatinib, both at a 1:1000 dilution, and were incubated for 30&nbsp;min at 37°C. Samples were centrifuged at 1500RPM for 5&nbsp;min, washed once in FACS buffer containing dasatinib, and resuspended with the pooled multimer mixture at a final staining volume of 50&nbsp;μL per sample with FACS buffer containing dasatinib. Samples were incubated with multimers at 37°C for 15&nbsp;min, and subsequently stained with the appropriate surface antibodies for 30&nbsp;min on ice. After incubation, samples were washed once with FACS buffer containing dasatinib and resuspended in 200&nbsp;μL FACS buffer containing dasatinib. Samples were acquired on a BD LSR Fortessa instrument.</div></section><section id="sec-4-4-11"><h4>CD107a mobilization assay</h4><div id="p0360" role="paragraph">For <i>ex&nbsp;vivo</i> detection, patient PBMCs were recalled with 2&nbsp;μM peptide or DMSO for 6 or 24h. For patient PBMCs pre-exposed to neoantigen peptide, CD3<sup>-</sup> APCs were isolated from fresh PBMCs using CD3 microbeads (Miltenyi) and co-cultured with CD3<sup>+</sup> T&nbsp;cells at a T&nbsp;cell:APC ratio of 2:1 and recalled with 2&nbsp;μM peptide or DMSO for 6 or 24h. Anti-CD107a antibody was added 6h prior to the end of co-culture. GolgiStop/Plug (BD Biosciences) were added 4h prior to the end of co-culture. Subsequently, cells were stained with cell surface antibodies at 4°C for 30&nbsp;min, followed by fixation/permeabilization with Fixation and Permeabilization Solution (BD Biosciences), and subsequently stained with antibodies against intracellular proteins at 4°C for 30&nbsp;min. Cells were stored in FACS buffer at 4°C until acquisition on a BD LSR Fortessa instrument.</div></section><section id="sec-4-4-12"><h4>Phenotyping and ICS of neoantigen-specific T&nbsp;cells</h4><div id="p0365" role="paragraph">For intracellular cytokine staining (ICS), patient PBMCs were stimulated with 2&nbsp;μM peptide or DMSO for 6 or 24h. GolgiStop/Plug (BD Biosciences) were added 4-5h prior to end of recall period with peptide. For phenotyping, patient PBMCs were treated with dasatinib at a 1:1000 dilution in X-Vivo media (Lonza) at 37°C for 30-60&nbsp;min followed by staining with tetramers (if applicable) at 4°C for 30&nbsp;min. For both assays, patient PBMCs were treated with benzonase (Millipore) at a 1:1000 dilution in X-Vivo media (Lonza) at 37°C for 30-60&nbsp;min, followed by staining of surface antibodies. Cells were fixed at 20°C for 30&nbsp;min using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) for phenotyping, and with the Intracellular Fixation and Permeabilization Buffer Set (eBioscience) for ICS, and subsequently stained for intracellular proteins at 4°C for 30&nbsp;min. Cells were stored in FACS buffer at 4°C until acquisition on a BD LSR Fortessa instrument.</div></section><section id="sec-4-4-13"><h4>Phenotypic analysis of peripheral samples</h4><div id="p0370" role="paragraph">Patient PBMCs were treated with benzonase (Millipore) at a 1:1000 dilution in X-Vivo media (Lonza) at 37°C for 30&nbsp;min. A total of 2&nbsp;× 10<sup>6</sup> cells per sample were plated for flow staining and washed once with FACS buffer (PBS&nbsp;+ 0.5% BSA). Cells were then incubated with cell surface antibodies for 30&nbsp;min on ice, followed by a wash with FACS buffer. Cells were fixed and permeabilized for intracellular staining using either the BD cyofix/cytoperm kit (BD Biosciences) or Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer’s instructions for 20&nbsp;min on ice. Cells were then incubated with intracellular antibodies in the corresponding permeabilization wash buffer for 30&nbsp;min on ice, washed with the appropriate permeabilization wash buffer and followed by a final wash with FACS buffer. Cells were stored in FACS buffer at 4°C until acquisition on a BD LSR Fortessa instrument.</div></section><section id="sec-4-4-14"><h4>RNA extraction from FFPE tumors and PBMCs</h4><div id="p0375" role="paragraph">For FFPE tumor blocks, 2-4 scrolls of 20&nbsp;μM thickness were deparaffinized using heptane and RNA was extracted using the AllPrep DNA/RNA FFPE kit according to the manufacturers’ instructions (QIAGEN). For PBMC samples, CD3<sup>+</sup> T&nbsp;cells were isolated using the Pan T&nbsp;cell Isolation Kit (Miltenyi) and subjected to RNA extraction using RNeasy Plus Mini or Micro Kit according to manufacturer’s instructions (QIAGEN). RNA was quantified using the Qubit RNA HS Assay Kit (ThermoFisher) according to manufacturers’ instruction. Quality and size distribution of extracted RNA was determined on an Agilent Bioanalyzer 2100 using either the RNA 6000 Nano Kit or RNA 6000 Pico Kit (Agilent).</div></section><section id="sec-4-4-15"><h4>TCR sequencing</h4><div id="p0380" role="paragraph">Bulk TCR sequencing was performed on RNA samples extracted from patient FFPE tumor blocks and CD3<sup>+</sup> T&nbsp;cell enriched PBMCs. Up to 1 ug of RNA was submitted to iRepertoire for targeted TCR sequencing (<span class="dropBlock reference-citations"><a id="body-ref-sref73" href="#" role="doc-biblioref" data-xml-rid="bib73" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref73" aria-controls="sref73">Wang et&nbsp;al., 2010</a><div class="dropBlock__holder" data-db-target-of="sref73"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">76.</div><div>Wang, C. ∙ Sanders, C.M. ∙ Yang, Q. ...</div><div><strong>High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T&nbsp;cell subsets</strong></div><div><em>Proc. Natl. Acad. Sci. USA.</em> 2010; <strong>107</strong>:1518-1523</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0913939107" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_76_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-76549090763" target="_blank" aria-label="Open Scopus in new tab">Scopus (220)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20080641/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.0913939107&amp;pmid=20080641" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) or processed according to iRepertoire protocol and sequenced using Illumina sequencers at a depth of ∼1 million reads per sample. BCL files were converted to FASTQ format. The first three bases of each read were trimmed, and the samples were then demultiplexed using either through the Illumina built-in software or the fastq-multx function from the ea-utils package (<span class="dropBlock reference-citations"><a id="body-ref-sref5" href="#" role="doc-biblioref" data-xml-rid="bib5" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref5" aria-controls="sref5">Aronesty, 2011</a><div class="dropBlock__holder" data-db-target-of="sref5"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">4.</div><div>Aronesty, E.</div><div><em>ea-utils: “Command-line tools for processing biological sequencing data.</em>GitHub, 2011</div><div><a id="interref0395" href="https://expressionanalysis.github.io/ea-utils/" target="_blank">https://expressionanalysis.github.io/ea-utils/</a></div></div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=E.Aronestyea-utils%3A+%E2%80%9CCommand-line+tools+for+processing+biological+sequencing+data2011GitHubhttps%3A%2F%2Fexpressionanalysis.github.io%2Fea-utils%2F" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). TCR repertoire data were generated from raw demultiplexed data using MiXCR, version 3.0.12, (<span class="dropBlock reference-citations"><a id="body-ref-sref12-2" href="#" role="doc-biblioref" data-xml-rid="bib12" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref12-2" aria-controls="sref12-2">Bolotin et&nbsp;al., 2015</a><div class="dropBlock__holder" data-db-target-of="sref12-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">12.</div><div>Bolotin, D.A. ∙ Poslavsky, S. ∙ Mitrophanov, I. ...</div><div><strong>MiXCR: software for comprehensive adaptive immunity profiling</strong></div><div><em>Nat. Methods.</em> 2015; <strong>12</strong>:380-381</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nmeth.3364" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_12_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928898852" target="_blank" aria-label="Open Scopus in new tab">Scopus (979)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25924071/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnmeth.3364&amp;pmid=25924071" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Analysis of TCR repertoire characteristics and features was performed in the R environment for statistical computing. Unless specifically stated, analyses were performed on the amino acid (AA) TCRbeta-CDR3 clonotypes, aggregating counts from various nucleotide CDR3 sequences encoding the same AA CDR3. Non-functional (out-of-frame or containing stop codons) CDR3 were excluded.</div><div id="p0385" role="paragraph">The unbiased gini coefficient, indicating the inequality in the AA CDR3 frequency distribution, was calculated using the “Gini” function from the DescTools package (<span class="dropBlock reference-citations"><a id="body-ref-sref4-2" href="#" role="doc-biblioref" data-xml-rid="bib4" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref4-2" aria-controls="sref4-2">Signorell et&nbsp;al., 2016</a><div class="dropBlock__holder" data-db-target-of="sref4-2"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">67.</div><div>Signorell, A. ∙ Aho, K.A. ∙ Alfons, A. ...</div><div><strong>DescTools: tools for descriptive statistics</strong></div><div>2016</div><div><a id="intref0065" href="https://rdrr.io/cran/DescTools/man/DescTools-package.html" target="_blank">https://rdrr.io/cran/DescTools/man/DescTools-package.html</a></div></div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=A.SignorellK.A.AhoA.AlfonsN.AndereggT.AragonA.ArppeA.BaddeleyK.BartonB.BolkerH.W.BorchersDescTools%3A+tools+for+descriptive+statistics2016https%3A%2F%2Frdrr.io%2Fcran%2FDescTools%2Fman%2FDescTools-package.html" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>), using the counts of all detected functional AA CDR3 clonotypes in each sample. The unbiased gini coefficient ranges from “0” (complete equality) to “1” (complete inequality).</div><div id="p0390" role="paragraph">The DE50 coefficient, a diversity and clonality index representing the minimal number of clones to cover half of the overall frequency space, was calculated by ranking the clones based on their AA CDR3 frequency from high to low. The rank of the clone was then obtained at which the cumulative frequency reaches 50% of the total sum of repertoire frequencies with low numbers indicating high clonality. The DE50 is the obtained rank divided by the maximal rank of the sample (the number of unique AA CDR3 clonotypes).</div><div id="p0395" role="paragraph">For single-cell TCR sequencing (scTCRseq), patient PBMCs were sorted in 96-well plates either based on tetramer staining or staining with T&nbsp;cell activation markers (CD69, CD107a, CD25, PD-1) after neoantigen peptide exposure for 5-6&nbsp;days and recall for 6-24h. Final sort gates for neoantigen-reactive subpopulations were determined based on control tetramer staining or control cocultures with DMSO. Plates were submitted to iRepertoire for scTCRseq (iPair-TCR). Paired sequencing information was used to determine clonal composition of sorted cell populations and candidate alpha/beta chain pairs were tested for neoantigen-reactivity after lentivirus-based T&nbsp;cell transductions (<span class="dropBlock reference-citations"><a id="body-ref-sref8" href="#" role="doc-biblioref" data-xml-rid="bib8" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref8" aria-controls="sref8">Banu et&nbsp;al., 2014</a><div class="dropBlock__holder" data-db-target-of="sref8"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">7.</div><div>Banu, N. ∙ Chia, A. ∙ Ho, Z.Z. ...</div><div><strong>Building and optimizing a virus-specific T&nbsp;cell receptor library for targeted immunotherapy in viral infections</strong></div><div><em>Sci. Rep.</em> 2014; <strong>4</strong>:4166</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep04166" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84894754369" target="_blank" aria-label="Open Scopus in new tab">Scopus (22)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24566718/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fsrep04166&amp;pmid=24566718" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>)</div></section><section id="sec-4-4-16"><h4>Cloning of neoantigen-specific TCRs</h4><div id="p0400" role="paragraph">Second generation lentivirus vectors were generated on 293FT producer cell lines using shuttle plasmids (GenScript) containing TCR beta and alpha chains under the control of a SFFV promoter and separated by a furin cleavage site and a P2A ribosomal skip sequence. Human TCR variable regions were fused to cysteine-modified mouse constant regions for both chains resulting in recombinant mTCR (<span class="dropBlock reference-citations"><a id="body-ref-sref22" href="#" role="doc-biblioref" data-xml-rid="bib22" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref22" aria-controls="sref22">Cohen et&nbsp;al., 2006</a><div class="dropBlock__holder" data-db-target-of="sref22"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">22.</div><div>Cohen, C.J. ∙ Zhao, Y. ∙ Zheng, Z. ...</div><div><strong>Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability</strong></div><div><em>Cancer Res.</em> 2006; <strong>66</strong>:8878-8886</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/0008-5472.CAN-06-1450" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_22_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-33749005425" target="_blank" aria-label="Open Scopus in new tab">Scopus (360)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16951205/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1158%2F0008-5472.CAN-06-1450&amp;pmid=16951205" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>; <span class="dropBlock reference-citations"><a id="body-ref-sref42" href="#" role="doc-biblioref" data-xml-rid="bib42" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref42" aria-controls="sref42">Kuball et&nbsp;al., 2007</a><div class="dropBlock__holder" data-db-target-of="sref42"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">42.</div><div>Kuball, J. ∙ Dossett, M.L. ∙ Wolfl, M. ...</div><div><strong>Facilitating matched pairing and expression of TCR chains introduced into human T&nbsp;cells</strong></div><div><em>Blood.</em> 2007; <strong>109</strong>:2331-2338</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-05-023069" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_42_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-33947217494" target="_blank" aria-label="Open Scopus in new tab">Scopus (289)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17082316/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2006-05-023069&amp;pmid=17082316" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). Neoantigen-reactivity of mTCR Jurkat cells was determined by IL-2 secretion measured by electrochemiluminescence (MSD) in 24h co-culture assays of mTCR transduced Jurkat cells with neoantigen peptide and allele matched antigen presenting cell lines or CD3<sup>+</sup> T&nbsp;cell depleted autologous patient PBMCs. Cytotoxicity of recombinant mTCR transduced PBMCs was assessed based on CD107a surface staining of effector cells and activated caspase-3 staining of target cells.</div></section><section id="sec-4-4-17"><h4>Cytotoxicity assay</h4><div id="p0405" role="paragraph">A375 target cells (ATCC) that were HLA-matched to the patient peptide of interest were harvested and plated in DMEM, high glucose, GlutaMAX Supplement, pyruvate (Thermo Fisher) supplemented with 10% FBS (Corning) at a density of 100,000 cells/well in a 96-well plate. The following day, the A375 cells were loaded with EPT length peptides (either containing the mutation or wild-type) by replacing the media in the wells with fresh AIM V Medium (GIBCO) containing peptide at a 2&nbsp;μM final concentration. Patient PBMCs from the pre-treatment time point were enriched for CD3<sup>+</sup> T&nbsp;cells using the Pan T Cell Isolation Kit (Miltenyi). Isolated CD3<sup>+</sup> T&nbsp;cells were transduced with neoantigen-specific TCRs and cocultured with target A375 cells at varying effector:target ratios for a period of 6 or 24h.</div></section><section id="sec-4-4-18"><h4>Gene expression</h4><div id="p0410" role="paragraph">Targeted gene expression analysis on total RNA extracted from FFPE blocks was performed using the NanoString nCounter platform (NanoString Technologies). A custom code set consisting of 800 genes, including markers for immune cell populations, cytolytic markers, immune activation and suppression, and the tumor microenvironment, was used. For each sample, either 50ng or 100ng of total RNA was hybridized with the custom gene expression code set for 16h at 65°C according to the manufacturer’s protocol. Hybridized samples were run on the NanoString nCounter SPRINT Profiler instrument (NanoString Technologies). Raw data was normalized to the 30 housekeeping genes included in the custom code set using the nSolver software (version 3.0). Modified PanCancer IO360 gene signature scores were calculated and provided by NanoString Technologies. Additional gene signature scores were calculated in house using normalized gene expression.</div></section><section id="sec-4-4-19"><h4>APOE Genotyping</h4><div id="p0415" role="paragraph">To assess the APOE genotype from patients, whole exome sequencing data (aligned to hg19) was queried for allele frequencies using pysam (v0.15.2)(<span class="dropBlock reference-citations"><a id="body-ref-optbvc1xdzVq0" href="#" role="doc-biblioref" data-xml-rid="bib77" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="optbvc1xdzVq0" aria-controls="optbvc1xdzVq0">Li et al., 2009</a><div class="dropBlock__holder" data-db-target-of="optbvc1xdzVq0"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">47.</div><div>Li, H. ∙ Handsaker, B. ∙ Wysoker, A. ..., 1000 Genome Project Data Processing Subgroup</div><div><strong>The Sequence Alignment/Map format and SAMtools</strong></div><div><em>Bioinformatics.</em> 2009; <strong>25</strong>:2078-2079</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btp352" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_47_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-68549104404" target="_blank" aria-label="Open Scopus in new tab">Scopus (37568)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19505943/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtp352&amp;pmid=19505943" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) at genomic locations chr19:45411941 (site A) and chr19:45412079 (site B) as determined in Atherosclerosis Risk in Communities (ARIC) study (<span class="dropBlock reference-citations"><a id="body-ref-optYxgDn5lAF7" href="#" role="doc-biblioref" data-xml-rid="bib78" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="optYxgDn5lAF7" aria-controls="optYxgDn5lAF7">Blair et al., 2005</a><div class="dropBlock__holder" data-db-target-of="optYxgDn5lAF7"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">10.</div><div>Blair, C.K. ∙ Folsom, A.R. ∙ Knopman, D.S. ...</div><div><strong>APOE genotype and cognitive decline in a middle-aged cohort</strong></div><div><em>Neurology.</em> 2005; <strong>64</strong>:268-276</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/01.WNL.0000149643.91367.8A" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_10_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-12544259479" target="_blank" aria-label="Open Scopus in new tab">Scopus (120)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15668424/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1212%2F01.WNL.0000149643.91367.8A&amp;pmid=15668424" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>). APOE E4 genotype was assigned if site A and B were both homozygous for cytosine.</div></section><section id="sec-4-4-20"><h4>Immunohistochemistry</h4><div id="p0420" role="paragraph">For each patient FFPE tumor block, histological and immunohistochemical analysis was done at Mosaic Laboratories (Lake Forest, CA). H&amp;E analysis was performed according to Mosaic Laboratories’ optimized protocols and reviewed for cellular quality, morphology, and presence of tumor by an independent pathologist. Immunohistochemical analysis for PD-L1 (DAKO kit, MOS504-APD) was performed according to Mosaic Laboratories’ optimized protocols. Staining was evaluated using ImageScope software and standard pathology review. PD-L1 staining was evaluated using scoring criteria provided by Bristol-Myers Squibb.</div><div id="p0425" role="paragraph">Immunohistochemistry for CD3 was performed on 5μm FFPE tumor sections. Slides were baked at 60°C overnight, dewaxed and rehydrated. Antigen retrieval was performed using a microwave (MWT) with antigen retrieval buffer (citric acid based, pH 6.0, Vector Labs) heated to 90°C for 15min. After cooling to room temperature (RT), slides were washed with TBST/0.5% Tween and blocked for 10min with Akoya blocking buffer (Akoya Biosciences). Primary antibody CD3 (Biocare Medical, clone LN10, 1:100) was incubated at RT for 30min. Slides were washed and incubated with HRP-conjugated secondary antibody diluted 1:1 in TBS for 30min (Vector Labs). CD3 was visualized with ImmPACT Vector Red chromogenic staining.</div></section><section id="sec-4-4-21"><h4>Multiplex IHC staining protocol</h4><div id="p0430" role="paragraph">Manual multiplex immunofluorescence (mIF) staining was performed on 5μm FFPE tumor sections using the TSA Plus Fluorescence kit (Akoya Biosciences). Slides were baked at 60°C overnight, dewaxed and rehydrated. Antigen retrieval was performed using a microwave (MWT) with antigen retrieval buffer (citric acid based, pH 6.0, Vector Labs) heated to 90°C for 15min. After cooling to room temperature (RT), slides were washed with TBST/0.5% Tween and incubated with 3% H<sub>2</sub>O<sub>2</sub> for 15min. Next, slides were blocked with 2% BSA, 5% NHS in TBST for 1h. Primary antibody TCF7 (Cell Signal Technology, clone C6D9, 1:50) was incubated at RT for 1h. Slides were washed and incubated with HRP-conjugated secondary antibody diluted 1:1 in TBS for 30min (Vector Labs). TCF7 was visualized with TSA Cy5 (1:50) for 10&nbsp;min.</div><div id="p0435" role="paragraph">Multiplex staining was performed by repeating staining cycles with MWT heating between each step to remove the antibody complex. Successive antibodies include: CD8 (Biocare Medical, clone SP16, 1:100, TSA plus Cy3) and S100 (Biocare Medical, clone 15E2E2&amp;4C4.9, 1:100, TSA Fluorescein) each incubated for 30min. Secondary HRP antibodies were diluted 1:1 with TBS and incubated for 30min (Vector Labs). Nuclei were stained with DAPI 1:3000 for 10min (Fisher Scientific), washed and mounted with Prolong gold (Fisher Scientific). Human tonsil FFPE tissues were used with and without primary antibodies to serve as positive and negative (autofluorescence) controls.</div></section></section><section id="sec-4-5"><h3>Quantification and Statistical Analysis</h3><section id="sec-4-5-1"><h4>Multispectral analysis</h4><div id="p0440" role="paragraph">The multiplex slides were scanned with a Vectra 3.0 microscope system (Perkin Elmer). Whole slide scans were performed using the 10x objective lens. Up to ten individual fields were selected in the Phenochart program (Phenochart 1.0.9, Perkin Elmer) for higher resolution scanning at 20x (669x500&nbsp;μm). Multispectral images were unmixed and analyzed using inForm software (inForm 2.4.2, Perkin Elmer) and analyzed with tissue component segmentation based on tumor cell staining: tumor&nbsp;= S100+ regions and stroma&nbsp;= S100- regions. Individual cells (defined by DAPI positive nuclei) were then phenotyped to characterize various cell populations. Density of cells in each ROI was calculated by combining the cell counts from all images and normalizing by the total area (cells/mm<sup>2</sup>).</div></section><section id="sec-4-5-2"><h4>Statistical analysis</h4><div id="p0445" role="paragraph">Anti-tumor activity was assessed for objective response rate (ORR), duration of response (DOR), progression free survival (PFS) and overall survival (OS). ORR is defined as the proportion of patients who achieve CR or PR based on RECIST v1.1. DOR is defined as the date of the first documented confirmed response to the date of the first documented PD or death. PFS is defined as the time from the date of first dosing to the date of first documented PD or death. OS is defined from the date of enrollment to death. Statistical efficacy analyses were performed separately for each indication for both the ITT set defined as receiving at least one dose of nivolumab and the safety set defined as receiving at least one dose of vaccine. The Kaplan–Meier method was used to estimate PFS and OS. For PFS, patients who did not have PFS event on study or who were lost to follow-up were censored at the time of last tumor assessment. For OS, patients who were alive or who were lost to follow-up were censored at the last record on database.</div><div id="p0450" role="paragraph">All other analyses were performed in either the R language and environment for statistical computing (version 3.5.1) or GraphPad Prism (version 7.01). Likewise, all figures were created using an R script on the “ggplot2” package (<span class="dropBlock reference-citations"><a id="body-ref-sref74" href="#" role="doc-biblioref" data-xml-rid="bib74" href-manipulated="true" class="reference-citations__ctrl" aria-expanded="false" data-db-target-for="sref74" aria-controls="sref74">Wickham, 2016</a><div class="dropBlock__holder" data-db-target-of="sref74"><div class="dropBlock__body__outer"><div class="dropBlock__body"><div class="citation"><div class="citation-content"><div class="citation-content"><div class="label">77.</div><div>Wickham, H.</div><div><strong>ggplot2: Elegant Graphics for Data Analysis</strong></div><div>Springer, 2016</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/978-3-319-24277-4" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1007%2F978-3-319-24277-4" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><button class="dropBlock__ctrl--close" title="Close info" aria-label="close info"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 70 128" height="24" width="14"><path d="M68.94 36.12L62 29 35 56 8 29l-7 7 27 27L1 90l7 7 27-27 27 27 7-7-27-27 26.94-26.88"></path></svg></button></div></div></span>) or GraphPad Prism. Unless otherwise specified, p values were derived from a two-tailed Student’s t test.</div></section></section><section id="sec-4-6"><h3>Additional Resources</h3><div id="p0455" role="paragraph">All data presented in this manuscript is from the multicenter phase I clinical trial NCT02897765. <a id="intref0055" href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a></div></section></section><section id="acknowledgments" role="doc-acknowledgments"><h2>Acknowledgments</h2><div id="p0460" role="paragraph">We thank all of the patients and their families who participated in the study. We are grateful to all of the members of Neon Therapeutics/BioNTech US for support of and assistance in the study. We thank April Lamb and Jennifer Tepper for clinical operations; Marc Wolfgang, Scott White, Stephen Crimlisk, and Yeimy Garcia for technical operations; Jonathan McGee, Brian Sullivan, Daniel Kallin, Jeff Zhang, Amanda Aldous, and Robyn Eisert for peptide synthesis and manufacturing process development; Janani Sridar and Paul Turcott for tetramer reagent generation; Myranda Maynard and Sagar Chhangawala for bioinformatics support; Kerry Chios and John Curran for lab operation support and biobank management; and Hugh O’Dowd for support and guidance on the study. We thank Bristol-Myers Squibb for the nivolumab supply. The study was sponsored by Neon Therapeutics/BioNTech US. This manuscript is dedicated to our late colleague, Ying Sonia Ting.</div><section id="sec-5"><h3>Author Contributions</h3><div id="p0465" role="paragraph">Conceptualization and Implementation of the Study, P.A.O., L.S., R.G., E.F., and J.G. Clinical Investigators on the Study, P.A.O., S.H.-L., B.C., R.G., A.N., N.B., K.M., M.M.A., M.D.H., J.J.L., and T.F. Biomarker and Sequencing Analysis, M.E.B., K.N.B., T.E.S., A.P., D.H., Y.S.T., and M.S.R. Patient Immune Analysis, V.K., S.J.T., R.B., R.R.C., K.N.B., and B.T. TCR Sequencing and Analysis, R.B., J.S., A.P., and Y.S.T. Peptide Synthesis and Purification, J.Z.D., Y.W., and Y.H. Tetramer Reagent Generation, D.B. Informatics Support and Clinical Data Management, Z.H. and A.W. Clinical Operations and Program Management, L.D.C., M.A.M., and K.M. Biostatistics Support, J.G. and Z.S.K. Medical Monitor on the Study, M.D. Manuscript Preparation (with input from all of the authors), P.A.O., L.S., R.B.G., M.D., Z.S.K., and M.S.R.</div></section><section id="sec-6"><h3>Declaration of Interests</h3><div id="p0470" role="paragraph">P.A.O.: research funding paid to the institution—Bristol-Myers Squibb, Merck, AstraZeneca, Celldex, CytomX, GlaxoSmithKline, ARMO Biosciences, Neon Therapeutics; consultant—Array, Bristol-Myers Squibb, Merck, Genentech, Pfizer, Novartis, Neon Therapeutics, CytomX, Celldex.</div><div id="p0475" role="paragraph">S.H.-L.: consultant—Amgen, Bristol-Myers Squibb, Genmab, Xencor; research support—Bristol-Myers Squibb, Merck, and Vaccinex.</div><div id="p0480" role="paragraph">B.C.: member of the speakers’ bureaus for Regeneron and Sanofi.</div><div id="p0485" role="paragraph">R.G.: advisory board member—Achilles; consultant—Horizon Pharma (spouse), GenePlus.</div><div id="p0490" role="paragraph">A.N.: research funding from NCI, EMD Serono, MedImmune, Healios Oncology Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Eli Lilly, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Kymab, PsiOxus, and Immune Deficiency Foundation (spouse); advisory board member—CytomX Therapeutics, Novartis, Kymab, and Genome; travel and accommodation expense—ARMO BioSciences.</div><div id="p0495" role="paragraph">N.B.: scientific advisory board member—Checkpoint Sciences, Curevac, Primevax, Novartis, Avidea, BI, Rome Therapeutics, Neon Therapeutics, Roche, and Genentech. Extramural member of the Parker Institute for Cancer Immunotherapy</div><div id="p0500" role="paragraph">K.M.: advisory boards or consultant—Nektar, ImaginAb, Neoleukin, and Akrevia; DSMB—IOvance.</div><div id="p0505" role="paragraph">M.M.A.: research grants—Genentech, Bristol-Myers Squibb, AstraZeneca, Lilly; consultant—Genentech, Bristol-Myers Squibb, AstraZeneca, Merck, Maverick, Blueprint Medicine, Syndax, Ariad, Nektar, Gritstone, and Neon Therapeutics</div><div id="p0510" role="paragraph">M.D.H.: research funding—Bristol-Myers Squibb; consultant—Merck, Bristol-Myers Squibb, AstraZeneca, Genentech/Roche, Nektar, Syndax, Mirati, Blueprint, Immunai, and Shattuck Labs; travel support/honoraria—AstraZeneca, Eli Lilly, Merck, and Bristol-Myers Squibb; and a patent has been filed by MSK related to the use of tumor mutation burden to predict the response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx.</div><div id="p0515" role="paragraph">J.J.L.: honoraria/consultant—Pfizer, C4 Therapeutics, Nuvalent, and Genentech; institutional research funding—Neon, Hengrui Therapeutics, Turning Point Therapeutics, and Novartis; travel fees—Pfizer; CME funding—OncLive.</div><div id="p0520" role="paragraph">T.F.: research funding—Janssen; research funding to the institute—Seattle Genetics, Incyte, Bristol-Myers Squibb, Neon Therapeutics, and Roche/Genentech.</div><div id="p0525" role="paragraph">R.B.G.: board of directors—Alkermes plc and Infinity Pharmaceuticals; scientific advisory board—Leap Therapeutics; stockholder and employee—Neon Therapeutics/BioNTech US.</div><div id="p0530" role="paragraph">Stockholder and either current or past employees of Neon Therapeutics/BioNTech US: M.E.B., K.N.B., T.E.S., V.K., S.J.T., R.B., R.R.C., B.T., J.S., A.P., D.H., D.B., Y.S.T., J.Z.D., Y.W., Y.H., Z.H., A.W., L.D.C., M.A.M., K.M., J.G., Z.S.K., M.S.R., M.D., E.F., and L.S.</div></section></section><section id="supplementary-material" data-type="supplementary-materials"><h2>Supplemental Information (2)</h2><div id="p0540" role="paragraph"><div class="core-supplementary-material"><div class="core-link"><button class="downloadAllSupplementary"><span>Download all</span></button></div></div><div id="mmc1" class="core-supplementary-material" data-category="pdf"><div class="core-link"><a href="/cms/10.1016/j.cell.2020.08.053/attachment/3efd16d5-bed8-43f4-a062-8c5f095482ae/mmc1.pdf" download="mmc1.pdf" aria-labelledby="mmc1-heading mmc1-link"><span id="mmc1-link">PDF (374.93 KB)</span></a></div><div class="core-description"><div id="mmc1-heading" class="heading">Document S1. Tables S1–S7</div></div></div><div id="mmc2" class="core-supplementary-material" data-category="spreadsheet"><div class="core-link"><a href="/cms/10.1016/j.cell.2020.08.053/attachment/a076963d-14fa-4283-9dae-d1a7ee23c39a/mmc2.xlsx" download="mmc2.xlsx" aria-labelledby="mmc2-heading mmc2-link"><span id="mmc2-link">Spreadsheet (184.40 KB)</span></a></div><div class="core-description"><div id="mmc2-heading" class="heading">Table S8. Vaccine and Immune Assay Peptide (IAP) Sequences Used in the Study; Additional Information, Related to STAR Methods</div><div id="espara0010" role="paragraph">All peptide sequences are denoted in the table. Tab labeled vaccine peptide of the excel file lists the vaccine/immunizing peptides for all patients and subsequent tabs list the immune assay peptides for each patient in a separate tab.</div></div></div></div></section></div></section><div class="core-linked-content">
    

        

</div><section id="backmatter" data-extent="backmatter"><div class="core-container"><section id="references"><h2>References</h2><div id="bibliography" role="doc-bibliography"><div role="list"><div role="listitem" data-has="label"><div id="bib1" class="citations"><div id="sref1" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref1-1" title="View in article">1.</a></div><div>Abelin, J.G. ∙ Keskin, D.B. ∙ Sarkizova, S. ...</div><div><strong>Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction</strong></div><div><em>Immunity.</em> 2017; <strong>46</strong>:315-326</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2017.02.007&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_1_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85013878753" target="_blank" aria-label="Open Scopus in new tab">Scopus (408)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28228285/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2017.02.007&amp;pmid=28228285" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib2" class="citations"><div id="sref2" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref2-1" title="View in article">2.</a></div><div>Abelin, J.G. ∙ Harjanto, D. ∙ Malloy, M. ...</div><div><strong>Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction</strong></div><div><em>Immunity.</em> 2019; <strong>51</strong>:766-779.e17</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2019.08.012&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.immuni.2019.08.012&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_2_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85073037953" target="_blank" aria-label="Open Scopus in new tab">Scopus (154)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31495665/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.immuni.2019.08.012&amp;pmid=31495665" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib3" class="citations"><div id="sref3" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref3" title="View in article">3.</a></div><div>Alspach, E. ∙ Lussier, D.M. ∙ Miceli, A.P. ...</div><div><strong>MHC-II neoantigens shape tumour immunity and response to immunotherapy</strong></div><div><em>Nature.</em> 2019; <strong>574</strong>:696-701</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1671-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_3_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85074223743" target="_blank" aria-label="Open Scopus in new tab">Scopus (490)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31645760/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1671-8&amp;pmid=31645760" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib5" class="citations"><div id="sref5" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref5" title="View in article">4.</a></div><div>Aronesty, E.</div><div><em>ea-utils: “Command-line tools for processing biological sequencing data.</em>GitHub, 2011</div><div><a id="interref0395" href="https://expressionanalysis.github.io/ea-utils/" target="_blank">https://expressionanalysis.github.io/ea-utils/</a></div></div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=E.Aronestyea-utils%3A+%E2%80%9CCommand-line+tools+for+processing+biological+sequencing+data2011GitHubhttps%3A%2F%2Fexpressionanalysis.github.io%2Fea-utils%2F" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib6" class="citations"><div id="sref6" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref6-1" title="View in article">5.</a></div><div>Ayers, M. ∙ Lunceford, J. ∙ Nebozhyn, M. ...</div><div><strong>IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade</strong></div><div><em>J.&nbsp;Clin. Invest.</em> 2017; <strong>127</strong>:2930-2940</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI91190" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_5_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85026675148" target="_blank" aria-label="Open Scopus in new tab">Scopus (2322)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28650338/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1172%2FJCI91190&amp;pmid=28650338" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib7" class="citations"><div id="sref7" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref7-1" title="View in article">6.</a></div><div>Balar, A.V. ∙ Galsky, M.D. ∙ Rosenberg, J.E. ..., IMvigor210 Study Group</div><div><strong>Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial</strong></div><div><em>Lancet.</em> 2017; <strong>389</strong>:67-76</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2816%2932455-2&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2816%2932455-2&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_6_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85007564166" target="_blank" aria-label="Open Scopus in new tab">Scopus (1629)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27939400/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2816%2932455-2&amp;pmid=27939400" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib8" class="citations"><div id="sref8" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref8" title="View in article">7.</a></div><div>Banu, N. ∙ Chia, A. ∙ Ho, Z.Z. ...</div><div><strong>Building and optimizing a virus-specific T&nbsp;cell receptor library for targeted immunotherapy in viral infections</strong></div><div><em>Sci. Rep.</em> 2014; <strong>4</strong>:4166</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep04166" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_7_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84894754369" target="_blank" aria-label="Open Scopus in new tab">Scopus (22)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24566718/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fsrep04166&amp;pmid=24566718" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib9" class="citations"><div id="sref9" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref9-1" title="View in article">8.</a></div><div>Bellmunt, J. ∙ de Wit, R. ∙ Vaughn, D.J. ..., KEYNOTE-045 Investigators</div><div><strong>Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>376</strong>:1015-1026</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1613683" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_8_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85015755043" target="_blank" aria-label="Open Scopus in new tab">Scopus (2522)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28212060/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1613683&amp;pmid=28212060" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib10" class="citations"><div id="sref10" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref10" title="View in article">9.</a></div><div>Betts, M.R. ∙ Brenchley, J.M. ∙ Price, D.A. ...</div><div><strong>Sensitive and viable identification of antigen-specific CD8+ T&nbsp;cells by a flow cytometric assay for degranulation</strong></div><div><em>J.&nbsp;Immunol. Methods.</em> 2003; <strong>281</strong>:65-78</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0022-1759(03)00265-5" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_9_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-0142185336" target="_blank" aria-label="Open Scopus in new tab">Scopus (1341)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14580882/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0022-1759%2803%2900265-5&amp;pmid=14580882" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib78" class="citations"><div id="optYxgDn5lAF7" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-optYxgDn5lAF7" title="View in article">10.</a></div><div>Blair, C.K. ∙ Folsom, A.R. ∙ Knopman, D.S. ...</div><div><strong>APOE genotype and cognitive decline in a middle-aged cohort</strong></div><div><em>Neurology.</em> 2005; <strong>64</strong>:268-276</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/01.WNL.0000149643.91367.8A" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_10_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-12544259479" target="_blank" aria-label="Open Scopus in new tab">Scopus (120)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15668424/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1212%2F01.WNL.0000149643.91367.8A&amp;pmid=15668424" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib11" class="citations"><div id="sref11" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref11" title="View in article">11.</a></div><div>Blank, C.U. ∙ Rozeman, E.A. ∙ Fanchi, L.F. ...</div><div><strong>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</strong></div><div><em>Nat. Med.</em> 2018; <strong>24</strong>:1655-1661</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0198-0" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_11_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85054564616" target="_blank" aria-label="Open Scopus in new tab">Scopus (582)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30297911/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-018-0198-0&amp;pmid=30297911" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib12" class="citations"><div id="sref12" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref12-1" title="View in article">12.</a></div><div>Bolotin, D.A. ∙ Poslavsky, S. ∙ Mitrophanov, I. ...</div><div><strong>MiXCR: software for comprehensive adaptive immunity profiling</strong></div><div><em>Nat. Methods.</em> 2015; <strong>12</strong>:380-381</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nmeth.3364" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_12_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928898852" target="_blank" aria-label="Open Scopus in new tab">Scopus (979)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25924071/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnmeth.3364&amp;pmid=25924071" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib13" class="citations"><div id="sref13" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref13-1" title="View in article">13.</a></div><div>Borghaei, H. ∙ Paz-Ares, L. ∙ Horn, L. ...</div><div><strong>Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2015; <strong>373</strong>:1627-1639</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1507643" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_13_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84944937210" target="_blank" aria-label="Open Scopus in new tab">Scopus (7626)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib14" class="citations"><div id="sref14" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref14-1" title="View in article">14.</a></div><div>Haas, B.J. ∙ Dobin, A. ∙ Stransky, N. ...</div><div><strong>STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq</strong></div><div><em>bioRxiv.</em> 2017;</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/120295" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_14_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85095631683" target="_blank" aria-label="Open Scopus in new tab">Scopus (0)</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2F120295" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib15" class="citations"><div id="sref15" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref15-1" title="View in article">15.</a></div><div>Carbone, D.P. ∙ Reck, M. ∙ Paz-Ares, L. ..., CheckMate 026 Investigators</div><div><strong>First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>376</strong>:2415-2426</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1613493" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_15_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85020964772" target="_blank" aria-label="Open Scopus in new tab">Scopus (1990)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28636851/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1613493&amp;pmid=28636851" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib16" class="citations"><div id="sref16" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref16-1" title="View in article">16.</a></div><div>Carreno, B.M. ∙ Magrini, V. ∙ Becker-Hapak, M. ...</div><div><strong>Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T&nbsp;cells</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:803-808</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa3828" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_16_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928195112" target="_blank" aria-label="Open Scopus in new tab">Scopus (966)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25837513/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa3828&amp;pmid=25837513" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib17" class="citations"><div id="sref17" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref17" title="View in article">17.</a></div><div>Carter, S.L. ∙ Cibulskis, K. ∙ Helman, E. ...</div><div><strong>Absolute quantification of somatic DNA alterations in human cancer</strong></div><div><em>Nat. Biotechnol.</em> 2012; <strong>30</strong>:413-421</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nbt.2203" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_17_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84860782006" target="_blank" aria-label="Open Scopus in new tab">Scopus (1404)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22544022/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnbt.2203&amp;pmid=22544022" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib18" class="citations"><div id="sref18" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref18-1" title="View in article">18.</a></div><div>Challis, D. ∙ Yu, J. ∙ Evani, U.S. ...</div><div><strong>An integrative variant analysis suite for whole exome next-generation sequencing data</strong></div><div><em>BMC Bioinformatics.</em> 2012; <strong>13</strong>:8</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2105-13-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_18_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84855593661" target="_blank" aria-label="Open Scopus in new tab">Scopus (206)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22239737/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2105-13-8&amp;pmid=22239737" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib19" class="citations"><div id="sref19" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref19-1" title="View in article">19.</a></div><div>Christoforides, A. ∙ Carpten, J.D. ∙ Weiss, G.J. ...</div><div><strong>Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs</strong></div><div><em>BMC Genomics.</em> 2013; <strong>14</strong>:302</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2164-14-302" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_19_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84876963318" target="_blank" aria-label="Open Scopus in new tab">Scopus (65)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23642077/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2164-14-302&amp;pmid=23642077" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib20" class="citations"><div id="sref20" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref20-1" title="View in article">20.</a></div><div>Cibulskis, K. ∙ McKenna, A. ∙ Fennell, T. ...</div><div><strong>ContEst: estimating cross-contamination of human samples in next-generation sequencing data</strong></div><div><em>Bioinformatics.</em> 2011; <strong>27</strong>:2601-2602</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btr446" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_20_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-80052707308" target="_blank" aria-label="Open Scopus in new tab">Scopus (191)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21803805/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtr446&amp;pmid=21803805" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib21" class="citations"><div id="sref21" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref21" title="View in article">21.</a></div><div>Cibulskis, K. ∙ Lawrence, M.S. ∙ Carter, S.L. ...</div><div><strong>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</strong></div><div><em>Nat. Biotechnol.</em> 2013; <strong>31</strong>:213-219</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nbt.2514" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_21_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84874025843" target="_blank" aria-label="Open Scopus in new tab">Scopus (3317)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23396013/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnbt.2514&amp;pmid=23396013" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib22" class="citations"><div id="sref22" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref22" title="View in article">22.</a></div><div>Cohen, C.J. ∙ Zhao, Y. ∙ Zheng, Z. ...</div><div><strong>Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability</strong></div><div><em>Cancer Res.</em> 2006; <strong>66</strong>:8878-8886</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/0008-5472.CAN-06-1450" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_22_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-33749005425" target="_blank" aria-label="Open Scopus in new tab">Scopus (360)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16951205/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1158%2F0008-5472.CAN-06-1450&amp;pmid=16951205" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib23" class="citations"><div id="sref23" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref23-1" title="View in article">23.</a></div><div>Corbière, V. ∙ Chapiro, J. ∙ Stroobant, V. ...</div><div><strong>Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases</strong></div><div><em>Cancer Res.</em> 2011; <strong>71</strong>:1253-1262</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/0008-5472.CAN-10-2693" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_23_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-79951848084" target="_blank" aria-label="Open Scopus in new tab">Scopus (152)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21216894/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1158%2F0008-5472.CAN-10-2693&amp;pmid=21216894" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib24" class="citations"><div id="sref24" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref24" title="View in article">24.</a></div><div>Cottrell, T.R. ∙ Thompson, E.D. ∙ Forde, P.M. ...</div><div><strong>Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)</strong></div><div><em>Ann. Oncol.</em> 2018; <strong>29</strong>:1853-1860</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_24_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1093%2Fannonc%2Fmdy218&amp;cf=fulltext&amp;site=annonc-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_24_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1093%2Fannonc%2Fmdy218&amp;cf=pdf&amp;site=annonc-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_24_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85055516713" target="_blank" aria-label="Open Scopus in new tab">Scopus (310)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29982279/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fannonc%2Fmdy218&amp;pmid=29982279" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib25" class="citations"><div id="sref25" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref25" title="View in article">25.</a></div><div>Cristescu, R. ∙ Mogg, R. ∙ Ayers, M. ...</div><div><strong>Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy</strong></div><div><em>Science.</em> 2018; <strong>362</strong>:eaar3593</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aar3593" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_25_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85054777584" target="_blank" aria-label="Open Scopus in new tab">Scopus (1457)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30309915/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aar3593&amp;pmid=30309915" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib26" class="citations"><div id="sref26" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref26" title="View in article">26.</a></div><div>Fairfax, B.P. ∙ Taylor, C.A. ∙ Watson, R.A. ...</div><div><strong>Peripheral CD8<sup>+</sup> T&nbsp;cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma</strong></div><div><em>Nat. Med.</em> 2020; <strong>26</strong>:193-199</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-019-0734-6" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_26_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85079320198" target="_blank" aria-label="Open Scopus in new tab">Scopus (184)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32042196/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-019-0734-6&amp;pmid=32042196" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib27" class="citations"><div id="sref27" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref27" title="View in article">27.</a></div><div>Garboczi, D.N. ∙ Hung, D.T. ∙ Wiley, D.C.</div><div><strong>HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides</strong></div><div><em>Proc. Natl. Acad. Sci. USA.</em> 1992; <strong>89</strong>:3429-3433</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.89.8.3429" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_27_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-0026529908" target="_blank" aria-label="Open Scopus in new tab">Scopus (579)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1565634/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.89.8.3429&amp;pmid=1565634" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib28" class="citations"><div id="sref28" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref28" title="View in article">28.</a></div><div>Gettinger, S.N. ∙ Choi, J. ∙ Mani, N. ...</div><div><strong>A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers</strong></div><div><em>Nat. Commun.</em> 2018; <strong>9</strong>:3196</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-018-05032-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_28_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85051529355" target="_blank" aria-label="Open Scopus in new tab">Scopus (131)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30097571/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41467-018-05032-8&amp;pmid=30097571" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib29" class="citations"><div id="sref29" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref29" title="View in article">29.</a></div><div>Havel, J.J. ∙ Chowell, D. ∙ Chan, T.A.</div><div><strong>The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy</strong></div><div><em>Nat. Rev. Cancer.</em> 2019; <strong>19</strong>:133-150</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41568-019-0116-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_29_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85061498033" target="_blank" aria-label="Open Scopus in new tab">Scopus (1509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30755690/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41568-019-0116-x&amp;pmid=30755690" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib30" class="citations"><div id="sref30" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref30" title="View in article">30.</a></div><div>Helmink, B.A. ∙ Reddy, S.M. ∙ Gao, J. ...</div><div><strong>B cells and tertiary lymphoid structures promote immunotherapy response</strong></div><div><em>Nature.</em> 2020; <strong>577</strong>:549-555</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1922-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_30_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85078126241" target="_blank" aria-label="Open Scopus in new tab">Scopus (1307)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31942075/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1922-8&amp;pmid=31942075" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib31" class="citations"><div id="sref31" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref31-1" title="View in article">31.</a></div><div>Herbst, R.S. ∙ Baas, P. ∙ Kim, D.W. ...</div><div><strong>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial</strong></div><div><em>Lancet.</em> 2016; <strong>387</strong>:1540-1550</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2815%2901281-7&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_31_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84950117835" target="_blank" aria-label="Open Scopus in new tab">Scopus (5239)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib32" class="citations"><div id="sref32" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref32-1" title="View in article">32.</a></div><div>Hilf, N. ∙ Kuttruff-Coqui, S. ∙ Frenzel, K. ...</div><div><strong>Actively personalized vaccination trial for newly diagnosed glioblastoma</strong></div><div><em>Nature.</em> 2019; <strong>565</strong>:240-245</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-018-0810-y" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_32_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85059762738" target="_blank" aria-label="Open Scopus in new tab">Scopus (603)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30568303/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-018-0810-y&amp;pmid=30568303" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib33" class="citations"><div id="sref33" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref33" title="View in article">33.</a></div><div>Hodi, F.S. ∙ Ballinger, M. ∙ Lyons, B. ...</div><div><strong>Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy</strong></div><div><em>J.&nbsp;Clin. Oncol.</em> 2018; <strong>36</strong>:850-858</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2017.75.1644" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_33_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85044243593" target="_blank" aria-label="Open Scopus in new tab">Scopus (264)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29341833/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2017.75.1644&amp;pmid=29341833" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib34" class="citations"><div id="sref34" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref34" title="View in article">34.</a></div><div>Hosoi, A. ∙ Takeda, K. ∙ Nagaoka, K. ...</div><div><strong>Increased diversity with reduced “diversity evenness” of tumor infiltrating T-cells for the successful cancer immunotherapy</strong></div><div><em>Sci. Rep.</em> 2018; <strong>8</strong>:1058</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41598-018-19548-y" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_34_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85040863881" target="_blank" aria-label="Open Scopus in new tab">Scopus (47)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29348598/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41598-018-19548-y&amp;pmid=29348598" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib35" class="citations"><div id="sref35" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref35" title="View in article">35.</a></div><div>Hu, Z. ∙ Ott, P.A. ∙ Wu, C.J.</div><div><strong>Towards personalized, tumour-specific, therapeutic vaccines for cancer</strong></div><div><em>Nat. Rev. Immunol.</em> 2018; <strong>18</strong>:168-182</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nri.2017.131" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_35_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85041594324" target="_blank" aria-label="Open Scopus in new tab">Scopus (704)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29226910/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnri.2017.131&amp;pmid=29226910" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib36" class="citations"><div id="sref36" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref36" title="View in article">36.</a></div><div>Huang, A.C. ∙ Orlowski, R.J. ∙ Xu, X. ...</div><div><strong>A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma</strong></div><div><em>Nat. Med.</em> 2019; <strong>25</strong>:454-461</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-019-0357-y" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_36_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85062071459" target="_blank" aria-label="Open Scopus in new tab">Scopus (436)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30804515/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41591-019-0357-y&amp;pmid=30804515" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib37" class="citations"><div id="sref37" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref37" title="View in article">37.</a></div><div>Jansen, C.S. ∙ Prokhnevska, N. ∙ Master, V.A. ...</div><div><strong>An intra-tumoral niche maintains and differentiates stem-like CD8 T&nbsp;cells</strong></div><div><em>Nature.</em> 2019; <strong>576</strong>:465-470</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1836-5" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_37_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85076588925" target="_blank" aria-label="Open Scopus in new tab">Scopus (450)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31827286/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1836-5&amp;pmid=31827286" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib38" class="citations"><div id="sref38" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref38-1" title="View in article">38.</a></div><div>Keskin, D.B. ∙ Anandappa, A.J. ∙ Sun, J. ...</div><div><strong>Neoantigen vaccine generates intratumoral T&nbsp;cell responses in phase Ib glioblastoma trial</strong></div><div><em>Nature.</em> 2019; <strong>565</strong>:234-239</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-018-0792-9" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_38_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85059785792" target="_blank" aria-label="Open Scopus in new tab">Scopus (901)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30568305/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-018-0792-9&amp;pmid=30568305" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib39" class="citations"><div id="sref39" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref39" title="View in article">39.</a></div><div>Kirsch, I. ∙ Vignali, M. ∙ Robins, H.</div><div><strong>T-cell receptor profiling in cancer</strong></div><div><em>Mol. Oncol.</em> 2015; <strong>9</strong>:2063-2070</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.molonc.2015.09.003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_39_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84952637397" target="_blank" aria-label="Open Scopus in new tab">Scopus (107)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26404496/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.molonc.2015.09.003&amp;pmid=26404496" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib40" class="citations"><div id="sref40" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref40-1" title="View in article">40.</a></div><div>Koboldt, D.C. ∙ Zhang, Q. ∙ Larson, D.E. ...</div><div><strong>VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing</strong></div><div><em>Genome Res.</em> 2012; <strong>22</strong>:568-576</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/gr.129684.111" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_40_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84863229597" target="_blank" aria-label="Open Scopus in new tab">Scopus (3360)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22300766/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2Fgr.129684.111&amp;pmid=22300766" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib41" class="citations"><div id="sref41" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref41-1" title="View in article">41.</a></div><div>Kreiter, S. ∙ Vormehr, M. ∙ van de Roemer, N. ...</div><div><strong>Mutant MHC class II epitopes drive therapeutic immune responses to cancer</strong></div><div><em>Nature.</em> 2015; <strong>520</strong>:692-696</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature14426" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_41_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928811341" target="_blank" aria-label="Open Scopus in new tab">Scopus (910)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25901682/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature14426&amp;pmid=25901682" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib42" class="citations"><div id="sref42" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref42" title="View in article">42.</a></div><div>Kuball, J. ∙ Dossett, M.L. ∙ Wolfl, M. ...</div><div><strong>Facilitating matched pairing and expression of TCR chains introduced into human T&nbsp;cells</strong></div><div><em>Blood.</em> 2007; <strong>109</strong>:2331-2338</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-05-023069" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_42_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-33947217494" target="_blank" aria-label="Open Scopus in new tab">Scopus (289)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17082316/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1182%2Fblood-2006-05-023069&amp;pmid=17082316" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib43" class="citations"><div id="sref43" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref43-1" title="View in article">43.</a></div><div>Lai, Z. ∙ Markovets, A. ∙ Ahdesmaki, M. ...</div><div><strong>VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research</strong></div><div><em>Nucleic Acids Res.</em> 2016; <strong>44</strong>:e108</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nar/gkw227" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_43_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84976448371" target="_blank" aria-label="Open Scopus in new tab">Scopus (509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27060149/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fnar%2Fgkw227&amp;pmid=27060149" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib44" class="citations"><div id="sref44" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref44-1" title="View in article">44.</a></div><div>Larkin, J. ∙ Minor, D. ∙ D’Angelo, S. ...</div><div><strong>Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial</strong></div><div><em>J.&nbsp;Clin. Oncol.</em> 2018; <strong>36</strong>:383-390</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.8023" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_44_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85041205158" target="_blank" aria-label="Open Scopus in new tab">Scopus (384)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28671856/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1200%2FJCO.2016.71.8023&amp;pmid=28671856" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib45" class="citations"><div id="sref45" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref45-1" title="View in article">45.</a></div><div>Li, B. ∙ Dewey, C.N.</div><div><strong>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</strong></div><div><em>BMC Bioinformatics.</em> 2011; <strong>12</strong>:323</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2105-12-323" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_45_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-79961123152" target="_blank" aria-label="Open Scopus in new tab">Scopus (13399)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21816040/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2F1471-2105-12-323&amp;pmid=21816040" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib46" class="citations"><div id="sref46" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref46-1" title="View in article">46.</a></div><div>Li, H. ∙ Durbin, R.</div><div><strong>Fast and accurate short read alignment with Burrows-Wheeler transform</strong></div><div><em>Bioinformatics.</em> 2009; <strong>25</strong>:1754-1760</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btp324" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_46_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-67649884743" target="_blank" aria-label="Open Scopus in new tab">Scopus (31658)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19451168/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtp324&amp;pmid=19451168" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib77" class="citations"><div id="optbvc1xdzVq0" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-optbvc1xdzVq0" title="View in article">47.</a></div><div>Li, H. ∙ Handsaker, B. ∙ Wysoker, A. ..., 1000 Genome Project Data Processing Subgroup</div><div><strong>The Sequence Alignment/Map format and SAMtools</strong></div><div><em>Bioinformatics.</em> 2009; <strong>25</strong>:2078-2079</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/btp352" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_47_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-68549104404" target="_blank" aria-label="Open Scopus in new tab">Scopus (37568)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19505943/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbtp352&amp;pmid=19505943" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib47" class="citations"><div id="sref47" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref47-1" title="View in article">48.</a></div><div>Łuksza, M. ∙ Riaz, N. ∙ Makarov, V. ...</div><div><strong>A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy</strong></div><div><em>Nature.</em> 2017; <strong>551</strong>:517-520</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature24473" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_48_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85034865728" target="_blank" aria-label="Open Scopus in new tab">Scopus (454)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29132144/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature24473&amp;pmid=29132144" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib48" class="citations"><div id="sref48" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref48-1" title="View in article">49.</a></div><div>McGranahan, N. ∙ Furness, A.J. ∙ Rosenthal, R. ...</div><div><strong>Clonal neoantigens elicit T&nbsp;cell immunoreactivity and sensitivity to immune checkpoint blockade</strong></div><div><em>Science.</em> 2016; <strong>351</strong>:1463-1469</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaf1490" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_49_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962301577" target="_blank" aria-label="Open Scopus in new tab">Scopus (2240)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26940869/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaf1490&amp;pmid=26940869" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib49" class="citations"><div id="sref49" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref49-1" title="View in article">50.</a></div><div>McKenna, A. ∙ Hanna, M. ∙ Banks, E. ...</div><div><strong>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</strong></div><div><em>Genome Res.</em> 2010; <strong>20</strong>:1297-1303</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1101/gr.107524.110" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_50_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-77956295988" target="_blank" aria-label="Open Scopus in new tab">Scopus (17473)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20644199/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1101%2Fgr.107524.110&amp;pmid=20644199" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib50" class="citations"><div id="sref50" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref50-1" title="View in article">51.</a></div><div>Nielsen, M. ∙ Andreatta, M.</div><div><strong>NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets</strong></div><div><em>Genome Med.</em> 2016; <strong>8</strong>:33</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13073-016-0288-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_51_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84962905590" target="_blank" aria-label="Open Scopus in new tab">Scopus (364)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27029192/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1186%2Fs13073-016-0288-x&amp;pmid=27029192" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib51" class="citations"><div id="sref51" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref51" title="View in article">52.</a></div><div>Ott, P.A.</div><div><strong>Immunotherapy: Immune-modified response criteria - an iterative learning process?</strong></div><div><em>Nat. Rev. Clin. Oncol.</em> 2018; <strong>15</strong>:267-268</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrclinonc.2018.36" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_52_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85045538104" target="_blank" aria-label="Open Scopus in new tab">Scopus (4)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29532797/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnrclinonc.2018.36&amp;pmid=29532797" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib52" class="citations"><div id="sref52" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref52-1" title="View in article">53.</a></div><div>Ott, P.A. ∙ Hu, Z. ∙ Keskin, D.B. ...</div><div><strong>An immunogenic personal neoantigen vaccine for patients with melanoma</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:217-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature22991" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_53_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024377220" target="_blank" aria-label="Open Scopus in new tab">Scopus (1897)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678778/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature22991&amp;pmid=28678778" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib53" class="citations"><div id="sref53" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref53" title="View in article">54.</a></div><div>Petitprez, F. ∙ de Reyniès, A. ∙ Keung, E.Z. ...</div><div><strong>B cells are associated with survival and immunotherapy response in sarcoma</strong></div><div><em>Nature.</em> 2020; <strong>577</strong>:556-560</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41586-019-1906-8" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_54_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85078153209" target="_blank" aria-label="Open Scopus in new tab">Scopus (1057)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31942077/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41586-019-1906-8&amp;pmid=31942077" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib54" class="citations"><div id="sref54" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref54-1" title="View in article">55.</a></div><div>Rimmer, A. ∙ Phan, H. ∙ Mathieson, I. ..., WGS500 Consortium</div><div><strong>Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications</strong></div><div><em>Nat. Genet.</em> 2014; <strong>46</strong>:912-918</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/ng.3036" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_55_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84905576523" target="_blank" aria-label="Open Scopus in new tab">Scopus (702)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25017105/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fng.3036&amp;pmid=25017105" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib55" class="citations"><div id="sref55" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref55" title="View in article">56.</a></div><div>Rizvi, N.A. ∙ Hellmann, M.D. ∙ Snyder, A. ...</div><div><strong>Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:124-128</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa1348" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_56_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928761118" target="_blank" aria-label="Open Scopus in new tab">Scopus (6221)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25765070/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa1348&amp;pmid=25765070" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib56" class="citations"><div id="sref56" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref56-1" title="View in article">57.</a></div><div>Rodenko, B. ∙ Toebes, M. ∙ Hadrup, S.R. ...</div><div><strong>Generation of peptide-MHC class I complexes through UV-mediated ligand exchange</strong></div><div><em>Nat. Protoc.</em> 2006; <strong>1</strong>:1120-1132</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nprot.2006.121" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_57_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-34347266953" target="_blank" aria-label="Open Scopus in new tab">Scopus (245)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17406393/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnprot.2006.121&amp;pmid=17406393" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib57" class="citations"><div id="sref57" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref57" title="View in article">58.</a></div><div>Sade-Feldman, M. ∙ Jiao, Y.J. ∙ Chen, J.H. ...</div><div><strong>Resistance to checkpoint blockade therapy through inactivation of antigen presentation</strong></div><div><em>Nat. Commun.</em> 2017; <strong>8</strong>:1136</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-017-01062-w" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_58_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85032288210" target="_blank" aria-label="Open Scopus in new tab">Scopus (627)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29070816/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs41467-017-01062-w&amp;pmid=29070816" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib58" class="citations"><div id="sref58" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref58" title="View in article">59.</a></div><div>Sade-Feldman, M. ∙ Yizhak, K. ∙ Bjorgaard, S.L. ...</div><div><strong>Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma</strong></div><div><em>Cell.</em> 2018; <strong>175</strong>:998-1013.e20</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_59_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2018.10.038&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_59_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2018.10.038&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_59_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85055560004" target="_blank" aria-label="Open Scopus in new tab">Scopus (1016)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30388456/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.cell.2018.10.038&amp;pmid=30388456" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib59" class="citations"><div id="sref59" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref59-1" title="View in article">60.</a></div><div>Sahin, U. ∙ Derhovanessian, E. ∙ Miller, M. ...</div><div><strong>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</strong></div><div><em>Nature.</em> 2017; <strong>547</strong>:222-226</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature23003" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_60_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85024396858" target="_blank" aria-label="Open Scopus in new tab">Scopus (11)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28678784/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature23003&amp;pmid=28678784" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib60" class="citations"><div id="sref60" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref60-1" title="View in article">61.</a></div><div>Saunders, C.T. ∙ Wong, W.S. ∙ Swamy, S. ...</div><div><strong>Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs</strong></div><div><em>Bioinformatics.</em> 2012; <strong>28</strong>:1811-1817</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/bioinformatics/bts271" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_61_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84864153492" target="_blank" aria-label="Open Scopus in new tab">Scopus (1123)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22581179/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1093%2Fbioinformatics%2Fbts271&amp;pmid=22581179" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib61" class="citations"><div id="sref61" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref61-1" title="View in article">62.</a></div><div>Schachter, J. ∙ Ribas, A. ∙ Long, G.V. ...</div><div><strong>Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)</strong></div><div><em>Lancet.</em> 2017; <strong>390</strong>:1853-1862</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2817%2931601-X&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS0140-6736%2817%2931601-X&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_62_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85027501801" target="_blank" aria-label="Open Scopus in new tab">Scopus (934)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28822576/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS0140-6736%2817%2931601-X&amp;pmid=28822576" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib79" class="citations"><div id="optLpDVvQM84K" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-optLpDVvQM84K" title="View in article">63.</a></div><div>Schneider, C.A. ∙ Rasband, W.S. ∙ Eliceiri, K.W.</div><div><strong>NIH Image to ImageJ: 25 years of image analysis</strong></div><div><em>Nature Methods.</em> 2012; <strong>9</strong>:671-675</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nmeth.2089" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_63_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84863205849" target="_blank" aria-label="Open Scopus in new tab">Scopus (42378)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22930834/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnmeth.2089&amp;pmid=22930834" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib62" class="citations"><div id="sref62" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref62-1" title="View in article">64.</a></div><div>Schumacher, T.N. ∙ Schreiber, R.D.</div><div><strong>Neoantigens in cancer immunotherapy</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:69-74</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa4971" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_64_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928770388" target="_blank" aria-label="Open Scopus in new tab">Scopus (3509)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25838375/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa4971&amp;pmid=25838375" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib63" class="citations"><div id="sref63" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref63" title="View in article">65.</a></div><div>Sharma, P. ∙ Allison, J.P.</div><div><strong>The future of immune checkpoint therapy</strong></div><div><em>Science.</em> 2015; <strong>348</strong>:56-61</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aaa8172" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_65_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84928774156" target="_blank" aria-label="Open Scopus in new tab">Scopus (3539)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25838373/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aaa8172&amp;pmid=25838373" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib64" class="citations"><div id="sref64" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref64-1" title="View in article">66.</a></div><div>Sharma, P. ∙ Callahan, M.K. ∙ Bono, P. ...</div><div><strong>Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial</strong></div><div><em>Lancet Oncol.</em> 2016; <strong>17</strong>:1590-1598</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS1470-2045%2816%2930496-X&amp;cf=fulltext&amp;site=lancet-site" target="_blank" aria-label="Open Full Text in new tab">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2FS1470-2045%2816%2930496-X&amp;cf=pdf&amp;site=lancet-site" target="_blank" aria-label="Open Full Text (PDF) in new tab">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_66_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84990852158" target="_blank" aria-label="Open Scopus in new tab">Scopus (565)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27733243/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2FS1470-2045%2816%2930496-X&amp;pmid=27733243" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib4" class="citations"><div id="sref4" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref4-1" title="View in article">67.</a></div><div>Signorell, A. ∙ Aho, K.A. ∙ Alfons, A. ...</div><div><strong>DescTools: tools for descriptive statistics</strong></div><div>2016</div><div><a id="intref0065" href="https://rdrr.io/cran/DescTools/man/DescTools-package.html" target="_blank">https://rdrr.io/cran/DescTools/man/DescTools-package.html</a></div></div><div class="external-links"><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=A.SignorellK.A.AhoA.AlfonsN.AndereggT.AragonA.ArppeA.BaddeleyK.BartonB.BolkerH.W.BorchersDescTools%3A+tools+for+descriptive+statistics2016https%3A%2F%2Frdrr.io%2Fcran%2FDescTools%2Fman%2FDescTools-package.html" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib65" class="citations"><div id="sref65" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref65" title="View in article">68.</a></div><div>Tavazoie, M.F. ∙ Pollack, I. ∙ Tanqueco, R. ...</div><div><strong>LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer</strong></div><div><em>Cell.</em> 2018; <strong>172</strong>:825-840.e18</div></div><div class="external-links"><div class="core-xlink-fulltext"><a href="/servlet/linkout?suffix=e_1_5_1_2_68_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2017.12.026&amp;cf=fulltext&amp;site=cell-site">Full Text</a></div><div class="core-xlink-pdf"><a href="/servlet/linkout?suffix=e_1_5_1_2_68_2&amp;dbid=4&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=10.1016%2Fj.cell.2017.12.026&amp;cf=pdf&amp;site=cell-site">Full Text (PDF)</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_68_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85040446099" target="_blank" aria-label="Open Scopus in new tab">Scopus (311)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29336888/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1016%2Fj.cell.2017.12.026&amp;pmid=29336888" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib66" class="citations"><div id="sref66" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref66" title="View in article">69.</a></div><div>Thomas, P.G. ∙ Handel, A. ∙ Doherty, P.C. ...</div><div><strong>Ecological analysis of antigen-specific CTL repertoires defines the relationship between naive and immune T-cell populations</strong></div><div><em>Proc. Natl. Acad. Sci. USA.</em> 2013; <strong>110</strong>:1839-1844</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.1222149110" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_69_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84873184482" target="_blank" aria-label="Open Scopus in new tab">Scopus (43)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23319654/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.1222149110&amp;pmid=23319654" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib67" class="citations"><div id="sref67" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref67" title="View in article">70.</a></div><div>Toebes, M. ∙ Coccoris, M. ∙ Bins, A. ...</div><div><strong>Design and use of conditional MHC class I ligands</strong></div><div><em>Nat. Med.</em> 2006; <strong>12</strong>:246-251</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nm1360" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_70_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-32244442535" target="_blank" aria-label="Open Scopus in new tab">Scopus (277)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16462803/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnm1360&amp;pmid=16462803" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib68" class="citations"><div id="sref68" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref68" title="View in article">71.</a></div><div>Topalian, S.L. ∙ Taube, J.M. ∙ Pardoll, D.M.</div><div><strong>Neoadjuvant checkpoint blockade for cancer immunotherapy</strong></div><div><em>Science.</em> 2020; <strong>367</strong>:eaax0182</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aax0182" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_71_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85078710390" target="_blank" aria-label="Open Scopus in new tab">Scopus (526)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32001626/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aax0182&amp;pmid=32001626" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib69" class="citations"><div id="sref69" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref69" title="View in article">72.</a></div><div>Tran, E. ∙ Turcotte, S. ∙ Gros, A. ...</div><div><strong>Cancer immunotherapy based on mutation-specific CD4+ T&nbsp;cells in a patient with epithelial cancer</strong></div><div><em>Science.</em> 2014; <strong>344</strong>:641-645</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.1251102" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_72_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84900301377" target="_blank" aria-label="Open Scopus in new tab">Scopus (1322)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24812403/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.1251102&amp;pmid=24812403" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib70" class="citations"><div id="sref70" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref70" title="View in article">73.</a></div><div>Tumeh, P.C. ∙ Harview, C.L. ∙ Yearley, J.H. ...</div><div><strong>PD-1 blockade induces responses by inhibiting adaptive immune resistance</strong></div><div><em>Nature.</em> 2014; <strong>515</strong>:568-571</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature13954" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_73_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84920956732" target="_blank" aria-label="Open Scopus in new tab">Scopus (5059)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25428505/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fnature13954&amp;pmid=25428505" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib71" class="citations"><div id="sref71" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref71" title="View in article">74.</a></div><div>Valpione, S. ∙ Galvani, E. ∙ Tweedy, J. ...</div><div><strong>Immune-awakening revealed by peripheral T&nbsp;cell dynamics after one cycle of immunotherapy</strong></div><div><em>Nat. Can.</em> 2020; <strong>1</strong>:210-221</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s43018-019-0022-x" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_74_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85082765119" target="_blank" aria-label="Open Scopus in new tab">Scopus (129)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32110781/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1038%2Fs43018-019-0022-x&amp;pmid=32110781" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib72" class="citations"><div id="sref72" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref72-1" title="View in article">75.</a></div><div>Van Allen, E.M. ∙ Miao, D. ∙ Schilling, B. ...</div><div><strong>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</strong></div><div><em>Science.</em> 2015; <strong>350</strong>:207-211</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/science.aad0095" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_75_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-84943516465" target="_blank" aria-label="Open Scopus in new tab">Scopus (1998)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26359337/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1126%2Fscience.aad0095&amp;pmid=26359337" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib73" class="citations"><div id="sref73" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref73" title="View in article">76.</a></div><div>Wang, C. ∙ Sanders, C.M. ∙ Yang, Q. ...</div><div><strong>High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T&nbsp;cell subsets</strong></div><div><em>Proc. Natl. Acad. Sci. USA.</em> 2010; <strong>107</strong>:1518-1523</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0913939107" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_76_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-76549090763" target="_blank" aria-label="Open Scopus in new tab">Scopus (220)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20080641/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1073%2Fpnas.0913939107&amp;pmid=20080641" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib74" class="citations"><div id="sref74" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref74" title="View in article">77.</a></div><div>Wickham, H.</div><div><strong>ggplot2: Elegant Graphics for Data Analysis</strong></div><div>Springer, 2016</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/978-3-319-24277-4" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1007%2F978-3-319-24277-4" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib75" class="citations"><div id="sref75" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref75-1" title="View in article">78.</a></div><div>Wolchok, J.D. ∙ Chiarion-Sileni, V. ∙ Gonzalez, R. ...</div><div><strong>Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>377</strong>:1345-1356</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMoa1709684" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_78_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85030460514" target="_blank" aria-label="Open Scopus in new tab">Scopus (2658)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28889792/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMoa1709684&amp;pmid=28889792" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div id="bib76" class="citations"><div id="sref76" class="citation"><div class="citation-content"><div class="label"><a href="#body-ref-sref76" title="View in article">79.</a></div><div>Yarchoan, M. ∙ Hopkins, A. ∙ Jaffee, E.M.</div><div><strong>Tumor Mutational Burden and Response Rate to PD-1 Inhibition</strong></div><div><em>N.&nbsp;Engl. J. Med.</em> 2017; <strong>377</strong>:2500-2501</div></div><div class="external-links"><div class="core-xlink-crossref"><a href="https://doi.org/10.1056/NEJMc1713444" target="_blank" aria-label="Open Crossref in new tab">Crossref</a></div><div class="core-xlink-scopus"><a href="/servlet/linkout?suffix=e_1_5_1_2_79_2&amp;dbid=137438953472&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;key=2-s2.0-85039783649" target="_blank" aria-label="Open Scopus in new tab">Scopus (2210)</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29262275/" target="_blank" aria-label="Open PubMed in new tab">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?doi=10.1056%2FNEJMc1713444&amp;pmid=29262275" target="_blank" aria-label="Open Google Scholar in new tab">Google Scholar</a></div></div></div></div></div></div></div></section></div></section><div class="core-linked-content">
    

        


    

            

            

            <div data-widget-id="8633d695-b258-4908-b86f-e2c268ec3c6b" data-widget-name="UX3HTMLWidget"><script type="text/javascript">
if($('.content-navigation__body__title').length){
$('.content-navigation__body__title').each(function(){
var html=this.innerHTML;
var div = document.createElement("div");
div.innerHTML = html;
var text = div.textContent || div.innerText || "";
this.innerHTML=text;
});
}
</script></div>

            

        

    

        


    

            

            

            <div data-widget-id="393effff-5b44-4681-a9b4-4f029b3540b7" data-widget-name="UX3HTMLWidget"><style>
.linkback-ad .pb-ad {
    display: block;
   height: auto;
    margin-left: 0px;
    margin-right: auto;
}
</style></div>

            

        

    

        

</div></div></div><div class="core-collateral-aside"><section id="core-collateral-figures"><h2>Figures (12)<button class="js--openFigureViewer"><span>Figure Viewer</span></button></h2><div class="core-collateral-aside-wrapper"><div class="grid"><a class="figure__open__ctrl" href="#fig1" aria-label="Go to Figure&amp;nbsp;1"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/65d86592-5420-43b2-aa15-d8ba1e4e222b/main.assets/gr1.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#fig2" aria-label="Go to Figure&amp;nbsp;2"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/ef9d342e-3fbb-44c3-af23-edb565aeee00/main.assets/gr2.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#figs1" aria-label="Go to Figure&amp;nbsp;S1"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/81daa4d3-7623-4bb7-b858-5b65f08ae185/main.assets/figs1.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#figs2" aria-label="Go to Figure&amp;nbsp;S2"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/4c785364-ff9d-4ce6-ae9c-688d65554174/main.assets/figs2.jpg" aria-hidden="true"></a></div><div id="collapsible-figures" data-expandable="item"><div class="content grid" style="display:none;" role="region" id="collapsible-figures_content"><a class="figure__open__ctrl" href="#fig3" aria-label="Go to Figure&amp;nbsp;3"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/e8af6642-db73-4973-a221-2dcdad1d684b/main.assets/gr3.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#fig4" aria-label="Go to Figure&amp;nbsp;4"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/1661b6d1-7375-4b97-b614-ba5e66176f87/main.assets/gr4.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#figs3" aria-label="Go to Figure&amp;nbsp;S3"><img class="figure-part" src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/b0eaac5e-c130-4043-9fa6-b9758b5721c5/main.assets/figs3a1.jpg" aria-hidden="true"><img class="figure-part" src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/c6becb5f-b57a-4afa-a8b4-8dcba9c40f23/main.assets/figs3c.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#fig5" aria-label="Go to Figure&amp;nbsp;5"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/c5814439-cf3e-40c1-a791-13cd8be4aec2/main.assets/gr5.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#figs4" aria-label="Go to Figure&amp;nbsp;S4"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/e14ad1de-f2c4-4095-8017-e927d4cbc10a/main.assets/figs4.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#figs5" aria-label="Go to Figure&amp;nbsp;S5"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/3c014e66-dcab-41a1-a509-b7cfdd736172/main.assets/figs5.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#figs6" aria-label="Go to Figure&amp;nbsp;S6"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/3a56cbc2-c389-43c6-b8c5-0975c9a1ee71/main.assets/figs6.jpg" aria-hidden="true"></a><a class="figure__open__ctrl" href="#fig6" aria-label="Go to Figure&amp;nbsp;6"><img src="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/asset/bab1776c-dcf4-4067-b8b3-8ae9ad1f476a/main.assets/gr6.jpg" aria-hidden="true"></a></div><button class="trigger" aria-controls="collapsible-figures_content" aria-expanded="false" tabindex="0" role="button"><span class="expand">Show all figures</span><span class="collapse">Hide figures</span><i class="icon-section_arrow_d" aria-hidden="true"></i></button></div></div></section>
    

        


    

            

            

            <section id="core-collateral-metrics" class="publication-list__axel-section"><h2>Article metrics</h2><div><ul class="publication-list rlist publication-list--list plum-x--lazy-load publication-list--axel" data-plum-x-url="/pb/widgets/ux3/publicationList/plumx?widgetId=66dd7e11-7768-4006-93d8-a72b60e2a264&amp;pbContext=%3Bproduct%3Aproduct%3Aelsevier%5C%3Aproduct%5C%3Acell%3Barticle%3Aarticle%3Apii%5C%3AS0092867420311417%3Bwebsite%3Awebsite%3Acell-site%3Bctype%3Astring%3AJournal+Content%3Bjournal%3Ajournal%3Acell%3Bissue%3Aissue%3Apii%5C%3AS0092867419X00227%3BpageGroup%3Astring%3AArticle+View%3Bpage%3Astring%3AShow+Full+Text%3BrequestedJournal%3Ajournal%3Acell%3Bwgroup%3Astring%3ADefault+Website+Group%3BsubPage%3Astring%3AFull+Text" data-pb-mode-enabled="false"><li aria-label="loading articles" role="alert" class="js--loading plum-x--spinner hidden"></li></ul></div></section>

            

        
<section id="core-collateral-supplementary"><h2>Supplemental information (2)</h2><div class="core-collateral-aside-wrapper"><div class="core-supplementary-material"><div class="core-link"><button class="downloadAllSupplementary"><span>Download all</span></button></div></div><div class="core-supplementary-material" data-category="pdf"><div class="core-link"><a href="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/attachment/3efd16d5-bed8-43f4-a062-8c5f095482ae/mmc1.pdf" download="mmc1.pdf"><span id="mmc1-link">PDF (374.93 KB)</span></a><div class="core-description">Document S1. Tables S1–S7</div></div></div><div class="core-supplementary-material" data-category="spreadsheet"><div class="core-link"><a href="https://www.cell.com/cms/10.1016/j.cell.2020.08.053/attachment/a076963d-14fa-4283-9dae-d1a7ee23c39a/mmc2.xlsx" download="mmc2.xlsx"><span id="mmc2-link">Spreadsheet (184.40 KB)</span></a><div class="core-description">Table S8. Vaccine and Immune Assay Peptide (IAP) Sequences Used in the Study; Additional Information, Related to STAR Methods</div></div></div></div></section>
    

        


    

            

            

            <section id="core-collateral-relatedArticles" class="axel-related-articles"><h2 id="relatedArticles" class="top axel-related-articles__title" data-title="Related articles">Related articles (40)</h2><div data-pb-widget-type="ux3-relatedArticles" data-widget-id="8d3844d1-450e-497c-ab75-a63fc41750ac" data-widget-name="AtyponTempUX3RelatedArticlesWidget" data-article-pii="S0092867420311417" class="ux3DeferredOnScrollWidget axel-related-articles__body ux3DeferredLoaded" data-show-more="true"><div class="section-paragraph linked-article axel-related-articles"><ul class="rlist axel-related-articles__items"><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(24)00312-X" target="_blank" title="Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer">Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Xu et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">September 09, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(22)00359-2" target="_blank" title="Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer">Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Awad et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">August 25, 2022</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(24)00595-0" target="_blank" title="PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers">PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Gu et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">November 12, 2024</span></div></li></ul><ul class="rlist axel-related-articles__items axel-related-articles__extra-items js--hidden"><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(24)00372-6" target="_blank" title="A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma">A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Jiang et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">October 11, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/heliyon/fulltext/S2405-8440(23)01773-5" target="_blank" title="Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses">Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Mortezaee et al.</li></ul></div><div class="linked-article__details"><span><i>Heliyon</i></span><span id="item_date">March 14, 2023</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(24)00241-6" target="_blank" title="Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip">Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Veith et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">May 3, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell/fulltext/S0092-8674(25)00291-0" target="_blank" title="A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer">A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Liu et al.</li></ul></div><div class="linked-article__details"><span><i>Cell</i></span><span id="item_date">March 26, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(25)00019-4" target="_blank" title="Contrasting cytotoxic and regulatory T&nbsp;cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer">Contrasting cytotoxic and regulatory T&nbsp;cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Guo et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">January 30, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/iscience/fulltext/S2589-0042(25)01065-X" target="_blank" title="Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer">Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Semitekolou et al.</li></ul></div><div class="linked-article__details"><span><i>iScience</i></span><span id="item_date">June 2, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports/fulltext/S2211-1247(24)01226-9" target="_blank" title="Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy">Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Keshari et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports</i></span><span id="item_date">October 23, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(24)00623-2" target="_blank" title="Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer">Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Chakraborty et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">December 9, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(24)00185-X" target="_blank" title="Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T&nbsp;cells exhibiting the full differentiation spectrum">Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T&nbsp;cells exhibiting the full differentiation spectrum</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Ingels et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">April 15, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(23)00598-1" target="_blank" title="Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy">Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Zhang et al.</li></ul></div><div class="linked-article__details"><span><i>Molecular Therapy</i></span><span id="item_date">November 2, 2023</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(20)30185-3" target="_blank" title="Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1">Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Poran et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">November 17, 2020</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(24)00443-4" target="_blank" title="Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1">Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Yang et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">December 12, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(25)00096-0" target="_blank" title="Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials">Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Zhang et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">April 14, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(24)00206-X" target="_blank" title="PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial">PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Wu et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">May 24, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/heliyon/fulltext/S2405-8440(24)03108-6" target="_blank" title="Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer">Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Wang et al.</li></ul></div><div class="linked-article__details"><span><i>Heliyon</i></span><span id="item_date">February 23, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/heliyon/fulltext/S2405-8440(23)07673-9" target="_blank" title="An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor">An online clinical model and risk stratification system to predict progression-free survival for advanced non-small-cell lung cancer patients treated with PD-(L)1 inhibitor</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Tu et al.</li></ul></div><div class="linked-article__details"><span><i>Heliyon</i></span><span id="item_date">September 26, 2023</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/developmental-cell/fulltext/S1534-5807(24)00629-4" target="_blank" title="A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression">A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Tang et al.</li></ul></div><div class="linked-article__details"><span><i>Developmental Cell</i></span><span id="item_date">November 7, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(24)00269-1" target="_blank" title="Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial">Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Xiao et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">August 1, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/heliyon/fulltext/S2405-8440(23)09868-7" target="_blank" title="Comparison of survival outcomes between clinical trial participants and non-participants of patients with advanced non-small cell lung cancer: A retrospective cohort study">Comparison of survival outcomes between clinical trial participants and non-participants of patients with advanced non-small cell lung cancer: A retrospective cohort study</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Jiang et al.</li></ul></div><div class="linked-article__details"><span><i>Heliyon</i></span><span id="item_date">November 19, 2023</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(24)00248-4" target="_blank" title="Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer">Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Wang et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">July 3, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(24)00318-0" target="_blank" title="Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer">Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Wang et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">September 19, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(24)00061-2" target="_blank" title="A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer">A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Altorki et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">February 23, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/heliyon/fulltext/S2405-8440(24)03607-7" target="_blank" title="Dual immunotherapy in advanced or metastatic non-small cell lung cancer: A network meta-analysis">Dual immunotherapy in advanced or metastatic non-small cell lung cancer: A network meta-analysis</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Yang et al.</li></ul></div><div class="linked-article__details"><span><i>Heliyon</i></span><span id="item_date">March 2, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(23)00432-4" target="_blank" title="A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)">A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Zhou et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">January 4, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(24)00303-9" target="_blank" title="Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial">Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>How et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">August 15, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports/fulltext/S2211-1247(25)00493-0" target="_blank" title="MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer">MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Park et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports</i></span><span id="item_date">May 19, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-stem-cell/fulltext/S1934-5909(24)00090-0" target="_blank" title="Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer">Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Yin et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Stem Cell</i></span><span id="item_date">April 8, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(24)00344-1" target="_blank" title="First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial">First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Zhou et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">October 9, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(22)00358-0" target="_blank" title="Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC">Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Leung et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">August 25, 2022</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(24)00487-2" target="_blank" title="IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial">IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Li et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">January 18, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(24)00407-5" target="_blank" title="Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance">Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Chen et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">August 20, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cancer-cell/fulltext/S1535-6108(23)00362-8" target="_blank" title="Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer">Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Hawley et al.</li></ul></div><div class="linked-article__details"><span><i>Cancer Cell</i></span><span id="item_date">November 2, 2023</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(25)00040-0" target="_blank" title="Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers">Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Champiat et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">February 10, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/med/fulltext/S2666-6340(24)00453-7" target="_blank" title="Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2− breast cancer: A phase 1b/2 trial">Targeting autophagy plus high-dose CDK4/6 inhibitors in advanced HR+HER2− breast cancer: A phase 1b/2 trial</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Gong et al.</li></ul></div><div class="linked-article__details"><span><i>Med</i></span><span id="item_date">December 27, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(25)00056-4" target="_blank" title="The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer">The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Sattler et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">February 27, 2025</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-host-microbe/fulltext/S1931-3128(24)00228-2" target="_blank" title="Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor">Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Kim et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Host &amp; Microbe</i></span><span id="item_date">July 25, 2024</span></div></li><li class="linked-article__item"><a class="linked-article__title link--underlined" href="/cell-reports-medicine/fulltext/S2666-3791(23)00001-0" target="_blank" title="Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results">Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results</a><div><ul class="meta__authors rlist--inline comma" title="list of authors"><li>Saeed et al.</li></ul></div><div class="linked-article__details"><span><i>Cell Reports Medicine</i></span><span id="item_date">January 25, 2023</span></div></li></ul><a href="javascript:void(0)" class="toggle-extra-items"><span>Show more</span><i aria-hidden="true" class="icon-arrow_d_n"></i></a></div></div></section>

            

        
</div></div><aside data-core-aside="right-rail"><div class="inner-wrapper">

    

        


    

            

            

            <div data-widget-id="dca7470d-9085-4d21-a6f4-a66397718146" data-widget-name="UX3HTMLWidget"><input type="hidden" id="gptPage" value="cell-videos"></div>

            

        











        <div data-widget-def="literatumAd" data-widget-id="481d10c2-bbe0-470e-a5ba-207a81ecc8dc" class="adplaceholders" style="right: 0px; position: static;">
        
    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd alignCenter  widget-verticalAd" id="481d10c2-bbe0-470e-a5ba-207a81ecc8dc">
                
                
                    
                

                <div class="wrapped " id="Marketplace-Recs">
                    
                    <div class="widget-body body body-verticalAd "><div class="verticalAdContainer">
    <div class="verticalAdLabelContainer">
        <div class="verticalAdLabel">
                <img src="/templates/jsp/_style2/_marlin/images/bg_adVert.gif" alt="Advertisement">
        </div>
    </div>
    <div class="verticalAd">
        





        <div class="pb-ad">
            <script src="//cdn.pbgrd.com/core-cell.js" async=""></script>
<div id="pbgrd-skyr-c"><div id="pbgrd-skyr" style="width: inherit; position: relative; background: transparent;"></div></div>
        </div>
    

    </div>
</div></div>
                </div>
                </div>

        

        </div>
    

</div></aside><div class="core-authors-details" style="display:none"><section class="core-authors"></section></div></article><div data-extent="article-wrapper"><div class="core-container"></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1016/j.cell.2020.08.053","data-is-retraction":false,"data-is-retired":false}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><template id="figure_nav_template"><a href="#" class="open-in-viewer btn btn-dark figure-pop-btn"><i aria-hidden="true" class="icon-export_citation"></i><span>Open in viewer</span></a></template><div id="figure-viewer" role="dialog" aria-modal="true" aria-label="Figure Viewer" class="showCaption showThumbstrip figure-viewer"><nav class="nav-bar figure-viewer__top"><a href="#" title="Close Figure Viewer" role="button" class="figure-viewer__close"><i aria-hidden="true" class="icon-tools_close"></i></a><div class="figure-viewer__title">A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer</div></nav><div class="frames"><ul class="frames__list"><li><div class="thumbnail__image"><img id="gr1" src="/cms/10.1016/j.cell.2020.08.053/asset/65d86592-5420-43b2-aa15-d8ba1e4e222b/main.assets/gr1.jpg" height="613" width="759" aria-labelledby="fig1-title fig1-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/7b80dff1-32bc-4774-8fb3-57c1835cde22/main.assets/gr1_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="gr2" src="/cms/10.1016/j.cell.2020.08.053/asset/ef9d342e-3fbb-44c3-af23-edb565aeee00/main.assets/gr2.jpg" height="274" width="753" aria-labelledby="fig2-title fig2-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/d5528583-3934-4805-b87a-cfb6a702fa8a/main.assets/gr2_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs1" src="/cms/10.1016/j.cell.2020.08.053/asset/81daa4d3-7623-4bb7-b858-5b65f08ae185/main.assets/figs1.jpg" height="941" width="743" aria-labelledby="figs1-title figs1-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/e047e0fd-9fd8-4ddd-80aa-a6d405c0e4c4/main.assets/figs1_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs2" src="/cms/10.1016/j.cell.2020.08.053/asset/4c785364-ff9d-4ce6-ae9c-688d65554174/main.assets/figs2.jpg" height="941" width="659" aria-labelledby="figs2-title figs2-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/accc0a4f-0870-4188-9353-4d1af89f534d/main.assets/figs2_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="gr3" src="/cms/10.1016/j.cell.2020.08.053/asset/e8af6642-db73-4973-a221-2dcdad1d684b/main.assets/gr3.jpg" height="758" width="657" aria-labelledby="fig3-title fig3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/6b0df645-307d-4627-bd9a-3858e1aea668/main.assets/gr3_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="gr4" src="/cms/10.1016/j.cell.2020.08.053/asset/1661b6d1-7375-4b97-b614-ba5e66176f87/main.assets/gr4.jpg" height="690" width="753" aria-labelledby="fig4-title fig4-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/037b9bd9-6d5b-42cb-b977-103f76f7b9c1/main.assets/gr4_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs3-part-1" src="/cms/10.1016/j.cell.2020.08.053/asset/b0eaac5e-c130-4043-9fa6-b9758b5721c5/main.assets/figs3a1.jpg" height="707" width="770" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/68e18bdb-a097-419f-a124-9e68eeac2ad3/main.assets/figs3a1_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs3-part-2" src="/cms/10.1016/j.cell.2020.08.053/asset/3c3f2ae9-eae4-463a-9ac2-aadf32a889cf/main.assets/figs3a2.jpg" height="699" width="762" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/2ed3fe98-a10d-4740-a2aa-20d0677d6dd7/main.assets/figs3a2_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs3-part-3" src="/cms/10.1016/j.cell.2020.08.053/asset/3336825f-f1fe-4aa3-a533-938c0763bb07/main.assets/figs3b.jpg" height="697" width="753" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/7693ef18-c728-4f8c-ae1a-5a76a06d0292/main.assets/figs3b_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs3-part-4" src="/cms/10.1016/j.cell.2020.08.053/asset/c6becb5f-b57a-4afa-a8b4-8dcba9c40f23/main.assets/figs3c.jpg" height="687" width="750" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/a31c6432-a875-4de7-a158-8c11f8e12ad6/main.assets/figs3c_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="gr5" src="/cms/10.1016/j.cell.2020.08.053/asset/c5814439-cf3e-40c1-a791-13cd8be4aec2/main.assets/gr5.jpg" height="941" width="493" aria-labelledby="fig5-title fig5-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/9248d812-1240-4453-8b29-cbc42e37080f/main.assets/gr5_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs4" src="/cms/10.1016/j.cell.2020.08.053/asset/e14ad1de-f2c4-4095-8017-e927d4cbc10a/main.assets/figs4.jpg" height="941" width="753" aria-labelledby="figs4-title figs4-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/443c0e86-cf4f-498d-be96-25a4dfa84248/main.assets/figs4_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs5" src="/cms/10.1016/j.cell.2020.08.053/asset/3c014e66-dcab-41a1-a509-b7cfdd736172/main.assets/figs5.jpg" height="940" width="629" aria-labelledby="figs5-title figs5-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/d8276e66-9f0d-486c-b0a2-54ed8c20ab6c/main.assets/figs5_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="figs6" src="/cms/10.1016/j.cell.2020.08.053/asset/3a56cbc2-c389-43c6-b8c5-0975c9a1ee71/main.assets/figs6.jpg" height="745" width="753" aria-labelledby="figs6-title figs6-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/f9964748-62d4-46b0-a6f4-ae5e110fe365/main.assets/figs6_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li><li><div class="thumbnail__image"><img id="gr6" src="/cms/10.1016/j.cell.2020.08.053/asset/bab1776c-dcf4-4067-b8b3-8ae9ad1f476a/main.assets/gr6.jpg" height="860" width="657" aria-labelledby="fig6-title fig6-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/4361eece-8ecd-4d95-89f7-4815d01df842/main.assets/gr6_lrg.jpg" loading="lazy" tabindex="0" class="ui-draggable ui-draggable-handle fw-loaded" style="position: relative;"></div></li></ul><a href="#" title="Previous Frame" class="frameButton previousFrameButton frames__prev"><!--span Previous Frame--><i class="icon-arrow_l"></i></a><a href="#" title="Next Frame" class="frameButton nextFrameButton frames__next"><!--span Next Frame--><i class="icon-arrow_r"></i></a></div><div class="caption"><div class="figure-viewer__caption-body"></div></div><div class="toolbar figure-viewer__toolbar"><span class="figure-viewer__counter"></span><a href="#" class="button toggle-caption-button figure-viewer__caption__ctrl"><i aria-hidden="true" class="icon icon-info"></i><span class="label">Hide Caption</span></a><a href="#" class="button download-options-button"><i aria-hidden="true" class="icon icon-gizmo-folder-in download-size-icon"></i><span class="label">Download</span></a><a href="#figures" class="button see-figures figure-viewer__see-figure__ctrl"><i aria-hidden="true" class="icon icon-gizmo-image_figure viewer-size-icon"></i><span class="label">See figure in Article</span></a></div><div class="thumbstrip"><a href="#" class="toggleButton thumbstrip__ctrl"><span>Toggle Thumbstrip</span></a><a href="#" title="Previous Thumbnails" class="thumbstripButton previousThumbstripButton thumbstrip__prev"><i aria-hidden="true" class="icon-arrow_l"></i></a><a href="#" title="Next Thumbnails" class="thumbstripButton nextThumbstripButton thumbstrip__next"><i aria-hidden="true" class="icon-arrow_r"></i></a><div class="thumbstrip__wrapper"><ul class="rlist figure-viewer__thumbslist"><li><div class="thumbnail__label">Figure&nbsp;1</div><div class="thumbnail"><div class="thumbnail__image"><img id="gr1" src="/cms/10.1016/j.cell.2020.08.053/asset/65d86592-5420-43b2-aa15-d8ba1e4e222b/main.assets/gr1.jpg" height="613" width="759" aria-labelledby="fig1-title fig1-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/7b80dff1-32bc-4774-8fb3-57c1835cde22/main.assets/gr1_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;2</div><div class="thumbnail"><div class="thumbnail__image"><img id="gr2" src="/cms/10.1016/j.cell.2020.08.053/asset/ef9d342e-3fbb-44c3-af23-edb565aeee00/main.assets/gr2.jpg" height="274" width="753" aria-labelledby="fig2-title fig2-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/d5528583-3934-4805-b87a-cfb6a702fa8a/main.assets/gr2_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S1</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs1" src="/cms/10.1016/j.cell.2020.08.053/asset/81daa4d3-7623-4bb7-b858-5b65f08ae185/main.assets/figs1.jpg" height="941" width="743" aria-labelledby="figs1-title figs1-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/e047e0fd-9fd8-4ddd-80aa-a6d405c0e4c4/main.assets/figs1_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S2</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs2" src="/cms/10.1016/j.cell.2020.08.053/asset/4c785364-ff9d-4ce6-ae9c-688d65554174/main.assets/figs2.jpg" height="941" width="659" aria-labelledby="figs2-title figs2-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/accc0a4f-0870-4188-9353-4d1af89f534d/main.assets/figs2_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;3</div><div class="thumbnail"><div class="thumbnail__image"><img id="gr3" src="/cms/10.1016/j.cell.2020.08.053/asset/e8af6642-db73-4973-a221-2dcdad1d684b/main.assets/gr3.jpg" height="758" width="657" aria-labelledby="fig3-title fig3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/6b0df645-307d-4627-bd9a-3858e1aea668/main.assets/gr3_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;4</div><div class="thumbnail"><div class="thumbnail__image"><img id="gr4" src="/cms/10.1016/j.cell.2020.08.053/asset/1661b6d1-7375-4b97-b614-ba5e66176f87/main.assets/gr4.jpg" height="690" width="753" aria-labelledby="fig4-title fig4-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/037b9bd9-6d5b-42cb-b977-103f76f7b9c1/main.assets/gr4_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S3</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs3-part-1" src="/cms/10.1016/j.cell.2020.08.053/asset/b0eaac5e-c130-4043-9fa6-b9758b5721c5/main.assets/figs3a1.jpg" height="707" width="770" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/68e18bdb-a097-419f-a124-9e68eeac2ad3/main.assets/figs3a1_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S3</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs3-part-2" src="/cms/10.1016/j.cell.2020.08.053/asset/3c3f2ae9-eae4-463a-9ac2-aadf32a889cf/main.assets/figs3a2.jpg" height="699" width="762" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/2ed3fe98-a10d-4740-a2aa-20d0677d6dd7/main.assets/figs3a2_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S3</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs3-part-3" src="/cms/10.1016/j.cell.2020.08.053/asset/3336825f-f1fe-4aa3-a533-938c0763bb07/main.assets/figs3b.jpg" height="697" width="753" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/7693ef18-c728-4f8c-ae1a-5a76a06d0292/main.assets/figs3b_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S3</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs3-part-4" src="/cms/10.1016/j.cell.2020.08.053/asset/c6becb5f-b57a-4afa-a8b4-8dcba9c40f23/main.assets/figs3c.jpg" height="687" width="750" aria-labelledby="figs3-title figs3-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/a31c6432-a875-4de7-a158-8c11f8e12ad6/main.assets/figs3c_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;5</div><div class="thumbnail"><div class="thumbnail__image"><img id="gr5" src="/cms/10.1016/j.cell.2020.08.053/asset/c5814439-cf3e-40c1-a791-13cd8be4aec2/main.assets/gr5.jpg" height="941" width="493" aria-labelledby="fig5-title fig5-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/9248d812-1240-4453-8b29-cbc42e37080f/main.assets/gr5_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S4</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs4" src="/cms/10.1016/j.cell.2020.08.053/asset/e14ad1de-f2c4-4095-8017-e927d4cbc10a/main.assets/figs4.jpg" height="941" width="753" aria-labelledby="figs4-title figs4-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/443c0e86-cf4f-498d-be96-25a4dfa84248/main.assets/figs4_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S5</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs5" src="/cms/10.1016/j.cell.2020.08.053/asset/3c014e66-dcab-41a1-a509-b7cfdd736172/main.assets/figs5.jpg" height="940" width="629" aria-labelledby="figs5-title figs5-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/d8276e66-9f0d-486c-b0a2-54ed8c20ab6c/main.assets/figs5_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;S6</div><div class="thumbnail"><div class="thumbnail__image"><img id="figs6" src="/cms/10.1016/j.cell.2020.08.053/asset/3a56cbc2-c389-43c6-b8c5-0975c9a1ee71/main.assets/figs6.jpg" height="745" width="753" aria-labelledby="figs6-title figs6-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/f9964748-62d4-46b0-a6f4-ae5e110fe365/main.assets/figs6_lrg.jpg" loading="lazy" tabindex="0"></div></div></li><li><div class="thumbnail__label">Figure&nbsp;6</div><div class="thumbnail"><div class="thumbnail__image"><img id="gr6" src="/cms/10.1016/j.cell.2020.08.053/asset/bab1776c-dcf4-4067-b8b3-8ae9ad1f476a/main.assets/gr6.jpg" height="860" width="657" aria-labelledby="fig6-title fig6-content" data-viewer-src="/cms/10.1016/j.cell.2020.08.053/asset/4361eece-8ecd-4d95-89f7-4815d01df842/main.assets/gr6_lrg.jpg" loading="lazy" tabindex="0"></div></div></li></ul></div></div><div class="download figure-viewer__download"><div class="pointer"></div><ul class="rlist downlad__wrapper"><li class="hidden-xs hidden-sm"><a href="/action/downloadFigures?pii=e00489&amp;id=" class="downloadAllButton"><i class="icon icon-gizmo-ppt figure-viewer__download__viewer-size-icon figure-viewer__download__viewer-size-icon--ppt"></i><span class="figure-viewer__download__text"> Download .PPT</span></a></li></ul></div></div><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-subdirectory_arrow_left"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-subdirectory_arrow_left"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-subdirectory_arrow_left"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--inverse"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-do="Digital Object" data-figures="Figures" data-metrics="Article Metrics" data-related="Related articles" data-supplementary="Supplemental information"></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template></div>
                </div>
                </div>

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd none  widget-  widget-compact-all" id="756cf18d-e910-4468-936c-0225ae7c669f">
                
                
                    
                

                <div class="wrapped " id="ad for nucleus-single-molecule-technologies">
                    
                    <div class="widget-body body body-  body-compact-all"><div class="pb-ad">
            <script type="text/javascript">
URL_var = 'https://www.cell.com/cell/fulltext/S0092-8674(20)31141-7';

if(URL_var.indexOf("S0165-6147(17)30205-5") > -1
|| URL_var.indexOf("S0167-7799(18)30204-X") > -1 
|| URL_var.indexOf("S0092-8674(18)31649-0") > -1 
|| URL_var.indexOf("S0092-8674(19)30404-0") > -1 
|| URL_var.indexOf("S1097-2765(18)30756-1") > -1 
|| URL_var.indexOf("S0092-8674(18)31452-1") > -1 
|| URL_var.indexOf("S1097-2765(19)30175-3") > -1 
|| URL_var.indexOf("S0092-8674(18)30852-3") > -1 
|| URL_var.indexOf("S0006-3495(18)30295-9") > -1 
|| URL_var.indexOf("S1097-2765(19)30063-2") > -1 
|| URL_var.indexOf("S0006-3495(17)33208-3") > -1 
|| URL_var.indexOf("S2211-1247(18)31639-5") > -1 
|| URL_var.indexOf("S1097-2765(18)30978-X") > -1 
)
    {
document.write('<input type="hidden" id="gpttc" value="nucleus-single-molecule-technologies" class="gpt-Target">')
}
</script>
        </div></div>
                </div>
                </div>

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd none  widget-" id="754b1780-1117-4371-9285-9cd7020963d5">
                
                

                <div class="wrapped ">
                    
                    <div class="widget-body body body- "><div class="pb-ad">
            <script type="text/javascript">
URL_var = 'https://www.cell.com/cell/fulltext/S0092-8674(20)31141-7';

if(URL_var.indexOf("S1535-6108(19)30104-7") > -1
|| URL_var.indexOf("S0092-8674(18)31394-1") > -1
|| URL_var.indexOf("S1074-7613(19)30033-0") > -1
|| URL_var.indexOf("S1535-6108(18)30473-2") > -1
|| URL_var.indexOf("S0092-8674(19)30154-0") > -1
|| URL_var.indexOf("S1550-4131(18)30178-5") > -1
|| URL_var.indexOf("S1535-6108(19)30242-9") > -1
|| URL_var.indexOf("S1074-7613(18)30431-X") > -1
|| URL_var.indexOf("S0092-8674(19)30618-X") > -1
|| URL_var.indexOf("S1535-6108(18)30472-0") > -1
|| URL_var.indexOf("S1535-6108(18)30120-X") > -1
|| URL_var.indexOf("S0092-8674(18)31247-9") > -1
|| URL_var.indexOf("S1074-7613(18)30085-2") > -1
|| URL_var.indexOf("S1074-7613(18)30080-3") > -1
|| URL_var.indexOf("S1471-4906(18)30210-2") > -1
|| URL_var.indexOf("S1550-4131(19)30304-3") > -1
|| URL_var.indexOf("S1934-5909(18)30599-X") > -1
|| URL_var.indexOf("S2405-8033(19)30024-X") > -1
|| URL_var.indexOf("S1535-6108(18)30109-0") > -1
|| URL_var.indexOf("S0962-8924(18)30127-2") > -1
)
    {
document.write('<input type="hidden" id="gpttc" value="nucleus-tumor-immune-microenvironment" class="gpt-Target">')
}
</script>
        </div></div>
                </div>
                </div>

        

    

        


    

            

            

            <div data-widget-id="9c9ff7a1-a035-49f6-a336-600c9419c518" data-widget-name="UX3HTMLWidget"><!-- Start of HubSpot Embed Code --> 

<script type="text/plain" class="optanon-category-4" id="hs-script-loader" async="" defer="" src="//js.hs-scripts.com/519224.js"></script> 

<!-- End of HubSpot Embed Code --></div>

            

        

    

        


    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget sessionValidationWidget none  widget-none  widget-compact-all" id="0257aef7-6074-4898-a989-1c3f693225a2">
                
                

                <div class="wrapped ">
                    
                    <div class="widget-body body body-none  body-compact-all"><script>
    $.ajax({
        url: "https://www.cell.com/ssoSessionCheck",
        type: "GET",
        dataType: "jsonp",
        success: function (data) {
            if(data.RefreshSession) {
                location.reload();
            }
        },
        error : function (){
            console.warn("can't validate CSAS session.");
        }
    });
</script></div>
                </div>
                </div>

        

    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                            
                        
                        
                            
                            
                            
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget csasSsoUrls none  widget-none  widget-compact-all" id="948bc5c4-8b0d-47be-b5ad-6570559802d1">
                
                

                <div class="wrapped ">
                    
                    <div class="widget-body body body-none  body-compact-all"><!-- clear SSO URLs after all iFrames are rendered or after passing a time out-->
<script>
    setTimeout(clearSsoUrlsFun,10000);
    var iFramesList = document.getElementById("sso-urls-div").getElementsByTagName("iframe");
    var renderedIFramesCount = 0;
    var numberOfIFrames = iFramesList.length;
    var skipRefresh = false;
    for (var i = 0; i < iFramesList.length; i++) {
        var iFrame = iFramesList[i];
        iFrame.addEventListener("load", function() {
            renderedIFramesCount = renderedIFramesCount + 1;
            if (renderedIFramesCount >= numberOfIFrames)
            {
                clearSsoUrlsFun();
            }
        });
    }

    function clearSsoUrlsFun() {
        if (skipRefresh == false && numberOfIFrames > 0)
        {
            skipRefresh = true;
            $.ajax({
                url: "https://www.cell.com/action/clearSsoUrls",
                type: "GET",
                dataType: "jsonp",
                error : errorCallingAjx
            });
        }
    }

    function errorCallingAjx(){
        console.log("can't delete sso urls .")
    }
</script></div>
                </div>
                </div>

        










        <div data-widget-def="ux3-layout-widget" data-widget-id="d95b4a46-dc4d-4ca8-83f9-8b6724c649ec" class="ux3 ">
        
    

        


    

            

            

            <div data-widget-id="d95b4a46-dc4d-4ca8-83f9-8b6724c649ec" data-widget-name="ux3-layout-widget" class="fonts-loaded"><div class="footer clearfix">
    

        


    

                
                
                
                
                
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                    
                
                    
                
                    
                        
                        
                        
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                    
                
                
                
                <div class="widget literatumAd none adplaceholder adplaceholder--header widget-horizontalAd" id="a07ee92b-3942-49f8-9186-a2a08fc3fc56">
                
                

                <div class="wrapped ">
                    
                    <div class="widget-body body body-horizontalAd "><div class="horizontalAdContainer">
    <div class="horizontalAdLabelContainer">
        <div class="horizontalAdLabel">
                <img src="/templates/jsp/_style2/_marlin/images/bg_adHoriz.gif" alt="Advertisement">
        </div>
    </div>
    <div class="horizontalAd">
        





        <div class="pb-ad">
            <!-- Beginning Async AdSlot 4 for Ad unit els.cellpress/cell  ### size: [[728,90]] -->
<div class="gpt-ad" data-adsize="cell-leaderboard" data-page="" data-site="cell" data-pos="4"></div>
<!-- End AdSlot 4 -->
        </div>
    

    </div>
</div></div>
                </div>
                </div>

        

    

        


    

            

            

            <div data-widget-id="23703bbc-af46-4f3f-a5bb-dd52891ff0ff" data-widget-name="UX3HTMLWidget"><div class="footer__top">
    <div class="footer__logo centered"><a href="/home" title="Cell Press"><!-- Generator: Adobe Illustrator 25.2.1, SVG Export Plug-In . SVG Version: 6.00 Build 0)  -->
<svg version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 300 72" style="enable-background:new 0 0 300 72;" xml:space="preserve">
<style type="text/css">
	.st0{fill:#007DBC;}
</style>
<g>
	<path class="st0" d="M39.4,7.5c-2.3-0.3-4.4,1.1-4.9,3.3l-1.8,7.4c-0.4,1.8-1.9,3.1-3.8,3.3l-10.5,1.2C7.1,24-1,34.3,0.7,45.6
		c1.3,9,8.6,15.7,17.2,17c2.3,0.3,4.4-1.1,4.9-3.3l1.8-7.4c0.4-1.8,1.9-3.1,3.8-3.3l10.5-1.2c11.3-1.2,19.4-11.6,17.8-22.9
		C55.3,15.4,48.1,8.8,39.4,7.5z M37.1,34l-6.6,0.8c-1.1,0.1-2,0.9-2.3,2l-1.9,8.1c-0.6,2.4-2.5,4.2-5,4.5c-3.8,0.4-7.1-2.4-7.4-6.2
		c-0.3-3.7,2.6-6.8,6.3-7.2l6.6-0.8c1.1-0.1,2-0.9,2.3-2l1.9-8.1c0.6-2.4,2.5-4.2,5-4.5c3.8-0.4,7.1,2.4,7.4,6.2
		C43.7,30.5,40.8,33.6,37.1,34z"></path>
	<rect x="153.1" y="13.9" class="st0" width="8.2" height="42.3"></rect>
	<path class="st0" d="M90.2,20.4c7.3,0,8.6,4.8,9.4,7.3h8.8c-0.5-6.2-5.6-14.9-18.2-14.9c-10.9,0-19.4,7.5-19.4,22.3
		c0,14.6,8.1,22.2,19.3,22.2c10.6,0,16.6-6.4,18.4-15.6h-8.8c-1.1,5.2-4.5,7.9-9.4,7.9c-7.5,0-10.5-6.8-10.5-14.4
		C79.7,23.3,85.9,20.4,90.2,20.4z"></path>
	<path class="st0" d="M125.2,24c-13.7,0-15,12.1-15,15.8c0,12.9,6.8,17.1,15.6,17.1c5.4,0,11.6-2.5,13.8-10H131
		c-0.7,2.2-3,3.4-5.3,3.4c-6.6,0-7.1-5.3-7.3-7.7h21.5v-1.5C139.9,27,131.3,24,125.2,24z M118.6,37.4c0.5-4.1,2.5-6.6,6.4-6.6
		c2.6,0,5.9,1.5,6.4,6.6H118.6z"></path>
	<rect x="142" y="13.9" class="st0" width="8.2" height="42.3"></rect>
	<path class="st0" d="M174,13.8h-9.8V21h7.2c4.3,0,8.2,0.9,8.2,6.4c0,5.4-3.9,6.4-8.2,6.4h-7.2V41h9.8c10.6,0,14.7-6.7,14.7-13.6
		C188.7,20.5,184.6,13.8,174,13.8z"></path>
	<path class="st0" d="M210.5,24.9c-0.5-0.2-1.2-0.3-1.8-0.3c-4.1,0-8.3,2.7-9.8,6.5h-0.1v-5.7h-8v30.7h8.4V42.3
		c0-5.4,2.1-9.9,8.3-9.9c1,0,2.3,0.1,3,0.3V24.9z"></path>
	<path class="st0" d="M225.6,24.6c-9.3,0-15.7,7-15.7,16.2c0,9.5,6,16.1,15.7,16.1c6.9,0,12-3.1,14.4-10.3h-7.4
		c-0.5,1.9-3.3,4-6.6,4c-4.7,0-7.3-2.4-7.5-7.8h22.1C241.1,33.4,236,24.6,225.6,24.6z M218.4,37.5c0.1-2.4,1.7-6.5,7-6.5
		c4.1,0,5.9,2.3,6.7,6.5H218.4z"></path>
	<path class="st0" d="M260.3,37.7c-4.8-1.1-9.6-1.5-9.6-4.6c0-2.5,2.8-2.9,4.7-2.9c3,0,5.5,0.9,5.8,4.2h8c-0.7-7.5-6.8-9.8-13.5-9.8
		c-6.6,0-13.4,2-13.4,9.9c0,5.4,4.9,7.1,9.7,8.2c6.1,1.3,9.6,2.2,9.6,4.8c0,3-3.1,3.9-5.5,3.9c-3.3,0-6.4-1.5-6.5-5.2h-8
		C242,54.3,248.9,57,256,57c7,0,14-2.6,14-10.7C270.1,40.6,265.2,38.8,260.3,37.7z"></path>
	<path class="st0" d="M289.8,37.7c-4.8-1.1-9.6-1.5-9.6-4.6c0-2.5,2.8-2.9,4.7-2.9c3,0,5.5,0.9,5.8,4.2h8c-0.7-7.5-6.8-9.8-13.5-9.8
		c-6.6,0-13.4,2-13.4,9.9c0,5.4,4.9,7.1,9.7,8.2c6.1,1.3,9.6,2.2,9.6,4.8c0,3-3.1,3.9-5.5,3.9c-3.3,0-6.4-1.5-6.5-5.2h-8
		c0.4,8.1,7.3,10.8,14.4,10.8c7,0,14-2.6,14-10.7C299.6,40.6,294.7,38.8,289.8,37.7z"></path>
	<path class="st0" d="M34.1,57.6c0.3-0.2,0.4-0.6,0.4-1c0-0.5-0.2-0.9-0.5-1.1c-0.3-0.2-0.8-0.3-1.4-0.3h-1.9v5.1h0.8V58h0.8
		l1.3,2.2h0.9l-1.4-2.2C33.6,57.9,33.9,57.8,34.1,57.6z M32.5,57.3h-0.9v-1.5h1c0.1,0,0.3,0,0.4,0c0.1,0,0.3,0,0.4,0.1
		c0.1,0,0.2,0.1,0.3,0.2c0.1,0.1,0.1,0.2,0.1,0.4c0,0.2,0,0.3-0.1,0.4c-0.1,0.1-0.2,0.2-0.3,0.2c-0.1,0.1-0.2,0.1-0.4,0.1
		C32.8,57.3,32.6,57.3,32.5,57.3z"></path>
	<path class="st0" d="M35.6,54.2c-0.4-0.4-0.9-0.7-1.4-0.9c-0.5-0.2-1.1-0.3-1.7-0.3c-0.6,0-1.2,0.1-1.7,0.3c-0.6,0.2-1,0.5-1.4,0.9
		c-0.4,0.4-0.7,0.9-1,1.5c-0.2,0.6-0.4,1.2-0.4,1.9c0,0.7,0.1,1.3,0.3,1.8c0.2,0.6,0.5,1,0.9,1.5c0.4,0.4,0.9,0.7,1.4,1
		c0.6,0.2,1.2,0.4,1.8,0.4c0.6,0,1.2-0.1,1.7-0.3c0.5-0.2,1-0.5,1.4-0.9c0.4-0.4,0.7-0.9,1-1.5c0.2-0.6,0.4-1.2,0.4-1.9
		c0-0.7-0.1-1.3-0.4-1.9C36.4,55.1,36,54.6,35.6,54.2z M35.7,59.1c-0.2,0.5-0.4,0.9-0.8,1.2c-0.3,0.3-0.7,0.6-1.1,0.8
		c-0.4,0.2-0.9,0.3-1.4,0.3c-0.6,0-1-0.1-1.5-0.3c-0.4-0.2-0.8-0.5-1.1-0.8c-0.3-0.3-0.5-0.7-0.7-1.2c-0.2-0.5-0.2-1-0.2-1.5
		c0-0.6,0.1-1.1,0.3-1.5c0.2-0.5,0.4-0.9,0.8-1.2c0.3-0.3,0.7-0.6,1.1-0.8c0.4-0.2,0.9-0.3,1.4-0.3c0.5,0,1,0.1,1.4,0.3
		c0.4,0.2,0.8,0.4,1.1,0.8c0.3,0.3,0.6,0.7,0.8,1.2c0.2,0.5,0.3,1,0.3,1.5C36,58.1,35.9,58.6,35.7,59.1z"></path>
</g>
</svg></a></div>
    <div class="footer__social-links">
        <ul class="rlist rlist--inline centered">
            <li><a href="http://on.fb.me/1tgHakh" title="Facebook" target="_blank"><i aria-hidden="true" class="icon-Icon_Facebook"></i></a></li>

            <li><a href="https://www.instagram.com/cellpress/" title="Instagram" target="_blank"><svg width="18px" height="18px" viewBox="0 0 18 18" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"> <g transform="translate(-147.000000, -16.000000)" fill-rule="nonzero" fill="#969696"> <g id="Instagram-Logo" transform="translate(147.000000, 16.000000)"> <path d="M9,1.62580645 C11.4096774,1.62580645 11.7,1.62580645 12.6290323,1.68387097 C13.5,1.71290323 13.9935484,1.85806452 14.3129032,2.00322581 C14.7193548,2.17741935 15.0387097,2.3516129 15.3580645,2.67096774 C15.6774194,2.99032258 15.8806452,3.28064516 16.0258065,3.71612903 C16.1419355,4.03548387 16.2870968,4.5 16.3451613,5.4 C16.3741935,6.35806452 16.4032258,6.61935484 16.4032258,9.02903226 C16.4032258,11.4387097 16.4032258,11.7290323 16.3451613,12.6580645 C16.316129,13.5290323 16.1709677,14.0225806 16.0258065,14.3419355 C15.8516129,14.7483871 15.6774194,15.0677419 15.3580645,15.3870968 C15.0387097,15.7064516 14.7483871,15.9096774 14.3129032,16.0548387 C13.9935484,16.1709677 13.5290323,16.316129 12.6290323,16.3741935 C11.6709677,16.4032258 11.4096774,16.4322581 9,16.4322581 C6.59032258,16.4322581 6.3,16.4322581 5.37096774,16.3741935 C4.5,16.3451613 4.00645161,16.2 3.68709677,16.0548387 C3.28064516,15.8806452 2.96129032,15.7064516 2.64193548,15.3870968 C2.32258065,15.0677419 2.11935484,14.7774194 1.97419355,14.3419355 C1.85806452,14.0225806 1.71290323,13.5580645 1.65483871,12.6580645 C1.62580645,11.7 1.62580645,11.4096774 1.62580645,9 C1.62580645,6.59032258 1.62580645,6.3 1.68387097,5.37096774 C1.71290323,4.5 1.85806452,4.00645161 2.00322581,3.68709677 C2.17741935,3.28064516 2.3516129,2.96129032 2.67096774,2.64193548 C2.99032258,2.32258065 3.28064516,2.11935484 3.71612903,1.97419355 C4.03548387,1.85806452 4.5,1.71290323 5.4,1.65483871 C6.3,1.62580645 6.59032258,1.62580645 9,1.62580645 L9,1.62580645 Z M9,0 C6.56129032,0 6.24193548,0 5.28387097,0.0580645161 C4.32580645,0.116129032 3.65806452,0.261290323 3.10645161,0.464516129 C2.52580645,0.696774194 2.00322581,1.01612903 1.50967742,1.50967742 C1.01612903,2.00322581 0.696774194,2.52580645 0.464516129,3.10645161 C0.232258065,3.68709677 0.0870967742,4.32580645 0.0580645161,5.28387097 C0,6.24193548 0,6.56129032 0,9 C0,11.4387097 0,11.7580645 0.0580645161,12.716129 C0.116129032,13.6741935 0.261290323,14.3419355 0.464516129,14.8935484 C0.696774194,15.4741935 1.01612903,15.9967742 1.50967742,16.4903226 C2.00322581,16.983871 2.52580645,17.3032258 3.10645161,17.5354839 C3.68709677,17.7677419 4.32580645,17.9129032 5.28387097,17.9419355 C6.24193548,18 6.56129032,18 9,18 C11.4387097,18 11.7580645,18 12.716129,17.9419355 C13.6741935,17.883871 14.3419355,17.7387097 14.8935484,17.5354839 C15.4741935,17.3032258 15.9967742,16.983871 16.4903226,16.4903226 C16.983871,15.9967742 17.3032258,15.4741935 17.5354839,14.8935484 C17.7677419,14.3129032 17.9129032,13.6741935 17.9419355,12.716129 C18,11.7580645 18,11.4387097 18,9 C18,6.56129032 18,6.24193548 17.9419355,5.28387097 C17.883871,4.32580645 17.7387097,3.65806452 17.5354839,3.10645161 C17.3032258,2.52580645 16.983871,2.00322581 16.4903226,1.50967742 C15.9967742,1.01612903 15.4741935,0.696774194 14.8935484,0.464516129 C14.3129032,0.232258065 13.6741935,0.0870967742 12.716129,0.0580645161 C11.7580645,0 11.4387097,0 9,0 L9,0 Z"></path> <path d="M9,4.38387097 C6.44516129,4.38387097 4.38387097,6.44516129 4.38387097,9 C4.38387097,11.5548387 6.44516129,13.616129 9,13.616129 C11.5548387,13.616129 13.616129,11.5548387 13.616129,9 C13.616129,6.44516129 11.5548387,4.38387097 9,4.38387097 Z M9,11.9903226 C7.34516129,11.9903226 6.00967742,10.6548387 6.00967742,9 C6.00967742,7.34516129 7.34516129,6.00967742 9,6.00967742 C10.6548387,6.00967742 11.9903226,7.34516129 11.9903226,9 C11.9903226,10.6548387 10.6548387,11.9903226 9,11.9903226 Z"></path> <circle id="Oval" cx="13.7903226" cy="4.20967742" r="1.07419355"></circle> </g> </g> </g></svg></a></li>
            
            <li><a href="https://www.linkedin.com/company/cell-press/" title="LinkedIn" target="_blank"><i aria-hidden="true" class="icon-linkedin"></i></a></li>
            
                        <li><a href="http://bit.ly/1zq7Q5T" title="Twitter" target="_blank">
                <!--<i aria-hidden="true" class="icon-Icon_Twitter"></i></a>-->
                
                <svg id="xicon" viewBox="0 0 1200 1227" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" role="none"><path fill="#969696" d="M714.163 519.284L1160.89 0H1055.03L667.137 450.887L357.328 0H0L468.492 681.821L0 1226.37H105.866L515.491 750.218L842.672 1226.37H1200L714.137 519.284H714.163ZM569.165 687.828L521.697 619.934L144.011 79.6944H306.615L611.412 515.685L658.88 583.579L1055.08 1150.3H892.476L569.165 687.854V687.828Z"></path></svg> 

                    <style>
                    .footer svg#xicon {
                      height: 16px;
                    }
                    </style>
            </a></li>

            
            <li><a href="/pb-assets/marketing/WeChat/WeChat-1557753222727.jpg" title="WeChat" target="_blank"><svg width="18px" height="15px" viewBox="0 0 18 15" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"> <g transform="translate(-122.000000, -17.000000)" fill-rule="nonzero" fill="#969696"> <g id="wechat" transform="translate(122.000000, 17.000000)"> <path d="M12.375,4.5 L12.375,4.5 L12.4875,4.5 L12.4875,4.5 C12.6898579,4.48604473 12.8520408,4.32704187 12.87,4.125 C12.8705905,4.04725572 12.8470025,3.9712499 12.8025,3.9075 C11.94,1.5675 9.4425,0 6.5625,0 C2.9475,0 0,2.52 0,5.625 C0.0313772094,7.34410122 0.895513317,8.94093526 2.3175,9.9075 L1.5675,11.46 C1.49009368,11.6087816 1.52088865,11.7908702 1.64291494,11.9059236 C1.76494122,12.0209769 1.94852501,12.0410168 2.0925,11.955 L4.08,10.8225 C4.61861992,11.0129999 5.17724298,11.1413322 5.745,11.205 C5.86564124,11.2178337 5.98503738,11.1715098 6.06545426,11.0806685 C6.14587113,10.9898272 6.17737153,10.865694 6.15,10.7475 C6.06148727,10.4219419 6.01114891,10.0871918 6,9.75 C6,6.855 8.8575,4.5 12.375,4.5 Z M8.25,3 C8.66421356,3 9,3.33578644 9,3.75 C9,4.16421356 8.66421356,4.5 8.25,4.5 C7.83578644,4.5 7.5,4.16421356 7.5,3.75 C7.5,3.33578644 7.83578644,3 8.25,3 Z M4.5,4.5 C4.08578644,4.5 3.75,4.16421356 3.75,3.75 C3.75,3.33578644 4.08578644,3 4.5,3 C4.91421356,3 5.25,3.33578644 5.25,3.75 C5.25,4.16421356 4.91421356,4.5 4.5,4.5 Z"></path> <path d="M18,9.75 C18,7.2675 15.48,5.25 12.375,5.25 C9.27,5.25 6.75,7.2675 6.75,9.75 C6.75,12.2325 9.27,14.25 12.375,14.25 C12.9568557,14.2502837 13.5364258,14.1772075 14.1,14.0325 L15.96,14.9625 C16.0114248,14.9874074 16.0678613,15.0002339 16.125,15 C16.2497193,14.9993787 16.3659682,14.9367912 16.4351508,14.8330172 C16.5043335,14.7292432 16.5173955,14.5978644 16.47,14.4825 L15.96,13.2075 C17.1784092,12.4716325 17.9450305,11.1723221 18,9.75 L18,9.75 Z M10.5,9 C10.0857864,9 9.75,8.66421356 9.75,8.25 C9.75,7.83578644 10.0857864,7.5 10.5,7.5 C10.9142136,7.5 11.25,7.83578644 11.25,8.25 C11.25,8.66421356 10.9142136,9 10.5,9 Z M14.25,9 C13.8357864,9 13.5,8.66421356 13.5,8.25 C13.5,7.83578644 13.8357864,7.5 14.25,7.5 C14.6642136,7.5 15,7.83578644 15,8.25 C15,8.66421356 14.6642136,9 14.25,9 Z" opacity="0.959999979"></path> </g> </g> </g></svg></a></li>
            
            <li><a href="https://www.weibo.com/CellPress" title="Weibo" target="_blank"><svg width="18px" height="15px" viewBox="0 0 18 15" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"> <g transform="translate(-99.000000, -17.000000)" fill-rule="nonzero" fill="#969696"> <g id="weibo" transform="translate(99.000000, 14.000000)"> <g transform="translate(0.000000, 3.000000)"> <path d="M13.2402211,7.47054172 C12.9918392,7.39866484 12.821608,7.34902326 12.9514975,7.03290287 C13.232804,6.34602189 13.2622915,5.75359781 12.9571055,5.33095486 C12.3847236,4.5380684 10.8191759,4.58064295 9.02514573,5.30975376 C9.02514573,5.30889193 8.46144724,5.54882627 8.60544724,5.11515185 C8.88150754,4.25435294 8.83953769,3.53386047 8.41043216,3.11759508 C7.43716583,2.17285363 4.84824121,3.15344733 2.62745729,5.3059617 C0.964944724,6.9186238 0,8.62798358 0,10.105855 C0,12.9324952 3.73748744,14.8235294 7.39429146,14.8235294 C12.1877186,14.8235294 15.3768844,11.9501778 15.3768844,9.80576471 C15.3768844,8.50974008 14.2514774,7.77442408 13.2402211,7.47054172 Z M7.40424121,13.5561176 C4.48625126,13.8315595 1.9678794,12.5686293 1.77811055,10.7327524 C1.58870352,8.89773735 3.80098492,7.18579207 6.71861307,6.90948837 C9.63678392,6.63266758 12.1556985,7.89663201 12.3447437,9.73164706 C12.533608,11.5675239 10.3227739,13.2796416 7.40424121,13.5561176 Z M18,5.16875787 C17.9985528,2.31402189 15.5695477,0 12.5728643,0 C12.222995,0 11.9396985,0.270098495 11.9396985,0.603283174 C11.9396985,0.936640219 12.222995,1.20656635 12.5728643,1.20656635 C14.8708945,1.20656635 16.7336683,2.98159781 16.7336683,5.17099863 C16.7336683,5.50435568 17.0173266,5.77428181 17.3668342,5.77428181 C17.7167035,5.77428181 18,5.50435568 18,5.17099863 C18,5.17099863 18,5.1696197 18,5.16875787 Z M15.4841608,5.08016142 C15.1948945,3.73415048 14.0812462,2.67323393 12.6683819,2.39744733 C12.3262915,2.33039672 11.9914372,2.54051163 11.9212462,2.86680164 C11.8506935,3.19309166 12.0712161,3.51179754 12.4133065,3.57919289 C13.3319397,3.75845417 14.0559196,4.44774829 14.2438794,5.32302599 C14.3146131,5.64931601 14.6491055,5.85925855 14.9915578,5.7923803 C15.3338291,5.72498495 15.5541709,5.40627907 15.4841608,5.08016142 Z M5.90761809,8.7069275 C4.7321005,8.9320383 3.93901508,9.87126402 4.1358392,10.8044569 C4.33248241,11.7378222 5.44504523,12.311803 6.62056281,12.0865198 C7.79571859,11.861409 8.58916583,10.922528 8.3921608,9.98899042 C8.19569849,9.0559699 7.08277387,8.48181669 5.90761809,8.7069275 Z"></path> </g> </g> </g> </g></svg></a></li>
            
            <li><a href="https://www.youtube.com/user/cellvideoabstracts" title="YouTube" target="_blank"><svg width="18px" height="13px" viewBox="0 0 18 13" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"> <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd"> <g transform="translate(-76.000000, -19.000000)" fill-rule="nonzero" fill="#969696"> <g id="youtube" transform="translate(76.000000, 14.000000)"> <path d="M17.2984219,6.41974219 C16.6486641,5.64735937 15.4490625,5.33232422 13.1580703,5.33232422 L4.84175391,5.33232422 C2.49834375,5.33232422 1.27838672,5.66771484 0.631089844,6.49001953 C0,7.29172266 0,8.47304297 0,10.1080547 L0,13.2243047 C0,16.3917773 0.748792969,18 4.84175391,18 L13.1581055,18 C15.1448555,18 16.2457383,17.7219844 16.9579688,17.040375 C17.688375,16.3413984 18,15.2001211 18,13.2243047 L18,10.1080547 C18,8.38381641 17.951168,7.19553516 17.2984219,6.41974219 Z M11.5560703,12.0963867 L7.77965625,14.0700586 C7.69524609,14.1141797 7.60289062,14.136082 7.51071094,14.136082 C7.40629687,14.136082 7.30212891,14.1079922 7.20987891,14.0521289 C7.03613672,13.9468711 6.93007031,13.7585391 6.93007031,13.5554414 L6.93007031,9.62075391 C6.93007031,9.41800781 7.03585547,9.22985156 7.20924609,9.12452344 C7.38267187,9.01919531 7.59839062,9.01198828 7.77832031,9.10546875 L11.5547344,11.0664141 C11.7468633,11.1661523 11.8675195,11.3645039 11.8678008,11.5809258 C11.8680469,11.7975586 11.747918,11.9961914 11.5560703,12.0963867 Z"></path> </g> </g> </g></svg></a></li>
            
        </ul>
    </div>
</div>

<style>

.ux3 .footer__logo svg {
    max-width: 160px !important;
}

.ux3 .footer__social-links a svg {
    max-width: 26px;
    height: 1.15rem;
    width: auto;
}

.ux3 .footer__social-links a:hover svg path {
    fill: #353535;
}

</style></div>

            

        

    

        


    

            

            
                <div class="footer__bottom text-onDark">
            

            <div data-widget-id="06227714-c621-4651-9879-b0ce5176cccc" data-widget-name="ux3-layout-widget"><div class="col-sm-4 col-md-5 clearfix">
    

        


    

            

            

            <div data-widget-id="07e1d276-b4dd-4870-b858-ed74e70d64ef" data-widget-name="UX3HTMLWidget"><div class="groups">
	<div class="group">
		<h2 class="group__title">Life &amp; medical sciences journals</h2>
		<ul class="rlist clearfix sided">
		<li>
			<a alt="Cell" href="/cell/home">Cell</a>
		</li>
		<li>
			<a alt="Cancer Cell" href="/cancer-cell/home">Cancer Cell</a>
		</li>
		<li>
			<a alt="Cell Chemical Biology" href="/cell-chemical-biology">Cell Chemical Biology</a>
		</li>
		<li>
			<a alt="Cell Genomics" href="/cell-genomics/home">Cell Genomics</a>
		</li>
		<li>
			<a alt="Cell Host and Microbe" href="/cell-host-microbe/home">Cell Host &amp; Microbe</a>
		</li>
		<li>
			<a alt="Cell Metabolism" href="/cell-metabolism/home">Cell Metabolism</a>
		</li>
		<li>
			<a alt="Cell Reports" href="/cell-reports/home">Cell Reports</a>
		</li>
		<li>
			<a alt="Cell Reports Medicine" href="/cell-reports-medicine/home">Cell Reports Medicine</a>
		</li>
		<li>
			<a alt="Cell Stem Cell" href="/cell-stem-cell/home">Cell Stem Cell</a>
		</li>
		<li>
			<a alt="Cell Systems" href="/cell-systems/home">Cell Systems</a>
		</li>
		<li>
			<a alt="Current Biology" href="/current-biology/home">Current Biology</a>
		</li>
		<li>
			<a alt="Developmental Cell" href="/developmental-cell/home">Developmental Cell</a>
		</li>
		<li>
			<a alt="Immunity" href="/immunity/home">Immunity</a>
		</li>
		<li>
			<a alt="Med" href="/med/home">Med</a>
		</li>
		<li>
			<a alt="Molecular Cell" href="/molecular-cell/home">Molecular Cell</a>
		</li>
		<li>
			<a alt="Neuron" href="/neuron/home">Neuron</a>
		</li>
		<li>
			<a alt="Structure" href="/structure/home">Structure</a>
		</li>
		<li>
			<a alt="American Journal of Human Genetics" href="/ajhg/home">American Journal of Human Genetics (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Biophysical Journal" href="/biophysj/home">Biophysical Journal (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Biophysical Reports" href="/biophysreports/home">Biophysical Reports (<i>partner</i>)</a>
		</li>	
		<li>
			<a alt="HGG Advances" href="/hgg-advances/home">Human Genetics and Genomics Advances (<i>partner</i>)</a></li>
		<li>
			<a alt="Molecular Plant" href="/molecular-plant/home">Molecular Plant (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Molecular Therapy" href="/molecular-therapy-family/molecular-therapy/home">Molecular Therapy (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Molecular Therapy Methods and Clinical Development" href="/molecular-therapy-family/methods/home">Molecular Therapy Methods &amp; Clinical Development (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Molecular Therapy Nucleic Acids" href="/molecular-therapy-family/nucleic-acids/home">Molecular Therapy Nucleic Acids (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Molecular Therapy Oncology" href="/molecular-therapy-family/oncology/home">Molecular Therapy Oncology (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Plant Communications" href="/plant-communications/home">Plant Communications (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Stem Cell Reports" href="/stem-cell-reports/home">Stem Cell Reports (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Trends in Biochemical Sciences" href="/trends/biochemical-sciences/home">Trends in Biochemical Sciences</a>
		</li>
		<li>
		</li><li>
			<a alt="Trends in Cancer" href="/trends/cancer/home">Trends in Cancer</a>
		</li>
		<li>
			<a alt="Trends in Cell Biology" href="/trends/cell-biology/home">Trends in Cell Biology</a>
		</li>
		<li>
			<a alt="Trends in Ecology and Evolution" href="/trends/ecology-evolution/home">Trends in Ecology &amp; Evolution</a>
		</li>
		<li>
			<a alt="Trends in Endocrinology and Metabolism" href="/trends/endocrinology-metabolism/home">Trends in Endocrinology &amp; Metabolism</a>
		</li>
		<li>
			<a alt="Trends in Genetics" href="/trends/genetics/home">Trends in Genetics</a>
		</li>
		<li>
			<a alt="Trends in Immunology" href="/trends/immunology/home">Trends in Immunology</a>
		</li>
		<li>
			<a alt="Trends in Microbiology" href="/trends/microbiology/home">Trends in Microbiology</a>
		</li>
		<li>
			<a alt="Trends in Molecular Medicine" href="/trends/molecular-medicine/home">Trends in Molecular Medicine</a>
		</li>
		<li>
			<a alt="Trends in Neurosciences" href="/trends/neurosciences/home">Trends in Neurosciences</a>
		</li>
		<li>
			<a alt="Trends in Parasitology" href="/trends/parasitology/home">Trends in Parasitology</a>
		</li>
		<li>
			<a alt="Trends in Pharmacological Sciences" href="/trends/pharmacological-sciences/home">Trends in Pharmacological Sciences</a>
		</li>
		<li>
			<a alt="Trends in Plant Science" href="/trends/plant-science/home">Trends in Plant Science</a>
		</li>
		</ul>
	</div>

	<div class="group">
		<h2 class="group__title">Physical sciences &amp; engineering journals</h2>
		<ul class="rlist clearfix sided">
		  <li><a alt="Cell Biomaterials" href="/cell-biomaterials/home">Cell Biomaterials</a></li>
		  <li>
			<a alt="Cell Reports Physical Science" href="/cell-reports-physical-science/home">Cell Reports Physical Science</a>
		</li>
		<li>
			<a alt="Chem" href="/chem/home">Chem</a>
		</li>
		<li>
			<a alt="Chem Catalysis" href="/chem-catalysis/home">Chem Catalysis</a>
		</li>
		<li>
			<a alt="Device" href="/device/home">Device</a>
		</li>
		<li>
			<a alt="Joule" href="/joule/home">Joule</a>
		</li>
		<li>
			<a alt="Matter" href="/matter/home">Matter</a>
		</li>	
		<li><a alt="Matter" href="/newton/home">Newton</a></li>
		<li>
			<a alt="Trends in Chemistry" href="/trends/chemistry/home">Trends in Chemistry</a>
		</li>			
		</ul>
	</div>

<div class="group">
	<h2 class="group__title">Multidisciplinary journals</h2>
	<ul class="rlist clearfix sided">
	  		<li>
			<a alt="Cell Reports Methods" href="/cell-reports-methods/home">Cell Reports Methods</a>
		</li>
		<li>
			<a alt="Cell Reports Sustainability" href="/cell-reports-sustainability/home">Cell Reports Sustainability</a>
		</li>
		<li>
			<a alt="Heliyon" href="/heliyon/home">Heliyon</a>
		</li>	
		<li>
			<a alt="iScience" href="/iscience/home">iScience</a>
		</li>
		<li>
			<a alt="One Earth" href="/one-earth/home">One Earth</a>
		</li>
		<li>
			<a alt="Patterns" href="/patterns/home">Patterns</a>
		</li>
		<li>
			<a alt="STAR Protocols" href="/star-protocols/home">STAR Protocols</a>
		</li>
		<li>
			<a alt="Nexus" href="/nexus/home">Nexus (<i>partner</i>)</a>
		</li>			
        <li>
			<a alt="The Innovation" href="/the-innovation/home">The Innovation (<i>partner</i>)</a>
		</li>
		<li>
			<a alt="Trends in Biotechnology" href="/trends/biotechnology/home">Trends in Biotechnology</a>
		</li>
		<li>
			<a alt="Trends in Cognitive Sciences" href="/trends/cognitive-sciences/home">Trends in Cognitive Sciences</a>
		</li>
	</ul>
</div>

</div>
</div>

            

        
</div><div class="col-sm-4 col-md-5 clearfix">
    

        


    

            

            

            <div data-widget-id="850476de-00cb-4c0d-943c-bf1881da24f9" data-widget-name="UX3HTMLWidget"><div class="groups">
	<div class="clearfix">
		<div class="group sided">
			<h2 class="group__title">Authors</h2>
			<ul class="rlist clearfix">
				<li>
					<a alt="Submit article" href="/submit-to-cell-press">Submit article</a>
				</li>
				<li>
					<a alt="Multi-Journal Submission" href="/multi-journal-submission">Multi-Journal Submission</a>
				</li>
				<li>
					<a alt="STAR Methods" href="/star-authors-guide">STAR Methods</a>
				</li>
				<li>
					<a alt="Sneak Peek – Preprints" href="/sneakpeek">Sneak Peek – Preprints</a>
				</li>
				<li>
					&nbsp;
				</li>
			</ul>
		<h2 class="group__title">Reviewers</h2>
			<ul class="rlist clearfix">
				<li>
					<a alt="Reviewers" href="/reviewers">Information for reviewers</a>
				</li>
				<li>
					&nbsp;
				</li>
			</ul>
		<h2 class="group__title">News &amp; events</h2>
			<ul class="rlist clearfix">
				<li>
					<a alt="Newsroom" href="/newsroom">Newsroom</a>
				</li>
				<li>
					<a alt="Events" href="/events">Events</a>
				</li>
				<li>
					<a alt="Cell Symposia" href="/symposia">Cell Symposia</a>
				</li>
				<li>
					<a alt="Consortia Hub" href="/consortia">Consortia Hub</a>
				</li>
				<li>
					<a alt="Webinars" href="/webinars">Webinars</a>
				</li>
								<li>
					&nbsp;
				</li>
			</ul>
		<h2 class="group__title">Multimedia</h2>
			<ul class="rlist clearfix">
				<li>
					<a alt="Cell Press Podcast" href="/podcast">Cell Press Podcast</a>
				</li>
				<li>
					<a alt="Cell Press Videos" href="/video">Cell Press Videos</a>
				</li>
				<li>
					<a alt="Color and Comics" href="/comics">Coloring and Comics</a>
				</li>
				<li>
					<a alt="Figure360" href="/video-guidelines">Figure360</a>
				</li>
				<li>
					<a alt="Cell Picture Show" href="/pictureshow">Cell Picture Show</a>
				</li>
				<li>
					<a alt="Research Arc" href="/research-arc">Research Arc</a>
				</li>
			</ul>
		</div>

		<div class="group sided">
			<h2 class="group__title">About</h2>
			<ul class="rlist clearfix">
				<li>
					<a alt="About Cell Press" href="/about">About Cell Press</a>
				</li>

				<li>
					<a alt="Open access" href="/open-access">Open access</a>
				</li>
				<li>
					<a alt="COVID Hub" href="/covid-19">COVID Hub</a>
				</li>
				<li>
					<a alt="Sustainability" href="/sustainability">Sustainability hub</a>
				</li>
				<li>
					<a alt="Inclusion and diversity" href="/diversity">Inclusion and diversity</a>
				</li>
				<li>
					&nbsp;
				</li>
			</ul>
			<h2 class="group__title">Contact</h2>
			<ul class="rlist clearfix">
				<li>
					<a alt="Contact us" href="/contact">Contact us</a>
				</li>
				<li>
					<a alt="Help and Support" href="https://service.elsevier.com/app/overview/cell-press/" target="_blank">Help &amp; Support</a>
				</li>
				<li>
					&nbsp;
				</li>
			</ul>
			<h2 class="group__title">Careers</h2>
			<ul class="rlist clearfix">
				<li>
					<a alt="Cell Press Careers" href="https://relx.wd3.myworkdayjobs.com/en-US/ElsevierJobs" target="_blank">Cell Press Careers</a>
				</li>
			</ul>
		</div>
	</div>
</div></div>

            

        
</div><div class="col-sm-4 col-md-2 clearfix">
    

        


    

            

            

            <div data-widget-id="beafac41-1cfc-440b-9b55-74aba4a5612c" data-widget-name="UX3HTMLWidget"><div class="groups">
	<div class="group">
		<h2 class="group__title">Access</h2>
		<ul class="rlist clearfix">
			<li>
				<a alt="Subscribe" href="/subscribe">Subscribe</a>
			</li>
			<li>
				<a alt="Claim" href="/activate">Claim</a>
			</li>
			<li>
				<a alt="Read It Now" href="/read-it-now">Read-It-Now</a>
			</li>
			<li>
				<a alt="Recommend to Librarian" href="http://info.cell.com/request-access-to-cell-press-content" target="_blank">Recommend to Librarian</a>
			</li>
			<li>
				<a alt="Publication Alerts" href="/action/showPreferences?menuTab=Alerts">Publication Alerts</a>
			</li>
		</ul>
	</div>
	<div class="group">
		<h2 class="group__title">Collections</h2>
		<ul class="rlist clearfix">
			<li>
				<a alt="Best of Cell Press" href="/bestof">Best of Cell Press</a>
			</li>
			<li>
				<a alt="Cell Press Reviews" href="/reviews">Cell Press Reviews</a>
			</li>
			<li>
				<a alt="Cell Selections" href="/selections">Cell Press Selections</a>
			</li>
			<li>
				<a alt="Nucleus Collections" href="/nucleus">Nucleus Collections</a>
			</li>
			<li>
				<a alt="SnapShots" href="/snapshots">SnapShot Archive</a>
			</li>
		</ul>
	</div>
	<div class="group">
		<h2 class="group__title">Information</h2>
		<ul class="rlist clearfix">
			<li>
				<a alt="For Advertisters" href="/media-kit">For Advertisers</a>
			</li>
			<li>
				<a alt="For Recruiters" target="_blank" href="/pb-assets/Cell/common/CP-RecruitmentKit-US-2018-LowRes-1712070648.pdf">For Recruiters</a>
			</li>
			<li>
				<a alt="For Librarians" target="_blank" href="https://www.elsevier.com/products/sciencedirect/journals/direct-subscription-journals">For Librarians</a>
			</li>
			<li>
				<a alt="Privacy Policy" target="_blank" href="https://www.elsevier.com/legal/privacy-policy">Privacy Policy</a>
			</li>
			<li>
				<a alt="Terms and Conditions" target="_blank" href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions">Terms and Conditions</a>
			</li>
			<li>
				<a alt="Accessibility" href="/accessibility">Accessibility</a>
			</li>
		</ul>
	</div>
</div></div>

            

        
</div></div>

            
                </div>
            

        

    

        


    

            

            

            <div data-widget-id="779ad11f-7bcd-4a2a-a2cd-8c67b649cbb2" data-widget-name="UX3HTMLWidget"><style>
 
button#cookieBtn {
   text-decoration: none;
   background-color: transparent;
   color: #005789;
   font-weight: bold;
   padding: 0;
   margin: 0;
   font-size: 14px;
}
 
button#cookieBtn:hover {
   text-decoration: underline;
}

</style>
<script>
// HIDE ONETRUST BACKGROUND AFTER USER PRESSES ESCAPE KEY
setTimeout(function(){ 
   $("#onetrust-pc-sdk").on("keydown", function(e) { 
      if (e.keyCode == 27) {  // ESC key
         setTimeout(function(){ 
            $(".onetrust-pc-dark-filter").css("display","none");
         }, 100); 
      }
   });
}, 5000);
</script>

<span class="align-center copy-right">
<hr>
<p align="center"><b>The content on this site is intended for healthcare professionals and researchers across all fields of science.</b></p>
<hr>
<div>
<p>We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the 
      <b><button id="cookieBtn" class="ot-sdk-show-settings" type="button" aria-label="Manage cookie consent preferences">Cookie Settings</button></b> for this site.<br>

All content on this site: Copyright © 2025 Elsevier Inc., its licensors, and contributors. <br>All rights are reserved, including those for text and data mining, AI training, and similar technologies. <br>For all open access content, the relevant licensing terms apply.
</p>
<ul class="rlist--inline">
			<li>
				<a alt="Privacy Policy" target="_blank" href="https://www.elsevier.com/legal/privacy-policy">Privacy Policy</a>&nbsp;&nbsp;
			</li>
			<li>
				<a alt="Terms and Conditions" target="_blank" href="https://www.elsevier.com/legal/elsevier-website-terms-and-conditions">Terms &amp; Conditions</a>&nbsp;&nbsp;
			</li>
			<li>
				<a alt="Accessibility" href="/accessibility">Accessibility</a>&nbsp;&nbsp;
			</li>
			<li>
				<a alt="Help and Support" target="_blank" href="https://service.elsevier.com/app/overview/cell-press/">Help &amp; Support</a>&nbsp;&nbsp;
			</li>
			<li>
				<a alt="Contact" href="/contact">Contact</a>
			</li>
			</ul>
<p>
<a href="https://www.relx.com"><img src="/pb/assets/raw/Health%20Advance/images/relx-1554393210983.png" alt="RELX" rel="nofollow" target="_new"></a></p>
</div>

</span></div>

            

        

    

        


    

            

            

            <div data-widget-id="c5e179c1-156e-41e3-af7f-5e307efa8acf" data-widget-name="UX3HTMLWidget"><style>#brandingRow{
    background-color:#fff;
    padding:7px 26px 7px 30px;
    color:#007DBC;
    font-size:14px;
    clear:both;
    width:100%
}
#brandingRow a{
    text-decoration:none;
    color:#007DBC
}
#brandingRow a:hover{
    text-decoration:underline
}
#brandingRowRight{
    display:inline;
    float:right;
    width:auto;
    padding:0;
    margin:0
}
svg#cp_logo {
  float: none;
  height: 36px;
  width: 36px;
  margin-left: 0px;
  margin-top: 0px;
}

footer hr {
  display: block;
}

@media screen and (max-width: 600px){
    #brandingRow{
        font-size:12px
    }
}
@media screen and (max-width: 750px){
    #brandingRow{
        padding:7px 18px 7px 16px
    }
    svg#cp_logo{
        margin-right:10px
    }
}
@media screen and (max-width: 800px) {
   a#cpIconLnk {
      display: none;
   }
}

.header__wrapper.clearfix .col-xs-6:first-of-type{
    width:55%
}
.header__wrapper.clearfix .col-xs-6:nth-of-type(2){
    width:45%
}
@media screen and (min-width: 800px) and (max-width: 1000px){
    .header__wrapper.clearfix .col-xs-6:first-of-type{
        width:75%
    }
    .header__wrapper.clearfix .col-xs-6:nth-of-type(2){
        width:25%
    }
}

</style>

<script>
var partnerx = false;
var overrideEndorsement = "";
var tmpj = $("input[name='journalCode']").attr("value");
	
if (window.location.pathname == "/molecular-therapy-family/home") {
	tmpj = "ymthe";
}
	
var ribbonx = "";
if (tmpj == "ajhg" || tmpj == "bpj" || tmpj == "molp" || tmpj == "xplc" || tmpj == "stemcr" || tmpj == "ymthe" || tmpj == "xhgg" || tmpj == "omtn" || tmpj == "omto" || tmpj == "omtm" || tmpj == "biophysreports" ||  tmpj == "bpr" || tmpj == "xinn" || tmpj == "omton") {
	partnerx = true;
	ribbonx = "<a href='https://www.cell.com' data-aa-name='cell press endorsement' data-aa-region='cp global header' title='Visit Cell.com'>A Cell Press partner journal</a>";
} else if (tmpj != "" && tmpj != "undefined" && tmpj != undefined) {
	ribbonx = "<a href='/' data-aa-name='cell press endorsement' data-aa-region='cp global header' title='Visit Cell.com'>A Cell Press journal</a>";
} else {
	ribbonx = "<a href='/' data-aa-name='cell press endorsement' data-aa-region='cp global header' title='Visit Cell.com'>A Cell Press resource</a>";
}
	
if (window.location.pathname == "/") {
	ribbonx = "";
}
if (overrideEndorsement != "") {
	ribbonx = overrideEndorsement;
}

$(".header__wrapper.clearfix").prepend("<div id='brandingRow'><a href='/' data-aa-name='science that inspires' data-aa-region='cp global header' title='Visit Cell.com'>Science that inspires</a><p id='brandingRowRight'>" + ribbonx + "</p></div>");
	
// handle scrolling effect on article pages
if ($("article").length > 0) {
	var scrollx;
	$(window).scroll(function() {
		scrollx = $(window).scrollTop();
		if (scrollx > 0) { 
			$("#brandingRow").css("display","none"); 
		} else {
			$("#brandingRow").css("display","block");
		}
	});
}

if (window.location.pathname == "/" || partnerx == false) {
               $("<a href='/home' id='cpIconLnk' data-aa-name='cell press logo' data-aa-region='cp global header' title='Cell Press' target='_blank'><svg id='cp_logo' version='1.1' xmlns='http://www.w3.org/2000/svg' xmlns:xlink='http://www.w3.org/1999/xlink' x='0px' y='0px' viewBox='0 0 100 98.1' style='enable-background:new 0 0 100 98.1;' xml:space='preserve' height='100' width='98.1'><path style='fill:#FFFFFF;' d='M69.09,0.09c-4.01-0.6-7.83,1.94-8.78,5.89l-3.14,13.11c-0.76,3.19-3.44,5.56-6.7,5.93l-18.6,2.13          C11.83,29.31-2.53,47.66,0.37,67.78c2.3,15.96,15.18,27.77,30.54,30.08c4.01,0.6,7.83-1.94,8.78-5.89l3.14-13.11 c0.76-3.19,3.44-5.56,6.69-5.93l18.6-2.13c20.04-2.17,34.41-20.52,31.5-40.65C97.32,14.21,84.45,2.39,69.09,0.09z M65.06,47.2  l-11.75,1.4c-1.98,0.21-3.62,1.65-4.08,3.59l-3.43,14.3c-1.01,4.22-4.5,7.39-8.8,8c-6.66,0.72-12.63-4.2-13.15-10.92                c-0.51-6.5,4.6-12.11,11.08-12.81l11.75-1.39c1.98-0.22,3.62-1.65,4.08-3.59l3.43-14.3c1.01-4.22,4.5-7.39,8.8-8          c6.66-0.72,12.63,4.19,13.15,10.92C76.66,40.89,71.55,46.5,65.06,47.2z'/></svg></a>").insertBefore(".header__wrapper.clearfix .journal-logos:eq(0)");
}


</script></div>

            

        

    

        


    

            

            

            <div data-widget-id="1af759b7-9bb6-4413-ada9-51a8333e8fb8" data-widget-name="UX3HTMLWidget"><style>
    /*This was added temporarily until the PB changelog tab issue got fixed. [LIT-444969 - c#4]*/
    [data-tab-id="changelogTab"] {
        display: none !important;
    }
    
    /*This was added temporarily until the PB changelog tab issue got fixed. [LIT-518839]*/
    @media (min-width: 769px) {
        .ux3 .quick-search .dropBlock [data-db-target-of],
        .quick-search .dropBlock [data-db-target-of] {
            width: 100vw !important;
        }
    }
</style></div>

            

        
</div></div>

            

        

        </div>
    

    

        


    

            

            

            <div data-widget-id="d7e0813b-a300-497a-ab37-9c3ddaf03e71" data-widget-name="UX3HTMLWidget"><!--
<div class="session-reminder hidden">
    <div class="session-reminder__overlay">
        <div class="session-reminder__dialog">
            <div class="session-reminder__dialog-inner">
                <div class="dialog-header" role="dialog" aria-labelledby="dialog-title" aria-describedby="dialog-desc">
                    <h2 class="dialog-header-title" id="dialog-title">
                        <span>Session Timeout</span>
                        <div class="dialog-timer">(2:00)</div>
                    </h2>
                    <button class="dialog-close" type="button" aria-label="close dialog">
                        <i class="icon-tools_close" aria-hidden="true"></i>
                    </button>
                </div>
                <div class="dialog-body">
                    <p class="dialog-desc" id="dialog-desc">Your session will expire shortly. If you are still working, click the ‘Keep Me Logged In’ button below. If you do not respond within the next minute, you will be automatically logged out.</p>
                    <p class="dialog-expired sr-only" aria-live="polite"></p>
                </div>
                <div class="dialog-footer">
                    <button class="session-reset" type="button">Keep Me Logged In</button>
                </div>
            </div>
        </div>
    </div>
</div>
<a class="sr-only" href="javascript:void(0)" aria-hidden="true"></a>
--></div>

            

        
        </div>
    </div>


































    



















        
        
            
                <script src="/products/marlin/cell/releasedAssets/js/main.bundle-90475670808d5d3eee41.js"></script>
            
        
        
        

    




<script type="text/javascript">
    var pageData =  {"journal":{"specialty":"Cell Press","issn":"0092-8674","name":"Cell"},"page":{"loadTimestamp":"1749587859780","server":"cell","environment":"prod","businessUnit":"ELS:RAP:JBS","noTracking":"","name":"fulltext:html","section":"Cell","language":"en","type":"CP-CA","productName":"JB"},"visitor":{"departmentName":"|ae:ScienceDirect Guests","accessType":"ae:ANON_GUEST|ae:ANON_GUEST","accountId":"ae:838949|ae:228598","accountName":"ae:Cell Guest Account|ae:ScienceDirect Guests","departmentId":"ae:977212|ae:291352","ipAddress":"189.120.74.179","loginStatus":"anonymous","userId":"ae:246228266|ae:12975512"},"content":[{"accessType":"article:free:openarchive","volumeNumber":"183","issueNumber":"2","viewState":"fulltext","format":"MIME-HTML","id":"pii:S0092867420311417","coverDate":"202010","type":"XOCS-JOURNAL:SCOPE-FULL","title":"A Phase Ib Trial of Personalized Neoantigen Therapy Plus AntiPD1 in Patients with Advanced Melanoma Nonsmall Cell Lung Cancer or Bladder Cancer","status":"S300"}]};
</script>

<script type="text/javascript">
    if(typeof pageDataTracker !== "undefined") {
        pageDataTracker.trackPageLoad();
    }
</script>
<script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94dbaaf4bed24292',t:'MTc0OTU4Nzg1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94dbaaf4bed24292&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.6.2&quot;,&quot;token&quot;:&quot;57a02315956f4b2e82817b3dfa99b1a2&quot;}" crossorigin="anonymous"></script>


<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="onetrust-consent-sdk" data-nosnippet="true"><div class="onetrust-pc-dark-filter ot-fade-in" style="z-index:2147483645;"></div><div id="onetrust-banner-sdk" class="otFlat bottom ot-wo-title ot-buttons-fw" tabindex="0" role="region" aria-label="Cookie banner"><div role="dialog" aria-modal="true" aria-label="Privacy"><div class="ot-sdk-container"><div class="ot-sdk-row"><div id="onetrust-group-container" class="ot-sdk-eight ot-sdk-columns"><div class="banner_logo"></div><div id="onetrust-policy"><div id="onetrust-policy-text">We use cookies that are necessary to make our site work. We may also use additional cookies to analyze, improve, and personalize our content and your digital experience. For more information, see our<a class="ot-cookie-policy-link" href="https://www.elsevier.com/legal/cookienotice" target="_blank" aria-label=", opens in a new tab" rel="noopener">Cookie Policy</a></div></div></div><div id="onetrust-button-group-parent" class="ot-sdk-three ot-sdk-columns"><div id="onetrust-button-group"><button id="onetrust-pc-btn-handler" class="cookie-setting-link">Cookie Settings</button>  <button id="onetrust-accept-btn-handler">Accept all cookies</button></div></div></div></div><!-- Close Button --><div id="onetrust-close-btn-container"></div><!-- Close Button END--></div></div><div id="onetrust-pc-sdk" class="otPcCenter ot-hide ot-fade-in" lang="en" aria-label="Preference center" role="region"><div role="dialog" aria-modal="true" style="height: 100%;" aria-label="Cookie Preference Center"><!-- Close Button --><div class="ot-pc-header"><!-- Logo Tag --><div class="ot-pc-logo" role="img" aria-label="Company Logo"><img alt="Company Logo" src="https://cdn.cookielaw.org/logos/static/ot_company_logo.png"></div></div><!-- Close Button --><div id="ot-pc-content" class="ot-pc-scrollbar"><div class="ot-optout-signal ot-hide"><div class="ot-optout-icon"><svg xmlns="http://www.w3.org/2000/svg"><path class="ot-floating-button__svg-fill" d="M14.588 0l.445.328c1.807 1.303 3.961 2.533 6.461 3.688 2.015.93 4.576 1.746 7.682 2.446 0 14.178-4.73 24.133-14.19 29.864l-.398.236C4.863 30.87 0 20.837 0 6.462c3.107-.7 5.668-1.516 7.682-2.446 2.709-1.251 5.01-2.59 6.906-4.016zm5.87 13.88a.75.75 0 00-.974.159l-5.475 6.625-3.005-2.997-.077-.067a.75.75 0 00-.983 1.13l4.172 4.16 6.525-7.895.06-.083a.75.75 0 00-.16-.973z" fill="#FFF" fill-rule="evenodd"></path></svg></div><span></span></div><h2 id="ot-pc-title">Cookie Preference Center</h2><div id="ot-pc-desc">We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our <a href="https://www.elsevier.com/legal/cookienotice/_nocache" target="_blank">Cookie Policy</a> and the list of <a href="https://support.google.com/admanager/answer/9012903" target="_blank">Google Ad-Tech Vendors</a>.
<br>
<br>
You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer. See the different category headings below to find out more or change your settings.
<br>
</div><button id="accept-recommended-btn-handler">Allow all</button><section class="ot-sdk-row ot-cat-grp"><h3 id="ot-category-title"> Manage Consent Preferences</h3><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="1"><button aria-expanded="false" ot-accordion="true" aria-controls="ot-desc-id-1" aria-labelledby="ot-header-id-1 ot-status-id-1"></button><!-- Accordion header --><div class="ot-acc-hdr ot-always-active-group"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-1">Strictly Necessary Cookies</h4><div id="ot-status-id-1" class="ot-always-active">Always active</div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-1">These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
<br><br></p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details List" data-parent-id="1">Cookie Details List‎</button></div></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="3"><button aria-expanded="false" ot-accordion="true" aria-controls="ot-desc-id-3" aria-labelledby="ot-header-id-3"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-3">Functional Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-3" id="ot-group-id-3" role="switch" class="category-switch-handler" data-optanongroupid="3" aria-labelledby="ot-header-id-3"> <label class="ot-switch" for="ot-group-id-3"><span class="ot-switch-nob"></span> <span class="ot-label-txt">Functional Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-3">These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details List" data-parent-id="3">Cookie Details List‎</button></div></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="2"><button aria-expanded="false" ot-accordion="true" aria-controls="ot-desc-id-2" aria-labelledby="ot-header-id-2"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-2">Performance Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-2" id="ot-group-id-2" role="switch" class="category-switch-handler" data-optanongroupid="2" aria-labelledby="ot-header-id-2"> <label class="ot-switch" for="ot-group-id-2"><span class="ot-switch-nob"></span> <span class="ot-label-txt">Performance Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-2">These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details List" data-parent-id="2">Cookie Details List‎</button></div></div></div><div class="ot-accordion-layout ot-cat-item ot-vs-config" data-optanongroupid="4"><button aria-expanded="false" ot-accordion="true" aria-controls="ot-desc-id-4" aria-labelledby="ot-header-id-4"></button><!-- Accordion header --><div class="ot-acc-hdr"><div class="ot-plus-minus"><span></span><span></span></div><h4 class="ot-cat-header" id="ot-header-id-4">Targeting Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-4" id="ot-group-id-4" role="switch" class="category-switch-handler" data-optanongroupid="4" aria-labelledby="ot-header-id-4"> <label class="ot-switch" for="ot-group-id-4"><span class="ot-switch-nob"></span> <span class="ot-label-txt">Targeting Cookies</span></label> </div></div><!-- accordion detail --><div class="ot-acc-grpcntr ot-acc-txt"><p class="ot-acc-grpdesc ot-category-desc" id="ot-desc-id-4">These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. If you do not allow these cookies, you will experience less targeted advertising.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details List" data-parent-id="4">Cookie Details List‎</button></div></div></div><!-- Groups sections starts --><!-- Group section ends --><!-- Accordion Group section starts --><!-- Accordion Group section ends --></section></div><section id="ot-pc-lst" class="ot-hide ot-hosts-ui ot-pc-scrollbar"><div id="ot-pc-hdr"><div id="ot-lst-title"><button class="ot-link-btn back-btn-handler" aria-label="Back"><svg id="ot-back-arw" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 444.531 444.531" xml:space="preserve"><title>Back Button</title><g><path fill="#656565" d="M213.13,222.409L351.88,83.653c7.05-7.043,10.567-15.657,10.567-25.841c0-10.183-3.518-18.793-10.567-25.835
                    l-21.409-21.416C323.432,3.521,314.817,0,304.637,0s-18.791,3.521-25.841,10.561L92.649,196.425
                    c-7.044,7.043-10.566,15.656-10.566,25.841s3.521,18.791,10.566,25.837l186.146,185.864c7.05,7.043,15.66,10.564,25.841,10.564
                    s18.795-3.521,25.834-10.564l21.409-21.412c7.05-7.039,10.567-15.604,10.567-25.697c0-10.085-3.518-18.746-10.567-25.978
                    L213.13,222.409z"></path></g></svg></button><h3>Cookie List</h3></div><div class="ot-lst-subhdr"><div class="ot-search-cntr"><p role="status" class="ot-scrn-rdr"></p><input id="vendor-search-handler" type="text" name="vendor-search-handler" placeholder="Search…" aria-label="Cookie list search"> <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 -30 110 110" aria-hidden="true"><title>Search Icon</title><path fill="#2e3644" d="M55.146,51.887L41.588,37.786c3.486-4.144,5.396-9.358,5.396-14.786c0-12.682-10.318-23-23-23s-23,10.318-23,23
            s10.318,23,23,23c4.761,0,9.298-1.436,13.177-4.162l13.661,14.208c0.571,0.593,1.339,0.92,2.162,0.92
            c0.779,0,1.518-0.297,2.079-0.837C56.255,54.982,56.293,53.08,55.146,51.887z M23.984,6c9.374,0,17,7.626,17,17s-7.626,17-17,17
            s-17-7.626-17-17S14.61,6,23.984,6z"></path></svg></div><div class="ot-fltr-cntr"><button id="filter-btn-handler" aria-label="Filter" aria-haspopup="true"><svg role="presentation" aria-hidden="true" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 402.577 402.577" xml:space="preserve"><title>Filter Icon</title><g><path fill="#fff" d="M400.858,11.427c-3.241-7.421-8.85-11.132-16.854-11.136H18.564c-7.993,0-13.61,3.715-16.846,11.136
      c-3.234,7.801-1.903,14.467,3.999,19.985l140.757,140.753v138.755c0,4.955,1.809,9.232,5.424,12.854l73.085,73.083
      c3.429,3.614,7.71,5.428,12.851,5.428c2.282,0,4.66-0.479,7.135-1.43c7.426-3.238,11.14-8.851,11.14-16.845V172.166L396.861,31.413
      C402.765,25.895,404.093,19.231,400.858,11.427z"></path></g></svg></button></div><div id="ot-anchor"></div><section id="ot-fltr-modal"><div id="ot-fltr-cnt"><button id="clear-filters-handler">Clear</button><div class="ot-fltr-scrlcnt ot-pc-scrollbar"><div class="ot-fltr-opts" role="list"><div class="ot-fltr-opt" role="listitem"><div class="ot-chkbox"><input id="chkbox-id" type="checkbox" class="category-filter-handler"> <label for="chkbox-id"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div><div class="ot-fltr-btns"><button id="filter-apply-handler">Apply</button> <button id="filter-cancel-handler">Cancel</button></div></div></div></section></div></div><section id="ot-lst-cnt" class="ot-host-cnt ot-pc-scrollbar"><div id="ot-sel-blk"><div class="ot-sel-all"><div class="ot-sel-all-hdr"><span class="ot-consent-hdr">Consent</span> <span class="ot-li-hdr">Leg.Interest</span></div><div class="ot-sel-all-chkbox"><div class="ot-chkbox" id="ot-selall-hostcntr"><input id="select-all-hosts-groups-handler" type="checkbox"> <label for="select-all-hosts-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-vencntr"><input id="select-all-vendor-groups-handler" type="checkbox"> <label for="select-all-vendor-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-licntr"><input id="select-all-vendor-leg-handler" type="checkbox"> <label for="select-all-vendor-leg-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div></div><div class="ot-sdk-row"><div class="ot-sdk-column"><ul id="ot-host-lst"></ul></div></div></section></section><div class="ot-pc-footer ot-pc-scrollbar"><div class="ot-btn-container"> <button class="save-preference-btn-handler onetrust-close-btn-handler">Confirm my choices</button></div><!-- Footer logo --><div class="ot-pc-footer-logo"><a href="https://www.onetrust.com/products/cookie-consent/" target="_blank" rel="noopener noreferrer" aria-label="Powered by OneTrust Opens in a new Tab"><img alt="Powered by Onetrust" src="https://cdn.cookielaw.org/logos/static/powered_by_logo.svg" title="Powered by OneTrust Opens in a new Tab"></a></div></div><!-- Cookie subgroup container --><!-- Vendor list link --><!-- Cookie lost link --><!-- Toggle HTML element --><!-- Checkbox HTML --><!-- plus minus--><!-- Arrow SVG element --><!-- Accordion basic element --><span class="ot-scrn-rdr" aria-atomic="true" aria-live="polite"></span><!-- Vendor Service container and item template --></div><iframe class="ot-text-resize" sandbox="allow-same-origin" title="onetrust-text-resize" style="position: absolute; top: -50000px; width: 100em;" aria-hidden="true"></iframe></div></div><div id="crossmark-widget" style="display: none;"><div class="crossmark-reset crossmark-overlay"></div><div class="crossmark-reset crossmark-popup"><div class="crossmark-reset crossmark-popup__offset"><div class="crossmark-reset crossmark-popup__inner"><div class="crossmark-reset crossmark-popup__header"><button class="crossmark-reset crossmark-popup__btn-close"><span class="sr-only">__("articleCrossmark.closePopup")</span></button></div><div class="crossmark-reset crossmark-popup__content-wrapper"><iframe class="crossmark-reset crossmark-popup__content" title="Crossmark service - Intentionally blank" aria-hidden="false" tabindex="0" src="https://crossmark.crossref.org/dialog?doi=10.1016%2Fj.cell.2020.08.053&amp;domain=www.cell.com&amp;uri_scheme=https%3A&amp;cm_version=v2.0"></iframe></div></div></div></div></div></body></html>